STEM CELL MICROPARTICLES AND miRNA

ABSTRACT

This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is continuation of U.S. patent application Ser. No. 15/027,424, filed Apr. 5, 2016, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/GB2014/053044, filed Oct. 9, 2014, which in turn claims priority to United Kingdom Patent Application No. 1317887.6, filed Oct. 9, 2013, and International Application No. PCT/GB2014/052509, filed Aug. 14, 2014, the content of each of which is hereby incorporated by reference into this application in its entirety.

REFERENCE TO A “SEQUENCE LISTING,” SUBMITTED AS ASCII TEXT FILED VIA EFS-WEB

The Sequence Listing written in file 104717-1149298-Sequence-Listing.txt created on Jul. 22, 2019, 112,099 bytes, machine format IBM-PC, MS-Windows operating system, in accordance with 37 C.F.R. §§ 1.821 to 1.825, is hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy.

BACKGROUND OF THE INVENTION

Stem cells have the ability to self-renew and to differentiate into functionally different cell types. They have the potential to be a powerful therapeutic tool, for example in the growing field of Regenerative Medicine, in particular regenerative therapy requiring tissue replacement, regeneration or repair (Banerjee et al. 2011). Endogenous stem cells have also been implicated as targets (endogenous “cancer stem cells”) of anti-cancer therapy, where it is proposed to treat the cancer by eliminating the cancer stem cells that are thought to drive cancer growth and metastasis. More recently, engineered mesenchymal stem cells have been proposed as delivery vehicles in anti-cancer therapy (Dai et al., 2011; Shah et al. 2012). However, there are drawbacks to the use of stem cells in therapy: there is a need for a consistent and substantial supply of stem cells with functional and phenotypic stability and the associated high costs and time delay caused by cell generation, storage, transport and handling; there is a requirement for immunological compatibility to avoid rejection of the stem cells by the recipient; and there are complex regulatory issues related to potential safety risks of tumour or ectopic tissue formation. Further, despite the therapeutic efficacy of stem cell transplantation, there is no convincing evidence for a direct long-term effect of the transplanted stem cells, for example through engraftment and differentiation into reparative or replacement cells.

Neural stem cells (NSCs) are self-renewing, multipotent stem cells that generate neurons, astrocytes and oligodendrocytes (Kornblum, 2007). The medical potential of neural stem cells is well-documented. Damaged central nervous system (CNS) tissue has very limited regenerative capacity so that loss of neurological function is often chronic and progressive. Neural stem cells (NSCs) have shown promising results in stem cell-based therapy of neurological injury or disease (Einstein et al. 2008). Implanting neural stem cells (NSCs) into the brains of post-stroke animals has been shown to be followed by significant recovery in motor and cognitive tests (Stroemer et al. 2009). It is not completely understood how NSCs are able to restore function in damaged tissues but it is now becoming increasingly recognised that NSCs have multimodal repairing properties, including site-appropriate cell differentiation, pro angiogenic and neurotrophic activity and immunomodulation promoting tissue repair by the native immune system and other host cells (Milj an & Sinden, 2009, Horie et al., 2011). It is likely that many of these effects are dependent on transient signalling from implanted neural stem cells to the host milieu, for example NSCs transiently express proinflammatory markers when implanted in ischaemic muscle tissue damage which directs and amplifies the natural pro-angiogenic and regulatory immune response to promote healing and repair (Katare et al., Clinical-grade human neural stem cells promote reparative neovascularization in mouse models of hindlimb ischemia. Arteriosclerosis, Thrombosis and Vascular Biology, vol 34, no. 2, pp. 408-418). In chronic stroke brain, NSCs also have a substantial neurotrophic effect. For example, they promote the repopulation of the stoke-damaged striatal brain tissue with host brain derived doublecortin positive neuroblasts (Hassani, O'Reilly, Pearse, Stroemer et al., PLoS One. 2012; 7(11)).

Furthermore, on the basis of a large body of NSC restorative effects in animal models with chronic stroke, a clinical trial using neural stem cells is being carried out by ReNeuron Limited (Surrey, UK), to trial the treatment of disabled stroke patients using its “CTX0E03” conditionally-immortalised cortex-derived neural stem cells (Clinicaltrials.gov Identifier: NCT01151124).

Mesenchymal stem cells (MSCs) are lineage-restricted stem cells which have the potential to differentiate into mesenchymal cell types only, namely of the adipocytic, chondrocytic and osteocytic lineages (Pittenger et al. 1999; Ding et al. 2011). MSCs (also referred to as Mesenchymal Stromal Cells and Mesenchymal Progenitor Cells) are derived from a variety of sources including bone marrow, blood, adipose and other somatic tissues. The therapeutic potential of MSCs, however, is more directed towards the application of their pro-angiogenic and immune modulating properties as undifferentiated cells. Production of human MSCs is limited by the inability of these cells to expand in numbers stably beyond approximately 15-20 population doublings.

Mesenchymal stem cell-conditioned medium (MSC-CM) has a therapeutic efficacy similar to that of MSCs themselves, suggesting a paracrine mechanism of MSC-based therapy (Timmers et al. 2007). WO-A-2009/105044 discloses that particles known as exosomes, secreted by MSCs, comprise at least one biological property of the MSCs and suggests the use of these MSC particles in therapy, while Théry et al. 2011 provides a general review of exosomes and other similar secreted vesicles. Whereas some of the drawbacks of using stem cells directly as therapeutic agents are overcome by using the mesenchymal stem cell-derived exosomes (e.g. storage, transport and handling), the problem remains of providing a consistent and substantial supply of functionally and phenotypically stable stem cells to produce the exosomes. For therapeutic use, the exosomes preferably need to be produced on a large scale. In the absence of a stem cell line, replenishment of the cells through repeated derivation from a source of stem cells is required, which incurs recurring costs for testing and validation of each new batch. Furthermore, the diseases and disorders that can be treated by MSCs may be limited.

WO-A-2013/150303 and WO-A-2014/013258 disclose microparticles produced by neural stem cells, methods for making those microparticles and uses of those microparticles, in particular for use in regenerative therapy.

There remains a need for improved stem cell-based therapies.

SUMMARY OF THE INVENTION

The present invention is based on the surprising finding that neural stem cells contain microparticles that are therapeutically useful, and that neural stem cell microparticles can be used in the therapy of diseases including fibrosis, cancer, rheumatoid arthritis, atherosclerosis, or unwanted or undesirable angiogenesis.

In particular, the inventors have surprisingly identified neural stem cell microparticles that are able to: inhibit cell migration of fibroblasts; inhibit migration of cancer cells; induce differentiation of cancer cells; and/or induce or enhance an immune response against cancer cells. These properties make the neural stem cell microparticles suitable for use in therapy, in particular for treating cancer. The cancer may be a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer.

Cell migration is well-known to play an important role in the progression of diseases such as cancer (for example during angiogenesis, tumour formation, metastasis and tissue invasion), fibrosis (for example during the accumulation of fibroblasts in the fibrotic tissue), atherosclerosis and rheumatoid arthritis. Microparticles that inhibit cell migration are therefore useful in the treatment or prevention of diseases that involve unwanted cell migration, such as cancer, in particular metastatic cancer, fibrosis, atherosclerosis and rheumatoid arthritis.

Microparticles of the invention are shown, in the Examples, to inhibit fibroblast migration. Fibroblasts and the migration of fibroblasts are known to play a role in angiogenesis and so the microparticles of the invention, which inhibit fibroblast migration, are also useful for use in the therapy of unwanted or undesirable angiogenesis.

Additionally, the Examples show that glioblastoma cells, pre-treated in vitro for 24 hours with neural stem cell exosomes did not engraft into the striatum of Balb-C mice in vivo. Histopathology demonstrated the presence of necrotic cell bodies at the site of implantation and evidence of a host cellular response. These data indicate that these microparticles are suitable for use in the treatment of cancer, particularly a cancer of the CNS such as a glioblastoma, by promoting the destruction of cancer cells by the immune system.

Neural stem cell microparticles that are able to inhibit fibroblast cell migration and induce or enhance an immune response against cancer cells have been isolated from neural stem cells cultured in a multi-compartment bioreactor for 11 weeks. Accordingly, one way to obtain these neural stem cell microparticles is to isolate them from neural stem cells that have been cultured in a multi-compartment bioreactor for at least 10 weeks, for example 71 days or more. The microparticles of the invention may also be obtained from other culture conditions and periods, in particular culture conditions that allow stem cell differentiation.

The Examples further show that tumour (glioblastoma U373) cells show significantly reduced migration when treated with neural stem cell microparticles. The microparticles of the invention may therefore be used to treat cancer, particularly a cancer of the CNS such as a glioblastoma, by inhibiting tumour cell migration.

Additionally, neural stem cell exosomes are shown in the Examples to promote differentiation of tumour (glioblastoma U373) cells in vitro. The Examples also show this differentiation in vivo, where tumour (glioblastoma U373) cells, treated with neural stem cell exosomes and implanted into mouse brains, demonstrate a reduction in the stem cell marker nestin. Cancer stem cells drive tumourigenesis, are linked with metastasis, high grade and poor prognosis. A more differentiated tumour typically correlates with improved prognosis, so exosomes that are able to effect differentiation are expected to be useful in the treatment of cancer. Therefore, the ability of microparticles isolated from neural stem cells to reduce the stemness of cancer cells indicates that these microparticles are useful in the treatment of cancer, in particular a cancer that is positive for nestin expression such as melanoma, breast cancer or glioblastoma. Typically, the cancer is a cancer of the CNS such as a glioblastoma. Nestin is reported to correlate with aggressive growth, metastasis, and poor prognosis in cancers, so agents that reduce nestin expression are greatly needed. Neural stem cell microparticles that are able to inhibit tumour cell migration and promote differentiation of tumour cells have been isolated from a neural stem cell line cultured under standard conditions. Accordingly, one way to obtain neural stem cell microparticles that are able to inhibit tumour cell migration and promote differentiation of tumour cells is to isolate them from neural stem cells that have been cultured under standard conditions. These cells may be from the CTX0E03 cell line (deposited with the ECACC as Accession No. 04091601). The standard culture conditions typically maintain the characteristics of the cell line, in particular the sternness of the cell line, typically do not permit differentiation, and typically provides proliferating cells. Typically, the cells proliferate with a doubling time of 2 to 4 days and are passaged when sub-confluent.

The Examples include a pilot in vivo study of the administration of microparticles of the invention to human glioblastoma xenografts, observing tumour sensitivity to the microparticles, a trend towards a reduction in tumour volume, and increased survival. Histopathology of the tumour cells shows, in one animal, a particularly dramatic and effective ablation of the tumour mass.

The Examples also provide Next Generation Sequence (NGS) analysis of the miRNA content of neural stem cell exosomes. One of the Examples revealed the presence of a set of miRNAs: hsa mir 1246, hsa mir 4488, hsa mir 4492, and hsa mir 4532, each of which is shown to reduce glioma cell proliferation. These data provide further evidence that microparticles containing the miRNAs may be used to treat cancer. These data also demonstrate that the various miRNAs identified in the Examples (as present in neural stem cell microparticles) have therapeutic utility themselves—alone or in combination with other identified miRNAs.

A first aspect of the invention provides a neural stem cell microparticle that: inhibits cell migration, typically fibroblast migration or cancer cell migration; and/or induces differentiation of a stem or cancer cell, typically a cancer cell that is positive for nestin expression such as a melanoma cell, breast cancer cell or glioblastoma cell. In one embodiment, the neural stem cell microparticle inhibits angiogenesis. In another embodiment, the microparticle promotes destruction of tumour cells by inducing or enhancing an immune response against the tumour cells.

The microparticle may be an exosome, microvesicle, membrane particle, membrane vesicle, exosome-like vesicle, ectosome-like vesicle, ectosome or exovesicle. Typically, the microparticle is an exosome. The microparticle may be derived from a neural stem cell that has been cultured in an environment that allows stem cell differentiation. The microparticle may or may not be isolated from partially differentiated neural stem cells; as discussed below, the presence of GFAP (an astrocyte marker) or DCX (an early neuronal marker) on the cells indicates that the neural stem cells have begun to differentiate. In one embodiment, an environment that allows stem cell differentiation is a multi-compartment bioreactor. The microparticle may be isolated from neural stem cells that have been cultured in a multi-compartment bioreactor for at least 10 weeks. The microparticle may be isolated from cultured neural stem cells that have been confluent on the membrane of a multi-compartment bioreactor for at least one week, at least 2 weeks, typically at least 3 weeks, at least 4 weeks, at least 5 weeks or more. Conversely, microparticles can be produced from neural stem cells that have not begun to differentiate, for example by isolation from sub-confluent cultured neural stem cells, or by isolation from cells that have been confluent for less than one week on the membrane of a multi-compartment bioreactor or in a standard cell culture flask such as a T-175 flask. As used herein, the term “confluent” is given its usual meaning in the art, wherein the cells in the culture are all in contact and have no further room to grow; confluent cells cover substantially all of the membrane in the multi-compartment bioreactor.

The microparticle may be derived from a neural stem cell line. In some embodiments, the neural stem cell line may be the “CTX0E03” cell line, the “STR0005” cell line, the “HPC0A07” cell line or the neural stem cell line disclosed in Milj an et al Stem Cells Dev. 2009. In some embodiments, the microparticle is derived from a stem cell line that does not require serum to be maintained in culture. The microparticle may have a size of between 30 nm and 1000 nm, or between 30 and 200 nm, or between 30 and 100 nm, as determined by electron microscopy; and/or a density in sucrose of 1.1-1.2 g/ml. The microparticle may comprise RNA. The RNA may be mRNA, miRNA, and/or any other small RNA. The microparticle may comprise one, two, three or four of hsa-miR-1246, hsa miR-4492, hsa-miR-4488 and hsa-miR-4532; alternatively, it may comprise 1, 2, 3, 4 or 5 of hsa-miR-181a-5p, hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p and hsa-miR-100-5p; or it may comprise 1, 2, 3, 4 or 5 of hsa-miR-181a-5p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-92b-3p, and hsa-miR-9-5p. The microparticle may comprise one or more lipids, typically selected from ceramide, cholesterol, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylcholine. The microparticle may comprise one or more tetraspanins, typically CD63, CD81, CD9, CD53, CD82 and/or CD37. The microparticle may comprise one or more of TSG101, Alix, CD109, thy-1 and CD133. The microparticle may comprise at least 10 of the proteins present in Table 20 or Table 22. The microparticle may comprise at least one biological activity of a neural stem cell or a neural stem cell-conditioned medium. At least one biological activity may be an anti-cell migration activity, a pro-differentiation activity or an anti-angiogenic activity. The microparticle of the invention is typically isolated or purified.

A second aspect of the invention provides the neural stem cell microparticle of the first aspect, for use in therapy. The therapy may be of a disease requiring inhibition of cell migration, such as cancer, fibrosis, atherosclerosis or rheumatoid arthritis. The therapy may also be of a disease requiring inhibition of angiogenesis, such as treating a solid tumour by inhibiting angiogenesis. When the disease to be treated is a cancer, it may be a cancer of the CNS, such as a glioma, meningioma, pituitary adenoma or a nerve sheath tumour. An exemplary CNS cancer is a glioblastoma, which may be a giant cell glioblastoma or a gliosarcoma.

In one embodiment, the neural stem cell microparticle is used to treat cancer. In one embodiment, the microparticles of the invention treat the cancer by inhibiting angiogenesis. This is typically useful in treating solid tumours.

In a further embodiment, the microparticles of the invention treat the cancer by inhibiting migration of the cancer cells.

In yet a further embodiment, the microparticles of the invention treat the cancer by inducing differentiation of cancer cells. Typically, differentiation is induced in cancer cells that express nestin.

In another embodiment, the microparticles of the invention treat the cancer by inducing or enhancing an immune response against the cancer cells. When the cancer is a CNS cancer, the immune response typically comprises the activation and/or proliferation of glial cells such as microglia.

In one embodiment, the therapeutic microparticle is an exosome isolated from neural stem cells that have been cultured in a multi-compartment bioreactor for at least 10 weeks. In another embodiment, the therapeutic microparticle is a microvesicle isolated from neural stem cells that have been cultured in the multi-compartment bioreactor for at least 10 weeks.

In an alternative embodiment, the therapeutic microparticle is an exosome isolated from proliferating neural stem cells that have been cultured under conditions that typically maintain the characteristics of the cell line, in particular the stemness of the cell line. These are typically the standard culture conditions for a given cell or cell line, which do not permit differentiation of the stem cells. Typically, proliferating cells have a doubling time of 2 to 4 days. These neural stem cells are typically passaged when sub-confluent.

The therapy may also be a prophylactic therapy to induce tolerance, typically immunotolerance, in a host that is subsequently, concurrently or simultaneously to receive the stem cells from which the microparticle is derived. The administration of one or more doses of microparticles of the invention to a patient, prior to or concurrent with administration of a stem cell therapy, can be used to reduce the risk of an adverse immune response, i.e. “rejection”, of the stem cell therapy.

A third aspect of the invention provides the use of the neural stem cell microparticle of the first aspect, in the manufacture of a medicament for the treatment of a disease. Typically, the disease is cancer.

It has also been found that it is possible to alter the production of microparticles by stem cells, by culturing the stem cells (optionally for at least 10 weeks) and adding components to the culture medium, by culturing the stem cells (optionally for at least 10 weeks) under hypoxic conditions, or by co-culture with other cell types (optionally for at least ten weeks), thereby providing an improved method of producing stem cell microparticles.

Accordingly, a fourth aspect of the invention provides a method of producing a stem cell microparticle that inhibits cell migration, typically a neural stem cell microparticle that inhibits cell migration. The stem cells may be cultured under conditions that allow the efficient removal of metabolic waste. The method may comprise culturing the stem cells for at least 10 weeks in an environment that allows stem cell differentiation and collecting the microparticles that are produced by the cells; microparticles produced by this method are typically able to inhibit fibroblast migration. The microparticles may be isolated from partially-differentiated neural stem cells. In one embodiment, an environment that allows stem cell differentiation is culture in a multi-compartment bioreactor, typically for a prolonged period of time, for example more than seven days and usually more than ten weeks.

The method may alternatively comprise culturing the cells under conditions that do not allow differentiation to occur, and collecting the microparticles that are produced by the cells; microparticles produced by this method are typically able to inhibit glioblastoma migration.

The method may comprise isolating a microparticle from a stem cell-conditioned medium. The stem cell-conditioned medium may comprise one or more additive components or agents which stimulate the release of microparticles by the stem cells into the medium. The one or more components may be selected from transforming growth factor-beta (TGF-β), interferon-gamma (IFN-γ) and/or tumour necrosis factor-alpha (TNF-α). The microparticles may be isolated from stem cell-conditioned medium wherein the stem cells were cultured under hypoxic conditions. The microparticles may be isolated from stem cell-conditioned medium produced by stem cells co-cultured with a different cell type, typically endothelial cells, in order to create the NSC niche environment.

A fifth aspect of the invention provides a microparticle obtainable by a method according to the fourth aspect of the invention.

A sixth aspect of the invention provides a composition comprising a neural stem cell microparticle according to the first aspect and a pharmaceutically acceptable excipient, carrier or diluent. In one embodiment, the microparticle of the invention inhibits fibroblast or glioblastoma cell migration, typically as determined in a transmembrane or wound healing (scratch) assay. In another embodiment, the microparticle of the invention induces differentiation of a tumour cell, optionally a glioblastoma cell, typically as determined by cell morphology and/or marker expression. A decrease in the stem cell marker nestin typically indicates differentiation.

An seventh aspect of the invention provides a kit for use in a method for producing a stem cell microparticle according to the first aspect, comprising: (a) a medium suitable for culturing stem cells; (b) a stem cell; (c) optionally the one or more components of the fourth aspect of the invention; (d) optionally a stem cell microparticle suitable for use as a control; (e) optionally a detection agent suitable for specific detection of the produced microparticles; and (f) instructions for producing the stem cell microparticle using the kit. The kit may optionally include means for performing a cell migration assay.

An eighth aspect of the invention provides a composition comprising one or more of the miRNAs identified in the Examples, in particular the miRNAs identified in FIGS. 13A-13H. In one embodiment, the composition comprises one, two, three or all four of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. In another embodiment, the composition comprises 1, 2, 3, 4 or 5 of hsa-miR-181a-5p, hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p and hsa-miR-100-5p. In a further embodiment, the composition comprises 1, 2, 3, 4 or 5 of hsa-miR-181a-5p, hsa-let-7a-5p, hsa-let-7f-5p, has miR-92b-3p, and hsa-miR-9-5p. The composition is optionally a pharmaceutical composition, comprising a pharmaceutically-acceptable carrier, diluent, vehicle and/or excipient. The pharmaceutical composition is suitable for use in therapy, typically in the same therapies as the microparticles of the invention, as noted above.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the effect of neural stem cell exosome treatment on human dermal fibroblast migration in a transmembrane assay. The top panel depicts the assay apparatus and the bottom panel compares the number of cells that migrated through the membrane in the presence of medium alone (a, “basal”), in the presence of 20 μg/ml exosomes isolated from “0”-week CTX0E03 neural stem cells (b, “Exosome (0)”) and in the presence of 20 μg/ml exosomes isolated from CTX0E03 neural stem cells cultured for 11 weeks in the Integra CELLine AD1000 culture system (c, “Exosome (11)”), determined after 6 hours and after 24 hours assay incubation.

FIG. 2 depicts the human dermal fibroblast cells that migrated through the membrane in the presence of each of the basal, 0-week and 11-week exosomes.

FIG. 3A shows the results of a wound closure/scratch assay representing the migration activity of normal human dermal fibroblasts (NHDF) in response to conditioned medium from CTX0E03 cells cultured for 2 weeks and exosomes purified from the conditioned medium of CTX0E03 cultured for 2 weeks in the Integra CELLine AD1000 culture system. FIG. 3B shows the results of a scratch assay after 72 hours, comparing the effect of 10 μg 2-week CTX0E03 exosomes to basal conditions (without exosomes). FIG. 3C shows the % of healed areas for basal conditions, 2 μg/ml exosomes, 6 μg/ml exosomes, 20 μg/ml exosomes and an LSGS (low serum growth supplement) positive control. The top panel of FIG. 3C shows exosomes isolated from CTX0E03 cells cultured for 2 weeks in the Integra Celline system and the bottom panel of FIG. 3C shows exosomes isolated from CTX0E03 cells cultured for 6 weeks in the Integra Celline system. FIG. 3D compares 2-week CTX0E03 cells to a negative control (saline) in an in vivo injection wound healing assay.

FIG. 4 depicts electron micrographs of CTX0E03 conditionally-immortalised neural stem cells producing microparticles. Panels A-E show intracellular multivesicular bodies (MVBs) containing exosomes between 30 nm and 50 nm in diameter and Panel F shows microvesicles >100 nm in diameter released from neural stem cells through a process of budding at the cell membrane.

FIG. 5 is an outline protocol for the identification, characterisation and production of microparticles from stem cells.

FIG. 6 shows the FACS detection (at 2 ug/ml, 1:250) of (i) CD63 in 2-week Integra cultured CTX0E03 exosomes (top left panel) and microvesicles (top right panel) and (ii) CD81 in 2-week Integra cultured CTX0E03 exosomes (bottom left panel) and microvesicles (bottom right panel).

FIGS. 7A and 7B show the results of NanoSight analysis undertaken to determine the particle size and concentration of CTX0E03 exosomes (FIG. 7A) and microvesicles (FIG. 7B) cultured in the Integra Celline system for 1, 2, 3, 4, 5 and 6 weeks.

FIG. 8A shows the amount of protein (measured by BCA assay) extracted from 15 ml of media containing microparticles purified from the Integra system compared to normal culture conditions (3 days T175). FIG. 8B shows the amount of isolated total RNA measured at 260/280 nm extracted from 15 ml of CTX0E03 conditioned media containing microparticles purified by filtration from the Integra system compared to normal culture conditions (3 days T175).

FIG. 9 shows the quantity of purified exosomes obtained per ml culture medium from standard CTX0E03 (T175) cultures vs. the Integra CELLine system at the 3 week time point.

FIG. 10A shows the concentration of exosomes harvested from two different flasks after 1 week, 2 weeks and 3 weeks of CTX0E03 Integra CELLine culture system. FIG. 10B shows the concentration of exosomes harvested from a single Integra CELLine flask during a 6 week continuous culture of CTX0E03 cells.

FIG. 11 shows the fold change of expression levels of various mRNA markers measured in CTX0E03 cells cultured for 3 weeks in the Integra CELLine system compared to standard (“control”) CTX0E03 (T175) cultures.

FIG. 12 shows the fold up and down regulation of various miRNAs in exosomes obtained from CTX0E03 cells cultured for 3 weeks in Integra bioreactor culture and microparticles obtained from standard CTX0E03 (T175) cultures, assessed against a baseline expression level in CTX0E03 cells in standard (T175) culture.

FIGS. 13A, 13B, 13C, 13D, 13E, 13F, 13G, and 13H depict miRNA deep sequencing results. The miRNA profiles obtained from deep sequencing of miRNA from CTX0E03 cells (“CTX”), microvesicles (“MV”) and exosomes (“EXO”) cultured under standard (T175) conditions are shown in FIGS. 13A and 13B (results from two standard cultures, “EH” and “EL”). FIG. 13C shows the percentage of miRNAs that are up-shuttled, the same, or down-shuttled in the exosomes compared to producer cells, for (i) the standard culture, (ii) 6 week Integra bioreactor culture and (iii) 11 week bioreactor culture (3 samples). Up-shuttled >2, same <2>, and down-regulated <2 fold change (log 2) accordingly. FIGS. 13D to 13H show the miRNAs that are shuttled into exosomes compared with the cells producing them. Up-shuttled miRNAs are expressed as fold change calculated using the log 2 of the normalized ratio of exosomes/cell producer. The normalization is obtained by dividing reads of each miRNA by total miRNA reads. (FIG. 13D) summarises the most abundant miRNAs in exosomes obtained from the standard CTX0E03 cultures (“EH” and “EL”); (FIG. 13E) shows exosomes obtained from CTX0E03 cells cultured for 6 weeks in an Integra bioreactor, and lists up-shuttled miRNAs with more than 250 reads per exosome sample; (FIG. 13F) shows the miRNAs up-shuttled in exosomes when compared with the producer cells cultured for 11 weeks in an Integra bioreactor. 9 miRNA species are up-shuttled, all of which have more than 250 reads; (FIG. 13G) shows a second sample of the miRNAs up-shuttled in exosomes when compared with the producer cells cultured for 11 weeks in an Integra bioreactor. The diagram lists up-shuttled miRNAs with more than 250 reads per exosome sample; and (FIG. 13H) shows a third sample of the miRNAs up-shuttled in exosomes when compared with cell producer cultured for 11 weeks in an Integra bioreactor, showing up-shuttled miRNAs with more than 250 reads per exosome sample.

FIG. 14 is an electropherogram showing the total RNA content profile in 2-week CTX0E03 cells, exosomes and microvesicles as determined by Agilent RNA bioanalyser.

FIG. 15 is a schematic presentation of the percentage of coding genes fully overlapping exon, and non-coding transcripts located with intron or intergenic sequences (produced by running NGS BAM files against GENCODE sequence data set).

FIG. 16 depicts the top ranking preferentially shuttled novel miRNAs in exosomes and MV compared to CTX0E03 producer cells.

FIGS. 17A, 17B, 17C, and 17D show Venn diagrams comparing the proteomic data from CTX0E03 exosomes and microvesicles (FIGS. 17A and 17B), and comparing neural stem cell exosomes with mesenchymal stem cell exosomes (FIGS. 17C and 17D). FIG. 17A illustrates the number of unique proteins within CTX0E03 exosomes and microvesicles, isolated from week 2 Integra culture system. FIG. 17B compares the biological processes associated with the identified proteins within the CTX0E03 exosomes and microvesicles. FIG. 17C compares the CTX0E03 neural stem cell exosome proteome to a Mesenchymal Stem Cell exosome, and FIG. 17D compares biological processes associated with the identified proteins in the MSC derived exosomes with the neural stem cell derived exosomes.

FIG. 18 shows the 30 biological processes found to be associated with NSC derived exosomes and not mesenchymal stem cell exosomes.

FIG. 19 shows the presence of necrotic cell bodies and evidence of a host cellular response in the striatum of Balb-C mice 24 hours after implantation of glioblastoma U373 cells that were pre-treated for 24 hours with exosomes isolated from CTX0E03 cells cultured for 11 weeks in a multi-compartment bioreactor.

FIG. 20 shows a reduction in nestin expression in glioblastoma U373 cells that have pre-treated in vitro for 24 hours with exosomes isolated from a proliferating culture of CTX0E03 cells and implanted into the striatum of Balb-C mice.

FIG. 21 shows that glioblastoma U373 cells that have been treated in vitro with exosomes isolated from a proliferating culture of CTX0E03 cells, appear morphologically differentiated and express Glial fibrillary acidic protein (GFAP).

FIGS. 22A, 22B, and 22C show that seeding glioblastoma cells together with 20 μg/ml CTX0E03 exosomes (FIGS. 22A and 22C) or have been pre-treating glioblastoma cells with 10 μg/ml CTX0E03 exosomes for 24 hours (FIG. 22B) reduces glioblastoma migration towards 10% FBS.

FIGS. 23A, 23B, and 23C show the inhibitory effects of individual miRNAs on the proliferation of glioma cells: (FIG. 23A) plot of percentage of U373MG cell proliferation, compared to 24 hrs control, measured by CyQUANT assay following transfection with hsa-mir-1246, hsa-mir-4488, hsa-mir-4492, or hsa-mir-4532; (FIG. 23B) plot of percentage of U373MG cell proliferation, compared to 0 hr control, measured by CyQUANT assay following transfection with hsa-mir-1246, hsa-mir-4488, hsa-mir-4492, or hsa-mir-4532; and (FIG. 23C) plot of percentage of U87 cell proliferation, compared to 0 hr control, measured by CyQUANT assay following transfection with hsa-mir-1246, hsa-mir-4488, hsa-mir-4492, or hsa-mir-4532.

FIG. 24 shows glioblastoma xenograft individual tumour volumes of mice on the day of assignment to each treatment group.

FIG. 25 shows the mean body weights of the mice during the xenograft study. The dotted vertical line indicates the commencement of the dosing phase (on day 12).

FIG. 26 summarises the mean tumour volume for the treatment groups measured during the study.

FIG. 27 displays the tumour volume data (% pre-dose) of FIG. 26 in a truncated format up to study day 25.

FIG. 28 shows the final tumour weights, expressed as group mean+standard error of the mean (tumour weight).

FIG. 29 shows survival analysis utilising mean tumour diameter (15 mm) as the humane survival endpoint.

FIG. 30 shows the absolute individual body weights of each mouse in the study.

FIG. 31 shows the relative individual body weights of each mouse in the study.

FIG. 32 shows the raw data for individual tumour volume measurements.

FIG. 33 shows the individual tumour volume plots.

FIG. 34 details the tumour weights.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors have surprisingly identified that neural stem cells produce microparticles that inhibit cell migration of fibroblasts and cancer cells, induce differentiation of cancer cells, and/or induce or enhance an immune response against the cancer cells. These microparticles are shown to inhibit cell migration and are therefore useful in therapy of diseases comprising unwanted, undesired or deleterious cell migration. The microparticles inhibit fibroblast migration and are therefore also useful in therapy of diseases comprising unwanted, undesired or deleterious angiogenesis, in which fibroblasts play a key role. The microparticles also inhibit tumour cell migration, induce differentiation of tumour cells and enhance an immune response against cancer cells, and are therefore useful in the treatment of cancer. The microparticles of the invention can be characterised and identified by these properties, using the assays described herein or other assays known to the skilled person.

The microparticles are advantageous over the corresponding stem cells because they are smaller and less complex, thereby being easier to produce, maintain, store and transport, and have the potential to avoid some of the regulatory issues that surround stem cells. The microparticles can be produced continuously, by isolation from conditioned media, for example in a bioreactor such as a multi-compartment bioreactor, which allows for large scale production and the provision of an “off-the-shelf” therapy. The multi-compartment bioreactor is typically a two-compartment bioreactor. An exemplary multi-compartment bioreactor is the CeLLine AD1000 bioreactor that is commercially available from Integra Biosciences AG, Zizers, Switzerland (Item No. 90025).

The inventors have found that the properties of neural stem cell microparticles differ depending on the culture conditions of the stem cells that produce the microparticles, in particular the length of time that the neural stem cells are cultured before the microparticles are harvested. In particular, the inventors have surprisingly identified neural stem cell microparticles that inhibit cell migration and/or induce differentiation of a stem or cancer cell.

In one embodiment, microparticles that inhibit fibroblast migration can be isolated from neural stem cells that have been cultured in a multi-compartment bioreactor for at least 10 weeks, e.g. more than 10 weeks. This is particularly surprising because microparticles isolated from the same neural stem cells that have been cultured for less than 10 weeks, for example about 2-6 weeks, have been shown to enhance fibroblast cell migration as seen in wound healing assays.

In another embodiment, microparticles that are able to induce or enhance a beneficial immune response against cancer cells can also be isolated from neural stem cells that have been cultured in a multi-compartment bioreactor for at least 10 weeks, e.g. more than 10 weeks.

In a further embodiment, microparticles that are able to reduce tumour cell migration and/or induce cancer or stem cell differentiation are isolated from a proliferating neural stem cell culture. This culture may be in a standard cell culture flask (such as a T-175 flask) or may be in a multi-compartment bioreactor. When the cells producing microparticles of this embodiment are cultured in a multi-compartment bioreactor, they are typically cultured for 4 weeks or less, for example 3 weeks or less, 2 weeks or less, or 1 week or less. This is because, as described elsewhere herein, prolonged culture in a multi-compartment bioreactor allows the stem cells to begin to differentiate, i.e. to express markers for defined neural cell types. Typically, the microparticles that are able to reduce tumour cell migration and/or induce differentiation are isolated from neural stem cells that are negative for markers of differentiated neural cells (e.g. GFAP⁻ and/or DCX⁻) but are positive for one or more markers of neural stem cells (e.g. Nestin⁺).

FIG. 1 (lower panel) and FIG. 2 show that exosomes isolated from a non-proliferating CTX0E03 culture significantly abrogate migration of human dermal fibroblasts. This is in contrast to exosomes isolated from a proliferating CTX0E03 culture, which significantly promote migration of human dermal fibroblasts. Accordingly, in one embodiment, microparticles that inhibit cell (e.g. fibroblast) migration may be isolated from non-proliferating neural stem cells. Optionally, these non-proliferating stem cells may be partly differentiated, i.e. express one or more early markers of differentiation. In one embodiment, the neural stem cells from which these microparticles are isolated are positive for DCX (doublecortin), which is an early neuronal marker. In another embodiment, the neural stem cells from which the microparticles are isolated are positive for GFAP (Glial fibrillary acidic protein), which is an astrocyte marker.

FIGS. 22A, 22B, and 22C show that exosomes isolated from a proliferating CTX0E03 culture inhibit the migration of glioblastoma cells towards a positive chemoattractant. Accordingly, in one embodiment, microparticles that inhibit cell (e.g. glioblastoma) migration may be isolated from proliferating neural stem cells that are typically negative for markers of differentiation. In one embodiment, the neural stem cells from which these microparticles are isolated are negative for DCX (doublecortin), which is an early neuronal marker. In another embodiment, the neural stem cells from which the microparticles are isolated are negative for GFAP (Glial fibrillary acidic protein), which is an astrocyte marker.

Cell migration is well-known to play an important role in the progression of diseases such as cancer (for example during angiogenesis, tumour formation, metastasis and tissue invasion), fibrosis (for example during the accumulation of fibroblasts in the fibrotic tissue), atherosclerosis and rheumatoid arthritis. The identification of microparticles that are able to inhibit these processes therefore provides a new therapy for these diseases.

Transmembrane and wound healing assays are physiologically relevant cell-based assays that are predictive of in vivo mechanisms of cell migration and allow the identification of compounds that are effective in promoting or inhibiting cell migration, and the recognition of potential undesirable effects. Furthermore there is a good correlation between the results obtained in scratch assays and transmembrane assays (Hulkower et al. 2011), so that these assays can be compared.

The data presented below demonstrate that microparticles that inhibit cell migration can be isolated from neural stem cells. The microparticles of the invention can be produced by any method, not limited to those disclosed or exemplified herein. Whether or not a microparticle is able to inhibit cell migration can be readily determined using the assays described herein.

It has further been found that, surprisingly, culturing stem cells (of any type, not limited to neural stem cells) in an environment that allows the stem cells to begin to differentiate, increases dramatically the yield of microparticles produced. Typically, the stem cells are NSCs, for example CTX0E03, cultured for at least 10 weeks, for example for 11 weeks, but optionally no more than 20 weeks, 30 weeks or 40 weeks.

The inventors have surprisingly observed that culturing stem cells (of any type, not limited to neural stem cells) in a multi-compartment bioreactor results in partial differentiation of the stem cells, into stem cells in a more differentiated form. This differentiation in culture does not require the addition of an agent to induce differentiation. This differentiation typically requires a culture period of at least one week, at least two weeks, at least three weeks, at least six weeks, at least eight weeks, or at least ten weeks, for example about 11 weeks, but optionally no more than 20 weeks. The changes to the stem cells that occur in culture in a multi-compartment bioreactor are reflected by the microparticles produced by the cultured stem cells. Therefore, by culturing stem cells in a multi-compartment bioreactor, it is possible to induce differentiation of the cells. Accordingly, microparticles from partially differentiated stem cells can be produced by harvesting microparticles from stem cells, for example NSCs such as CTX0E03, cultured in a multi-compartment bioreactor, typically for at least one week, at least two weeks, at least three weeks, at least four weeks, at least five weeks or at least six weeks, at least eight weeks, or at least ten weeks, for example about 11 weeks, but optionally no more than 20 weeks. Typically, the NSCs have been cultured for more than ten weeks. In one embodiment, the invention provides a method of producing microparticles by isolating the microparticles from partially-differentiated neural stem cells as described above.

The inventors have also found that it is possible to induce the secretion of microparticles from stem cells. Typically, the stem cells are NSCs, for example CTX0E03, typically cultured for at least 10 weeks, for example for 11 weeks or more, but optionally no more than 20 weeks. This finding, which also is not limited to neural stem cells and can be used for the production of microparticles from any stem cell, allows for an improved yield of microparticles to be obtained from a stem cell culture. Several agents have been identified that enhance the secretion of microparticles to different degrees, which has the further advantage of being able to control the amount of microparticles that are secreted. Culturing stem cells under hypoxic conditions also improves microparticle production. Further, it has been found that co-culturing a stem cell with a different cell type, in particular an endothelial cell type can beneficially alter the microparticles that are produced by the stem cell.

In a further embodiment, the invention provides microparticles, typically exosomes, produced by serum-free stem cells. Typically, the stem cells are NSCs, for example CTX0E03, cultured for at least 10 weeks, for example for 11 weeks, but optionally no more than 20 weeks. Serum is required for the successful culture of many cell lines, but contains many contaminants including its own exosomes. As described below, the inventors have produced microparticles from stem cells that do not require serum for successful culture.

Neural Stem Cell Microparticles

The invention provides, in one aspect, microparticles that inhibit cell migration and/or induce differentiation of a stem or cancer cell, obtainable from a neural stem cell. The microparticle is, in one embodiment, obtainable from a neural stem cell that has been cultured in a multi-compartment bioreactor, typically for at least 10 weeks, for example 11 weeks or more, or 12 weeks or more. In another embodiment, the microparticle is obtainable from a proliferating neural stem cell that has been cultured in: a standard cell culture flask such as a T-175 flask; or in a multi-compartment bioreactor for 4 weeks or less.

A neural stem cell microparticle is a microparticle that is produced by a neural stem cell. Typically, the microparticle is secreted by the neural stem cell. More typically, the microparticle is an exosome or a microvesicle. Microparticles from other cells, such as mesenchymal stem cells, are known in the art.

A “microparticle” is an extracellular vesicle of 30 to 1000 nm diameter that is released from a cell. It is limited by a lipid bilayer that encloses biological molecules. The term “microparticle” is known in the art and encompasses a number of different species of microparticle, including a membrane particle, membrane vesicle, microvesicle, exosome-like vesicle, exosome, ectosome-like vesicle, ectosome or exovesicle. The different types of microparticle are distinguished based on diameter, subcellular origin, their density in sucrose, shape, sedimentation rate, lipid composition, protein markers and mode of secretion (i.e. following a signal (inducible) or spontaneously (constitutive)). Four of the common microparticles and their typical distinguishing features are described in Table 1, below.

TABLE 1 Various Microparticles Microparticle Size Shape Markers Lipids Origin Microvesicles 100-1000 nm Irregular Integrins, Phosphatidylserine Plasma selectins, membrane CD40 ligand Exosome-like  20-50 nm Irregular TNFRI No lipid rafts MVB from vesicles other organelles Exosomes  30-100 nm; Cup Tetraspanins Cholesterol, Multivesicular (<200 nm) shaped (e.g. CD63, sphingomyelin, endosomes CD9), ceramide, lipid Alix, rafts, TSG101, phosphatidylserine ESCRT Membrane  50-80 nm Round CD133, Unknown Plasma particles no CD63 membrane

Microparticles are thought to play a role in intercellular communication by acting as vehicles between a donor and recipient cell through direct and indirect mechanisms. Direct mechanisms include the uptake of the microparticle and its donor cell-derived components (such as proteins, lipids or nucleic acids) by the recipient cell, the components having a biological activity in the recipient cell. Indirect mechanisms include microvesicle-recipient cell surface interaction, and causing modulation of intracellular signalling of the recipient cell. Hence, microparticles may mediate the acquisition of one or more donor cell-derived properties by the recipient cell. It has been observed that, despite the efficacy of stem cell therapies in animal models, the stem cells do not appear to engraft into the host. Accordingly, the mechanism by which stem cell therapies are effective is not clear. Without wishing to be bound by theory, the inventors believe that the microparticles secreted by neural stem cells play a role in the therapeutic utility of these cells and are therefore therapeutically useful themselves.

The microparticles and stem cells of the invention are isolated. The term “isolated” indicates that the microparticle, microparticle population, cell or cell population to which it refers is not within its natural environment. The microparticle, microparticle population, cell or cell population has been substantially separated from surrounding tissue. In some embodiments, the microparticle, microparticle population, cell or cell population is substantially separated from surrounding tissue if the sample contains at least about 75%, in some embodiments at least about 85%, in some embodiments at least about 90%, and in some embodiments at least about 95% microparticles and/or stem cells. In other words, the sample is substantially separated from the surrounding tissue if the sample contains less than about 25%, in some embodiments less than about 15%, and in some embodiments less than about 5% of materials other than the microparticles and/or stem cells. Such percentage values refer to percentage by weight. The term encompasses cells or microparticles which have been removed from the organism from which they originated, and exist in culture. The term also encompasses cells or microparticles which have been removed from the organism from which they originated, and subsequently re-inserted into an organism. The organism which contains the re-inserted cells may be the same organism from which the cells were removed, or it may be a different organism.

Neural stem cells naturally produce microparticles by a variety of mechanisms, including budding of the plasma membrane (to form membrane vesicles and microvesicles) and as a result of the fusion of intracellular multivesicular bodies (which contain microparticles) with the cell membrane and the release of the microparticles into the extracellular compartment (to secrete exosomes and exosome-like vesicles).

The neural stem cell that produces the microparticles of the invention can be a fetal, an embryonic, or an adult neural stem cell, such as has been described in U.S. Pat. Nos. 5,851,832, 6,777,233, 6,468,794, 5,753,506 and WO-A-2005121318. The fetal tissue may be human fetal cortex tissue. The cells can be selected as neural stem cells from the differentiation of induced pluripotent stem (iPS) cells, as has been described by Yuan et al. (2011) or a directly induced neural stem cell produced from somatic cells such as fibroblasts (for example by constitutively inducing Sox2, Klf4, and c-Myc while strictly limiting Oct4 activity to the initial phase of reprogramming as recently by Their et al, 2012). Human embryonic stem cells may be obtained by methods that preserve the viability of the donor embryo, as is known in the art (e.g. Klimanskaya et al., 2006, and Chung et al. 2008). Such non-destructive methods of obtaining human embryonic stem cell may be used to provide embryonic stem cells from which microparticles of the invention can be obtained. Alternatively, microparticles of the invention can be obtained from adult stem cells, iPS cells or directly-induced neural stem cells. Accordingly, microparticles of the invention can be produced by multiple methods that do not require the destruction of a human embryo or the use of a human embryo as a base material.

Typically, the neural stem cell population from which the microparticles are produced, is substantially pure. The term “substantially pure” as used herein, refers to a population of stem cells that is at least about 75%, in some embodiments at least about 85%, in some embodiments at least about 90%, and in some embodiments at least about 95% pure, with respect to other cells that make up a total cell population. For example, with respect to neural stem cell populations, this term means that there are at least about 75%, in some embodiments at least about 85%, in some embodiments at least about 90%, and in some embodiments at least about 95% pure, neural stem cells compared to other cells that make up a total cell population. In other words, the term “substantially pure” refers to a population of stem cells of the present invention that contain fewer than about 25%, in some embodiments fewer than about 15%, and in some embodiments fewer than about 5%, of lineage committed cells in the original unamplified and isolated population prior to subsequent culturing and amplification.

A neural stem cell microparticle comprises at least one lipid bilayer which typically encloses a milieu comprising lipids, proteins and nucleic acids. The nucleic acids may be deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA). RNA may be messenger RNA (mRNA), micro RNA (miRNA) or any miRNA precursors, such as pri-miRNA, pre-miRNA, and/or small nuclear RNA (snRNA).

A neural stem cell microparticle retains at least one biological function of the stem cell from which it is derived. Biological functions that may be retained include the ability to inhibit cell migration, for example of fibroblasts or fibroblast-like cells, or of a tumour cell such as a glioblastoma cell. In one embodiment, the at least one biological function is that of a neural stem cell that has been cultured in a multi-compartment bioreactor, for at least 10 weeks and optionally no more than 20 weeks. Alternatively the at least one biological function may be that of a neural stem cell-conditioned medium from a neural stem cell that has been cultured in a multi-compartment bioreactor, for at least 10 weeks and optionally no more than 20 weeks. In another embodiment, the at least one biological function is that of a neural stem cell that has been cultured in a T-175 flask under standard conditions.

FIGS. 1 and 2 (Example 1) demonstrate that exosomes isolated from the conditioned medium of CTX0E03 cells that have been cultured for 11 weeks have the ability to inhibit fibroblast migration in a transmembrane assay model of cell migration. Accordingly, one biological function that microparticles of the invention may retain is the ability to inhibit migration of fibroblast or fibroblast-like cells, for example of normal human dermal fibroblasts (NHDF).

In contrast, exosomes isolated from the conditioned medium of CTX0E03 cells that have been cultured for 0-6 weeks promote cell migration as determined using a scratch/wound closure assay. Examples 1 and 2, Table 2 and FIGS. 1-3 demonstrate that exosomes isolated from the conditioned medium of CTX0E03 cells that have been cultured for 0-6 weeks retain the ability to close a wound in a “scratch” model of wound healing. The results in FIG. 3A show that the migration activity of normal human dermal fibroblasts (NHDF) cultured in CTX0E03 conditioned media is almost the same as the migration activity observed on the addition of purified exosomes.

The Examples also demonstrate that exosomes isolated from the conditioned medium of CTX0E03 cells that have been cultured for 11 weeks have the ability to promote the destruction of cancer cells by the immune system. Accordingly, one biological function that microparticles of the invention may retain is the ability to promote the destruction of cancer cells by the immune system.

The Examples further demonstrate that exosomes isolated from the conditioned medium of proliferating CTX0E03 cells have the ability to inhibit tumour cell migration. Accordingly, one biological function that microparticles of the invention may retain is the ability to inhibit tumour cell migration, typically of glioblastoma cells.

Yet further, the Examples demonstrate that exosomes isolated from the conditioned medium of proliferating CTX0E03 cells have the ability to induce differentiation of tumour cells. Accordingly, one biological function that microparticles of the invention may retain is the ability to induce differentiation of tumour cells, typically glioblastoma cells. Differentiation may readily be determined by known assays, including cell morphology and the presence of stem cell markers (e.g. nestin) and/or differentiated cell markers (e.g. DCX, GFAP). In one embodiment, differentiation is determined by assaying for the stem cell marker nestin (as demonstrated in the Examples). A reduction in nestin expression indicates differentiation of the cell.

Inhibition of Cell Migration

Microparticles of the invention are able to inhibit cell migration. Typically, the migration of fibroblasts or glioblastoma cells is inhibited. Cell migration assays are known in the art. Two exemplary assays are described below, and are used in the Examples.

Transmembrane assays (sometimes referred to as “transwell” assays) are known in the art and an exemplary assay is described in Example 1. The assay uses a chamber separated into two compartments by a porous filter membrane. The cells are seeded on one side of the membrane, while medium containing the purified microparticles is placed on the opposing (lower) side. Example 1 uses fibroblasts, but other cells may be used. After an incubation period (e.g. 6-24 hours), the membrane is fixed and stained to reveal migrated cells (e.g. cell nuclei). The number of cells which have migrated through the pores of the membrane is counted microscopically.

An alternative transmembrane assay was used in Example 6, as shown in FIGS. 22A, 22B, and 22C. Here, glioblastoma cells are seeded on one side of the porous filter membrane. These cells are either seeded together with 20 μg/ml microparticles (FIGS. 22A and C) or have been pre-treated with 10 μg/ml microparticles for 24 hours (FIG. 22B). Medium containing a chemoattractant is placed on the opposing (lower) side. In Example 6, the chemoattractant is FBS. After an incubation period (e.g. 6-24 hours), the membrane is fixed and stained to reveal migrated cells (e.g. cell nuclei). The number of cells which have migrated through the pores of the membrane is again counted microscopically.

Cell migration is calculated as the number of cells that have migrated through the pores of the membrane in relation to basal conditions (without the microparticles). Inhibition of cell migration in this assay may typically be defined as a decrease in the number of cells that have migrated through the membrane, typically the number of migrated cells is less than 90%, more typically less than 80%, more typically less than 75%, less than 60% or less than 50% of the number of cells that have migrated through the membrane under basal conditions (without the microparticles) after the same incubation period (e.g. 6 hours or 24 hours). As a guideline, inhibition of cell migration is achieved if after 24 hours incubation in the transmembrane assay, the number of human dermal fibroblasts or glioblastoma cells that have migrated through the membrane in the presence of 20 μg/ml of the microparticles is less than 80% of the number of fibroblasts that migrated under basal conditions (i.e. in the absence of the microparticles).

In one embodiment, “inhibition of cell migration” is a statistically significant reduction in cell migration of human dermal fibroblasts or glioblastoma cells in a transmembrane assay with a p value of p<0.05, typically p<0.001, in the presence of the microparticles, compared to the migration in the absence of the microparticles. Typically, this is determined after a 24 hour assay incubation period.

Cell migration may also be determined using an in vitro scratch (wound closure) assay, for example the assay of Example 2. Scratch assays were first used as models of wound healing for epithelial or mesenchymal cells. In this assay, cells are seeded into an assay plate and allowed to attach, spread, and form a confluent monolayer. Example 2 uses fibroblasts, but other cells may be used. A pin or needle is used to scratch and remove cells from a discrete area of the confluent monolayer to form a cell-free zone into which cells at the edges of the wound can migrate. Alternatively, a removable insert having a defined shape is placed on contact with the well bottom before the cells are seeded and allowed to form a confluent monolayer excluding the area covered by the insert. The insert is then removed, allowing the cells to migrate onto the newly revealed surface. Using either setup, molecules of interest as potential therapeutics (e.g. the purified microparticles of the invention) are added to the well and images of cell movement are captured at regular intervals, for example within a 24-72 hour period, for data analysis.

Cell migration/wound closure is calculated as the area covered by cells in relation to the initial wound area as determined at 0 hours. Inhibition of cell migration in this assay is typically defined as a decrease in wound closure, typically a wound closure less than 90%, more typically less than 80%, more typically less than 75%, less than 60% or less than 50% of the wound closure observed under basal conditions (without the microparticles) after 24 hours. After 48 hours, the wound closure is typically less than 90% or less than 80% of the wound closure observed using in the absence of the microparticles.

Inhibition of cell migration may also be defined as delaying a wound closure of 100%, as determined by the scratch assay, by at least 24 hours compared to the wound closure observed under basal conditions. Typically, this delay is achieved by using 2 μg/ml of the isolated microparticles, as used in Example 2.

The proteomic analysis in Example 18 indicates that neural stem cell exosomes comprise biological functions associated with the production, packaging, function and degradation of genetic material. Accordingly, in one embodiment, exosomes of the invention retain these functions, typically one or more of RNA polymerase function, RNA degradation function, ribosome function and spliceosome function.

The microparticle obtained from the neural stem cell has a diameter of 1000 nm or less. Typically, the microparticle of the invention will have a diameter of 200 nm or less, for example 100 nm or less. As noted in Table 1 above, microvesicles have a diameter of 100 nm to 1000 nm. Exosomes are typically defined as having a diameter of 30-100 nm, but more recent studies confirm that exosomes can also have a diameter between 100 nm and 200 nm, (e.g. Katsuda et al, Proteomics 2013 and Katsuda et al, Scientific Reports 2013). Accordingly, exosomes typically have a diameter between 30 nm and 150 nm. Membrane particles have a diameter of 50 nm to 80 nm and exosome-like particles have a diameter of 20 nm-50 nm. The diameter can be determined by any suitable technique, for example electron microscopy or dynamic light scattering. The term microparticle includes, but is not limited to: membrane particle, membrane vesicle, microvesicle, exosome-like vesicle, exosome, ectosome-like vesicle, ectosome or exovesicle.

FIG. 4 panels A-E show the presence in neural stem cells of multivesicular bodies (MVBs) containing exosomes between 30-50 nm in diameter, while panel F shows microvesicles >100 nm in diameter. Table 21 and FIGS. 7A and 7B (below) show that typical neural stem cell exosomes were measured to have a diameter ranging from approximately 70 nm to approximately 150 nm, which is consistent with the size of exosomes (from mesenchymal stem cells) described in the art. Accordingly, exosomes of the invention typically have a diameter between 30 nm and 200 nm, more typically between 50 nm and 150 nm. As noted above, exosomes are typically positive for the Alix marker (UNIPROT Accession No. Q8WUM4).

FIG. 4F and Table 21 shows the observed size of typical neural stem cell microvesicles, with a mode diameter of approximately 150 nm-200 nm, or a median diameter of approximately 180 nm-350 nm. Accordingly, microvesicles of the invention typically have a diameter between 100 and 1000 nm, more typically between 150 nm and 350 nm.

Some microparticles of the invention express the CD133 surface marker. Other microparticles of the invention do not express the CD133 surface marker.

“Marker” refers to a biological molecule whose presence, concentration, activity, or phosphorylation state may be detected and used to identify the phenotype of a cell.

Exosomes are endosome-derived lipid microparticles of typically 30-100 nm diameter and sometimes between 100 nm and 200 nm diameter, that are released from the cell by exocytosis. Exosome release occurs constitutively or upon induction, in a regulated and functionally relevant manner. During their biogenesis, exosomes incorporate a wide range of cytosolic proteins (including chaperone proteins, integrins, cytoskeletal proteins and the tetraspanins) and genetic material. Consequently, exosomes are considered to be inter-cellular communication devices for the transfer of proteins, lipids and genetic material between cells, in the parent cell microenvironment and over considerable distance. Although the invention is not bound by this theory, it is possible that the exosomes are responsible for the efficacy of the neural stem cells. Therefore, exosomes from neural stem cells are themselves expected to be therapeutically efficacious.

Microparticles Designed to have Desired Functions

Microparticles retain at least some of the functions of the stem cells that produce them. Therefore, it is possible to design microparticles by manipulating the stem cell (which can be any stem cell type and is not limited to neural stem cells, although the neural stem cell microparticles of the invention are expressly included as an embodiment) to possess one or more desired functions, typically protein or miRNA. The manipulation will typically be genetic engineering, to introduce one or more exogenous coding, non-coding or regulatory nucleic acid sequences into the stem cell. For example, if an exosome containing VEGF and/or bFGF is desired, then the exosome-producing stem cell can be transformed or transfected to express (high levels of) VEGF and/or bFGF, which would then be incorporated into the microparticles produced by that stem cell. Similarly, iPS cells can be used to produce microparticles, and these cells can be designed to produce the proteins and nucleic acids (e.g. miRNA) that are required in the microparticles produced by the iPS cells. The invention therefore provides ad hoc microparticles, from any stem cell type, that contain a function that is not naturally present in the stem cell from which is produced, i.e. the microparticles (e.g. exosomes) contain one or more exogenous protein or nucleic acid sequences, are not naturally-occurring and are engineered.

In one embodiment, isolated or purified microparticles from the conditioned medium of neural stem cells that have been cultured for more than 10 weeks, for example for 11 weeks, and optionally no longer than 20 weeks, are loaded with one or more exogenous nucleic acids, lipids, proteins, drugs or prodrugs which are intended to perform a desired function in a target cell. This does not require manipulation of the stem cell and the exogenous material can optionally be directly added to the microparticles. For example, exogenous nucleic acids can be introduced into the microparticles by electroporation. The microparticles can then be used as vehicles or carriers for the exogenous material. In one embodiment, microparticles that have been isolated from the cells that produced them are loaded with exogenous siRNA, typically by electroporation, to produce microparticles that can be deployed to silence one or more pathological genes. In this way, microparticles can be used as vehicles to deliver one or more agents, typically therapeutic or diagnostic agents, to a target cell, for example to enhance or complement their endogenous inhibition of cell migration. An example of this is a neural stem cell exosome comprising exogenous siRNA capable of silencing one or more pathological genes.

Microparticle Marker

The invention provides a population of isolated neural stem cell microparticles, wherein the population essentially comprises only microparticles of the invention, i.e. the microparticle population is pure. In many aspects, the microparticle population comprises at least about 80% (in other aspects at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or 100%) of the microparticles of the invention.

The isolated neural stem cell microparticle of the invention is characterised in that it has a distinctive expression profile for certain markers and is distinguished from microparticles from other cell types. When a marker is described herein, its presence or absence may be used to distinguish the microparticle. For example, the term “may comprise” or “may express” also discloses the contrary embodiment wherein that marker is not present, e.g. the phrase “the microparticle may comprise one or more tetraspanins, typically CD63, CD81, CD9, CD53, CD82 and/or CD37” also describes the contrary embodiment wherein the microparticle may not comprise one or more tetraspanins, typically CD63, CD81, CD9, CD53, CD82 and/or CD37.

The neural stem cell microparticle of the invention is typically considered to carry a marker if at least about 70% of the microparticles of the population, e.g. 70% of the membrane particles, membrane vesicles, microvesicles, exosome-like vesicles, exosomes, ectosome-like vesicles, ectosomes or exovesicles show a detectable level of the marker. In other aspects, at least about 80%, at least about 90% or at least about 95% or at least about 97% or at least about 98% or more of the population show a detectable level of the marker. In certain aspects, at least about 99% or 100% of the population show detectable level of the markers. Quantification of the marker may be detected through the use of a quantitative RT-PCR (qRT-PCR) or through fluorescence activated cell sorting (FACS). It should be appreciated that this list is provided by way of example only, and is not intended to be limiting. Typically, a neural stem cell microparticle of the invention is considered to carry a marker if at least about 90% of the microparticles of the population show a detectable level of the marker as detected by FACS.

The markers described herein are considered to be expressed by a cell of the population of the invention, if its expression level, measured by qRT-PCR has a crossing point (Cp) value below or equal to 35 (standard cut off on a qRT-PCR array). The Cp represents the point where the amplification curve crosses the detection threshold, and can also be reported as crossing threshold (ct).

In one embodiment, the invention relates to microparticles produced by a neural stem cell population characterised in that the cells of the population express one or more of the markers Nestin, Sox2, GFAP, βIII tubulin, DCX, GALC, TUBB3, GDNF and IDO. In another embodiment, the microparticle is an exosome and the population of exosomes expresses one or more of DCX (doublecortin—an early neuronal marker), GFAP (Glial fibrillary acidic protein—an astrocyte marker), GALC, TUBB3, GDNF and IDO.

The neural stem cell microparticles of the invention may express one or more protein markers at a level which is lower or higher than the level of expression of that marker in a mesenchymal stem cell microparticle of the same species. Protein markers that are expressed by the CTX0E03 cell microparticles are identified herein and below. In some embodiments, the microparticles may express a protein marker at a level relative to a tubulin or other such control protein(s). In some embodiments, the microparticles of the invention may express that protein at a level of at least +/−1.2 fold change relative to the control protein, typically at least +/−1.5 fold change relative to the control protein, at least +/−2 fold change relative to the control protein or at least +/−3 fold change relative to the control protein. In some embodiments, the microparticles may express a protein marker at a level of between 10^(¬¬¬−2) and 10⁻⁶ copies per cell relative to a tubulin or other control protein. In some embodiments, the microparticles of the invention may express that protein at a level of between 10⁻² and 10⁻³ copies per cell relative to a tubulin or other control protein.

The neural stem cell microparticles of the invention may express one or more miRNAs (including miRNA precursors) at a level which is lower or higher than the level of expression of that miRNA (including miRNA precursors) in a mesenchymal stem cell microparticle of the same species. miRNA markers that are expressed by the CTX0E03 cell microparticles are identified below. In some embodiments, the microparticles of the invention may express the marker miRNA at a level of least +/−1.5 fold change, typically at least +/−2 fold change or at least +/−3 fold change (calculated according to the ΔΔct method, which is well-known) relative to U6B or 15a, or any other miRNA reference gene, also referred to as an internal control gene.

The neural stem cell microparticles of the invention may express one or more mRNAs at a level which is lower or higher than the level of expression of that mRNA in a mesenchymal stem cell microparticle of the same species. In some embodiments, the microparticles of the invention may express the marker mRNA at a level of least +/−1.5 fold change, typically at least +/−2 fold change or at least +/−3 fold change (calculated according to the ΔΔct method) relative to ATPSB or YWHAZ, or any other reference gene, also referred to as an internal control gene.

Exosomes of the invention typically express specific integrins, tetraspanins, MHC Class I and/or Class II antigens, CD antigens and cell-adhesion molecules on their surfaces, which may facilitate their uptake by specific cell types. Exosomes contain a variety of cytoskeletal proteins, GTPases, clathrin, chaperones, and metabolic enzymes (but mitochondrial, lysosomal and ER proteins are excluded, so the overall profile does not resemble the cytoplasm). They also contain mRNA splicing and translation factors. Finally, exosomes generally contain several proteins such as HSP70, HSP90, and annexins that are known to play signalling roles yet are not secreted by classical (ER-Golgi) mechanisms.

The lipid bilayer of an exosome is typically enriched with cholesterol, sphingomyelin and ceramide. Exosomes also express one or more tetraspanin marker proteins. Tetraspanins include CD81, CD63, CD9, CD53, CD82 and CD37. Exosomes can also include growth factors, cytokines and RNA, in particular miRNA. Exosomes typically express one or more of the markers TSG101, Alix, CD109, thy-1 and CD133. Alix (Uniprot accession No. Q8WUM4), TSG101 (Uniprot accession No. Q99816) and the tetraspanin proteins CD81 (Uniprot accession No. P60033) and CD9 (Uniprot accession No. P21926) are characteristic exosome markers.

Alix is an endosomal pathway marker. Exosomes are endosomal-derived and, accordingly, a microparticle positive for this marker is characterised as an exosome. Exosomes of the invention are typically positive for Alix. Microvesicles of the invention are typically negative for Alix.

Microparticle Proteome

Tables 19 and 21 list all proteins detected by mass spectrometry in exosomes and microvesicles, respectively, isolated from CTX0E03 cells cultured for two weeks in an Integra Celline multi-compartment bioreactor. Exosomes and microvesicles of the invention may contain at least a proportion of the proteins identified in Tables 19 and 21, respectively. Thus, in one embodiment, exosomes of the invention comprise at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% of the proteins listed in Table 19. Similarly, microvesicles of the invention typically comprise at least 70% at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% of the proteins listed in Table 21. In a further embodiment, the proteome of a microvesicle or exosome of the invention is least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% identical to the proteome provided in Table 19 (exosome) or Table 21 (microvesicle). When determining the protein content of a microparticle or exosome, mass spectrometry is typically used, for example the LC/MS/MS method described in Example 18.

Tables 20 and 22 show the 100 most abundant proteins detected by mass spectrometry in exosomes and microvesicles, respectively, isolated from CTX0E03 cells cultured for two weeks in an Integra Celline multi-compartment bioreactor. Exosomes and microvesicles of the invention may contain at least a proportion of the proteins identified in Tables 20 and 22, respectively. Typically, an exosome of the invention comprises the first ten proteins listed in Table 20, more typically the first 20, the first 30, the first 40 or the first 50 proteins listed in Table 20. Similarly, a microparticle of the invention typically comprises the first ten proteins listed in Table 22, more typically the first 20, the first 30, the first 40 or the first 50 proteins listed in Table 22. In one embodiment, an exosome of the invention comprises all 100 proteins listed in Table 20. In one embodiment, a microvesicle of the invention comprises all 100 proteins listed in Table 22. Typically, the 100 most abundant proteins in an exosome or microvesicle of the invention contain at least 70 of the proteins identified in Table 20 (exosome) or Table 22 (microparticle). More typically, the 100 most abundant proteins in an exosome or microvesicle of the invention contain at least 80, at least 90, at least 95, 96, 97, 98 or 99, or all 100 of the proteins identified in Table 20 (exosome) or Table 22 (microparticle).

Microparticle miRNA Content

Examples 17A-17C (and the related FIGS. 13A and 13B) shows the results of deep sequencing of miRNA present in CTX0E03 cells (standard culture) and in microvesicles and exosomes produced by these cells. This Example shows that, surprisingly, the number of different miRNA species present in the microparticles is greatly reduced compared to the number of different miRNA species present in the cells; the microparticles contain fewer than 120 different miRNAs whereas the cells contain between 450 and 700 miRNA species. The microparticles contain a majority of hsa-miR-1246.

The data in Example 17 (Tables 5-10) also show that the microparticles are characterised by four main miRNA species, namely hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. These four miRNAs are the only miRNAs present at a read count of greater than 1000 in the microparticles; these four miRNAs are present in massive excess compared to the other miRNAs in the microparticles. This is in contrast to the profile in the cells, which contain a much greater number of miRNAs present at high (read count greater than 1000) or very high (read count greater than 10,000) levels. Although not bound by theory, the inventors propose that hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 are selectively trafficked (or otherwise incorporated) into the microparticles and are thought to play a role in the function of the microparticles. A composition may comprise two, three or all four of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. This composition is optionally a pharmaceutical composition, comprising a pharmaceutically-acceptable carrier, diluent, vehicle and/or excipient. The pharmaceutical composition is suitable for use in therapy, typically in the same therapies as the microparticles of the invention, as noted above.

Exosomes and microvesicles of the invention may contain at least a proportion of the miRNA species identified in Tables 7-10. In one embodiment, exosomes of the invention comprise at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% of the miRNAs listed in Tables 8 and 10. Similarly, microvesicles of the invention typically comprise at least 70% at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% of the miRNAs listed in Tables 7 and 9. In a further embodiment, the total miRNA profile of a microvesicle or exosome of the invention is least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 99.5% identical to the total miRNA profile provided in Tables 8 and 10 (exosome) or Tables 7 and 9 (microvesicle). When determining the total miRNA profile of a microparticle or exosome, deep sequencing is typically used, for example the method described in Example 17.

Typically, in one embodiment microparticles, e.g. exosomes, of the invention contain one, two, three or all four of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. Each of these miRNA markers is typically present at a read count (optionally determined using the deep sequence technique described in Example 17) of at least 1000 per microparticle. hsa-miR-1246 may optionally have a read count of at least 2000, 5000, 10,000, 20,000, or 25,000 per microparticle. Hsa-miR-4492 may optionally have a read count of at least 2000, 3000, 4000 or 5000 per microparticle. Hsa-miR-4532 may optionally have a read count of at least 2000 or 3000 per microparticle.

In one embodiment, each of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and/or hsa-miR-4532 is present in the microparticle, e.g. exosome, at a higher read count than is present in the cell that produced the microparticle. In particular, miR-1246 typically has a read count in the microparticle at least twice the read count in the cell, more typically at least 4, 5, 6, 7, or 8 times the read count in the cell, and optionally 10, 15 or 20 times the read count in the cell.

In one embodiment, microparticles of the invention contain hsa-let-7a-5p, has-miR-92b-3p, hsa-miR-21-5p, hsa-miR-92a-3p, hsa-miR-10a-5p, hsa-100-5p and/or hsa-99b-5p at a lower read count than is present in the cell that produced the microparticle. Typically, each of these miRNAs has a read count of less than 1000 in the microparticles of the invention, more typically less than 100, for example less than 50. Optionally, microparticles of the invention contain hsa-let-7a-5p at a read count of less than 50 or less than 25.

In one embodiment, microparticles of the invention contain fewer than 150 types of miRNA (i.e. different miRNA species) when analysed by deep sequencing, typically fewer than 120 types of miRNA.

In one embodiment, hsa-miR-1246 is the most abundant miRNA in the microparticles of the invention (optionally determined using the deep sequence technique described in Example 17). Typically, at least 40% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-1246. Typically, at least 50% of the total count of miRNA in exosomes of the invention is hsa-miR-1246.

hsa-miR-4492 is typically the second-most abundant miRNA in the microparticles of the invention. Typically, at least 3% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-4492. More typically, at least 4% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-4492.

Typically, at least 2% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-4532.

Typically, at least 1% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-4488.

In one embodiment microparticles of the invention contain one or both of hsa-miR-4508, hsa-miR-4516 at a level at least 0.1% of the total miRNA content of the particle.

One or more of hsa-miR-3676-5p, hsa-miR-4485, hsa-miR-4497, hsa-miR-21-5p, hsa-miR-3195, hsa-miR-3648, hsa-miR-663b, hsa-miR-3656, hsa-miR-3687, hsa-miR-4466, hsa-miR-4792, hsa-miR-99b-5p and hsa-miR-1973 may be present in the microparticles of the invention.

Typically, each of hsa-let-7a-5p and hsa-100-5p is present at less than 1%, more typically less than 0.1% or less than 0.05% of the total miRNA count in microparticles of the invention.

In a typical exosome of the invention, at least 50% of the total count of miRNA is hsa-miR-1246, and less than 0.1% of the total miRNA count is hsa-let-7a-5p.

In one embodiment, at least 90% of the total count of miRNA in microparticles of the invention comprises hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. Typically, at least 95% or 96% of the total count of miRNA in microparticles of the invention comprises hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. Less than 10% of the total miRNA content of these microparticles is an miRNA that is not hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532.

Combinations of the miRNA embodiments discussed above are provided. For example, a microparticle of the invention typically contains each of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 at a read count of at least 1000 and contains each of hsa-let-7a-5p, hsa-miR-92b-3p, hsa-miR-21-5p, hsa-miR-92a-3p, hsa-miR-10a-5p, hsa-100-5p and hsa-99b-5p at a read count of less than 100. Typically, at least 90% or at least 95% of the total miRNA in these microparticles is hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532.

A microparticle (e.g. microvesicle or exosome) of the invention typically has hsa-miR-1246 as the most abundant miRNA and hsa-miR-4492 is the second-most abundant miRNA. In this embodiment, at least 40% of the total count of miRNA in microparticles (e.g. microvesicles and exosomes) of the invention is hsa-miR-1246 and at least 3% of the total count of miRNA in the microparticle is hsa-miR-4492. At least 2% of the total count of miRNA in these microparticles is hsa-miR-4532 and at least 1% of the total count of miRNA in these microparticles is hsa-miR-4488. Each of hsa-let-7a-5p and hsa-100-5p is present at less than 0.1% of the total miRNA count in these microparticles.

Plotting the deep sequencing results in the exosomes and microvesicles as relative fold change compared to the cells confirms that hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 are significantly upregulated in the exosomes and microvesicles compared to the cells. This comparison also shows that miRNA hsa-miR-3195 is the miRNA that is most upregulated, in both exosomes and microvesicles. Although the absolute reads of hsa-miR-3195 are in the range of ˜40 for exosomes and microvesicles, there is no hsa-miR-3195 detected in the cells. Accordingly, hsa-miR-3195 is uniquely found in the exosomes and microvesicles and, optionally, in one embodiment, an exosome or microvesicle of the invention comprises hsa-miR-3195.

In one embodiment, microparticles of the invention comprise one or more of the following miRNA precursors:

AC079949.1 (SEQ ID NO: 738) GGCCGCGCCCCGTTTCCCAGGACAAAGGGCACTCCGCACCGGACCC TGGTCCCAGCG; AP000318.1 (SEQ ID NO: 739) CCCACTCCCTGGCGCCGCTTGTGGAGGGCCCAAGTCCTTCTGATTG AGGCCCAACCCGTGGAAG; AL161626.1 (SEQ ID NO: 740) CGCCGGGACCGGGGTCCGGGGCGGAGTGCCCTTCCTCCTGGGAAAC GGGGTGCGGC; AC004943.1 (SEQ ID NO: 741) GCTTCACGTCCCCACCGGCGGCGGCGGCGGTGGCAGTGGCGGCGGC GGCGGCGGTGGCGGCGGCGGCGGCGGCGGCGGCTC; and AL121897.1 (SEQ ID NO: 742) GCCGCCCCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCC GCTTTCGGCTCGGGCCTCAGGTGAGTCGGAGGGGCCGGGCGCC

In one embodiment, microparticles of the invention comprise one, two or three of the following mature miRNAs derived from the precursors listed above (as detailed in part D of Example 17):

(derived from AL161626.1-201) (SEQ ID NO: 743) ggcggagugcccuucuuccugg (derived from AP000318.1-201) (SEQ ID NO: 744) ggagggcccaaguccuucugau (derived from AC079949.1-201) (SEQ ID NO: 745) gaccaggguccggugcggagug

Accordingly, in one aspect, the invention provides a composition comprising one or more of the miRNA precursors AC079949.1, AP000318.1, AL161626.1, AC004943.1 and AL121897.1 in combination with a neural stem cell microparticle of the invention. In another embodiment, the invention provides a composition comprising one or more of the mature miRNAs ggcggagugcccuucuuccugg (derived from AL161626.1-201), ggagggcccaaguccuucugau (derived from AP000318.1-201) and gaccaggguccggugcggagug (derived from AC079949.1-201) in combination with a neural stem cell microparticle of the invention. Optionally, the composition is a pharmaceutical composition comprising one or more of the miRNA precursors and/or one or more of the mature miRNAs and a pharmaceutically-acceptable carrier or diluent in combination with a neural stem cell microparticle of the invention.

Example 17 shows that neural stem cell microparticles isolated from CTX0E03 cells comprise a variety of non-coding RNA species. It is expected that microparticles isolated from CTX0E03 cells cultured for at least 10 weeks, e.g. for about 11 weeks, in an Integra Celline multicompartment bioreactor will contain at least a proportion of those non-coding RNA species. Thus, in one embodiment, microparticles of the invention comprise one or more of ribosomal RNA, small nucleolar RNA, small nuclear RNA, microRNA, large intergenic non coding RNA and miscellaneous other RNA (e.g. RMRP, vault RNA, metazoan SRP and/or RNY).

Example 12 shows miRNAs present in microparticles produced by the CTX0E03 cells and having a Cp below 35 as determined by a qRT-PCR array. Microparticles isolated from CTX0E03 cells cultured for at least 10 weeks, e.g. for about 11 weeks, in an Integra Celline multi-compartment bioreactor may, in one embodiment contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60 or more, or all, of the following miRNAs (identified according by name according to Ambros et al and accessible at www.mirbase.org):

hsa-let-7a hsa-let-7b hsa-let-7c hsa-let-7d hsa-let-7e hsa-let-7f hsa-let-7g hsa-let-7i hsa-miR-100 hsa-miR-101 hsa-miR-103a hsa-miR-106b hsa-miR-10a hsa-miR-10b hsa-miR-124 hsa-miR-125a-5p hsa-miR-125b hsa-miR-126 hsa-miR-127-5p hsa-miR-128 hsa-miR-129-5p hsa-miR-130a hsa-miR-132 hsa-miR-134 hsa-miR-137 hsa-miR-141 hsa-miR-146b-5p hsa-miR-150 hsa-miR-155 hsa-miR-15a hsa-miR-15b hsa-miR-16 hsa-miR-17 hsa-miR-181a hsa-miR-182 hsa-miR-183 hsa-miR-185 hsa-miR-18a hsa-miR-18b hsa-miR-192 hsa-miR-194 hsa-miR-195 hsa-miR-196a hsa-miR-205 hsa-miR-20a hsa-miR-20b hsa-miR-21 hsa-miR-210 hsa-miR-214 hsa-miR-218 hsa-miR-219-5p hsa-miR-22 hsa-miR-222 hsa-miR-23b hsa-miR-24 hsa-miR-26a hsa-miR-301a hsa-miR-302a hsa-miR-302c hsa-miR-33a hsa-miR-345 hsa-miR-375 hsa-miR-378 hsa-miR-424 hsa-miR-7 hsa-miR-9 hsa-miR-92a hsa-miR-93 hsa-miR-96 hsa-miR-99a

In one embodiment, the CTX0E03 microparticles contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more of the following miRNAs (which are selected from the list above):

hsa-let-7g hsa-miR-101 hsa-miR-10a hsa-miR-10b hsa-miR-126 hsa-miR-128 hsa-miR-129-5p hsa-miR-130a hsa-miR-134 hsa-miR-137 hsa-miR-155 hsa-miR-15a hsa-miR-15b hsa-miR-16 hsa-miR-17 hsa-miR-182 hsa-miR-183 hsa-miR-185 hsa-miR-18b hsa-miR-192 hsa-miR-194 hsa-miR-195 hsa-miR-20a hsa-miR-20b hsa-miR-210 hsa-miR-218 hsa-miR-301a hsa-miR-302a hsa-miR-302c hsa-miR-345 hsa-miR-375 hsa-miR-378 hsa-miR-7 hsa-miR-9 hsa-miR-93 hsa-miR-96 hsa-miR-99a miRNAs Present in Exosomes from Cells Cultured in a Bioreactor for Longer Periods

Examples 17D and 17E (in particular FIGS. 13D to 13H and Tables E2 to E4) demonstrate that hsa-miR-1246, hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are still present in exosomes isolated from CTX0E03 cells that have been cultured in a bioreactor for six weeks. hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are shown to be almost absent in exosomes isolated from CTX0E03 cells that have been cultured in a bioreactor for eleven weeks.

Exosomes and microvesicles of the invention may contain at least a proportion of the miRNA species identified in Table E3, or at least a proportion of the miRNA species identified in Table E4.

Hsa-miR-181a-5p, hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p, and hsa-miR-100-5p are shown to be the top 5 miRNAs present in the EXO 6W sample. Accordingly, in one embodiment, exosomes of the invention comprise 1, 2, 3, 4 or 5 of these miRNAs. In another embodiment, exosomes of the invention comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or all of the miRNAs listed in Table E3. When determining the total miRNA profile of a microparticle or exosome, deep sequencing is typically used, for example the method described in Example 17.

Hsa-miR-181a-5p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-92b-3p, and hsa-miR-9-5p are shown to be the top 5 miRNAs present in EXO 11W samples. Accordingly, in one embodiment, exosomes of the invention comprise 1, 2, 3, 4 or 5 of these miRNAs. In another embodiment, exosomes of the invention comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or all of the miRNAs listed in Table E4. When determining the total miRNA profile of a microparticle or exosome, deep sequencing is typically used, for example the method described in Example 17.

Hsa-miR-486-5p is observed to be shuttled into all three of the samples of exosomes obtained from CTX0E03 cells that have been cultured in a bioreactor for six weeks. Accordingly, in one embodiment, exosomes of the invention comprise hsa-miR-486-5p.

Individual miRNAs are Able to Reduce Cell Proliferation and have Therapeutic Utility

The data in the Example 20 and FIGS. 23A, 23B, and 23C show that each of the four main miRNA species identified in neural stem cell microparticles, namely hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532, significantly reduced cell proliferation in glioma proliferation assays. In addition to these data supporting the therapeutic efficacy of the microparticles that contain these miRNAs, these data also show that each of these individual miRNAs is therapeutically useful on its own. In one embodiment, the individual miRNA is useful in the treatment of cancer (optionally glioblastoma), as described below.

In one embodiment, hsa-miR-1246 is provided for use in therapy. In another embodiment, hsa-miR-4492 is provided for use in therapy. In a further embodiment, hsa-miR-4488 is provided for use in therapy. In another embodiment, has miR 4532 is provided for use in therapy. These therapeutics can be provided in a composition that does not comprise any of the other four “main” miRNA species.

For example, in one embodiment when hsa-miR-1246 is provided for therapy, none of hsa-miR-4492, hsa-miR-4488 or hsa-miR-4532 are part of the therapy. This therapy comprises hsa-miR-1246 and does not comprise any of hsa-miR-4492, hsa-miR-4488 or hsa-miR-4532.

In one embodiment, when hsa-miR-4492 is provided for therapy, none of hsa-miR-1246, hsa-miR-4488 or hsa-miR-4532 are part of the therapy. This therapy comprises hsa-miR-4492 and does not comprise any of hsa-miR-1246, hsa-miR-4488 or hsa-miR-4532.

In one embodiment, when hsa-miR-4488 is provided for therapy, none of hsa-miR-1246, hsa-miR-4492 or hsa-miR-4532 are part of the therapy. This therapy comprises hsa-miR-4488 and does not comprise any of hsa-miR-1246, hsa-miR-4492 or hsa-miR-4532.

In one embodiment, when hsa-miR-4532 is provided for therapy, none of hsa-miR-1246, hsa-miR-4492 or hsa-miR-4488 are part of the therapy. This therapy comprises hsa-miR-4532 and does not comprise any of hsa-miR-1246, hsa-miR-4492 or hsa-miR-4488.

The invention therefore provides, in one aspect, a composition that comprises only one of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. In this aspect, the composition does not comprise two or more, e.g. two, three or four of these miRNAs.

Typically, the composition does not comprise other miRNA, i.e. the composition comprises miRNA that consists of one miRNA species selected from hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. The composition is typically a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent, vehicle or excipient, as described in detail below. The miRNAs of this aspect of the invention are typically isolated, i.e. not comprised within a microparticle. In one embodiment, the composition consists of, or consists essentially of, the single miRNA species and one or more pharmaceutically acceptable carrier, diluent, vehicle or excipient.

miRNA Compositions and Combinations

In a separate aspect of the invention, the identification of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 as the four main miRNA species in neural stem cell microparticles, provides for compositions that comprise two or more, e.g. two, three or four of these miRNAs. Any combination of these miRNAs may be provided. In one embodiment, the composition may comprise hsa-miR-1246 and one or more of hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. Typically, the composition does not comprise other miRNA, i.e. the composition comprises miRNA that consists of two or more of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. The composition is typically a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent, vehicle or excipient, as described in detail below. The miRNAs of this aspect of the invention are typically isolated, i.e. not comprised within a microparticle. In one embodiment, the composition consists of, or consists essentially of, the 2, 3 or 4 miRNA species and one or more pharmaceutically acceptable carrier, diluent, vehicle or excipient.

hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 are shown in the Examples to reduce cell proliferation in glioma proliferation assays. Accordingly, the miRNA composition comprising two or more of these miRNAs is useful in therapy. In one embodiment, the miRNA composition comprising two or more of these miRNAs is useful in the treatment of cancer (optionally glioblastoma), as described below.

Hsa-miR-181a-5p, hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p, and hsa-miR-100-5p are shown to be the top 5 miRNAs present in the EXO 6W sample. Accordingly, one embodiment provides for compositions that comprise 1, 2, 3, 4 or 5 of these miRNAs. Any one, or any combination of these miRNAs may be provided. The composition is typically a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent, vehicle or excipient, as described in detail below. The miRNAs of this aspect of the invention are typically isolated, i.e. not comprised within a microparticle. In one embodiment, the composition consists of, or consists essentially of, the 1, 2, 3, 4 or 5 miRNA species and one or more pharmaceutically acceptable carrier, diluent, vehicle or excipient. These miRNAs and compositions are provided, in one embodiment, for use in therapy, typically the therapy of cancer (optionally glioblastoma), as described herein.

Hsa-miR-181a-5p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-92b-3p, and hsa-miR-9-5p are shown to be the top 5 miRNAs present in EXO 11W samples. Accordingly, one embodiment provides for a composition that comprises 1, 2, 3, 4 or 5 of these miRNAs. Any one, or any combination of these miRNAs may be provided. The composition is typically a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent, vehicle or excipient, as described in detail below. The miRNAs of this aspect of the invention are typically isolated, i.e. not comprised within a microparticle. In one embodiment, the composition consists of, or consists essentially of, the 1, 2, 3, 4 or 5 miRNA species and one or more pharmaceutically acceptable carrier, diluent, vehicle or excipient. These miRNAs and compositions are provided, in one embodiment, for use in therapy, typically the therapy of cancer (optionally glioblastoma), as described herein.

Hsa-miR-486-5p is observed to be shuttled into all three of the samples of exosomes obtained from CTX0E03 cells that have been cultured in a bioreactor for 11 weeks. Accordingly, one embodiment provides for compositions that comprise hsa-miR-486-5p. The composition is typically a pharmaceutical composition and comprises a pharmaceutically acceptable carrier, diluent, vehicle or excipient, as described in detail below. The miRNA of this aspect of the invention are typically isolated, i.e. not comprised within a microparticle. This miRNA and composition are provided, in one embodiment, for use in therapy, typically the therapy of cancer (optionally glioblastoma), as described herein.

Proteins Detected by a Dot-Blot

Example 13 shows proteins present in microparticles produced by the CTX0E03 cells, as detected by a dot-blot. Microparticles of the invention may typically contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all of the following proteins:

EDA-A2 Galectin-3 IGFBP-2 IGFBP-rp1/IGFBP-7 IL-1a LECT2 MCP-1 SPARC TIMP-1 Thrombospondin-1 VEGF

Galectin-3 and Thrombospondin-1 are also identified as present in exosomes and microvesicles in Example 18. TIMP-1 is identified in Example 18 as being present in exosomes. Microparticles of the invention may contain one or more of Galectin-3, Thrombospondin and TIMP-1.

Example 13 also shows that the microparticles produced by the CTX0E03 cells may also express 1, 2, 3, 4 or 5 of the following proteins:

EGF-R/ErbB1 MDC Endostatin Follistatin Csk

EGF-R and Csk are also identified as present in exosomes and microvesicles in Example 18.

Neural Stem Cells in Multi-Compartment Bioreactor Culture

As shown in Example 15 and FIG. 11 below, after multi-compartment bioreactor culture for three weeks, neural stem cells express a number of markers at significantly higher levels than neural stem cells cultured according to standard procedure in a standard single-compartment T175 flask. Neural stem cells cultured for even longer periods, e.g. at least 10 weeks, may also express a number of these markers at significantly higher levels than neural stem cells cultured according to standard procedure in a standard single-compartment T175 flask or neural stem cells cultured in a multi-compartment bioreactor culture for three weeks. In one embodiment, microparticles of the invention are isolated from NSCs that have been cultured, typically in a multi-compartment bioreactor, for at least 10 weeks, typically at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks or at least 15 weeks. Optionally, the NSCs have been cultured for no more than 20 weeks, e.g. between 10 and 20 weeks, between 11 and 20 weeks, between 12 and 20 weeks, between 13 and 20 weeks, between 14 and 20 weeks or between 15 and 20 weeks.

CTX0E03 neural stem cells cultured for three weeks in a multi-compartment bioreactor express DCX, GALC, GFAP, TUBB3, GDNF and IDO at a higher level than neural stem cells cultured in a standard single-compartment T175 cell culture. Neural stem cells cultured for even longer periods, e.g. at least 10 weeks, may also express a number of these markers at significantly higher levels than neural stem cells cultured according to standard procedure in a standard single-compartment T175 flask or, optionally, than neural stem cells cultured in a multi-compartment bioreactor culture for three weeks. Accordingly neural stem cells that produce microparticles of the invention may express one or more of DCX, GALC, GFAP, TUBB3, GDNF and IDO. Cells cultured in a two-compartment bioreactor typically show increased expression of one or more of DCX, GALC, GFAP, TUBB3, GDNF and IDO compared to the stem cells cultured under standard conditions for three weeks. The expression level of these markers in the multi-compartment bioreactor-cultured cells is typically significantly higher than in the cells cultured in a standard single-compartment T175 culture flask. Typically, a stem cell cultured in a multi-compartment bioreactor, that produces microparticles of the invention, expresses one or more of DCX1, GALC, GFAP, TUBB3, GDNF or IDO at a level least 2 fold higher than in CTX0E03 cells cultured in a T-175 flask according to standard culture procedure.

In one embodiment, microparticles, typically exosomes, are obtained from neural stem cells that show increased expression of one or more of DCX, GALC, GFAP, TUBB3, GDNF and IDO compared to the stem cells cultured under standard conditions or, optionally than in a multi-compartment bioreactor culture for three weeks. For example, microparticles can be obtained from freshly filtered conditioned medium collected from Integra CeLLine bioreactor cultured neural stem cells.

The upregulated markers include DCX (doublecortin—an early neuronal marker), GFAP (Glial fibrillary acidic protein—an astrocyte marker), GALC, TUBB3, GDNF and IDO. CTX0E03 cells are able to differentiate into 3 different cell types: neurons, astrocytes and oligodendrocytes. The high levels of DCX and GFAP after only three weeks in a multi-compartment bioreactor indicates that the cultured stem cells have partially differentiated and have entered the neuronal (DCX+ cells) and/or astrocytic (GFAP+ cells) lineage. Accordingly, in one embodiment the invention provides a microparticle that inhibits cell migration, produced by a neural stem cell population that expresses (i) one or more markers associated with a neuronal lineage, typically DCX and/or (ii) one or more markers associated with an astrocytic lineage, typically GFAP. These cells may optionally have been cultured for at least 10 weeks in a multi-compartment bioreactor. In another embodiment, the invention provides neural stem cell microparticles, typically exosomes, that express (i) one or more markers associated with a neuronal lineage, typically DCX and/or (ii) one or more markers associated with an astrocytic lineage, typically GFAP. These cells, or the microparticles (typically exosomes) derived from these cells, express DCX and/or GFAP at a higher level than the corresponding stem cells in standard (T-175) culture or, optionally, than the cells cultured in a multi-compartment bioreactor for three weeks. Typically, these cells or microparticles express DCX and/or GFAP at a level at least 2 fold more than the stem cells in standard culture, more typically at least 2.5 fold more than the corresponding stem cells in standard culture (or cultured in a multi-compartment bioreactor culture for three weeks), at least 5 fold more than the corresponding stem cells in standard culture (or cultured in a multi-compartment bioreactor culture for three weeks), at least 7.5 fold more than the corresponding stem cells in standard culture (or cultured in a multi-compartment bioreactor culture for three weeks) or at least 10 fold more than the corresponding stem cells in standard culture (or cultured in a multi-compartment bioreactor culture for three weeks). For expression of DCX, the fold change in the cells or microparticles compared to the corresponding stem cells in standard (T-175) culture (or cultured in a multi-compartment bioreactor culture for three weeks) can optionally be at least 20 fold, at least 50 fold, at least 100 fold, at least 500 fold or at least 1000 fold more than the standard stem cells (or cells cultured in a multi-compartment bioreactor culture for three weeks).

The term “bioreactor” is to be given its usual meaning in the art, i.e. an apparatus used to carry out a bioprocess. The bioreactors described herein are suitable for use in stem cell culture. Simple bioreactors for cell culture are single compartment flasks, such as the commonly-used T-175 flask (e.g. the BD FALCON™ 175 cm² Cell Culture Flask, 750 ml, tissue-culture treated polystyrene, straight neck, blue plug-seal screw cap, BD product code 353028).

Bioreactors can have multiple compartments, as is known in the art. These multi-compartment bioreactors typically contain at least two compartments separated by one or more membranes or barriers that separate the compartment containing the cells from one or more compartments containing gas and/or culture medium. Multi-compartment bioreactors are well-known in the art. An example of a multi-compartment bioreactor is the Integra CeLLine bioreactor, which contains a medium compartment and a cell compartment separated by means of a 10 kDa semi-permeable membrane; this membrane allows a continuous diffusion of nutrients into the cell compartment with a concurrent removal of any inhibitory waste product. The individual accessibility of the compartments allows to supply cells with fresh medium without mechanically interfering with the culture. A silicone membrane forms the cell compartment base and provides an optimal oxygen supply and control of carbon dioxide levels by providing a short diffusion pathway to the cell compartment. Any multi-compartment bioreactor may be used according to the invention. As shown in the Examples below, CTX0E03 cells that have been cultured in the Integra CeLLine AD1000 bioreactor for 11 weeks produce microparticles that are able to inhibit cell migration.

Example 16, Table 4 and FIG. 12 show that the miRNA content of exosomes produced by neural stem cells that have been cultured in a multi-compartment bioreactor, for three weeks, is different from the miRNA content of stem cells cultured in standard T-175 flasks and from microparticles produced by the neural stem cells cultured in a single-compartment T175 culture flask for three weeks. The miRNA content of exosomes of the invention may also differ from the miRNA content of stem cells cultured in standard T-175 or microparticles derived therefrom. In one embodiment, the invention provides a microparticle, typically an exosome, wherein at least two, three, four, five, six or seven miRNAs are up or down regulated compared to in the corresponding stem cells cultured in standard T-175 flasks, as calculated by Fold Regulation (see Example 16), and wherein the microparticle inhibits cell migration. The Fold Regulation of each miRNA is optionally at least two-fold up or down.

In one embodiment, neural stem cell exosomes of the invention express one, two, three, four, five, six or seven of the following miRNAs at a higher level than is expressed in the corresponding stem cells cultured in standard T-175 flasks, as calculated by Fold Regulation (where an asterisk indicates an miRNA where at least a two-fold regulation increase is preferred):

hsa-miR-146b-5p* hsa-let-7c* hsa-miR-99a* hsa-miR-132* hsa-miR-378* hsa-miR-181a* hsa-let-7b*

In one embodiment, neural stem cell exosomes of the invention express one, two, three, four, five, six, seven, eight, nine, ten or more of the following miRNAs at a lower level than is expressed in the corresponding stem cells cultured in standard T-175 flasks, as calculated by Fold Regulation (where an asterisk indicates an miRNA where at least a two-fold regulation decrease is preferred):

hsa-miR-7* hsa-miR-106b* hsa-miR-101* hsa-miR-302a* hsa-miR-301a* hsa-miR-183* hsa-miR-219-5p* hsa-miR-18a* hsa-miR-15a* hsa-miR-182* hsa-miR-33a* hsa-miR-96* hsa-miR-18b*

In a further embodiment, NSC exosomes of the invention comprise (i) an increased level of at least one, two, three, four, five, six or seven of the miRNAs indicated above as being increased in exosomes compared to the corresponding cells in standard culture and (ii) a decreased level of at least one, two, three, four, five, six, seven, eight, nine, ten or more or more of the miRNAs indicated above as being decreased in exosomes compared to the corresponding cells in standard culture. For example, a neural stem cell exosome may contain a fold-regulation increase in three or more or more of the miRNAs indicated above as being increased in exosomes compared to the corresponding cells in standard culture and a fold-regulation decrease in three or more of the miRNAs indicated above as being decreased in exosomes compared to the corresponding cells in standard culture. In another exemplary embodiment, a neural stem cell exosome may contain a fold-regulation increase in five or more of the miRNAs indicated above as being increased in exosomes compared to the corresponding cells in standard culture and a fold-regulation decrease in five or more of the miRNAs indicated above as being decreased in exosomes compared to the corresponding cells in standard culture.

The term “expressed” is used to describe the presence of a marker within a cell or microparticle. In order to be considered as being expressed, a marker must be present at a detectable level. By “detectable level” is meant that the marker can be detected using one of the standard laboratory methodologies such as qRT-PCR, or qPCR, blotting, Mass Spectrometry or FACS analysis. A gene is considered to be expressed by a cell or microparticle of the population of the invention if expression can be reasonably detected at a crossing point (cp) values below or equal 35. The terms “express” and “expression” have corresponding meanings. At an expression level below this cp value, a marker is considered not to be expressed. The comparison between the expression level of a marker in a stem cell or microparticle of the invention, and the expression level of the same marker in another cell or microparticle, such as for example an mesenchymal stem cell, may preferably be conducted by comparing the two cell/microparticle types that have been isolated from the same species. Preferably this species is a mammal, and more preferably this species is human. Such comparison may conveniently be conducted using a reverse transcriptase polymerase chain reaction (RT-PCR) experiment.

As used herein, the term “significant expression” or its equivalent terms “positive” and “+” when used in regard to a marker shall be taken to mean that, in a cell or microparticle population, more than 20%, preferably more than, 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 98%, 99% or even all of the cells of the cells/microparticles express said marker.

As used herein, “negative” or “−” as used with respect to markers shall be taken to mean that, in a cell or microparticle population, less than 20%, 10%, preferably less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or none of the cells/microparticles express said marker.

Expression of microparticle surface markers may be determined, for example, by means of flow cytometry and/or FACS for a specific cell surface marker using conventional methods and apparatus (for example a Beckman Coulter Epics XL FACS system used with commercially available antibodies and standard protocols known in the art) to determine whether the signal for a specific microparticle surface marker is greater than a background signal. The background signal is defined as the signal intensity generated by a non-specific antibody of the same isotype as the specific antibody used to detect each surface marker. For a marker to be considered positive the specific signal observed is typically more than 20%, preferably stronger than 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 500%, 1000%, 5000%, 10000% or above, greater relative to the background signal intensity. Alternative methods for analysing expression of microparticle surface markers of interest include visual analysis by electron microscopy using antibodies against cell-surface markers of interest.

“Fluorescence activated cell sorting (FACS)” is a method of cell purification based on the use of fluorescent labelled antibodies. The antibodies are directed to a marker on the cell surface, and therefore bind to the cells of interest. The cells are then separated based upon the fluorescent emission peak of the cells.

Microparticle markers (including surface and intracellular proteins) can also be analysed by various methods known to one skilled in the art to assay protein expression, including but not limited to gel electrophoresis followed by western blotting with suitable antibodies, immunoprecipitation followed by electrophoretic analysis, and/or electron microscopy as described above, with microparticle permeabilisation for intraparticle markers. For example, expression of one or more tetraspanins may be assayed using one or more of the above methods or any other method known to one skilled in the art. RNA levels may also be analysed to assess marker expression, for example qRT-PCR.

Microparticle Function

As noted above, a neural stem cell microparticle typically retains at least one biological function of the stem cell from which it is derived. Biological functions that may be retained include the ability to: inhibit cell migration, for example of fibroblast or fibroblast-like cells, or of tumour cells such as glioblastoma cells; inhibit wound healing, for example in a scratch assay; or treat a disease or condition that involves or is characterised by undesirable or excessive cell migration, such as cancer, fibrosis, atherosclerosis or rheumatoid arthritis.

In one embodiment, the at least one biological activity is that of a neural stem cell that has been cultured, typically in a multi-compartment bioreactor, for at least 10 weeks and optionally no more than 20 weeks. Alternatively the at least one biological activity may be that of a neural stem cell-conditioned medium from a neural stem cell that has been cultured, typically in a multi-compartment bioreactor, for at least 10 weeks and optionally no more than 20 weeks. FIGS. 1 and 2 (Example 1) demonstrate that exosomes isolated from the conditioned medium of CTX0E03 cells that have been cultured in a CeLLine bioreactor for 11 weeks have the ability to inhibit fibroblast migration in a transmembrane assay model of cell migration. Accordingly, one biological function that microparticles of the invention may retain is the ability to inhibit migration of fibroblast or fibroblast-like cells, for example of normal human dermal fibroblasts (NHDF).

Example 2, Table 2 and FIG. 3 demonstrate that CTX0E03 stem cell exosomes, obtained from cells cultured for 2 weeks and 6 weeks, retain the ability to close a wound in a “scratch” model of wound healing. The results show that the migration activity of normal human dermal fibroblasts (NHDF) cultured in CTX0E03 conditioned media is almost the same as the migration activity observed on the addition of purified exosomes. In contrast, microparticles of the invention are able to inhibit cell migration. Accordingly, one biological function that microparticles of the invention may retain is the ability to inhibit migration activity of normal human dermal fibroblasts (NHDF). NHDF migration assays are known in the art. Stimulation of NHDF migration may be determined using an in vitro scratch (wound closure) assay, for example the assay of Example 2. Wound closure is calculated as the area covered by NHDF cells in relation to the initial wound area as determined at 0 hours. Inhibition of NHDF migration in this assay is typically defined as a decrease in wound closure, as defined above.

CTX0E03 cells are known to inhibit T cell activation in a PBMC assay and, in one embodiment, the microparticles of the invention retain this ability to inhibit T cell activation in a PBMC assay. PBMC assays are well-known to the skilled person and kits for performing the assay are commercially available.

The proteomic analysis in Example 18 indicates that neural stem cell exosomes comprise biological functions associated with the production, packaging, function and degradation of genetic material. Accordingly, in one embodiment, exosomes of the invention retain these functions, typically one or more of RNA polymerase function, RNA degradation function, ribosome function and spliceosome function.

Immunogenicity

The (allogeneic) neural stem cell microparticles of the invention typically either do not trigger an immune response in vitro or in vivo or trigger an immune response which is substantially weaker than that which would be expected to be triggered upon injection of an allogeneic stem cell population into a patient. In certain aspects of the invention, the neural stem cell microparticles are considered not to trigger an immune response if at least about 70% of the microparticles do not trigger an immune response. In some embodiments, at least about 80%, at least about 90% or at least about 95%, 99% or more of the microparticles do not trigger an immune response. Preferably the microparticles of the invention do not trigger an antibody mediated immune response or do not trigger a humoral immune response. More preferably the microparticles of the invention do not trigger either an antibody mediated response or a humoral immune response in vitro. More preferably still, the microparticles of the invention do not trigger a mixed lymphocyte immune response. It will be understood by one skilled in the art that the ability of the cells of the invention to trigger an immune response can be tested in a variety of ways.

CTX0E03 cells transplanted in a rodent model of limb ischemia have been previously demonstrated a faster and transient up-regulation of host genes involved in angiogenesis, such as CCL11, CCL2, CXCL1, CXCL5, IGF1, IL1β, IL6, HGF, HIF 1□, bFGF, VEGFA, and VEGFC, compared to vehicle treated controls. hNSC treatment transiently elevates host innate immune and angiogenic responses and accelerates tissue regeneration.

The CTX0E03 cell line has been previously demonstrated, using a human PBMC assay, not to be immunogenic. Accordingly, microparticles produced by CTX0E03 cells are also expected to be non-immunogenic. The lack of immunogenicity allows the microparticles to avoid clearance by the host/patient immune system and thereby exert their therapeutic effect without a deleterious immune and inflammatory response.

Neural Stem Cells

The neural stem cell that produces the microparticle may be a stem cell line, i.e. a culture of stably dividing stem cells. A stem cell line can to be grown in large quantities using a single, defined source. Immortalisation may arise from a spontaneous event or may be achieved by introducing exogenous genetic information into the stem cell which encodes immortalisation factors, resulting in unlimited cell growth of the stem cell under suitable culture conditions. Such exogenous genetic factors may include the gene “myc”, which encodes the transcription factor Myc. The exogenous genetic information may be introduced into the stem cell through a variety of suitable means, such as transfection or transduction. For transduction, a genetically engineered viral vehicle may be used, such as one derived from retroviruses, for example lentivirus.

Additional advantages can be gained by using a conditionally immortalised stem cell line, in which the expression of the immortalisation factor can be regulated without adversely affecting the production of therapeutically effective microparticles. This may be achieved by introducing an immortalisation factor which is inactive unless the cell is supplied with an activating agent. Such an immortalisation factor may be a gene such as c-mycER. The c-MycER gene product is a fusion protein comprising a c-Myc variant fused to the ligand-binding domain of a mutant estrogen receptor. C-MycER only drives cell proliferation in the presence of the synthetic steroid 4-hydroxytamoxifen (4-OHT) (Littlewood et al. 1995). This approach allows for controlled expansion of neural stem cells in vitro, while avoiding undesired in vivo effects on host cell proliferation (e.g. tumour formation) due to the presence of c-Myc or the gene encoding it in microparticles derived from the neural stem cell line. A suitable c-mycER conditionally immortalized neural stem cell is described in U.S. Pat. No. 7,416,888. The use of a conditionally immortalised neural stem cell line therefore provides an improvement over existing stem cell microparticle isolation and production.

Preferred conditionally-immortalised cell lines include the CTX0E03, STR0005 and HPC0A07 neural stem cell lines, which have been deposited at the European Collection of Animal Cultures (ECACC), Vaccine Research and Production laboratories, Public Health Laboratory Services, Porton Down, Salisbury, Wiltshire, SP4 0JG, with Accession No. 04091601 (CTX0E03); Accession No. 04110301 (STR0005); and Accession No. 04092302 (HPC0A07). The derivation and provenance of these cells is described in EP1645626 B1. The advantages of these cells are retained by microparticles produced by these cells.

The cells of the CTX0E03 cell line may be cultured in the following culture conditions:

-   -   Human Serum Albumin 0.03%     -   Transferrin, Human 5 μg/ml     -   Putrescine Dihydrochloride 16.2 μg/ml     -   Insulin Human recombinant 5     -   Progesterone 60 ng/ml     -   L-Glutamine 2 mM     -   Sodium Selenite (selenium) 40 ng/ml

Plus basic Fibroblast Growth Factor (10 ng/ml), epidermal growth factor (20 ng/ml) and 4-hydroxytamoxifen 100 nM for cell expansion. The cells can be differentiated by removal of the 4-hydroxytamoxifen. Typically, the cells can either be cultured at 5% CO₂/37° C. or under hypoxic conditions of 5%, 4%, 3%, 2% or 1% 02. These cell lines do not require serum to be cultured successfully. Serum is required for the successful culture of many cell lines, but contains many contaminants including its own exosomes. A further advantage of the CTX0E03, STR0005 or HPC0A07 neural stem cell lines, or any other cell line that does not require serum, is that the contamination by serum is avoided.

The cells of the CTX0E03 cell line (and microparticles derived from these cells) are multipotent cells originally derived from 12 week human fetal cortex. The isolation, manufacture and protocols for the CTX0E03 cell line is described in detail by Sinden, et al. (U.S. Pat. No. 7,416,888 and EP1645626 B1). The CTX0E03 cells are not “embryonic stem cells”, i.e. they are not pluripotent cells derived from the inner cell mass of a blastocyst; isolation of the original cells did not result in the destruction of an embryo. In growth medium CTX0E03 cells are nestin-positive with a low percentage of GFAP positive cells (i.e. the population is negative for GFAP).

CTX0E03 is a clonal cell line that contains a single copy of the c-mycER transgene that was delivered by retroviral infection and is conditionally regulated by 4-OHT (4-hydroxytamoxifen). The C-mycER transgene expresses a fusion protein that stimulates cell proliferation in the presence of 4-OHT and therefore allows controlled expansion when cultured in the presence of 4-OHT. This cell line is clonal, expands rapidly in culture (doubling time 50-60 hours) and has a normal human karyotype (46 XY). It is genetically stable and can be grown in large numbers. The cells are safe and non-tumorigenic. In the absence of growth factors and 4-OHT, the cells undergo growth arrest and differentiate into neurons and astrocytes. Once implanted into an ischemia-damaged brain, these cells migrate only to areas of tissue damage.

The development of the CTX0E03 cell line has allowed the scale-up of a consistent product for clinical use. Production of cells from banked materials allows for the generation of cells in quantities for commercial application (Hodges et al, 2007).

Pollock et al 2006 describes that transplantation of CTX0E03 in a rat model of stroke (MCAo) caused statistically significant improvements in both sensorimotor function and gross motor asymmetry at 6-12 weeks post-grafting. These data indicate that CTX0E03 has the appropriate biological and manufacturing characteristics necessary for development as a therapeutic cell line.

Stevanato et al 2009 confirms that CTX0E03 cells downregulated c-mycERTAM transgene expression both in vitro following EGF, bFGF and 4-OHT withdrawal and in vivo following implantation in MCAo rat brain. The silencing of the c-mycERTAM transgene in vivo provides an additional safety feature of CTX0E03 cells for potential clinical application.

Smith et al 2012 describe preclinical efficacy testing of CTX0E03 in a rat model of stroke (transient middle cerebral artery occlusion). The results indicate that CTX0E03 implants robustly recover behavioural dysfunction over a 3 month time frame and that this effect is specific to their site of implantation. Lesion topology is potentially an important factor in the recovery, with a stroke confined to the striatum showing a better outcome compared to a larger area of damage.

Neural retinal stem cell lines (for example as described in U.S. Pat. No. 7,514,259) may also be used according to the invention.

The term “culture medium” or “medium” is recognized in the art, and refers generally to any substance or preparation used for the cultivation of living cells. The term “medium”, as used in reference to a cell culture, includes the components of the environment surrounding the cells. Media may be solid, liquid, gaseous or a mixture of phases and materials. Media include liquid growth media as well as liquid media that do not sustain cell growth. Media also include gelatinous media such as agar, agarose, gelatin and collagen matrices. Exemplary gaseous media include the gaseous phase to which cells growing on a petri dish or other solid or semisolid support are exposed. The term “medium” also refers to material that is intended for use in a cell culture, even if it has not yet been contacted with cells. In other words, a nutrient rich liquid prepared for culture is a medium. Similarly, a powder mixture that when mixed with water or other liquid becomes suitable for cell culture may be termed a “powdered medium”. “Defined medium” refers to media that are made of chemically defined (usually purified) components. “Defined media” do not contain poorly characterized biological extracts such as yeast extract and beef broth. “Rich medium” includes media that are designed to support growth of most or all viable forms of a particular species. Rich media often include complex biological extracts. A “medium suitable for growth of a high density culture” is any medium that allows a cell culture to reach an OD600 of 3 or greater when other conditions (such as temperature and oxygen transfer rate) permit such growth. The term “basal medium” refers to a medium which promotes the growth of many types of microorganisms which do not require any special nutrient supplements. Most basal media generally comprise of four basic chemical groups: amino acids, carbohydrates, inorganic salts, and vitamins. A basal medium generally serves as the basis for a more complex medium, to which supplements such as serum, buffers, growth factors, lipids, and the like are added. In one aspect, the growth medium may be a complex medium with the necessary growth factors to support the growth and expansion of the cells of the invention while maintaining their self-renewal capability. Examples of basal media include, but are not limited to, Eagles Basal Medium, Minimum Essential Medium, Dulbecco's Modified Eagle's Medium, Medium 199, Nutrient Mixtures Ham's F-10 and Ham's F-12, McCoy's 5A, Dulbecco's MEM/F-I 2, RPMI 1640, and Iscove's Modified Dulbecco's Medium (IMDM).

Culture Period

In the context of this invention, “culturing” cells for specified periods of time (e.g. at least 10 weeks) refers to a time period wherein day zero or “day 0” is the time point at which the cells are transferred to the culture vessel. The culture vessel may be a flask, for example the standard T-175 cell culture flask. Typically, the culture vessel is a multi-compartment bioreactor such as the Integra CELLine bioreactor, and day zero is the day on which the stem cells are transferred into the bioreactor. Accordingly, cells “that have been cultured for at least 10 weeks” refers to cells that have been cultured for at least 10 weeks following transfer into the culture vessel. In this 10 week period, the cells are not passaged or subcultured, i.e. they are not transferred to a new culture vessel. Optionally, cells can be removed from the culture vessel during the culture period, typically for sampling, but this does not change the cells that remain in the culture vessel, which have been in that culture vessel since day 0.

In one embodiment, as described in Example 10, on day zero approximately 15×10⁶ CTX0E03 cells in a total of 15 ml of complete growth medium are introduced into the cell compartment of the CeLLine bioreactor, followed by the addition of a further 460 ml of complete growth medium to the cell compartment.

Pharmaceutical Compositions

The neural stem cell microparticle of the invention, and the miRNA of the invention, is useful in therapy and can therefore be formulated as a pharmaceutical composition. A pharmaceutically acceptable composition typically includes at least one pharmaceutically acceptable carrier, diluent, vehicle and/or excipient in addition to the microparticles of the invention. An example of a suitable carrier is Ringer's Lactate solution. A thorough discussion of such components is provided in Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The composition, if desired, can also contain minor amounts of pH buffering agents. The carrier may comprise storage media such as HYPOTHERMOSOL®, commercially available from BioLife Solutions Inc., USA. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E W Martin. Such compositions will contain a prophylactically or therapeutically effective amount of a prophylactic or therapeutic microparticle preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject. The formulation should suit the mode of administration. In a preferred embodiment, the pharmaceutical compositions are sterile and in suitable form for administration to a subject, preferably an animal subject, more preferably a mammalian subject, and most preferably a human subject.

The pharmaceutical composition of the invention may be in a variety of forms. These include, for example, semi-solid, and liquid dosage forms, such as lyophilized preparations, liquid solutions or suspensions, injectable and infusible solutions. The pharmaceutical composition is preferably injectable. A particular advantage of the microparticles of the invention is their improved robustness compared to the stem cells from which they are obtained; the microparticles can therefore be subjected to formulation, such as lyophilisation, that would not be suitable for stem cells. This is also an advantage of the miRNA compositions of the invention.

It is preferred that the methods, medicaments and compositions and microparticles of the invention are used for treating cancer, fibrosis, atherosclerosis or rheumatoid arthritis, and/or for the treatment, modulation, prophylaxis, and/or amelioration of one or more symptoms associated with these disorders.

Pharmaceutical compositions will generally be in aqueous form. Compositions may include a preservative and/or an antioxidant.

To control tonicity, the pharmaceutical composition can comprise a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride and calcium chloride.

Compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. Buffers will typically be included at a concentration in the 5-20 mM range. The pH of a composition will generally be between 5 and 8, and more typically between 6 and 8 e.g. between 6.5 and 7.5, or between 7.0 and 7.8.

The composition is preferably sterile. The composition is preferably gluten free. The composition is preferably non pyrogenic.

In a typical embodiment, the microparticles are suspended in a composition comprising 6 hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (TROLOX®), Na⁺, K⁺, Ca²⁺, Mg²⁺, CI⁻, H₂P0₄-, HEPES, lactobionate, sucrose, mannitol, glucose, dextron-40, adenosine and glutathione. Typically, the composition will not include a dipolar aprotic solvent, e.g. DMSO. Suitable compositions are available commercially, e.g. HYPOTHERMASOL®-FRS. Such compositions are advantageous as they allow the microparticles to be stored at 4° C. to 25° C. for extended periods (hours to days) or preserved at cryothermic temperatures, i.e. temperatures below −20° C. The microparticles may then be administered in this composition after thawing.

The pharmaceutical composition can be administered by any appropriate route, which will be apparent to the skilled person depending on the disease or condition to be treated. Typical routes of administration include intravenous, intra-arterial, intramuscular, subcutaneous, intracranial, intranasal or intraperitoneal. For treatment of a disorder of the brain, one option is to administer the microparticles or miRNA intra-cerebrally, typically to the site of damage or disease.

The microparticles or miRNA will be administered at a therapeutically or prophylactically-effective dose, which will be apparent to the skilled person. Due to the low or non-existent immunogenicity of the microparticles, it is possible to administer repeat doses without inducing a deleterious immune response.

Therapeutic Uses

The microparticles and miRNA of the invention are useful in the treatment or prophylaxis of disease. Accordingly, the invention includes a method of treating or preventing a disease or disorder in a patient using a microparticle or miRNA of the invention. The term “patient” includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.

As noted above, the compositions comprising miRNAs of the invention are also useful in these therapies, and references to therapeutic uses of microparticles herein therefore applies equally to the compositions comprising miRNAs.

The Examples below demonstrate that neural stem cell exosomes have been identified that inhibit cell migration. Inhibition of migration has been observed in human fibroblasts. This inhibition is particularly surprising because, as also shown in the examples and as described in PCT/GB2013/050879, neural stem cell microparticles have previously been shown to stimulate fibroblast migration. Inhibition of migration has also been observed in glioblastoma cells.

Microparticles of the invention inhibit cell migration and are therefore useful in treating or preventing a disease, disorder or condition that involves or is characterised by undesired or excessive cell migration. In particular, the microparticles of the invention are particularly suitable for treating or preventing cancer, fibrosis, atherosclerosis or rheumatoid arthritis. The microparticles of the invention are also suitable in the therapy of unwanted or undesirable angiogenesis, for example treating the angiogenic component of a solid tumour. Typically, the microparticles are exosomes.

In one embodiment, the microparticles of the invention are used in the therapy of fibrosis. Fibrosis is well-known to be the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. The fibrosis may be kidney fibrosis, liver fibrosis, cardiac fibrosis, lung fibrosis, skin fibrosis, age-related fibrosis, or spleen fibrosis.

In one embodiment, the microparticles of the invention are used in the therapy of cancer. The cancer may, in one embodiment, comprise a liquid tumour. In another embodiment, the cancer may comprise a solid tumour. In a further embodiment, the microparticles of the invention treat the cancer by inhibiting migration of the cancer cells. In yet a further embodiment, the microparticles of the invention treat the cancer by inducing differentiation of cancer cells, typically differentiation of a nestin-positive cancer cell. In another embodiment, the microparticles of the invention treat the cancer by inducing or enhancing an immune response against the cancer cells. When the cancer is a CNS cancer, the immune response typically comprises the activation and/or proliferation of glial cells such as microglia.

The cancer may be a solid tumour cancer, for example a sarcoma or carcinoma. The solid tumour cancer may also be a solid lymphoma. Exemplary solid tumour cancers include breast cancer, lung cancer, prostate cancer, bowel cancer, renal cancer, hepatic cancer, pancreatic cancer, cervical cancer, testicular cancer, gastric (stomach) cancer, uterine cancer, ovarian cancer, cancers of the head and neck, mouth cancer, thyroid cancer, oesophagus cancer, brain cancer including glioma (e.g. glioblastoma) and meningioma, Kaposi's sarcoma, Castleman's disease, cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma, and skin cancer such as basal cell carcinoma, squamous cell carcinoma and melanoma.

In one embodiment, the solid tumour cancer is breast cancer, typically ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma, inflammatory breast cancer or Paget's disease.

In another embodiment, the solid tumour cancer is lung cancer, typically squamous cell carcinoma, adenocarcinoma or large cell carcinoma, or a small cell lung cancer.

In a further embodiment, the solid tumour cancer is prostate cancer, typically prostate adenocarcinoma.

In a further embodiment, the solid tumour cancer is skin cancer, typically a basal cell carcinoma, squamous cell carcinoma or melanoma.

The cancer may be a liquid tumour, which is typically a tumour of the blood, bone marrow, or lymph nodes. Such cancers include leukemia, lymphoma and myeloma. Exemplary liquid tumours include acute lymphoblastic leukemia, acute myelogenous leukemia (AML), multiple myeloma, Hodgkin's lymphoma and non-Hodgkins lymphoma.

The cancer may be a cancer of the CNS, typically a glioma, meningioma, pituitary adenoma or a nerve sheath tumour. An exemplary CNS cancer is a glioblastoma, which may be a giant cell glioblastoma or a gliosarcoma. The in vivo xenograft pilot data in the Examples demonstrate trends in the treatment of glioblastoma.

The Examples below demonstrate that microparticles of the invention (in the case of Example 4, exosomes isolated from proliferating CTX0E03 cell culture) reduce the expression of nestin on tumour cells. Accordingly, in one embodiment, the cancer to be treated is nestin-positive. Nestin-positive cancers include melanoma, breast cancer, CNS cancers such as glioma and typically glioblastoma, pancreatic cancer, gastrointestinal stromal tumours (GISTs), dermatofibrsarcoma protuberances, thyroid tumours and prostate cancer (see, for example, Ishiwata et al World J Gastroenterol. 2011 Jan. 28; 17(4):409-418). The nestin-positive breast cancer is typically “triple negative, nestin positive” breast cancer (ERα⁻/PR⁻/Her2⁻/Nestin⁺). Triple negative breast cancer is an aggressive disease, recurring and metastasizing more often than other kinds of breast cancer, and treatments for this are urgently needed. The effectiveness of microparticles of the invention in treating this cancer can readily be tested in vivo using a triple negative breast cancer mouse model, for example as described by Kaur et al, BMC cancer 2012m 12:120. In vivo models for other cancers exist and can be used to test the effectiveness of microparticles of the invention; for example, xenograft models of melanoma (e.g. Rofstad Br. J. Cancer (1994), 70, 804-812) and glioblastoma (e.g. Jacobs et al, ASN Neuro. 2011; 3(3); 2011).

Nestin is also reported to be expressed in endothelial cells involved in angiogenesis (Mokry et al, Stem Cells Dev. 2004; 13:658-664) and so the ability of microparticles of the invention to reduce nestin expression provides a further mechanism to inhibit angiogenesis.

Microparticles of the invention may also be used to treat or prevent metastatic cancers, for example metastasis of each of the cancers listed above.

The microparticles of the invention may also be used to treat a benign (non-cancerous, non-malignant) solid tumour, or a premalignant solid tumour.

Fibroblasts are known to play a role in angiogenesis during tumour formation. Without being bound by theory, it is thought that this is mediated in part by a paracrine mechanism wherein factors secreted by the fibroblasts, including Fibroblast Growth Factor (FGF), act on endothelial cells in the nascent or growing blood vessel. Therefore, inhibiting the migration of fibroblasts is expected to inhibit angiogenesis. Accordingly, the microparticles of the invention may be used as an anti-angiogenic therapy, i.e. in the therapy of unwanted, deleterious or undesirable angiogenesis. In one embodiment, the unwanted or undesirable angiogenesis is a component or a precursor of a solid tumour, typically a cancerous solid tumour. In this embodiment, the microparticles are used in the therapy of the tumour by preventing, inhibiting or reducing angiogenesis in the tumour. Typically, the solid tumour that is treated by targeting angiogenesis is one of the tumours described above, for example a sarcoma or carcinoma. The solid tumour cancer in this embodiment may also be a solid lymphoma. Exemplary solid tumour cancers that can be treated by targeting the angiogenic component of the tumour include breast cancer, lung cancer, prostate cancer, bowel cancer, renal cancer, hepatic cancer, pancreatic cancer, cervical cancer, testicular cancer, gastric (stomach) cancer, uterine cancer, ovarian cancer, cancers of the head and neck, mouth cancer, thyroid cancer, oesophagus cancer, brain cancer including glioma (e.g. glioblastoma) and meningioma, Kaposi's sarcoma, Castleman's disease, cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma, and skin cancer such as basal cell carcinoma, squamous cell carcinoma and melanoma.

In one embodiment, the microparticles and compositions containing them are not used for immune modulation. In one embodiment, the therapy is not related to immunomodulation.

The invention also provides a method for treating or preventing a disease or condition comprising administering an effective amount of the microparticle of the invention, thereby treating or preventing the disease. Typically, the disease or condition is as identified above.

In one embodiment, the microparticles for use in therapy are isolated from NSCs (typically CTX0E03 cells) that have been cultured (typically in a multi-compartment bioreactor) for at least 10 weeks, typically at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks or at least 15 weeks. Optionally, the NSCs have been cultured for no more than 20 weeks, e.g. between 10 and 20 weeks, between 11 and 20 weeks, between 12 and 20 weeks, between 13 and 20 weeks, between 14 and 20 weeks or between 15 and 20 weeks. Typically, the microparticles are exosomes. In the examples, microparticles produced according to this embodiment are shown to inhibit fibroblast migration and induce or enhance tumour destruction by the immune system.

The observed increased efficacy of exosomes isolated from NSCs (CTX0E03 cells) that have been cultured (in a multi-compartment bioreactor) for 6 weeks correlates with the observed reduction in size of the exosomes to around 70 nm diameter, which also occurred after culturing the cells for 6 weeks. Accordingly, in one embodiment exosomes isolated from NSCs (typically CTX0E03 cells) having a diameter less than 100 nm, typically less than 80 nm, for example around 70 nm diameter, are used in therapy as described above.

In another embodiment, the microparticles for use in therapy are isolated from proliferating NSCs (typically CTX0E03 cells) that have been cultured in a standard culture vessel such as a T-175 flask, or have been cultured in a multi-compartment bioreactor for 4 weeks or less, 3 weeks or less, 2 weeks or less, or 1 week or less e.g. exosomes isolated on day 0 of the multi-compartment culture. These cells are typically passaged when sub-confluent, are positive for a stem cell marker (e.g. nestin) and negative for markers of differentiated cells (e.g. GFAP or DCX). These exosomes may have a diameter greater than 100 nm. In the examples, microparticles produced according to this embodiment are shown to inhibit cancer cell migration and induce tumour cell differentiation.

In prophylactic applications, pharmaceutical compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of, a particular disease in an amount sufficient to eliminate or reduce the risk or delay the outset of the disease. In therapeutic applications, compositions or medicaments are administered to a patient suspected of, or already suffering from such a disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a therapeutically-or pharmaceutically-effective dose. In both prophylactic and therapeutic regimes, agents are typically administered in several dosages until a sufficient response has been achieved. Typically, the response is monitored and repeated dosages are given if the response starts to fade.

The microparticles of the invention may optionally be combined with a stem cell to provide a combination therapy. The stem cell is optionally the stem cell from which the microparticle is derived, e.g. if the microparticle is an exosome from a CTX0E03 cell, then the stem cell for use in combination therapy may be a CTX0E03 cell, typically but not necessarily cultured for the same period of time as the cells from which the microparticles were derived. A stem cell and microparticle can optionally be (i) administered together in a single pharmaceutical composition, (ii) administered contemporaneously or simultaneously but separately, or (iii) administered separately and sequentially, e.g. stem cell followed by microparticle, or microparticle followed by stem cell. When the stem cell and microparticle are administered separately and sequentially, the duration between the administration of the cell and microparticle may be one hour, one day, one week, two weeks or more.

In one embodiment, a prophylactic therapy induces tolerance, typically immunotolerance, in a host that is to receive the stem cells from which the microparticle is derived. In one embodiment, the administration of one or more doses of microparticles of the invention to a patient, prior to administration of a stem cell therapy, can be used to reduce the risk of an adverse immune response, i.e. “rejection”, of the stem cell therapy. In another embodiment, tolerance to the stem cells can be increased by administering stem cells together with microparticles of the invention, as discussed above.

Effective doses of the compositions of the present invention, for the treatment of the above described conditions vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human.

The CTX0E03 cell line has been shown to be effective in treating stroke, peripheral arterial disease, brain damage such as motor, sensory and/or cognitive deficit, and psychiatric disorders. The cells are currently being tested in a clinical trial for treatment of disabled stroke patients (Clinicaltrials.gov Identifier: NCT01151124). WO-A-2012/004611 describes the use of the CTX0E03 cells in treating psychiatric disorders including unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.

As used herein, the terms “treat”, “treatment”, “treating” and “therapy” when used directly in reference to a patient or subject shall be taken to mean the amelioration of one or more symptoms associated with a disorder, or the prevention or prophylaxis of a disorder or one or more symptoms associated with a disorder. The disorders to be treated include, but are not limited to, cancer, fibrosis, rheumatoid arthritis, atherosclerosis, and other diseases involving deleterious cell migration. Amelioration or prevention of symptoms results from the administration of the microparticles of the invention, or of a pharmaceutical composition comprising these microparticles, to a subject in need of said treatment.

Tracing Administered Cells and Microparticles In Vivo

The present invention provides a distinct marker profile for microparticles produced by neural stem cells. It is therefore possible to detect the presence of these microparticles in vivo, by testing a sample obtained from a patient and determining whether the marker profile in the sample matches that of the microparticles. If the sample profile matches the profile of the microparticles described herein, then this confirms the presence of the microparticles. This can be used to detect not only the presence and/or biodistribution of the microparticles themselves, but also the presence of stem cells producing the microparticles. This is particularly useful when detecting whether a stem cell administered in vivo has engrafted into the host tissue, and/or has migrated, for example in ADME(T) studies.

Detection of the microparticles in vivo can be used to monitor the course of a treatment wherein microparticles or stem cells are administered to a patient. Determining the presence, absence or amount of microparticles or cells producing microparticles of the invention in a patient allows the dosage regime to be altered accordingly, e.g. to increase or decrease the dose as required to provide an effective amount of microparticles or stem cells in vivo.

Methods of Producing Microparticles

Microparticles are isolated from stem cell conditioned media. The “conditioned medium” (CM) may be a growth medium for stem cells, which has been used to culture a mass culture of stem cells for at least about 12 hours, at least about 24 hours, at least about 48 hours or least about 72 hours, typically up to 168 hours (7 days), removed and sterilized by any suitable means, preferably by filtration, prior to use, if required.

Microparticles that are able to inhibit fibroblast cell migration have been isolated from stem cells that have been cultured for at least 10 weeks. Accordingly, one way to produce microparticles that are able to inhibit cell migration is to culture the cells in a multi-compartment bioreactor for at least about 10 weeks before the microparticles are harvested, typically at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, and optionally no longer than 20 weeks. Example 10 describes a typical culture protocol using a CeLLine bioreactor.

Microparticles that are able to inhibit glioblastoma cell migration have been isolated from proliferating stem cells that have been cultured for 4 weeks or less. Accordingly, one way to produce microparticles that are able to inhibit cell migration is to culture the cells so that they are able to proliferate, for example by culturing in a T-175 flask, or in a multi-compartment bioreactor for 4 weeks or less, 3 weeks or less, 2 weeks or less, or 1 week or less e.g. exosomes isolated on day 0 of the multi-compartment culture.

Typically, microparticles may be harvested from a multi-compartment, e.g. two-compartment, bioreactor which allows the cell culture, and hence the conditioned media, to be maintained for longer periods of time, for example more than 10 weeks, at least 11 weeks, at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, and optionally no longer than 20 weeks. The system maintains the cells and secreted microparticles within a small cell compartment (approximately 15 ml) which is separated from a larger reservoir of medium by a 10 kDa semi-permeable membrane. This allows the efficient removal of metabolic waste products while effectively maintaining an extremely high cell density to maximize microparticle production. Example 14, and FIGS. 9 and 10, demonstrate that use of a two-compartment bioreactor results in a much higher yield of microparticles than is obtained when a standard cell culture flask (T175 flask) is used.

The microparticles may be separated from other media components based on molecular weight, size, shape, hydrodynamic radius, composition, charge, substrate-ligand interaction, absorbance or scattering of electromagnetic waves, or biological activity. In one embodiment, the conditioned media is filtered using a filter of appropriate size to separate the desired microparticle, for example a 100K MWCO filter. Optionally, the stem cell-conditioned medium is concentrated prior to the isolation of the microparticles by subjecting the concentrated NSC-conditioned medium to size exclusion chromatography. The UV absorbant fractions can then be selected for isolation of the microparticles of interest.

Different microparticles can be isolated from the media by using different isolation techniques and parameters. For example, exosomes have a vesicle density of 1.13-1.19 g/mL and can be isolated by differential centrifugation and sucrose gradient ultracentrifugation at 100,000-200,000 g. Microvesicles can be isolated by filtration (100K MWCO) and differential centrifugation at 18,000-20,000 g. Membrane particles have a density of 1.04-01.07 g/ml and Exosome-like vesicles have a density of 1.1 g/ml.

A typical production method comprises: culturing stem cells to produce conditioned media; removing cell debris by centrifugation at 1500 rpm; isolating microvesicles (<1000 kDa) by ultrafiltration through a 100K MWCO filter or isolating exosomes (30-100 nm) by ultracentrifugation at 120,000 g; followed by quantification using a BCA protein assay.

Conditionally Immortalised Stem Cells as Producer Cells for Microparticles

In one aspect of the invention, conditionally immortalised stem cells are used to produce microparticles such as microvesicles and/or exosomes. These conditionally immortalised stem cells are typically neural stem cells, but may be a stem cell of any type, for example a haematopoietic stem cell or a mesenchymal stem cell. A method of producing stem cell microparticles is therefore provided, comprising the steps of culturing conditionally-immortalised stem cells and harvesting the microparticles that are produced by the cells, as described above. Conditional immortalisation of stem cells is known in the art, as described above. For the avoidance of doubt, this method is not limited to the use of neural stem cells.

When the stem cell used to produce microparticles is a neural stem cell, it may be any of the neural stem cells described herein, for example the CTX0E03 conditionally-immortalised cell line which is clonal, standardised, shows clear safety in vitro and in vivo and can be manufactured to scale thereby providing a unique resource for stable exosome production. Alternatively, the neural stem cells may be neural retinal stem cell lines, optionally as described in U.S. Pat. No. 7,514,259.

When the stem cell used to produce microparticles is a mesenchymal stem cell, it may optionally be a conditionally-immortalised adipose-derived stem cell (“ADSC”) or a conditionally-immortalised version of the mesenchymal stem cells described in WO-A-2009/105044; these cells are CD29+, CD44+, CD49a+/e+, CD105+, CD166+, CD34-, CD45-.

Methods of Inducing Microparticle Secretion

The inventors have found that it is possible to increase the production of microparticles by stem cells. This finding, which is not limited to neural stem cells and can be used for the production of microparticles from any stem cell, allows for an improved yield of microparticles to be obtained from a stem cell culture.

A first technique to increase the production of microparticles by the stem cells is to treat the stem cells with one or more of TGF-β, IFN-γ or TNF-α, typically at between 1 and 25 ng/ml e.g. 10 ng/ml, for between 12 to 96 hours prior to the removal of conditioned media.

As explained in Example 8 below, the frequency of the occurrence of multivesicular bodies (MVBs) was observed to be altered by the presence of TGF-β, IFN-γ or TNF-α (long/ml). The frequency was highest in the presence of TGF-β, followed by IFN-γ, followed by TNF-α. Therefore, adding one or more of TGF-β, IFN-γ or TNF-α to the stem cell culture medium will stimulate the production of microparticles by the cells. The microparticles can then be harvested, by separating the microparticles from other components as described above.

A second technique to increase the production of microparticles by the stem cells is to culture the cells under hypoxic conditions. Culturing cells under hypoxic conditions is well-known to the skilled person, and involves culturing the cells in an atmosphere that has less than atmospheric level of 02, i.e. less than 21% 02. This is typically achieved by placing the cells in an incubator that allows oxygen levels to be changed. Hypoxic culture typically involves culturing in an atmosphere containing less than 10% 02, more typically 5% or less 02, for example 4% or less, 3% or less, 2% or less, or 1% or less 02.

The inventors have also realised that co-culturing a stem cell with a different cell type can alter the production of microparticles by the stem cell. The different cell type may be a non-stem cell, i.e. a terminally differentiated cell type. Typically, the different cell type is one with which the stem cell would interact in vivo. In one embodiment, neural stem cells are co-cultured with epithelial cells such as endothelial cells, typically Human Umbilical Vein Endothelial Cells (HUVEC). It has been observed that in vivo, NSCs and the vasculature interact, with proliferating NSCs being localized in close proximity or adjacent to blood vessels. Receptor tyrosine kinase activation and signal protein secretion has also been observed to be upregulated when NSCs are co-cultured with endothelial cells, again indicating that the vasculature modulates the proliferation capacity of NSCs.

Therefore, culturing a stem cell with a different cell type may improve the amount of microparticles produced and/or may refine the content of the microparticles, typically so that the microparticles produced by the stem cells are further biased towards astate of inhibition of cell migration. Accordingly, microparticles produced by stem cells that have been co-cultured with other cells, e.g. NSCs co-cultured with endothelial cells, are advantageous. These microparticles may be obtained by isolation from the co-cultured stem-cell conditioned media, as described herein.

Surprisingly, the present inventors have realised that the amount of microparticles produced by stem cells can be increased greatly simply by culturing stem cells in a multi-compartment bioreactor. This finding is not limited to neural stem cells and applies generally to the culture of all stem cells. Accordingly, one aspect of the invention provides a method of producing microparticles from stem cells that have been cultured in a multi-compartment bioreactor. The cells from which the microparticles are harvested have typically been cultured for at least one week, typically at least 8, 9, 10, 11, 12, 13 or 14 days, for example 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days or more, for example at least three weeks, four weeks, five weeks, six weeks or more. To produce microparticles that inhibit cell migration, the cells from which the microparticles are harvested have typically been cultured for more than ten weeks. It can be seen from FIG. 10 that the increase in microparticle production, week on week, is not merely additive but is exponential. The prolonged culture typically has been observed in the Integra Celline system two-compartment bioreactor (commercially available from Integra Biosciences AG, Zizers, Switzerland) but the findings are not limited to this specific multi-compartment bioreactor; any multi-compartment bioreactor can be used. This culture method can be used to produce microparticles from any stem cell type, including but not limited to neural stem cells and mesenchymal stem cells.

Method of Screening for an Agent that Alters Microparticle Production

The invention provides a method of screening for an agent that alters the production of a microparticle by a stem cell. This method comprises contacting a stem cell with a candidate agent, typically under conditions suitable for microparticle production, and observing whether (i) the rate of production of microparticles by the contacted stem cell increases or decreases, or (ii) the characteristics (e.g. size, protein, mRNA or miRNA content) of the microparticles changes, compared to a control stem cell that is not contacted with the agent.

Method for Screening Total RNA Composition of Conditioned Medium

Following centrifugation (5 min at 1500 rpm), microparticles are collected from conditioned medium through filtration (0.02-0.2 μm, or 100K MWCO). Total RNA is obtained using trizol based extraction followed by purification using Qiagen RNaesy mini kit. The extract in water has a 260:280 nm absorbance suggesting that it may be RNA. Total RNA is retro-transcribed with either a protocol suitable for mRNA (Superscript II RT, Invitrogen) or miRNA (mScript RT kit, Qiagen). Validation of mRNA and miRNA presence is proven by qRT-PCR using primers for ATPSB and YWHAZ for mRNA, and U6B and 15a for miRNA housekeeping genes respectively. The RNA may further be assessed by a generic gene expression analysis assay such as an array (micro array or PCR based array), and sequencing.

Kits

The invention provides a kit for use in a method for producing the microparticle of the invention. The kit comprises a neural stem cell culture medium, a neural stem cell and instructions for producing the microparticle of any of claim 1-17 or 40 using the kit. Optionally, the kit comprises one or more components of claims 36 to 38. The kit may also comprise a microparticle according to the invention, for use as a control. The control microparticle is optionally lypohilised. The kit may also contain optionally a detection agent suitable for detection of the produced microparticles, for example an antibody that binds specifically to a marker protein that can be used to identify the microparticle.

Embodiments of the Invention

The invention comprises at least the following numbered embodiments:

-   -   1. A neural stem cell microparticle that (i) inhibits cell         migration; and/or (ii) induces differentiation of a cancer cell.     -   2. The neural stem microparticle of embodiment 1, wherein the         microparticle inhibits angiogenesis.     -   3. The neural stem cell microparticle of embodiment 1, wherein         the microparticle induces or enhances an immune response against         cancer cells.     -   4. The microparticle of any one of embodiments 1-3, wherein the         microparticle inhibits cell migration as determined using a         transmembrane cell migration assay, or induces differentiation         as determined by a reduction in nestin expression.     -   5. The neural stem cell microparticle of any one of embodiments         1-4, wherein the microparticle inhibits migration of a         fibroblast or a fibroblast-like cell, or a cancer cell,         typically a glioblastoma cell.     -   6. The neural stem cell microparticle of any preceding         embodiment, wherein the microparticle is derived from a neural         stem cell that:         -   (a) is not proliferating;         -   (b) expresses DCX or GFAP; and/or         -   (c) has been cultured in a multi-compartment bioreactor for             at least 10 weeks and optionally no more than 20 weeks.     -   7. The neural stem cell microparticle of any one of embodiments         1-5, wherein the microparticle is derived from a neural stem         cell that:         -   (a) is proliferating;         -   (b) does not express DCX or GFAP; and/or         -   (c) has been cultured in a multi-compartment bioreactor for             less than 4 weeks and optionally no more than 1 week.     -   8. The neural stem cell microparticle of any one of embodiments         1-7, wherein the microparticle is an exosome, microvesicle,         membrane particle, membrane vesicle, exosome-like vesicle,         ectosome-like vesicle, ectosome or exovesicle.     -   9. The neural stem cell microparticle of any one of embodiments         1-8, wherein the microparticle is derived from a neural stem         cell line.     -   10. The neural stem cell microparticle of embodiment 9, wherein         the neural stem cell line is conditionally-immortalised and/or         grown in serum free medium.     -   11. The neural stem cell microparticle of embodiment 10, wherein         the neural stem cell line is CTX0E03 having ECACC Accession No.         04091601, STR0005 having ECACC Accession No. 04110301 and         HPC0A07 having ECACC Accession No. 04092302.     -   12. The neural stem cell microparticle of any preceding         embodiment, wherein the microparticle has:         -   (a) a size of between 30 nm and 1000 nm, or between 30 and             200 nm, or between 30 and 100 nm, as determined by electron             microscopy; or         -   (b) a density in sucrose of 1.1-1.2 g/ml.     -   13. The neural stem cell microparticle of any preceding         embodiment, comprising RNA.     -   14. The neural stem cell microparticle of embodiment 13, wherein         the RNA is mRNA and/or miRNA.     -   15. The neural stem cell microparticle of embodiment 14, wherein         the microparticle comprises:         -   one, two, three or four of hsa-miR-1246, hsa miR-4492,             hsa-miR-4488 and hsa-miR-4532;         -   one, two, three, four or five of hsa-miR-181a-5p,             hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p, and             hsa-miR-100-5p;         -   one, two, three, four or five of hsa-miR-181a-5p,             hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-92b-3p, and             hsa-miR-9-5p; or         -   hsa-miR-486-5p.     -   16. The neural stem cell microparticle of any preceding         embodiment, comprising one or more of:         -   (a) a lipid selected from ceramide, cholesterol,             sphingomyelin, phosphatidylserine, phosphatidylinositol,             and/or phosphatidylcholine;         -   (b) miRNA, optionally selected from hsa-let-7g, hsa-miR-101,             hsa-miR-10a, hsa-miR-10b, hsa-miR-126, hsa-miR-128,             hsa-miR-129-5p, hsa-miR-130a, hsa-miR-134, hsa-miR-137,             hsa-miR-155, hsa-miR-15a, hsa-miR-15b, hsa-miR-16,             hsa-miR-17, hsa-miR-182, hsa-miR-183, hsa-miR-185,             hsa-miR-18b, hsa-miR-192, hsa-miR-194, hsa-miR-195,             hsa-miR-20a, hsa-miR-20b, hsa-miR-210, hsa-miR-218,             hsa-miR-301a, hsa-miR-302a, hsa-miR-302c, hsa-miR-345,             hsa-miR-375, hsa-miR-378, hsa-miR-7, hsa-miR-9, hsa-miR-93,             hsa-miR-96, and hsa-miR-99a;         -   (c) a tetraspanin, optionally selected from CD63, CD81, CD9,             CD53, CD82 and/or CD37;         -   (d) TSG101, Alix, CD109 and/or thy-1; and/or         -   (e) CD133.     -   17. The neural stem cell microparticle of any preceding         embodiment, comprising at least 10 of the proteins present in         Table 20 or Table 22.     -   18. The neural stem cell microparticle of any preceding         embodiment, for use in therapy.     -   19. The neural stem cell microparticle of embodiment 18, wherein         the therapy is of a disease or condition involving unwanted or         undesirable cell migration.     -   20. The neural stem cell microparticle of embodiment 18 or         embodiment 19, wherein the therapy is of fibrosis, cancer,         rheumatoid arthritis, atherosclerosis, or unwanted or         undesirable angiogenesis.     -   21. The neural stem cell microparticle of embodiment 20, wherein         the cancer comprises a liquid tumour or a solid tumour.     -   22. The neural stem cell microparticle of embodiment 21, wherein         the therapy of the solid tumour comprises inhibiting         angiogenesis.     -   23. The neural stem cell microparticle of embodiment 22, wherein         the angiogenesis is inhibited by inhibiting migration of         fibroblasts.     -   24. The neural stem cell microparticle of embodiment 20 or         embodiment 21, wherein the cancer is treated by inducing or         enhancing or inducing an immune response against the cancer         cells.     -   25. The neural stem cell microparticle of any of embodiments 22         to 24, wherein the microparticle is as defined in embodiment 6.     -   26. The neural stem cell microparticle of embodiment 20 or         embodiment 21, wherein the cancer is treated by inhibiting         migration of the cancer cells.     -   27. The neural stem cell microparticle of embodiment 20 or         embodiment 21, wherein the cancer is treated by inducing         differentiation of the cancer cells.     -   28. The neural stem cell microparticle of embodiment 26 or         embodiment 27, wherein the microparticle is as defined in         embodiment 7.     -   29. The neural stem cell microparticle of any of embodiments 20         to 28, wherein the cancer is a nestin-positive cancer.     -   30. The neural stem cell of embodiment 29, wherein the         nestin-positive cancer is a melanoma, breast cancer, glioma,         pancreatic cancer or prostate cancer.     -   31. The neural stem cell microparticle of any of embodiments 20         to 30, wherein the cancer is glioblastoma.     -   32. The neural stem cell microparticle of any of embodiments 20         to 30, wherein the cancer is triple-negative breast cancer.     -   33. The neural stem cell microparticle of any of embodiments 20         to 30, wherein the cancer is melanoma.     -   34. Use of a neural stem cell microparticle according to any of         embodiments 1 to 17, in the manufacture of a medicament for the         treatment of a disease, optionally cancer.     -   35. A method of producing a neural stem cell microparticle as         defined in any one of embodiments 1-17, comprising isolating a         microparticle from a neural stem cell-conditioned medium from a         neural stem cell that has been cultured, typically in a         multi-compartment bioreactor, typically for less than 4 weeks or         at least 10 weeks and optionally no more than 20 weeks.     -   36. A method of producing a stem cell microparticle, comprising         isolating a microparticle from a stem cell-conditioned medium         wherein the neural stem cell-conditioned medium is from a neural         stem cell that has been cultured, typically in a         multi-compartment bioreactor, typically for less than 4 weeks or         at least 10 weeks and optionally no more than 20 weeks and         wherein:         -   (i) the stem cell-conditioned medium comprises one or more             components which induce the release of microparticles by the             stem cells into the medium;         -   (ii) the stem cells were cultured under hypoxic conditions;         -   (iii) the stem cells were co-cultured with a different cell             type;         -   (iv) the stem cells were cultured in a multi-compartment             bioreactor; and/or         -   (v) the stem cells were partially-differentiated;     -   37. The method according to embodiment 36, wherein the stem cell         is a neural stem cell, optionally as defined in any of         embodiments 9 to 11.     -   38. The method according to embodiment 36(i), or embodiment 37         when dependent upon embodiment 32(i), wherein the one or more         components are selected from: transforming growth factor-beta         (TGF-β), interferon-gamma (INF-γ) and tumour necrosis         factor-alpha (TNF-α).     -   39. The method according to embodiment 36(iii), embodiment 37 or         38 when dependent upon embodiment 32(iii), wherein the different         cell type is an endothelial cell.     -   40. A microparticle obtainable by the method of any of         embodiments 35-39.     -   41. A composition comprising:         -   (i) one, two, three or four of hsa-miR-1246, hsa miR-4492,             hsa-miR-4488 and hsa miR-4532;         -   (ii) one, two, three, four or five of hsa-miR-181a-5p,             hsa-miR-1246, has miR 127-3p, hsa-miR-21-5p, and             hsa-miR-100-5p; or         -   (iii) one, two, three, four or five of hsa-miR-181a-5p,             hsa-let-7a-5p, has let 7f 5p, hsa-miR-92b-3p, and             hsa-miR-9-5p.     -   42. A composition according to embodiment 41, for use in therapy         as defined in any of embodiments 19 to 33.     -   43. A composition according to embodiment 41 for use in the         treatment of cancer, wherein:         -   (i) the composition of embodiment 41(i) is for use in             therapy as defined in embodiments 26 or 27; or         -   (ii) the composition of embodiment 41(iii) is for use in             therapy as defined in any of embodiments 22 to 24.     -   44. A composition comprising a microparticle according to any of         embodiments 1-17 or 40, or miRNA according to embodiment 41, and         a pharmaceutically acceptable excipient, carrier or diluent.     -   45. A kit for use in a method for producing the microparticle of         any of embodiments 1-17 or 40 comprising: (a) a medium; (b) a         neural stem cell; (c) optionally the one or more components of         embodiments 36 to 38; (d) optionally the microparticle of any of         embodiments 1-17 or 40 suitable for use as a control; (e)         optionally a detection agent suitable for specific detection of         the produced microparticles; and (f) instructions for producing         the microparticle of any of embodiments 1-17 or 40 using the         kit.     -   46. A method of screening for an agent that alters the rate of         production of a microparticle by a stem cell, comprising         contacting a stem cell with a candidate agent and observing         whether the rate production of microparticles by the contacted         stem cell increases or decreases compared to a control.

The invention is further described with reference to the following non-limiting examples.

EXAMPLES Example 1: NSC Exosomes that Inhibit Cell Migration

A transwell assay was used to study the migratory response of human dermal fibroblasts to different populations of exosomes. Experiments were performed in triplicate. 200,000 human dermal fibroblast cells (“FBs”) were placed on the upper layer of a cell permeable membrane (8 μm pore size; 24-well plate) and a solution (basal medium) containing or lacking 20 μg/ml exosomes was placed in contact with the underside of the cell permeable membrane (FIG. 1, top panel). The exosomes were collected from CTX0E03 cells cultured for 0 weeks (“0”) or 11 weeks (“11”) in an Integra CeLLine AD1000 multi-chamber bioreactor. Following an incubation period (6 or 24 hours; control: 0 hours), the human dermal fibroblast cells that migrated through the membrane were stained (using a fluorescent-dye conjugated anti-actin antibody and Hoechst Fluorescent Stain for nuclei) and counted (six random microscope fields per sample) as an indicator of the cells' migratory response to exosomes.

FIG. 1 (lower panel) and FIG. 2 show that exosomes isolated from a proliferating CTX0E03 culture (“0”) significantly promote migration of human dermal fibroblasts compared to medium lacking exosomes (“basal”), both after a 6 hour and after a 24 hour incubation period. In contrast, exosomes isolated from a more differentiated CTX0E03 culture (“11”) significantly abrogate migration of human dermal fibroblasts compared to medium lacking exosomes (“basal”), both after a 6 hour and after a 24 hour incubation period.

It can be seen that cell migration is increased in the presence of exosomes from 0-week NSCs but decreased in the presence of exosomes from 11-week NCSs, compared to control (“basal”).

In summary, NSC microparticles have been identified that significantly abrogate cell migration.

These data show that neural stem cell microparticles can stimulate or inhibit cell migration. This is surprising and useful in applications where either stimulating (e.g. wound healing) or inhibiting (e.g. cancer, fibrosis, rheumatoid arthritis, atherosclerosis) cell migration is desired. The involvement of fibroblasts in angiogenesis also makes the microparticles that inhibit fibroblast migration useful in applications where inhibition of angiogenesis is desired. Angiogenesis is involved in tumour formation, survival and metastasis. These data therefore demonstrate potential for the exosomes of the invention to treat many types of cancer.

Example 2: Exosomes Isolated from the Medium of NSCs Cultured for 2 or 6 Weeks Promote Fibroblast Migration Method—

Wound closure/scratch assay

-   -   Seed 0.25×10⁶ NHDF (normal human dermal fibroblasts) per well of         a 12 well plate and allow to become confluent (24 hours)     -   Remove growth factors for 24 hrs     -   Remove cells (scratch) and incubate with exosomes/conditioned         media     -   Image effected area over 48 hrs     -   Estimate area using Image J

Results

TABLE 2 Wound closure/scratch assay representing the migration activity of normal human dermal fibroblasts (NHDF) cultured in CTX0E03 conditioned media or upon the addition of purified exosomes. Wound closure (%) 0 h 24 h 48 h CTX0E03 conditioned media 0%  100% 2 ug/ml exosomes 0% 95.4%  100% Control 0% 48.1% 49.7%

Wound closure was calculated as the area covered by cells in relation to the initial wound area, as determined at 0 h. Wound closure is expressed as the percentage of the initial wound area at time 0 h. These data are also shown, photographically, in FIG. 3A. The figure shows that, in contrast to exosomes from 11-week NSCs as described in FIGS. 1 and 2, exosomes from 2-week NSCs stimulate cell migration.

FIG. 3B shows that 10 μg CTX0E03 exosomes significantly increase wound closure (as determined in the HDNF scratch/migration assay) after 72 hours, compared to basal conditions (without exosomes).

Further experiments confirmed that exosomes purified (by ultracentrifugation; quantified by BCA protein assay; characterised as >99% positive for CD63 and CD81 and having a greater expression level of Alix compared to the corresponding microparticle fraction) from all time points (weeks 2-6) during continuous culture (using Integra CELLine bioreactors in the presence of growth factors and 4OHT) significantly enhanced fibroblast migration and wound healing, with a peak response between 5-10 μg/ml compared to basal conditions. FIG. 3C shows the % healed areas for basal conditions, 2 μg/ml exosomes, 6 μg/ml exosomes, 20 μg/ml exosomes and an LSGS (low serum growth supplement) positive control. The top panel of FIG. 3C shows exosomes isolated from CTX0E03 cells cultured for 2 weeks in the Integra Celline system and the bottom panel of FIG. 3C shows exosomes isolated from CTX0E03 cells cultured for 6 weeks in the Integra Celline system. These data show that all doses of all tested NSC exosomes provide increased healing compared to basal conditions, with % healing approaching the positive control (LSGS) after 72 hours.

The data in FIG. 3C also show that the exosomes isolated from NSCs cultured for 6 weeks cause faster healing (than 2 week exosomes), with the % healed approaching 100% after only 48 hours, for all doses.

FIG. 3D shows the results of an in vivo injection wound assay in a mouse, confirming that CTX0E03 cells stimulated wound healing to a statistically-significant degree in vivo. This is a simple in vivo bioassay which can be used to confirm the efficacy of microparticles in vivo.

Conclusion

Exosomes released from the human neural stem cell line CTX0E03 enhance fibroblast migration in an in vitro model of wound healing, suggesting that exosomes may contribute to the mechanisms by which hNSCs promote repair. Exosomes isolated from cells cultured for 6 weeks show improved wound healing efficacy in vitro, compared to exosomes isolated from cells cultured for 2 weeks.

Example 3: Glioblastoma Engraftment Assay—Destruction of Tumour Cells

U373 glioblastoma cells were pre-treated in vitro for 24 hours with exosomes isolated from CTX0E03 cells cultured for 11 weeks in an Integra CeLLine bioreactor before implantation into the striatum of Balb-C mice brains.

As shown in FIG. 19, the exosome-treated glioblastoma cells did not engraft into the striatum. Histopathology demonstrated the presence of necrotic U373 cell bodies at the site of implantation and evidence of gliosis—a host cellular immune response.

These data suggest utility of these exosomes in the treatment of cancer, by promoting the destruction of a tumour by the immune system, particularly a tumour of the CNS such as a glioblastoma.

Example 4: Glioblastoma Engraftment Assay—Differentiation of Tumour Cells

U373 glioblastoma cells were pre-treated in vitro for 24 hours with exosomes isolated from standard CTX0E03 cell culture (“exosome 0”—proliferating cells, cultured in an Integra CeLLine bioreactor for less than 24 hours) before implantation into the striatum of Balb-C mice brains. Marker expression was then observed after 24 hours.

As shown in FIG. 20, the exosome-treated glioblastoma cells demonstrated a reduction in nestin expression 24 hours post implantation into the striatum of Balb-C mice. Nestin is a stem cell marker; cancer stem cells drive tumourigenesis, are linked with metastasis, high grade and poor prognosis. The treatment of cancer by inducing cellular differentiation is particularly attractive because the therapy can be target-cell specific (i.e. will only target the undifferentiated, malignant, cells) and likely less toxic than standard chemotherapies.

These data suggest utility of these exosomes in the treatment of cancer, by inducing differentiation of the cancer cells, typically for treating a nestin-positive cancer and particularly a tumour of the CNS such as a glioblastoma.

Example 5: In Vitro Glioblastoma Differentiation Assay—Differentiation of Tumour Cells

U373 glioblastoma cells were cultured for 24 hours in the presence of: (i) basal medium; (ii)+20 μg exosomes isolated from standard CTX0E03 cell culture (“exosome 0”-proliferating cells, cultured in an Integra CeLLine bioreactor for less than 24 hours); or (iii) +20 μg exosomes isolated from CTX0E03 cells cultured for 11 weeks in an Integra CeLLine bioreactor (“exosome 11”). The U373 cells were then stained for the presence of Nestin (a stem cell marker) and GFAP (an astrocyte marker of a differentiated cell).

As shown in FIG. 21, exosome 0 promoted differentiation of the glioblastoma cells in vitro. The exosome 0 treated cells appeared morphologically differentiated, with the presence of long processes. Additionally, these cells expressed Glial fibrillary acidic protein (GFAP), a marker of differentiated astroglial cells. These in vitro data agree with the in vivo data immediately above. As noted above, more differentiated (less malignant) glioblastoma tumours are linked with more favourable prognosis. These data further suggest utility of these exosomes in the treatment of cancer, by inducing differentiation of the cancer cells, particularly a tumour of the CNS such as a glioblastoma.

In contrast, the exosomes isolated from CTX0E03 cells cultured for 11 weeks (“exosome 11”) promoted “sternness” in the glioblastoma cells in vitro, demonstrated by nestin expression and proliferation. However, in the in vivo assay above, these exosomes were observed to promote destruction of the tumour cells.

Example 6: Glioblastoma Migration Assays

Three separate in vitro transmembrane migration assays have demonstrated that treatment of glioblastoma (U373) cells with exosomes isolated from standard CTX0E03 cell culture (“exosome 0”—proliferating cells, cultured in an Integra CeLLine bioreactor for less than 24 hours) significantly reduces their migration towards a positive chemoattractant (Foetal Bovine Serum). These assay results are shown in FIGS. 22A, 22B, and 22C.

Glioblastoma cells were seeded on one side of a porous filter membrane. These cells were either seeded together with 20 μg/ml CTX0E03 “exosome 0” (FIGS. 22A and 22C) or have been pre-treated with 10 μg/ml CTX0E03 “exosome 0” for 24 hours (FIG. 22B). Medium containing a 10% FBS was placed on the opposing (lower) side. After a 24 hour incubation period, the membrane was fixed and stained to reveal migrated cells (e.g. cell nuclei), which were counted microscopically.

These data show that exosomes of the invention (isolated from standard “week 0” CTX0E03 cells) are able to reduce migration of glioblastoma cells. Glioblastomas are the most common and malignant brain tumors of the central nervous system and exhibit high invasive capacity, which hinders effective therapy. Therefore, therapeutics that can inhibit glioma cell migration and invasion are highly desirable. These data demonstrate the utility of neural stem cell exosomes in the treatment of cancer, typically a glioblastoma, by reducing tumour migration/invasion.

Summary: Treatment of Cancer Using Neural Stem Cell Exosomes

The data provided above indicate therapeutic utility in the treatment of cancer using exosomes produced by neural stem cells, by one or more of: reducing tumour migration/invasion (exosome 0, glioblastoma assay); inducing tumour differentiation (exosome 0, glioblastoma assay); promoting tumour destruction (exosome 11, glioblastoma transplant); or inhibiting angiogenesis (exosome 11, fibroblast assay).

Example 7: Preparation of Neural Stem Cells and Neural Stem Cell Microparticles for Visualisation by Electron Microscopy Method

Embedding CTX0E03 Cells for Electron Microscopy

-   -   5×70% CTX0E03 cultures     -   Treat with +/−4OHT, IFNγ, TNFα and TGFβ (all at 10 ng for 24         hrs)     -   Detach cells and fix overnight in 2.5% Gluteraldehyde in 0.1M         Cacodylate pH7.4     -   Cells spun down 300 g     -   Buffered osmium 2%, 1.5 hrs     -   Spin, wash water, overnight     -   Uranium acetate 2%, 2 hrs     -   Spin, wash water, 30 mins     -   Ethanol gradient 20, 35, 50, 70, 80, 90, 100%, over weekend.     -   100% propylene oxide (PO), 1 hr     -   Spin, 50% Agar LV resin in PO, 1 hr     -   75% LV resin/PO 5 hrs     -   100% resin overnight at 60° C.     -   Cool to RT before cutting (60-80 nm), Imaged TEM at 200 Kv.

Results

FIG. 4A-E shows the electron micrographs of the multivesicular bodies (MVBs) containing exosomes of approximately 30 nm-50 nm in diameter. FIG. 4F shows microvesicles >100 nm in diameter.

Example 8: Production of Neural Stem Cell Microparticles from a Neural Stem Cell Line Method

5 Sub-confluent flasks containing the same culture of CTX0E03 cells were individually treated with either 10 ng/ml TGF-β, 10 ng/ml IFNγ, or 10 ng/ml TNFα alongside full growth media controls with or without the addition of 4OHT. 72 hours after treatment, the cells were collected using trypzean/EDTA, washed and fixed overnight in 2.5% Gluteraldehyde in 0.1M Cacodylate pH7.4 ready for electron microscopy evaluation.

Results

The frequency of the occurrence of multivesicular bodies (MVBs) was observed to be altered by the presence of TGF-β, IFN-γ or TNF-α. The frequency was highest in the presence of TGF-β, followed by IFN-γ, followed by TNF-α.

Conclusion

The production of microparticles from neural stem cells can be stimulated by the addition of the factors TGF-β, IFN-γ or TNF-α. This has the potential for more efficient production of microparticles.

Example 9: Purification, Quantification and Characterisation of Neural Stem Cell Microparticles Method

An outline protocol for producing large quantities of microparticles is provided in FIG. 5. The main steps are purification, quantification, characterisation, efficacy testing and manufacture.

(1) Purification

-   -   Microparticles can be purified from stem cell-conditioned medium         by ultracentrifugation, e.g. at 100000×g for 1-2 hours.         Alternative or additional methods for purification of may be         used, such as antibody-based methods, e.g. immunoprecipitation,         magnetic bead purification, resin-based purification, using         specific antibodies.

(2) Quantification

-   -   Purified microparticles can be quantified by quantification of         total nucleic acid or protein levels, e.g. various PCR or         colorimetric protein quantification methods such as such as the         BCA assay. Other quantification techniques may alternatively be         used, including an electron microscopy grid or an immune-assay         using antibodies or antibody fragments that specifically bind to         microparticle-specific markers (e.g. ELISA, immunoblotting).

(3) Characterisation

-   -   The microparticles can be functionally or structurally         characterised. RNA/mRNA/miRNA and protein profiling can be used         using methods well known in the art (SDS-PAGE, mass         spectrometry, PCR). Constitutively secreted microparticles can         be tested and compared to microparticles that have been induced         by addition of an inducing agent such as transforming growth         factor-beta (TGF-β), interferon-gamma (INF-γ) and/or tumour         necrosis factor-alpha (TNF-α).

(4) Therapeutic Efficacy

-   -   The efficacy of the microparticles can be tested by in vitro and         in vivo assays. For in vitro evaluation, neural stem cell         microparticles can be added to cultures of monocytes, PBMCs,         endothelial cells and/or fibroblasts and the effect of the         microparticles on these cells evaluated. Administration of         neural stem cell microparticles to suitable animal models can be         used to evaluate the in vivo efficacy. Clinical trials can be         performed to evaluate safety and outcome of neural stem cell         microparticles in human subjects.

(5) Manufacture/Scale-Up

-   -   Bioreactors, such as the Integra disposable T1000, can be used         for the large-scale manufacture of neural stem cell         microparticles. The purified microparticles are then formulated         as a therapeutic product.

Example 10: Integra CELLINE—Disposable Bioreactor for the Production of Micro Particles from CTX0E03 Cells

Efficient micro particle production and harvest from a cell line relies upon maintaining optimal culture conditions for the greatest density of cells. Any restriction in the oxygen or nutrients supplied to the cells or an accumulation of waste metabolic products will limit the life span of the culture, and hence the micro particle production.

The two-compartment CELLine AD 1000 is designed to accommodate adherent cells attached to a matrix inlay within a small cell compartment, separated from a larger media reservoir by means of a 10 kDa semi-permeable membrane. This membrane allows a continuous diffusion of nutrients and removal of waste products, while concentrating any micro particles produced by the cell within the smaller cell compartment. Due to the large volume capacity (1 litre) of the media compartment, the system has the potential to maintain high density cultures for longer periods of time without the need for a media change. The production of exosomes from mesothelioma tumour cell cultures is described in Mitchell et al, 2008.

Method

In order to obtain optimal performance of the CELLine AD1000, place 25 ml of complete growth medium (RMM with growth factors and 4OHT) into the medium compartment of the flask to pre-wet the semi-permeable membrane. Allow the flask to sit for 5 minutes at room temperature before coating the matrix inlay with mouse Laminin by adding 15 ml of laminin solution (20 μg/ml in DMEM/F12) to the cell compartment for a minimum of 1 hour at 37° C. Remove the laminin solution and add 15 ml of warm DMEM/F12 to the cell compartment to remove any excess laminin. Avoiding the matrix inlay drying, slowly introduce approximately 15×10⁶ CTX0E03 cells in a total of 15 ml of complete growth medium. Take care to remove any air bubbles from the cell compartment. Carefully add a further 460 ml of complete growth medium to the cell compartment before incubating the flask overnight in 5% CO₂ at 37° C. The next day remove the medium from the cell compartment and replace with 15 ml of pre warmed growth medium.

Every 7 days harvest the microparticles/medium from the cell compartment. Centrifuge the medium at 1500 rpm for 5 minutes to remove any cell debris and store at −80° C. Carefully add another 15 ml of pre-warmed complete growth medium in to the cell compartment and 485 ml of complete growth medium to the medium compartment and incubate for another 7 days. Microparticles were isolated by 100K MWCO filtration. Repeat as necessary.

Marker characterizations indicated that both purified populations (microvesicles and exosomes) express CD63 and CD81 (determined by FACS—FIG. 6). Only the exosomes express the endosomal marker Alix (determined by Western blot, data not shown).

FIG. 8A shows the amount of protein extracted from 15 ml of media containing microparticles purified using the Integra system compared to normal culture conditions (3 days T175). Milligrams of protein measured by BCA assay. FIG. 8B shows the corresponding quantity of isolated total RNA measured at 260/280 nm.

Example 11: Size Distribution of Microparticles

NanoSight analysis was undertaken to determine the particle size and concentration of microvesicles (“mv1” to “mv6”) and exosomes (“exo1” to “exo6”) isolated from CTX0E03 cells cultured in the Integra Celline system for 1, 2, 3, 4, 5 and 6 weeks. All results are based on 5 replicate measurements.

Particle size distribution was measured using Nanoparticle Tracking Analysis (NTA). NTA detects the movement of particles in solution and relates it to particle size. Mode and median particle size was calculated for all samples. Exosome samples were analysed using the most sensitive camera settings in order to capture the smallest vesicles. Microvesicle samples were analysed using less sensitive camera settings to prevent over exposure of the larger vesicles. As a result, some smaller vesicles were not detected in the samples. Although smaller vesicles were present in the MV samples, these represent a small percentage of the sample in terms of mass.

A proportion of Exo1 was labelled with a fluorescent membrane-specific dye (CELLMASK™) and a combination of NTA analysis with the CELLMASK™ labelling confirmed that the events detected by NTA correspond to membrane vesicles (data not shown).

The results are shown in Table 3 below, and in FIGS. 7A and 7B.

The exosomes show a drop in size at week six, from a mode of approximately 110 nm to approximately 70 nm, or from a median of approximately 130 nm to approximately 75 nm. The overall size range, from 70 nm to 150 nm, is consistent with the size of exosomes from other cell types, described in the art. The observed reduction in size of the exosomes to around 70 nm diameter after culturing the cells for 6 weeks correlates with the increased efficacy of exosomes isolated from CTX0E03 cells that have been cultured in a multi-compartment bioreactor for 6 weeks correlates, as reported in Example 2 and FIG. 3.

The microvesicles are, as expected, larger, with a mode diameter of approximately 150 nm-200 nm, or a median diameter of approximately 180 nm-350 nm.

TABLE 3 Size distribution of CTX0E03 microvesicles and exosomes. Mode Median Sample Count Dilution Concentration × 10¹²/ml (nm) (nm) Exo1 (1) 5.204 10000 32.26 107 151 Exo1 (2) 1.734 10000 10.75 135 164 Exo1 (3) 6.55 10000 40.61 108 128 Exo2 14.33 10000 88.85 118 153 Exo3 (1)* 2.52 10000 15.62 89 115 Exo3 (2) 10.06 10000 62.37 115 146 Exo3 (3) 8.98 10000 55.68 128 147 Exo4 (1) 3.04 10000 18.85 111 136 Exo4 (2) 2.89 10000 17.92 110 120 Exo4 (3) 2.77 10000 17.17 116 134 Exo5 (1) 2.34 100 0.15 99 117 Exo5 (2) 2.02 100 0.13 102 124 Exo5 (3) 2.08 100 0.13 116 127 Exo6 (1) 1.45 100 0.09 68 74 Exo6 (2) 1.19 100 0.07 69 75 MV1 (1) 9.314 200 1.15 183 212 MV1 (2) 10.76 200 1.33 161 214 MV1 (3) 10.738 200 1.33 173 198 MV2 5.89 1000 3.65 177 194 MV3 (1)* 5.68 2000 7.04 150 186 MV3 (2) 11.5 2000 14.26 221 351 MV3 (3) 9.57 2000 11.87 214 270 MV4 (1) 4.894 400 1.21 209 240 MV4 (2) 2.934 1000 1.82 195 212 MV4 (3) 2.55 1000 1.58 184 221 MV5 (1) 1.086 200 0.13 164 237 MV5 (2) 1.458 200 0.18 205 205 MV5 (3) 1.3 200 0.16 219 210 MV6 (1) 0.346 200 0.04 171 186 MV6 (2) 0.37 200 0.05 168 212 Media 0.14 10 0.00 100 149 *large aggregates.

Example 12: miRNA Characterization in CTX0E03 Microparticles Methods

-   -   3 conditions: CTX0E03 cells in standard culture; microparticles         obtained from CTX0E03 cells in standard culture; and purified         exosomes derived from CTX0E03 cells in Integra CELLine system         (see Examples 10 to 16)     -   Investigation of miRNA array using qRT-PCR panel (Qiagen)         according to manufacturer's instruction. This assay provides         high precision and high sensitivity, with data normalization         sensitive to method/choice of reference genes. It does not         provide genome wide sequencing.

Results:

A) List of miRNAs with a cp≤35 found in (i) standard CTX0E03 cells, (ii) filtered conditioned medium (0.02-0.2 μm filter) i.e. microparticles and (iii) exosomes derived from Integra CELLine system (preliminary miRNA qRT-PCR miscript array (Qiagen) results).

B) Arithmetic and geometric mean of the reference (housekeeping) genes

CTX0E03 CM CM exosome Mature miRNA std culture microparticles Integra A hsa-miR-21-5p 19.52 20.9 20.72 hsa-let-7a-5p 22.64 23.11 22.36 hsa-miR-125b-5p 21.64 23.25 21.74 hsa-miR-9-5p 22.58 23.64 22.94 hsa-miR-92a-3p 23.2 23.94 24.01 hsa-miR-24-3p 23.73 24.24 23.83 hsa-miR-20a-5p 23.45 24.43 25.06 hsa-miR-16-5p 23.14 24.72 24.32 hsa-miR-100-5p 23.28 24.74 23.04 hsa-let-7b-5p 24.67 24.75 23.7 hsa-let-7f-5p 23.93 25.09 23.86 hsa-miR-17-5p 24.56 25.24 26.13 hsa-miR-23b-3p 24.3 25.3 24.13 hsa-miR-106b-5p 24.4 25.41 26.16 hsa-miR-222-3p 23.25 25.49 23.17 hsa-let-7e-5p 24.57 25.58 24.16 hsa-miR-26a-5p 23.4 25.63 24.2 hsa-miR-181a-5p 25.16 25.7 24.32 hsa-miR-125a-5p 23.56 25.75 24.88 hsa-miR-103a-3p 24.65 25.8 25.77 hsa-let-7i-5p 24.37 25.98 24.23 hsa-miR-99a-5p 24.44 26.05 23.44 hsa-let-7c 25.76 26.12 24.07 hsa-let-7g 25.2 26.15 25.17 hsa-miR-195-5p 24.72 26.34 25.67 hsa-miR-93-5p 25.15 26.48 26.06 hsa-miR-22-3p 25.03 26.49 25.66 hsa-miR-20b-5p 26.03 26.86 27.42 hsa-miR-18a-5p 26.71 26.87 29.06 hsa-miR-15b-5p 25.1 26.92 26.43 hsa-let-7d-5p 26.84 26.96 26.52 hsa-miR-424-5p 25.56 27.72 26.66 hsa-miR-15a-5p 26.88 27.89 29.3 hsa-miR-130a-3p 27.23 28.26 28.49 hsa-miR-33a-5p 30.34 28.54 34.18 hsa-miR-128- 26.94 28.64 27.66 hsa-miR-218-5p 27.79 28.68 28.03 hsa-miR-301a-3p 29.53 28.69 31.57 hsa-miR-134 28.3 28.76 28.76 hsa-miR-101-3p 28.44 28.82 31.64 hsa-miR-7-5p 29.71 28.82 30.22 hsa-miR-18b-5p 28.83 28.85 35.47 hsa-miR-185-5p 28.34 28.99 28.13 hsa-miR-378-3p 29.76 29.25 28.97 hsa-miR-132-3p 28.65 29.32 27.72 hsa-miR-345-5p 28.49 29.52 29.66 hsa-miR-219-5p 30.58 29.52 32.7 hsa-miR-127-5p 30.05 29.95 31.11 hsa-miR-146b-5p 30.53 30.54 28.07 hsa-miR-10a-5p 27.1 30.69 28.32 hsa-miR-210 29.85 30.83 30.65 hsa-miR-129-5p 32.51 30.98 31.69 hsa-miR-137 31.46 31.13 30.95 hsa-miR-182-5p 28.34 31.64 31.27 hsa-miR-124-3p 33.38 31.71 33.07 hsa-miR-96-5p 29.77 32.27 34.67 hsa-miR-192-5p 31.42 32.42 32.52 hsa-miR-126-3p 31.73 32.44 32.05 hsa-miR-194-5p 31.11 32.49 31.72 hsa-miR-375 33.77 32.94 30.94 hsa-miR-205-5p 35 33.01 32.72 hsa-miR-183-5p 29.88 33.21 31.74 hsa-miR-10b-5p 29.6 33.22 30.79 hsa-miR-302a-3p 29.67 33.6 31.69 hsa-miR-214-3p 34.19 33.76 32.11 hsa-miR-141-3p 35 33.96 34.51 hsa-miR-302c-3p 31.6 34.29 33.93 hsa-miR-196a-5p 35 34.65 35.75 hsa-miR-150-5p 34.59 34.76 34.59 hsa-miR-155-p 32.04 35.75 32.76 B Avg. of Arithmetic 23.54 23.82 24.79 Mean Avg. of Geometric 23.48 23.8 24.62 Mean

Example 13: CTX0E03 Conditioned Medium Analysis Using a Protein Dot Blot Methods

-   -   Conditioned 24 hr and 72 hrs conditioned medium (RMM and ITS         medium)     -   The collected media has been ‘concentrated’ by dialysis and the         proteins biotinylated (typical total protein concentration         appears to be 0.5 mg/ml). The media is then incubated with the         Raybiotech L507 human protein arrays (total protein         concentration 0.1 mg/ml). Following washing and incubation of         the array with HRP-conjugated streptavidin, the presence of         proteins is detected by chemiluminescence.

The array provides qualitative data (i.e. the protein is present, but no indication of its level of expression compared to other proteins).

Results

Cytokine Name Cytokine Full Name Function EDA-A2 ectodysplasin-A2 May be involved in proper formation of skin appendages Galectin-3* Galectin-3 Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. IGFBP-2 Insulin-like growth factor binding IGF-binding proteins prolong proteins 2 the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. IGFBP- Insulin-like Growth Factor Binding soluble proteins that bind IGFs rp1/IGFBP-7 Protein Related Protein-1 Insulin-like with high affinity. Growth Factor Binding Protein-7 IL-1a† Interleukin 1 alpha potent mediator of inflammation and immunity LECT2† Leukocyte cell-derived chemotaxin-2 Has a neutrophil chemotactic activity. Also a positive regulator of chondrocyte proliferation. MCP-1† Monocyte chemoattractant protein 1 plays a role in the recruitment of monocytes to sites of injury and infection. SPARC* Secreted Protein, Acidic Cysteine- matricellular protein that rich-related modular calcium-binding modulates cell adhesion and protein 1 [Precursor] proliferation and is thought to function in tissue remodeling and angiogenesis TINIP-1* Tissue inhibitor of Complexes with metalloproteinasess-2 metalloproteinases (such as collagenases) and irreversibly inactivates them. Also mediates erythropoiesis in vitro; but, unlike IL-3, it is species- specific, stimulating the growth and differentiation of only human and murine erythroid progenitors. Thrombospondin- Thrombospondin-1 multimodular secreted protein 1* that associates with the extracellular matrix and possesses a variety of biologic functions, including a potent angiogenic activity. VEGF* Vascular endothelial growth factor Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. These proteins show expression in some instances-though may also be present in media. EGF R/ErbB1 Epidermal growth factor receptor Receptor for EGF, but also for other members of the EGF family, as TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor MDC * A disintegrin and metalloproteinase Probable ligand for integrin in domain 11 the brain. This is a non catalytic Metalloproteinase-like, disintegrin- metalloprotease-like protein. like, and cysteine-rich protein MDC Endostatin* Endostatin Angiogenesis inhibitor; inhibits endothelial cell migration but may not effect proliferation. May work in balance with VEGF to maintain level of angiogenesis. Follistatin Follistatin Regulates stem cell renewal versus differentiation by inhibiting pro-differentiation proteins Csk† cytoplasmic tyrosine kinase Activity is required for interleukin 6 (IL-6) induced differentiation. May play a role in the growth and differentiation of hematopoietic cells. May be involved in signal transduction in endocardial and arterial endothelial cells. *angiogenesis †inflammation

Example 14: Production of Exosomes Using the Integra CELLine System

CTX0E03 cells were cultured using the Integra CELLine system and exosomes were purified as described in Example 10. The concentration of exosomes purified from the medium using the CELLine system at the 3 week time point, and as a control a standard T175 system as routinely used in the art, was quantified (using a BCA assay to estimate protein content). FIG. 9 shows that the production of exosomes using the Integra CELLine system is increased several fold, compared to using conventional culture (T175 flasks).

Using the Integra CELLine system, CTX0E03 cells were cultured over a 3-week period and medium was harvested at week 1, 2 and 3 for purification and quantification of exosomes, as described in Example 10. FIG. 10A shows that the production of microparticles increases exponentially over the 3-week culture period, enabling efficient and large-scale production of microparticles. The concentration of exosomes harvested from a single Integra CELLine flask was then monitored over 1-6 weeks of continuous CTX0E03 culture, with the results shown below and depicted in FIG. 10B:

Integra Total quantity time of exosomes Exosomes point (ug) ug/ml Week 1 12 0.80 Week 2 112 7.47 Week 3 88 5.87 Week 4 148 9.87 Week 5 240 16.00 Week 6 440 29.33

These results show that exosome production is surprisingly enhanced when stem cells are cultured in a multi-compartment bioreactor for weeks, typically at least three weeks.

Example 15: Characterisation of Phenotype of Cells Obtained from the Integra CELLine and the Standard (T175) Culture System

CTX0E03 cells were cultured using the Integra CELLine bioreactor and standard culture, as described in Example 10. Expression of DCX and GFAP protein markers was confirmed using marker-specific antibodies and fluorescence microscopy.

Expression of DCX, GALC, GFAP, TUBB3, GDNF and IDO markers was detected by qRT-PCR in samples obtained from the cells. Marker expression was compared between microparticles obtained from standard (T175) culture and exosomes obtained from the 3 week cultured Integra CELLine system, assessed against a baseline of the expression level in CTX0E03 cells in standard (T175) culture.

The inventors observed a striking difference in marker expression of cells obtained from the Integra CELLine system as compared to control cells obtained from standard. Markers of partially-differentiated cells were increased several fold in cells cultured in the Integra CELLine system, compared to control cells obtained from standard cultures (FIG. 11). Particularly striking changes are increased expression of the markers DCX1 (doublecortin—a marker for entry into the neural lineage), GFAP (glial fibrillary acidic protein—a marker for entry into the astrocytic lineage), GDNF (glial cell-derived neurotrophic factor) and IDO (indoleamine 2,3-dioxygenase). This indicates that in neural stem cells cultured in a two-compartment bioreactor partially differentiate into cells of neural (DCX+) or astrocytic (GFAP+) lineage. The expression of DCX and GFAP in the Integra-cultured cells was confirmed by fluorescence microscopy, demonstrating that CTX0E03 cells cultured using the Integra CELLine bioreactor have a more differentiated neuronal phenotype than standard CTX0E03 cells.

Example 16: Characterisation of miRNA Expression Profiles of Exosomes Obtained from Integra CELLine Cultures and Microparticles Obtained from Standard (T175) Cultures

CTX0E03 cells were cultured for three weeks using the Integra CELLine culture and in the standard culture in single-compartment T-175 flasks. Exosomes were purified from the Integra culture and microparticles were purified from the standard T-175 culture as described in Example 10. The relative expression levels of various miRNAs expressed in the exosomes and microparticles obtained from either the standard culture or the Integra CELLine system were determined with an miRNA array using qRT-PCR panel (Qiagen) according to manufacturer's instruction, and converted into fold up and down regulation levels as compared to a standard CTX0E03 cell line control group (see Table 4 and FIG. 12). These data show a differential miRNA expression profile between exosomes obtained from the Integra CELLine culture system for 3 weeks, microparticles, and cells obtained from the standard single-flask culture.

TABLE 4 Fold-regulation of miRNAs in microparticles obtained from standard culture or exosomes from the Integra CELLine system, relative to control (CTX0E03 cells). Standard Culture Integra (microparticles) (exosomes) miRNA Fold regulation relative to control (CTX0E03 cells) hsa-miR-146b-5p −1.0222 10.5805 hsa-let-7c −1.6954 4.7678 hsa-miR-99a-5p −3.5349 3.3714 hsa-miR-132-3p −1.9163 3.088 hsa-miR-378-3p 1.2731 3.0175 hsa-miR-181a-5p −1.7431 2.9147 hsa-let-7b-5p −1.4658 2.7574 hsa-miR-100-5p −3.208 1.977 hsa-let-7e-5p −2.7101 1.9274 hsa-miR-23b-3p −2.3322 1.8834 hsa-miR-185-5p −1.9119 1.8532 hsa-let-7i-5p −3.5677 1.8404 hsa-let-7a-5p −1.851 1.7736 hsa-let-7d-5p −1.5 1.7654 hsa-let-7g-5p −2.2527 1.7092 hsa-miR-222-3p −5.8092 1.6779 hsa-let-7f-5p −2.8712 1.5948 hsa-miR-218-5p −1.9611 1.5619 hsa-miR-24-3p −1.6721 1.5511 hsa-miR-9-5p −2.2475 1.4109 hsa-miR-126-3p −2.1263 1.203 hsa-miR-134 −1.6567 1.1783 hsa-miR-128 −3.5842 1.0743 hsa-miR-155-5p −8.8458 1.0425 hsa-miR-22-3p −3.4782 −1.0023 hsa-miR-26a-5p −5.3579 −1.0187 hsa-miR-210 −2.3107 −1.0449 hsa-miR-92a-3p −1.9885 −1.0693 hsa-miR-93-5p −3.056 −1.1701 hsa-miR-424-5p −4.9189 −1.2086 hsa-miR-195-5p −3.8951 −1.2541 hsa-miR-127-5p −1.1316 −1.2953 hsa-miR-21-5p −2.8845 −1.3044 hsa-miR-103a-3p −2.6482 −1.3287 hsa-miR-16-5p −3.5267 −1.3692 hsa-miR-125a-5p −5.1159 −1.434 hsa-miR-10a-5p −14.4701 −1.434 hsa-miR-10b-5p −15.1194 −1.4373 hsa-miR-345-5p −2.5521 −1.4406 hsa-miR-130a-3p −2.6178 −1.5728 hsa-miR-15b-5p −4.4025 −1.6058 hsa-miR-20b −2.1312 −1.6096 hsa-miR-20a-5p −2.3107 −1.8319 hsa-miR-17-5p −1.9296 −1.8319 hsa-miR-7-5p −1.5105 −2.042 hsa-miR-106b-5p −2.4708 −2.1287 hsa-miR-101-3p 1.4794 −2.4453 hsa-miR-302a-3p −18.0634 −2.4623 hsa-miR-301a-3p 1.4931 −2.5257 hsa-miR-183-5p −13.9772 −2.5847 hsa-miR-219-5p 1.6994 −2.7321 hsa-miR-18a-5p −1.4028 −3.2792 hsa-miR-15a-5p −2.4766 −3.3714 hsa-miR-182-5p −12.5099 −4.9588 hsa-miR-33a-5p 2.7927 −9.1472 hsa-miR-96-5p −7.0047 −18.9396 hsa-miR-18b-5p −1.3519 −49.18

Values were calculated from raw data using the following equations:

Δ CT  (sample/control) = Average  CT  (GOI) − Average  CT  (HKG) Fold  expression  (sample/control) = 2^(−(Average  Δ CT)) ${{Fold}\mspace{14mu} {change}} = \frac{{Fold}\mspace{14mu} {expression}\mspace{14mu} ({sample})}{{Fold}\mspace{14mu} {expression}\mspace{14mu} ({control})}$ If  (fold  change) > 1  then  (fold  regulation) = (fold  change) ${{{If}\mspace{14mu} \left( {{fold}\mspace{14mu} {change}} \right)} < {1\mspace{14mu} {then}\mspace{14mu} \left( {{fold}\mspace{14mu} {regulation}} \right)}} = {- \left( \frac{1}{{fold}\mspace{14mu} {change}} \right)}$

Wherein:

CT=cycle threshold

GOI=gene of interest (investigated miRNA)

HKG=housekeeping genes (reference miRNAs used to normalize the data)

Example 17: Total miRNA Analysis

Cells can shuttle RNA into microparticles determined for release into the extracellular space. This allows the conveyance of genetically encoded messages between cells. We here collectively refer to extracellular RNA as ‘shuttle RNA’. We aimed to analyze comprehensively non coding RNA species released by CTX0E03 neural stem cells (NSCs) using Next Generation Sequencing.

Non coding RNAs are divided in two categories (small and long). Small non coding RNA biotypes include ribosomal RNA (rRNA), small nucleolar (snoRNA), small nuclear RNA (snRNA), microRNA (miRNA), miscellaneous other RNA (misc_RNA, e.g. RMRP, vault RNA, metazoa SRP, and RNY), and long non coding RNA biotypes includes long non-coding RNAs (lncRNAs) and large intergenic non-coding RNAs (lincRNAs).

Here, we characterized shuttle RNAs, including small and long non coding RNAs, released from NSC derived exosomes and microvesicles (MV) and compared with the RNA contents of the producer NSCs.

A) Total RNA Contents in Cells, Exosomes and Microvesicles Identified by Agilent RNA Bioanalyser

The RNA in both exosomes and microvesicles mainly consists of small RNA species as shown in FIG. 14. The majority of the nucleotides (nt) was ≤200 as shown against the molecular ladder.

B) RNA Composition

Small RNA sequencing libraries were generated to investigate the composition of shuttle and cellular RNA by deep sequencing (Next Generation Sequencing). The results are shown in FIG. 15.

C) Deep Sequencing of CTX0E03 Cell, Microvesicle and Exosome miRNA Expression from Standard (T175) Cultures.

Deep sequencing is based on the preparation of a cDNA library following by sequencing and provides information regarding the total sequence read out of different miRNAs in the microvesicles and exosomes. These deep sequence data complement the qRT-PCR array data shown above and provide a comprehensive analysis of the miRNA profile of the cells and microparticles. Unlike the qRT-PCR array analysis, deep sequencing is not restricted to identification of sequences present in the probe array and so the sequences to be identified do not need to be known in advance. Deep sequencing also provides direct read-out and the ability to sequence very short sequences. However, deep sequencing is not suitable for detection of transcripts with low expression.

Method

The presence of a variety of miRNAs in parental cells and their exosomes (30-100 μm) and microvesicles (100-1000 μm), purified by differential centrifugation, was identified by deep sequencing, following construction of 1 tagged miRNA library for each sample.

Additionally, specific primers for highly shuttled miRNAs (e.g. hsa-miR-1246) were designed and used in real-time reverse transcription PCR (qRT-PCR) to trace exosomes/microvesicles following in vivo implantation.

Deep sequencing was performed by GATC Biotech (Germany) and required the preparation of a tagged miRNA library for each samples followed by sequencing, and miRBase scanning:

-   -   Construction of tagged miRNA libraries (22 to 30 nt)         -   Sequencing libraries were generated by ligation of specific             RNA adapter to both 3′ and 5′ ends for each sample followed             by reverse transcription, amplification, and purification of             smallRNA libraries (size range of contained smallRNA             fraction 22-30 nt).     -   Sequencing on an Illumina HiSeq 2000 (single read)         -   Sequencing was performed using Illumina HiSeq 2000 (single             read). Analysis of one pool could include up to 45,000,000             single read, and each read length is up to 50 bases.             Sequencing was quality controlled by using FastQ Files             (sequences and quality scores).     -   Identification of known miRNAs was performed as followed:         -   RNA adapters were trimmed from resulting sequences and raw             data cleaned. Raw data were clustered and for each cluster a             number of reads was provided. MiRNAs were identified by             miRBase scanning (Ssearch).

Results

Many microvesicle and exosome miRNAs were enriched relative to the cells, indicating that cells specially sort miRNAs for extracellular release. Furthermore, miRNA contents were similar in both exosomes and microvesicles, indicating a common apparatus of selective miRNA uptake in excreted microvesicles. Without wishing to be bound by theory, this may indicate that miRNA content in secreted microvesicles and exosomes can be used as a fingerprint to identify hNSC subtypes.

The deep sequencing analysis therefore identified a unique set of miRNAs in both hNSC exosomes and microvesicles not previously reported. MiRNA content in excreted vesicles is similar, but showed a preferential miRNA uptake compared with hNSC. These findings could support biological effects mediated by shuttle miRNA not previously described for hNSC.

The results are detailed in Tables 5 to 10, below. The data are also depicted in FIGS. 13A-13H, which clearly shows the significantly different miRNA profiles present in the microvesicles and exosomes, compared to the cells. In summary, these data show a massive increase in the amount (read counts) of hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 in microvesicles and exosomes compared to the cells. Large increases are also seen in hsa-miR-4508, hsa-miR-4516, hsa-miR-3676-5p and hsa-miR-4485. Massive decreases are seen in the amounts (read counts) of certain miRNAs, including hsa-let-7a-5p, has-miR-92b-3p, has-miR-21-5p. hsa-miR-92a-3p, hsa-miR-10a-5p, hsa-100-5p and hsa-99b-5p.

The presence of each of hsa-miR-1246, hsa-miR-4488, hsa-miR-4492, hsa-miR-4508, hsa-miR-4516 and hsa-miR-4532 in the exosomes was validated by qRT-PCR (data not shown).

Plotting the deep sequencing results in the exosomes and microvesicles as relative fold change compared to the cells confirms that hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532 are significantly upregulated in the exosomes and microvesicles compared to the cells. This comparison also shows that miRNA hsa-miR-3195 is the miRNA that is most upregulated, in both exosomes and microvesicles. Although the absolute reads of hsa-miR-3195 are in the range of ˜40 for exosomes and microvesicles, there is no hsa-miR-3195 present in the cells.

As noted in Example 16 above, miRNA contents in exosomes, microparticles, and parental cells were also tested and validated using PCR array analysis. The following miRNAs were found present by qRT-PCR: hsa-let-7g-5p, hsa-miR-101-3p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-128, hsa-miR-130a-3p, hsa-miR-134, hsa-miR-137, hsa-miR-146b-5p, hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-181a-5p, hsa-miR-182-5p, hsa-miR-185-5p, hsa-miR-18b-5p, hsa-miR-192-5p, hsa-miR-194-5p, hsa-miR-195-5p, hsa-miR-20a-5p, hsa-miR-20b-5p, hsa-miR-210, hsa-miR-21-5p, hsa-miR-218-5p, hsa-miR-219-5p, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-26a-5p, hsa-miR-301a-3p, hsa-miR-302a-3p, hsa-miR-302c-3p, hsa-miR-345-5p, hsa-miR-378a-3p, hsa-miR-7-5p, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-9-5p, hsa-miR-96-5p, and hsa-miR-99a-5p.

TABLE 5 Cells EH Cells: CTX0E03 07EH SEQ MIRNA READ MIRNA MIRNA.SEQUENCE ID NO: LENGTH COUNTS hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22 75110 hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG   2 23 52927 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22 52451 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22 39457 hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG   5 22 20310 hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC   6 21 16900 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22 14359 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23 12591 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22 11943 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU  10 22 11760 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22 10349 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22  9900 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22  9794 hsa-miR-127-3p UCGGAUCCGUCUGAGCUUGGCU  14 22  7064 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23  6956 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24  5531 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22  5103 hsa-miR-379-5p UGGUAGACUAUGGAACGUAGG  18 21  4746 hsa-miR-146b-5p UGAGAACUGAAUUCCAUAGGCU  19 22  4552 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21  4089 hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19  3973 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  22 22  3015 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17  2847 hsa-miR-183-5p UAUGGCACUGGUAGAAUUCACU  24 22  2695 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  25 21  2681 hsa-miR-501-3p AAUGCACCCGGGCAAGGAUUCU  26 22  2649 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU  27 22  2449 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22  2435 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22  2173 hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG  30 22  2001 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  31 22  1977 hsa-miR-409-5p AGGUUACCCGAGCAACUUUGCAU  32 23  1871 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22  1826 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17  1754 hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA  35 24  1451 hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU  36 21  1422 hsa-miR-151a-5p UCGAGGAGCUCACAGUCUAGU  37 21  1386 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23  1382 hsa-miR-221-5p ACCUGGCAUACAAUGUAGAUUU  39 22  1363 hsa-miR-186-5p CAAAGAAUUCUCCUUUUGGGCU  40 22  1225 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23  1080 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22  1002 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU  43 22   959 hsa-miR-500a-3p AUGCACCUGGGCAAGGAUUCUG  44 22   923 hsa-miR-30e-5p UGUAAACAUCCUUGACUGGAAG  45 22   911 hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC  46 21   867 hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU  47 22   865 hsa-miR-148b-3p UCAGUGCAUCACAGAACUUUGU  48 22   856 hsa-miR-125b-1-3p ACGGGUUAGGCUCUUGGGAGCU  49 22   851 hsa-miR-410 AAUAUAACACAGAUGGCCUGU  50 21   848 hsa-miR-381 UAUACAAGGGCAAGCUCUCUGU  51 22   842 hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG  52 22   773 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  53 22   765 hsa-miR-148a-3p UCAGUGCACUACAGAACUUUGU  54 22   702 hsa-miR-23a-3p AUCACAUUGCCAGGGAUUUCC  55 21   654 hsa-miR-28-3p CACUAGAUUGUGAGCUCCUGGA  56 22   593 hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU  57 23   557 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23   518 hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC  59 21   508 hsa-miR-941 CACCCGGCUGUGUGCACAUGUGC  60 23   492 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18   485 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA  62 23   459 hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA  63 22   436 hsa-miR-889 UUAAUAUCGGACAACCAUUGU  64 21   411 hsa-miR-378a-3p ACUGGACUUGGAGUCAGAAGG  65 21   410 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  66 23   378 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20   358 hsa-miR-125b-2-3p UCACAAGUCAGGCUCUUGGGAC  68 22   352 hsa-miR-671-3p UCCGGUUCUCAGGGCUCCACC  69 21   350 hsa-miR-361-5p UUAUCAGAAUCUCCAGGGGUAC  70 22   337 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC  71 22   294 hsa-miR-1271-5p CUUGGCACCUAGCAAGCACUCA  72 22   288 hsa-miR-589-5p UGAGAACCACGUCUGCUCUGAG  73 22   282 hsa-miR-374a-5p UUAUAAUACAACCUGAUAAGUG  74 22   275 hsa-miR-769-5p UGAGACCUCUGGGUUCUGAGCU  75 22   263 hsa-miR-345-5p GCUGACUCCUAGUCCAGGGCUC  76 22   249 hsa-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC  77 22   236 hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  78 22   229 hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC  79 23   225 hsa-miR-31-5p AGGCAAGAUGCUGGCAUAGCU  80 21   213 hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU  81 23   205 hsa-miR-136-3p CAUCAUCGUCUCAAAUGAGUCU  82 22   203 hsa-miR-493-3p UGAAGGUCUACUGUGUGCCAGG  83 22   192 hsa-miR-720 UCUCGCUGGGGCCUCCA  84 17   154 hsa-miR-7-5p UGGAAGACUAGUGAUUUUGUUGU  85 23   154 hsa-miR-130b-3p CAGUGCAAUGAUGAAAGGGCAU  86 22   150 hsa-miR-192-5p CUGACCUAUGAAUUGACAGCC  87 21   138 hsa-miR-493-5p UUGUACAUGGUAGGCUUUCAUU  88 22   115 hsa-miR-204-5p UUCCCUUUGUCAUCCUAUGCCU  89 22   113 hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU  90 21   107 hsa-miR-1307-5p UCGACCGGACCUCGACCGGCU  91 21   105 hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU  92 22   103 hsa-miR-340-5p UUAUAAAGCAAUGAGACUGAUU  93 22   100 hsa-miR-134 UGUGACUGGUUGACCAGAGGGG  94 22    99 hsa-miR-432-5p UCUUGGAGUAGGUCAUUGGGUGG  95 23    97 hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU  96 22    96 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA  97 22    95 hsa-miR-100-3p CAAGCUUGUAUCUAUAGGUAUG  98 22    94 hsa-miR-744-5p UGCGGGGCUAGGGCUAACAGCA  99 22    89 hsa-miR-181a-3p ACCAUCGACCGUUGAUUGUACC 100 22    86 hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 101 22    85 hsa-miR-181a-2-3p ACCACUGACCGUUGACUGUACC 102 22    81 hsa-miR-190a UGAUAUGUUUGAUAUAUUAGGU 103 22    79 hsa-miR-132-3p UAACAGUCUACAGCCAUGGUCG 104 22    78 hsa-miR-181c-5p AACAUUCAACCUGUCGGUGAGU 105 22    76 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 106 22    75 hsa-miR-301a-3p CAGUGCAAUAGUAUUGUCAAAGC 107 23    75 hsa-miR-411-5p UAGUAGACCGUAUAGCGUACG 108 21    75 hsa-miR-128 UCACAGUGAACCGGUCUCUUU 109 21    74 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17    74 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 111 23    72 hsa-miR-130b-5p ACUCUUUCCCUGUUGCACUAC 112 21    71 hsa-miR-130a-3p CAGUGCAAUGUUAAAAGGGCAU 113 22    67 hsa-miR-30d-3p CUUUCAGUCAGAUGUUUGCUGC 114 22    65 hsa-miR-654-5p UGGUGGGCCGCAGAACAUGUGC 115 22    65 hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 116 23    65 hsa-miR-487b AAUCGUACAGGGUCAUCCACUU 117 22    63 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 118 22    62 hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 119 22    61 hsa-miR-4677-3p UCUGUGAGACCAAAGAACUACU 120 22    61 hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC 121 23    56 hsa-miR-197-3p UUCACCACCUUCUCCACCCAGC 122 22    56 hsa-miR-96-5p UUUGGCACUAGCACAUUUUUGCU 123 23    56 hsa-miR-1307-3p ACUCGGCGUGGCGUCGGUCGUG 124 22    55 hsa-miR-34c-5p AGGCAGUGUAGUUAGCUGAUUGC 125 23    53 hsa-miR-370 GCCUGCUGGGGUGGAACCUGGU 126 22    52 hsa-miR-148b-5p AAGUUCUGUUAUACACUCAGGC 127 22    51 hsa-miR-335-5p UCAAGAGCAAUAACGAAAAAUGU 128 23    51 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC 129 23    50 hsa-miR-27a-5p AGGGCUUAGCUGCUUGUGAGCA 130 22    49 hsa-miR-363-3p AAUUGCACGGUAUCCAUCUGUA 131 22    47 hsa-miR-431-5p UGUCUUGCAGGCCGUCAUGCA 132 21    47 hsa-miR-877-5p GUAGAGGAGAUGGCGCAGGG 133 20    46 hsa-miR-550a-5p AGUGCCUGAGGGAGUAAGAGCCC 134 23    45 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17    44 hsa-miR-541-3p UGGUGGGCACAGAAUCUGGACU 136 22    42 hsa-miR-135b-5p UAUGGCUUUUCAUUCCUAUGUGA 137 23    40 hsa-miR-140-3p UACCACAGGGUAGAACCACGG 138 21    39 hsa-miR-362-5p AAUCCUUGGAACCUAGGUGUGAGU 139 24    37 hsa-miR-455-3p GCAGUCCAUGGGCAUAUACAC 140 21    37 hsa-miR-758 UUUGUGACCUGGUCCACUAACC 141 22    37 hsa-miR-101-3p UACAGUACUGUGAUAACUGAA 142 21    36 hsa-miR-374b-5p AUAUAAUACAACCUGCUAAGUG 143 22    36 hsa-miR-148a-5p AAAGUUCUGAGACACUCCGACU 144 22    35 hsa-miR-17-5p CAAAGUGCUUACAGUGCAGGUAG 145 23    35 hsa-miR-20a-5p UAAAGUGCUUAUAGUGCAGGUAG 146 23    35 hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA 147 22    35 hsa-miR-193b-3p AACUGGCCCUCAAAGUCCCGCU 148 22    34 hsa-miR-548ah-3p CAAAAACUGCAGUUACUUUUGC 149 22    34 hsa-miR-539-3p AUCAUACAAGGACAAUUUCUUU 150 22    33 hsa-miR-421 AUCAACAGACAUUAAUUGGGCGC 151 23    31 hsa-miR-28-5p AAGGAGCUCACAGUCUAUUGAG 152 22    30 hsa-miR-485-3p GUCAUACACGGCUCUCCUCUCU 153 22    29 hsa-miR-2467-5p UGAGGCUCUGUUAGCCUUGGCUC 154 23    26 hsa-miR-4449 CGUCCCGGGGCUGCGCGAGGCA 155 22    26 hsa-miR-24-2-5p UGCCUACUGAGCUGAAACACAG 156 22    25 hsa-miR-181d AACAUUCAUUGUUGUCGGUGGGU 157 23    24 hsa-miR-323a-3p CACAUUACACGGUCGACCUCU 158 21    24 hsa-miR-106b-3p CCGCACUGUGGGUACUUGCUGC 159 22    23 hsa-miR-125a-3p ACAGGUGAGGUUCUUGGGAGCC 160 22    23 hsa-miR-330-5p UCUCUGGGCCUGUGUCUUAGGC 161 22    23 hsa-miR-1275 GUGGGGGAGAGGCUGUC 162 17    22 hsa-miR-19b-3p UGUGCAAAUCCAUGCAAAACUGA 163 23    22 hsa-miR-301b CAGUGCAAUGAUAUUGUCAAAGC 164 23    21 hsa-miR-485-5p AGAGGCUGGCCGUGAUGAAUUC 165 22    21 hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU 166 23    20 hsa-miR-3158-3p AAGGGCUUCCUCUCUGCAGGAC 167 22    20 hsa-miR-431-3p CAGGUCGUCUUGCAGGGCUUCU 168 22    20 hsa-miR-454-3p UAGUGCAAUAUUGCUUAUAGGGU 169 23    20 hsa-miR-106b-5p UAAAGUGCUGACAGUGCAGAU 170 21    19 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19    19 hsa-miR-31-3p UGCUAUGCCAACAUAUUGCCAU 172 22    19 hsa-miR-374a-3p CUUAUCAGAUUGUAUUGUAAUU 173 22    19 hsa-miR-433 AUCAUGAUGGGCUCCUCGGUGU 174 22    19 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18    19 hsa-miR-143-3p UGAGAUGAAGCACUGUAGCUC 176 21    18 hsa-miR-19a-3p UGUGCAAAUCUAUGCAAAACUGA 177 23    18 hsa-miR-532-5p CAUGCCUUGAGUGUAGGACCGU 178 22    18 hsa-miR-561-5p AUCAAGGAUCUUAAACUUUGCC 179 22    18 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22    18 hsa-miR-1301 UUGCAGCUGCCUGGGAGUGACUUC 181 24    17 hsa-miR-299-3p UAUGUGGGAUGGUAAACCGCUU 182 22    17 hsa-miR-9-3p AUAAAGCUAGAUAACCGAAAGU 183 22    17 hsa-miR-17-3p ACUGCAGUGAAGGCACUUGUAG 184 22    15 hsa-miR-376c AACAUAGAGGAAAUUCCACGU 185 21    15 hsa-miR-424-5p CAGCAGCAAUUCAUGUUUUGAA 186 22    15 hsa-miR-660-5p UACCCAUUGCAUAUCGGAGUUG 187 22    15 hsa-miR-153 UUGCAUAGUCACAAAAGUGAUC 188 22    14 hsa-miR-3605-5p UGAGGAUGGAUAGCAAGGAAGCC 189 23    14 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24    14 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18    14 hsa-miR-455-5p UAUGUGCCUUUGGACUACAUCG 192 22    14 hsa-miR-543 AAACAUUCGCGGUGCACUUCUU 193 22    14 hsa-miR-1276 UAAAGAGCCCUGUGGAGACA 194 20    13 hsa-miR-330-3p GCAAAGCACACGGCCUGCAGAGA 195 23    13 hsa-miR-369-3p AAUAAUACAUGGUUGAUCUUU 196 21    13 hsa-miR-4786-5p UGAGACCAGGACUGGAUGCACC 197 22    13 hsa-miR-548k AAAAGUACUUGCGGAUUUUGCU 198 22    13 hsa-miR-1226-3p UCACCAGCCCUGUGUUCCCUAG 199 22    12 hsa-miR-188-3p CUCCCACAUGCAGGGUUUGCA 200 21    12 hsa-miR-27b-5p AGAGCUUAGCUGAUUGGUGAAC 201 22    12 hsa-miR-377-5p AGAGGUUGCCCUUGGUGAAUUC 202 22    12 hsa-miR-487a AAUCAUACAGGGACAUCCAGUU 203 22    12 hsa-miR-92a-1-5p AGGUUGGGAUCGGUUGCAAUGCU 204 23    12 hsa-miR-135b-3p AUGUAGGGCUAAAAGCCAUGGG 205 22    11 hsa-miR-218-5p UUGUGCUUGAUCUAACCAUGU 206 21    11 hsa-miR-3943 UAGCCCCCAGGCUUCACUUGGCG 207 23    11 hsa-miR-92b-5p AGGGACGGGACGCGGUGCAGUG 208 22    11 hsa-miR-1185-1-3p AUAUACAGGGGGAGACUCUUAU 209 22    10 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21    10 hsa-miR-2355-5p AUCCCCAGAUACAAUGGACAA 211 21    10 hsa-miR-23a-5p GGGGUUCCUGGGGAUGGGAUUU 212 22    10 hsa-miR-30c-1-3p CUGGGAGAGGGUUGUUUACUCC 213 22    10 hsa-miR-329 AACACACCUGGUUAACCUCUUU 214 22    10 hsa-miR-337-3p CUCCUAUAUGAUGCCUUUCUUC 215 22    10 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24    10 hsa-miR-378a-5p CUCCUGACUCCAGGUCCUGUGU 217 22    10 hsa-miR-3929 GAGGCUGAUGUGAGUAGACCACU 218 23    10 hsa-miR-4745-5p UGAGUGGGGCUCCCGGGACGGCG 219 23    10 hsa-miR-5096 GUUUCACCAUGUUGGUCAGGC 220 21    10 hsa-miR-656 AAUAUUAUACAGUCAACCUCU 221 21    10 hsa-let-7a-3p CUAUACAAUCUACUGUCUUUC 222 21     9 hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG 223 22     9 hsa-miR-185-5p UGGAGAGAAAGGCAGUUCCUGA 224 22     9 hsa-miR-25-5p AGGCGGAGACUUGGGCAAUUG 225 21     9 hsa-miR-3065-5p UCAACAAAAUCACUGAUGCUGGA 226 23     9 hsa-miR-3176 ACUGGCCUGGGACUACCGG 227 19     9 hsa-miR-339-3p UGAGCGCCUCGACGACAGAGCCG 228 23     9 hsa-miR-374b-3p CUUAGCAGGUUGUAUUAUCAUU 229 22     9 hsa-miR-4435 AUGGCCAGAGCUCACACAGAGG 230 22     9 hsa-miR-4448 GGCUCCUUGGUCUAGGGGUA 231 20     9 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17     9 hsa-miR-4521 GCUAAGGAAGUCCUGUGCUCAG 233 22     9 hsa-miR-539-5p GGAGAAAUUAUCCUUGGUGUGU 234 22     9 hsa-miR-548ah-5p AAAAGUGAUUGCAGUGUUUG 235 20     9 hsa-miR-1910 CCAGUCCUGUGCCUGCCGCCU 236 21     8 hsa-miR-376a-3p AUCAUAGAGGAAAAUCCACGU 237 21     8 hsa-miR-382-5p GAAGUUGUUCGUGGUGGAUUCG 238 22     8 hsa-miR-3940-3p CAGCCCGGAUCCCAGCCCACUU 239 22     8 hsa-miR-494 UGAAACAUACACGGGAAACCUC 240 22     8 hsa-miR-495 AAACAAACAUGGUGCACUUCUU 241 22     8 hsa-miR-545-3p UCAGCAAACAUUUAUUGUGUGC 242 22     8 hsa-miR-99b-3p CAAGCUCGUGUCUGUGGGUCCG 243 22     8 hsa-miR-1197 UAGGACACAUGGUCUACUUCU 244 21     7 hsa-miR-181b-3p CUCACUGAACAAUGAAUGCAA 245 21     7 hsa-miR-212-5p ACCUUGGCUCUAGACUGCUUACU 246 23     7 hsa-miR-3200-3p CACCUUGCGCUACUCAGGUCUG 247 22     7 hsa-miR-340-3p UCCGUCUCAGUUACUUUAUAGC 248 22     7 hsa-miR-3607-5p GCAUGUGAUGAAGCAAAUCAGU 249 22     7 hsa-miR-361-3p UCCCCCAGGUGUGAUUCUGAUUU 250 23     7 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17     7 hsa-miR-532-3p CCUCCCACACCCAAGGCUUGCA 252 22     7 hsa-miR-574-3p CACGCUCAUGCACACACCCACA 253 22     7 hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA 254 23     6 hsa-miR-127-5p CUGAAGCUCAGAGGGCUCUGAU 255 22     6 hsa-miR-18a-5p UAAGGUGCAUCUAGUGCAGAUAG 256 23     6 hsa-miR-26a-2-3p CCUAUUCUUGAUUACUUGUUUC 257 22     6 hsa-miR-296-5p AGGGCCCCCCCUCAAUCCUGU 258 21     6 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21     6 hsa-miR-382-3p AAUCAUUCACGGACAACACUU 260 21     6 hsa-miR-3939 UACGCGCAGACCACAGGAUGUC 261 22     6 hsa-miR-432-3p CUGGAUGGCUCCUCCAUGUCU 262 21     6 hsa-miR-4423-5p AGUUGCCUUUUUGUUCCCAUGC 263 22     6 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18     6 hsa-miR-454-5p ACCCUAUCAAUAUUGUCUCUGC 265 22     6 hsa-miR-4746-5p CCGGUCCCAGGAGAACCUGCAGA 266 23     6 hsa-miR-496 UGAGUAUUACAUGGCCAAUCUC 267 22     6 hsa-miR-548o-3p CCAAAACUGCAGUUACUUUUGC 268 22     6 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 269 27     5 hsa-miR-1254 AGCCUGGAAGCUGGAGCCUGCAGU 270 24     5 hsa-miR-1296 UUAGGGCCCUGGCUCCAUCUCC 271 22     5 hsa-miR-136-5p ACUCCAUUUGUUUUGAUGAUGGA 272 23     5 hsa-miR-199a-5p CCCAGUGUUCAGACUACCUGUUC 273 23     5 hsa-miR-296-3p GAGGGUUGGGUGGAGGCUCUCC 274 22     5 hsa-miR-3177-3p UGCACGGCACUGGGGACACGU 275 21     5 hsa-miR-324-3p ACUGCCCCAGGUGCUGCUGG 276 20     5 hsa-miR-337-5p GAACGGCUUCAUACAGGAGUU 277 21     5 hsa-miR-342-5p AGGGGUGCUAUCUGUGAUUGA 278 21     5 hsa-miR-365b-3p UAAUGCCCCUAAAAAUCCUUAU 279 22     5 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15     5 hsa-miR-502-3p AAUGCACCUGGGCAAGGAUUCA 281 22     5 hsa-miR-505-3p CGUCAACACUUGCUGGUUUCCU 282 22     5 hsa-miR-550a-3p UGUCUUACUCCCUCAGGCACAU 283 22     5 hsa-miR-5587-3p GCCCCGGGCAGUGUGAUCAUC 284 21     5 hsa-miR-641 AAAGACAUAGGAUAGAGUCACCUC 285 24     5 hsa-miR-655 AUAAUACAUGGUUAACCUCUUU 286 22     5 hsa-miR-664-3p UAUUCAUUUAUCCCCAGCCUACA 287 23     5 hsa-miR-671-5p AGGAAGCCCUGGAGGGGCUGGAG 288 23     5 hsa-miR-760 CGGCUCUGGGUCUGUGGGGA 289 20     5 hsa-let-7e-3p CUAUACGGCCUCCUAGCUUUCC 290 22     4 hsa-miR-1268a CGGGCGUGGUGGUGGGGG 291 18     4 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19     4 hsa-miR-1286 UGCAGGACCAAGAUGAGCCCU 293 21     4 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24     4 hsa-miR-141-3p UAACACUGUCUGGUAAAGAUGG 295 22     4 hsa-miR-1468 CUCCGUUUGCCUGUUUCGCUG 296 21     4 hsa-miR-328 CUGGCCCUCUCUGCCCUUCCGU 297 22     4 hsa-miR-424-3p CAAAACGUGAGGCGCUGCUAU 298 21     4 hsa-miR-4454 GGAUCCGAGUCACGGCACCA 299 20     4 hsa-miR-4463 GAGACUGGGGUGGGGCC 300 17     4 hsa-miR-4671-3p UUAGUGCAUAGUCUUUGGUCU 301 21     4 hsa-miR-4775 UUAAUUUUUUGUUUCGGUCACU 302 22     4 hsa-miR-500a-5p UAAUCCUUGCUACCUGGGUGAGA 303 23     4 hsa-miR-548b-5p AAAAGUAAUUGUGGUUUUGGCC 304 22     4 hsa-miR-573 CUGAAGUGAUGUGUAACUGAUCAG 305 24     4 hsa-miR-576-5p AUUCUAAUUUCUCCACGUCUUU 306 22     4 hsa-miR-625-3p GACUAUAGAACUUUCCCCCUCA 307 22     4 hsa-miR-652-3p AAUGGCGCCACUAGGGUUGUG 308 21     4 hsa-miR-665 ACCAGGAGGCUGAGGCCCCU 309 20     4 hsa-miR-766-3p ACUCCAGCCCCACAGCCUCAGC 310 22     4 hsa-miR-935 CCAGUUACCGCUUCCGCUACCGC 311 23     4 hsa-miR-937 AUCCGCGCUCUGACUCUCUGCC 312 22     4 hsa-miR-1180 UUUCCGGCUCGCGUGGGUGUGU 313 22     3 hsa-miR-1185-2-3p AUAUACAGGGGGAGACUCUCAU 314 22     3 hsa-miR-132-5p ACCGUGGCUUUCGAUUGUUACU 315 22     3 hsa-miR-16-2-3p CCAAUAUUACUGUGCUGCUUUA 316 22     3 hsa-miR-20b-5p CAAAGUGCUCAUAGUGCAGGUAG 317 23     3 hsa-miR-2116-3p CCUCCCAUGCCAAGAACUCCC 318 21     3 hsa-miR-299-5p UGGUUUACCGUCCCACAUACAU 319 22     3 hsa-miR-30b-3p CUGGGAGGUGGAUGUUUACUUC 320 22     3 hsa-miR-30c-2-3p CUGGGAGAAGGCUGUUUACUCU 321 22     3 hsa-miR-3187-3p UUGGCCAUGGGGCUGCGCGG 322 20     3 hsa-miR-3615 UCUCUCGGCUCCUCGCGGCUC 323 21     3 hsa-miR-3620 UCACCCUGCAUCCCGCACCCAG 324 22     3 hsa-miR-3654 GACUGGACAAGCUGAGGAA 325 19     3 hsa-miR-3662 GAAAAUGAUGAGUAGUGACUGAUG 326 24     3 hsa-miR-3681-5p UAGUGGAUGAUGCACUCUGUGC 327 22     3 hsa-miR-4286 ACCCCACUCCUGGUACC 328 17     3 hsa-miR-4640-3p CACCCCCUGUUUCCUGGCCCAC 329 22     3 hsa-miR-4717-3p ACACAUGGGUGGCUGUGGCCU 330 21     3 hsa-miR-542-3p UGUGACAGAUUGAUAACUGAAA 331 22     3 hsa-miR-5584-5p CAGGGAAAUGGGAAGAACUAGA 332 22     3 hsa-miR-570-3p CGAAAACAGCAAUUACCUUUGC 333 22     3 hsa-miR-574-5p UGAGUGUGUGUGUGUGAGUGUGU 334 23     3 hsa-miR-628-3p UCUAGUAAGAGUGGCAGUCGA 335 21     3 hsa-miR-654-3p UAUGUCUGCUGACCAUCACCUU 336 22     3 hsa-miR-769-3p CUGGGAUCUCCGGGGUCUUGGUU 337 23     3 hsa-miR-943 CUGACUGUUGCCGUCCUCCAG 338 21     3 hsa-let-7b-3p CUAUACAACCUACUGCCUUCCC 339 22     2 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 340 26     2 hsa-miR-1255a AGGAUGAGCAAAGAAAGUAGAUU 341 23     2 hsa-miR-1273e UUGCUUGAACCCAGGAAGUGGA 342 22     2 hsa-miR-1289 UGGAGUCCAGGAAUCUGCAUUUU 343 23     2 hsa-miR-152 UCAGUGCAUGACAGAACUUGG 344 21     2 hsa-miR-194-5p UGUAACAGCAACUCCAUGUGGA 345 22     2 hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC 346 21     2 hsa-miR-200c-3p UAAUACUGCCGGGUAAUGAUGGA 347 23     2 hsa-miR-212-3p UAACAGUCUCCAGUCACGGCC 348 21     2 hsa-miR-222-5p CUCAGUAGCCAGUGUAGAUCCU 349 22     2 hsa-miR-3065-3p UCAGCACCAGGAUAUUGUUGGAG 350 23     2 hsa-miR-3115 AUAUGGGUUUACUAGUUGGU 351 20     2 hsa-miR-3126-5p UGAGGGACAGAUGCCAGAAGCA 352 22     2 hsa-miR-3174 UAGUGAGUUAGAGAUGCAGAGCC 353 23     2 hsa-miR-324-5p CGCAUCCCCUAGGGCAUUGGUGU 354 23     2 hsa-miR-33a-5p GUGCAUUGUAGUUGCAUUGCA 355 21     2 hsa-miR-3677-3p CUCGUGGGCUCUGGCCACGGCC 356 22     2 hsa-miR-369-5p AGAUCGACCGUGUUAUAUUCGC 357 22     2 hsa-miR-425-3p AUCGGGAAUGUCGUGUCCGCCC 358 22     2 hsa-miR-4426 GAAGAUGGACGUACUUU 359 17     2 hsa-miR-4467 UGGCGGCGGUAGUUAUGGGCUU 360 22     2 hsa-miR-4482-3p UUUCUAUUUCUCAGUGGGGCUC 361 22     2 hsa-miR-4515 AGGACUGGACUCCCGGCAGCCC 362 22     2 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18     2 hsa-miR-659-5p AGGACCUUCCCUGAACCAAGGA 364 22     2 hsa-miR-663a AGGCGGGGCGCCGCGGGACCGC 365 22     2 hsa-miR-940 AAGGCAGGGCCCCCGCUCCCC 366 21     2 hsa-miR-99a-3p CAAGCUCGCUUCUAUGGGUCUG 367 22     2 hsa-miR-1185-5p AGAGGAUACCCUUUGUAUGUU 368 21     1 hsa-miR-1225-3p UGAGCCCCUGUGCCGCCCCCAG 369 22     1 hsa-miR-1237 UCCUUCUGCUCCGUCCCCCAG 370 21     1 hsa-miR-1252 AGAAGGAAAUUGAAUUCAUUUA 371 22     1 hsa-miR-1257 AGUGAAUGAUGGGUUCUGACC 372 21     1 hsa-miR-1260b AUCCCACCACUGCCACCAU 373 19     1 hsa-miR-1273d GAACCCAUGAGGUUGAGGCUGCAGU 374 25     1 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19     1 hsa-miR-1306-3p ACGUUGGCUCUGGUGGUG 376 18     1 hsa-miR-1321 CAGGGAGGUGAAUGUGAU 377 18     1 hsa-miR-1343 CUCCUGGGGCCCGCACUCUCGC 378 22     1 hsa-miR-138-5p AGCUGGUGUUGUGAAUCAGGCCG 379 23     1 hsa-miR-140-5p CAGUGGUUUUACCCUAUGGUAG 380 22     1 hsa-miR-146b-3p UGCCCUGUGGACUCAGUUCUGG 381 22     1 hsa-miR-186-3p GCCCAAAGGUGAAUUUUUUGGG 382 22     1 hsa-miR-1908 CGGCGGGGACGGCGAUUGGUC 383 21     1 hsa-miR-1915-3p CCCCAGGGCGACGCGGCGGG 384 20     1 hsa-miR-1915-5p ACCUUGCCUUGCUGCCCGGGCC 385 22     1 hsa-miR-193a-3p AACUGGCCUACAAAGUCCCAGU 386 22     1 hsa-miR-19b-1-5p AGUUUUGCAGGUUUGCAUCCAGC 387 23     1 hsa-miR-208b AUAAGACGAACAAAAGGUUUGU 388 22     1 hsa-miR-2110 UUGGGGAAACGGCCGCUGAGUG 389 22     1 hsa-miR-219-1-3p AGAGUUGAGUCUGGACGUCCCG 390 22     1 hsa-miR-26b-3p CCUGUUCUCCAUUACUUGGCUC 391 22     1 hsa-miR-2964a-3p AGAAUUGCGUUUGGACAAUCAGU 392 23     1 hsa-miR-29a-5p ACUGAUUUCUUUUGGUGUUCAG 393 22     1 hsa-miR-3126-3p CAUCUGGCAUCCGUCACACAGA 394 22     1 hsa-miR-3130-3p GCUGCACCGGAGACUGGGUAA 395 21     1 hsa-miR-3130-5p UACCCAGUCUCCGGUGCAGCC 396 21     1 hsa-miR-3140-5p ACCUGAAUUACCAAAAGCUUU 397 21     1 hsa-miR-3155a CCAGGCUCUGCAGUGGGAACU 398 21     1 hsa-miR-3157-3p CUGCCCUAGUCUAGCUGAAGCU 399 22     1 hsa-miR-3180-3p UGGGGCGGAGCUUCCGGAGGCC 400 22     1 hsa-miR-323b-5p AGGUUGUCCGUGGUGAGUUCGCA 401 23     1 hsa-miR-339-5p UCCCUGUCCUCCAGGAGCUCACG 402 23     1 hsa-miR-34a-3p CAAUCAGCAAGUAUACUGCCCU 403 22     1 hsa-miR-34b-3p CAAUCACUAACUCCACUGCCAU 404 22     1 hsa-miR-34c-3p AAUCACUAACCACACGGCCAGG 405 22     1 hsa-miR-3658 UUUAAGAAAACACCAUGGAGAU 406 22     1 hsa-miR-365a-5p AGGGACUUUUGGGGGCAGAUGUG 407 23     1 hsa-miR-3676-3p CCGUGUUUCCCCCACGCUUU 408 20     1 hsa-miR-3691-5p AGUGGAUGAUGGAGACUCGGUAC 409 23     1 hsa-miR-376a-5p GUAGAUUCUCCUUCUAUGAGUA 410 22     1 hsa-miR-378g ACUGGGCUUGGAGUCAGAAG 411 20     1 hsa-miR-3909 UGUCCUCUAGGGCCUGCAGUCU 412 22     1 hsa-miR-3928 GGAGGAACCUUGGAGCUUCGGC 413 22     1 hsa-miR-3942-3p UUUCAGAUAACAGUAUUACAU 414 21     1 hsa-miR-3944-5p UGUGCAGCAGGCCAACCGAGA 415 21     1 hsa-miR-3960 GGCGGCGGCGGAGGCGGGGG 416 20     1 hsa-miR-4326 UGUUCCUCUGUCUCCCAGAC 417 20     1 hsa-miR-4444 CUCGAGUUGGAAGAGGCG 418 18     1 hsa-miR-4450 UGGGGAUUUGGAGAAGUGGUGA 419 22     1 hsa-miR-4642 AUGGCAUCGUCCCCUGGUGGCU 420 22     1 hsa-miR-4668-5p AGGGAAAAAAAAAAGGAUUUGUC 421 23     1 hsa-miR-4673 UCCAGGCAGGAGCCGGACUGGA 422 22     1 hsa-miR-4688 UAGGGGCAGCAGAGGACCUGGG 423 22     1 hsa-miR-4700-3p CACAGGACUGACUCCUCACCCCAGUG 424 26     1 hsa-miR-4731-3p CACACAAGUGGCCCCCAACACU 425 22     1 hsa-miR-4749-3p CGCCCCUCCUGCCCCCACAG 426 20     1 hsa-miR-4769-5p GGUGGGAUGGAGAGAAGGUAUGAG 427 24     1 hsa-miR-4800-5p AGUGGACCGAGGAAGGAAGGA 428 21     1 hsa-miR-491-5p AGUGGGGAACCCUUCCAUGAGG 429 22     1 hsa-miR-501-5p AAUCCUUUGUCCCUGGGUGAGA 430 22     1 hsa-miR-5092 AAUCCACGCUGAGCUUGGCAUC 431 22     1 hsa-miR-541-5p AAAGGAUUCUGCUGUCGGUCCCACU 432 25     1 hsa-miR-542-5p UCGGGGAUCAUCAUGUCACGAGA 433 23     1 hsa-miR-551b-3p GCGACCCAUACUUGGUUUCAG 434 21     1 hsa-miR-5690 UCAGCUACUACCUCUAUUAGG 435 21     1 hsa-miR-577 UAGAUAAAAUAUUGGUACCUG 436 21     1 hsa-miR-584-3p UCAGUUCCAGGCCAACCAGGCU 437 22     1 hsa-miR-589-3p UCAGAACAAAUGCCGGUUCCCAGA 438 24     1 hsa-miR-616-5p ACUCAAAACCCUUCAGUGACUU 439 22     1 hsa-miR-628-5p AUGCUGACAUAUUUACUAGAGG 440 22     1 hsa-miR-629-5p UGGGUUUACGUUGGGAGAACU 441 21     1 hsa-miR-644b-3p UUCAUUUGCCUCCCAGCCUACA 442 22     1 hsa-miR-664-5p ACUGGCUAGGGAAAAUGAUUGGAU 443 24     1 hsa-miR-922 GCAGCAGAGAAUAGGACUACGUC 444 23     1

TABLE 6 Cells El CELLS-CTX0E03 07EI SEQ MIRNA READ MIRNA MIRNA.SEQUENCE ID NO: LENGTH COUNTS hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22 305060 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22 242715 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22 154626 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22 137412 hsa-miR-127-3p UCGGAUCCGUCUGAGCUUGGCU  14 22 110806 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22 109290 hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC   6 21  91902 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23  89150 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22  88724 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22  87399 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22  78395 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23  47686 hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG   5 22  41639 hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG  30 22  35465 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU  10 22  30440 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  25 21  29047 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21  27733 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  31 22  27307 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22  27224 hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG   2 23  26908 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22  26456 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24  25885 hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU  36 21  22187 hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA  35 24  20960 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22  19856 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22  19774 hsa-miR-151a-5p UCGAGGAGCUCACAGUCUAGU  37 21  19773 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU  27 22  19035 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22  17965 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  22 22  17802 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU  43 22  15467 hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU  47 22  14133 hsa-miR-30e-5p UGUAAACAUCCUUGACUGGAAG  45 22  13889 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23  12606 hsa-miR-186-5p CAAAGAAUUCUCCUUUUGGGCU  40 22  12441 hsa-miR-381 UAUACAAGGGCAAGCUCUCUGU  51 22   9851 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23   8893 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  66 23   8737 hsa-miR-410 AAUAUAACACAGAUGGCCUGU  50 21   8509 hsa-miR-146b-5p UGAGAACUGAAUUCCAUAGGCU  19 22   8434 hsa-miR-654-3p UAUGUCUGCUGACCAUCACCUU 336 22   8392 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23   7957 hsa-miR-28-3p CACUAGAUUGUGAGCUCCUGGA  56 22   7767 hsa-miR-148a-3p UCAGUGCACUACAGAACUUUGU  54 22   6599 hsa-miR-379-5p UGGUAGACUAUGGAACGUAGG  18 21   6135 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  53 22   5972 hsa-miR-183-5p UAUGGCACUGGUAGAAUUCACU  24 22   5477 hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA  63 22   5303 hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU  57 23   5225 hsa-miR-889 UUAAUAUCGGACAACCAUUGU  64 21   4597 hsa-miR-221-5p ACCUGGCAUACAAUGUAGAUUU  39 22   4379 hsa-miR-125b-1-3p ACGGGUUAGGCUCUUGGGAGCU  49 22   4192 hsa-miR-409-5p AGGUUACCCGAGCAACUUUGCAU  32 23   3970 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17   3864 hsa-miR-148b-3p UCAGUGCAUCACAGAACUUUGU  48 22   3593 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA  62 23   3518 hsa-miR-1271-5p CUUGGCACCUAGCAAGCACUCA  72 22   3477 hsa-miR-136-3p CAUCAUCGUCUCAAAUGAGUCU  82 22   3373 hsa-miR-769-5p UGAGACCUCUGGGUUCUGAGCU  75 22   2957 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17   2915 hsa-miR-378a-3p ACUGGACUUGGAGUCAGAAGG  65 21   2895 hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG  52 22   2767 hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC  79 23   2764 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC  71 22   2441 hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU  90 21   2432 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18   2391 hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC  46 21   2385 hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC  59 21   2316 hsa-miR-500a-3p AUGCACCUGGGCAAGGAUUCUG  44 22   2144 hsa-miR-941 CACCCGGCUGUGUGCACAUGUGC  60 23   2114 hsa-miR-23a-3p AUCACAUUGCCAGGGAUUUCC  55 21   2086 hsa-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC  77 22   2045 hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU  96 22   1936 hsa-miR-501-3p AAUGCACCCGGGCAAGGAUUCU  26 22   1895 hsa-miR-130b-3p CAGUGCAAUGAUGAAAGGGCAU  86 22   1862 hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19   1783 hsa-miR-140-3p UACCACAGGGUAGAACCACGG 138 21   1735 hsa-miR-31-5p AGGCAAGAUGCUGGCAUAGCU  80 21   1705 hsa-miR-493-3p UGAAGGUCUACUGUGUGCCAGG  83 22   1698 hsa-miR-181c-5p AACAUUCAACCUGUCGGUGAGU 105 22   1554 hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 116 23   1492 hsa-miR-181a-2-3p ACCACUGACCGUUGACUGUACC 102 22   1491 hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  78 22   1465 hsa-miR-7-5p UGGAAGACUAGUGAUUUUGUUGU  85 23   1460 hsa-miR-192-5p CUGACCUAUGAAUUGACAGCC  87 21   1453 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 111 23   1432 hsa-miR-204-5p UUCCCUUUGUCAUCCUAUGCCU  89 22   1378 hsa-miR-340-5p UUAUAAAGCAAUGAGACUGAUU  93 22   1360 hsa-miR-190a UGAUAUGUUUGAUAUAUUAGGU 103 22   1305 hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 101 22   1283 hsa-miR-20a-5p UAAAGUGCUUAUAGUGCAGGUAG 146 23   1257 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 106 22   1206 hsa-miR-361-5p UUAUCAGAAUCUCCAGGGGUAC  70 22   1173 hsa-miR-671-3p UCCGGUUCUCAGGGCUCCACC  69 21   1166 hsa-miR-411-5p UAGUAGACCGUAUAGCGUACG 108 21   1130 hsa-miR-589-5p UGAGAACCACGUCUGCUCUGAG  73 22   1067 hsa-miR-130a-3p CAGUGCAAUGUUAAAAGGGCAU 113 22   1020 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA  97 22    994 hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC 121 23    948 hsa-miR-335-5p UCAAGAGCAAUAACGAAAAAUGU 128 23    945 hsa-miR-134 UGUGACUGGUUGACCAGAGGGG  94 22    941 hsa-miR-17-5p CAAAGUGCUUACAGUGCAGGUAG 145 23    939 hsa-miR-493-5p UUGUACAUGGUAGGCUUUCAUU  88 22    876 hsa-miR-34c-5p AGGCAGUGUAGUUAGCUGAUUGC 125 23    846 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 118 22    835 hsa-miR-181a-3p ACCAUCGACCGUUGAUUGUACC 100 22    803 hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 119 22    740 hsa-miR-128 UCACAGUGAACCGGUCUCUUU 109 21    707 hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU  81 23    698 hsa-miR-454-3p UAGUGCAAUAUUGCUUAUAGGGU 169 23    690 hsa-miR-1307-5p UCGACCGGACCUCGACCGGCU  91 21    616 hsa-miR-487b AAUCGUACAGGGUCAUCCACUU 117 22    590 hsa-miR-130b-5p ACUCUUUCCCUGUUGCACUAC 112 21    568 hsa-miR-197-3p UUCACCACCUUCUCCACCCAGC 122 22    544 hsa-miR-432-5p UCUUGGAGUAGGUCAUUGGGUGG  95 23    542 hsa-miR-374a-5p UUAUAAUACAACCUGAUAAGUG  74 22    537 hsa-miR-345-5p GCUGACUCCUAGUCCAGGGCUC  76 22    527 hsa-miR-744-5p UGCGGGGCUAGGGCUAACAGCA  99 22    515 hsa-miR-376c AACAUAGAGGAAAUUCCACGU 185 21    506 hsa-miR-181d AACAUUCAUUGUUGUCGGUGGGU 157 23    497 hsa-miR-363-3p AAUUGCACGGUAUCCAUCUGUA 131 22    493 hsa-miR-539-3p AUCAUACAAGGACAAUUUCUUU 150 22    493 hsa-miR-758 UUUGUGACCUGGUCCACUAACC 141 22    477 hsa-miR-323a-3p CACAUUACACGGUCGACCUCU 158 21    443 hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA 254 23    431 hsa-miR-720 UCUCGCUGGGGCCUCCA  84 17    427 hsa-miR-654-5p UGGUGGGCCGCAGAACAUGUGC 115 22    409 hsa-miR-370 GCCUGCUGGGGUGGAACCUGGU 126 22    406 hsa-miR-421 AUCAACAGACAUUAAUUGGGCGC 151 23    399 hsa-miR-30d-3p CUUUCAGUCAGAUGUUUGCUGC 114 22    358 hsa-miR-148b-5p AAGUUCUGUUAUACACUCAGGC 127 22    354 hsa-miR-1301 UUGCAGCUGCCUGGGAGUGACUUC 181 24    346 hsa-miR-374b-5p AUAUAAUACAACCUGCUAAGUG 143 22    339 hsa-miR-125b-2-3p UCACAAGUCAGGCUCUUGGGAC  68 22    333 hsa-miR-28-5p AAGGAGCUCACAGUCUAUUGAG 152 22    332 hsa-miR-495 AAACAAACAUGGUGCACUUCUU 241 22    321 hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG 223 22    320 hsa-miR-100-3p CAAGCUUGUAUCUAUAGGUAUG  98 22    314 hsa-miR-193b-3p AACUGGCCCUCAAAGUCCCGCU 148 22    305 hsa-miR-330-5p UCUCUGGGCCUGUGUCUUAGGC 161 22    303 hsa-miR-376a-3p AUCAUAGAGGAAAAUCCACGU 237 21    298 hsa-miR-135b-5p UAUGGCUUUUCAUUCCUAUGUGA 137 23    289 hsa-miR-301a-3p CAGUGCAAUAGUAUUGUCAAAGC 107 23    280 hsa-miR-218-5p UUGUGCUUGAUCUAACCAUGU 206 21    276 hsa-miR-143-3p UGAGAUGAAGCACUGUAGCUC 176 21    256 hsa-miR-27b-5p AGAGCUUAGCUGAUUGGUGAAC 201 22    255 hsa-miR-369-3p AAUAAUACAUGGUUGAUCUUU 196 21    255 hsa-miR-877-5p GUAGAGGAGAUGGCGCAGGG 133 20    249 hsa-miR-19b-3p UGUGCAAAUCCAUGCAAAACUGA 163 23    246 hsa-miR-424-5p CAGCAGCAAUUCAUGUUUUGAA 186 22    245 hsa-miR-660-5p UACCCAUUGCAUAUCGGAGUUG 187 22    244 hsa-miR-532-5p CAUGCCUUGAGUGUAGGACCGU 178 22    238 hsa-miR-299-3p UAUGUGGGAUGGUAAACCGCUU 182 22    235 hsa-miR-431-3p CAGGUCGUCUUGCAGGGCUUCU 168 22    231 hsa-miR-374a-3p CUUAUCAGAUUGUAUUGUAAUU 173 22    220 hsa-miR-148a-5p AAAGUUCUGAGACACUCCGACU 144 22    214 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17    207 hsa-miR-92b-5p AGGGACGGGACGCGGUGCAGUG 208 22    206 hsa-miR-16-2-3p CCAAUAUUACUGUGCUGCUUUA 316 22    202 hsa-miR-101-3p UACAGUACUGUGAUAACUGAA 142 21    201 hsa-let-7a-3p CUAUACAAUCUACUGUCUUUC 222 21    199 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20    195 hsa-miR-455-3p GCAGUCCAUGGGCAUAUACAC 140 21    192 hsa-miR-185-5p UGGAGAGAAAGGCAGUUCCUGA 224 22    188 hsa-miR-1185-1-3p AUAUACAGGGGGAGACUCUUAU 209 22    187 hsa-miR-1197 UAGGACACAUGGUCUACUUCU 244 21    185 hsa-miR-106b-3p CCGCACUGUGGGUACUUGCUGC 159 22    178 hsa-miR-24-2-5p UGCCUACUGAGCUGAAACACAG 156 22    178 hsa-miR-4677-3p UCUGUGAGACCAAAGAACUACU 120 22    177 hsa-miR-380-3p UAUGUAAUAUGGUCCACAUCUU 445 22    174 hsa-miR-548k AAAAGUACUUGCGGAUUUUGCU 198 22    171 hsa-miR-1307-3p ACUCGGCGUGGCGUCGGUCGUG 124 22    169 hsa-miR-485-3p GUCAUACACGGCUCUCCUCUCU 153 22    168 hsa-miR-494 UGAAACAUACACGGGAAACCUC 240 22    165 hsa-miR-17-3p ACUGCAGUGAAGGCACUUGUAG 184 22    163 hsa-miR-561-5p AUCAAGGAUCUUAAACUUUGCC 179 22    160 hsa-miR-27a-5p AGGGCUUAGCUGCUUGUGAGCA 130 22    158 hsa-miR-874 CUGCCCUGGCCCGAGGGACCGA 147 22    151 hsa-miR-9-3p AUAAAGCUAGAUAACCGAAAGU 183 22    151 hsa-miR-96-5p UUUGGCACUAGCACAUUUUUGCU 123 23    151 hsa-miR-656 AAUAUUAUACAGUCAACCUCU 221 21    147 hsa-miR-379-3p UAUGUAACAUGGUCCACUAACU 446 22    145 hsa-miR-382-5p GAAGUUGUUCGUGGUGGAUUCG 238 22    144 hsa-miR-541-3p UGGUGGGCACAGAAUCUGGACU 136 22    141 hsa-miR-337-3p CUCCUAUAUGAUGCCUUUCUUC 215 22    139 hsa-miR-15b-3p CGAAUCAUUAUUUGCUGCUCUA 447 22    137 hsa-miR-20b-5p CAAAGUGCUCAUAGUGCAGGUAG 317 23    136 hsa-miR-329 AACACACCUGGUUAACCUCUUU 214 22    136 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15    134 hsa-miR-543 AAACAUUCGCGGUGCACUUCUU 193 22    134 hsa-miR-365b-3p UAAUGCCCCUAAAAAUCCUUAU 279 22    133 hsa-miR-125a-3p ACAGGUGAGGUUCUUGGGAGCC 160 22    131 hsa-miR-3065-5p UCAACAAAAUCACUGAUGCUGGA 226 23    130 hsa-miR-1296 UUAGGGCCCUGGCUCCAUCUCC 271 22    126 hsa-miR-935 CCAGUUACCGCUUCCGCUACCGC 311 23    118 hsa-miR-132-3p UAACAGUCUACAGCCAUGGUCG 104 22    116 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18    116 hsa-miR-487a AAUCAUACAGGGACAUCCAGUU 203 22    113 hsa-miR-574-5p UGAGUGUGUGUGUGUGAGUGUGU 334 23    113 hsa-miR-301b CAGUGCAAUGAUAUUGUCAAAGC 164 23    111 hsa-miR-548o-3p CCAAAACUGCAGUUACUUUUGC 268 22    105 hsa-miR-18a-5p UAAGGUGCAUCUAGUGCAGAUAG 256 23    104 hsa-miR-485-5p AGAGGCUGGCCGUGAUGAAUUC 165 22    104 hsa-miR-548ah-5p AAAAGUGAUUGCAGUGUUUG 235 20    103 hsa-miR-361-3p UCCCCCAGGUGUGAUUCUGAUUU 250 23    101 hsa-miR-433 AUCAUGAUGGGCUCCUCGGUGU 174 22    101 hsa-miR-337-5p GAACGGCUUCAUACAGGAGUU 277 21    100 hsa-miR-1276 UAAAGAGCCCUGUGGAGACA 194 20     99 hsa-miR-30c-1-3p CUGGGAGAGGGUUGUUUACUCC 213 22     99 hsa-miR-31-3p UGCUAUGCCAACAUAUUGCCAU 172 22     96 hsa-miR-424-3p CAAAACGUGAGGCGCUGCUAU 298 21     96 hsa-miR-550a-5p AGUGCCUGAGGGAGUAAGAGCCC 134 23     95 hsa-miR-4454 GGAUCCGAGUCACGGCACCA 299 20     94 hsa-miR-541-5p AAAGGAUUCUGCUGUCGGUCCCACU 432 25     92 hsa-miR-106b-5p UAAAGUGCUGACAGUGCAGAU 170 21     89 hsa-miR-153 UUGCAUAGUCACAAAAGUGAUC 188 22     88 hsa-miR-135b-3p AUGUAGGGCUAAAAGCCAUGGG 205 22     87 hsa-miR-574-3p CACGCUCAUGCACACACCCACA 253 22     87 hsa-miR-1226-3p UCACCAGCCCUGUGUUCCCUAG 199 22     85 hsa-miR-576-5p AUUCUAAUUUCUCCACGUCUUU 306 22     84 hsa-miR-127-5p CUGAAGCUCAGAGGGCUCUGAU 255 22     83 hsa-miR-155-5p UUAAUGCUAAUCGUGAUAGGGGU 448 23     83 hsa-miR-3176 ACUGGCCUGGGACUACCGG 227 19     83 hsa-miR-382-3p AAUCAUUCACGGACAACACUU 260 21     83 hsa-miR-1275 GUGGGGGAGAGGCUGUC 162 17     82 hsa-miR-671-5p AGGAAGCCCUGGAGGGGCUGGAG 288 23     82 hsa-miR-23a-5p GGGGUUCCUGGGGAUGGGAUUU 212 22     81 hsa-miR-25-5p AGGCGGAGACUUGGGCAAUUG 225 21     80 hsa-miR-641 AAAGACAUAGGAUAGAGUCACCUC 285 24     80 hsa-miR-19a-3p UGUGCAAAUCUAUGCAAAACUGA 177 23     79 hsa-miR-377-3p AUCACACAAAGGCAACUUUUGU 449 22     78 hsa-miR-454-5p ACCCUAUCAAUAUUGUCUCUGC 265 22     78 hsa-miR-496 UGAGUAUUACAUGGCCAAUCUC 267 22     78 hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU 166 23     77 hsa-miR-26a-2-3p CCUAUUCUUGAUUACUUGUUUC 257 22     76 hsa-miR-1260b AUCCCACCACUGCCACCAU 373 19     74 hsa-miR-2467-5p UGAGGCUCUGUUAGCCUUGGCUC 154 23     74 hsa-miR-377-5p AGAGGUUGCCCUUGGUGAAUUC 202 22     74 hsa-miR-330-3p GCAAAGCACACGGCCUGCAGAGA 195 23     73 hsa-miR-1180 UUUCCGGCUCGCGUGGGUGUGU 313 22     71 hsa-miR-99b-3p CAAGCUCGUGUCUGUGGGUCCG 243 22     71 hsa-miR-299-5p UGGUUUACCGUCCCACAUACAU 319 22     69 hsa-miR-374b-3p CUUAGCAGGUUGUAUUAUCAUU 229 22     69 hsa-miR-4746-5p CCGGUCCCAGGAGAACCUGCAGA 266 23     69 hsa-miR-331-3p GCCCCUGGGCCUAUCCUAGAA 450 21     68 hsa-miR-340-3p UCCGUCUCAGUUACUUUAUAGC 248 22     68 hsa-miR-92a-1-5p AGGUUGGGAUCGGUUGCAAUGCU 204 23     68 hsa-miR-542-3p UGUGACAGAUUGAUAACUGAAA 331 22     66 hsa-miR-431-5p UGUCUUGCAGGCCGUCAUGCA 132 21     65 hsa-miR-1254 AGCCUGGAAGCUGGAGCCUGCAGU 270 24     61 hsa-miR-3158-3p AAGGGCUUCCUCUCUGCAGGAC 167 22     61 hsa-miR-362-5p AAUCCUUGGAACCUAGGUGUGAGU 139 24     61 hsa-miR-30c-2-3p CUGGGAGAAGGCUGUUUACUCU 321 22     59 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC 129 23     59 hsa-miR-3200-3p CACCUUGCGCUACUCAGGUCUG 247 22     57 hsa-miR-215 AUGACCUAUGAAUUGACAGAC 451 21     56 hsa-miR-1185-5p AGAGGAUACCCUUUGUAUGUU 368 21     55 hsa-miR-328 CUGGCCCUCUCUGCCCUUCCGU 297 22     55 hsa-miR-655 AUAAUACAUGGUUAACCUCUUU 286 22     55 hsa-miR-181b-3p CUCACUGAACAAUGAAUGCAA 245 21     54 hsa-miR-376b AUCAUAGAGGAAAAUCCAUGUU 452 22     54 hsa-miR-486-3p CGGGGCAGCUCAGUACAGGAU 453 21     54 hsa-miR-760 CGGCUCUGGGUCUGUGGGGA 289 20     54 hsa-miR-3909 UGUCCUCUAGGGCCUGCAGUCU 412 22     53 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17     53 hsa-miR-4521 GCUAAGGAAGUCCUGUGCUCAG 233 22     53 hsa-let-7e-3p CUAUACGGCCUCCUAGCUUUCC 290 22     52 hsa-miR-455-5p UAUGUGCCUUUGGACUACAUCG 192 22     52 hsa-miR-93-3p ACUGCUGAGCUAGCACUUCCCG 454 22     51 hsa-miR-151b UCGAGGAGCUCACAGUCU 455 18     49 hsa-miR-887 GUGAACGGGCGCCAUCCCGAGG 456 22     49 hsa-miR-152 UCAGUGCAUGACAGAACUUGG 344 21     48 hsa-miR-324-3p ACUGCCCCAGGUGCUGCUGG 276 20     48 hsa-miR-1266 CCUCAGGGCUGUAGAACAGGGCU 457 23     47 hsa-miR-302b-3p UAAGUGCUUCCAUGUUUUAGUAG 458 23     47 hsa-miR-548e AAAAACUGAGACUACUUUUGCA 459 22     47 hsa-miR-502-3p AAUGCACCUGGGCAAGGAUUCA 281 22     46 hsa-miR-302d-3p UAAGUGCUUCCAUGUUUGAGUGU 460 23     45 hsa-miR-3943 UAGCCCCCAGGCUUCACUUGGCG 207 23     45 hsa-miR-1286 UGCAGGACCAAGAUGAGCCCU 293 21     44 hsa-miR-3605-5p UGAGGAUGGAUAGCAAGGAAGCC 189 23     44 hsa-miR-505-3p CGUCAACACUUGCUGGUUUCCU 282 22     44 hsa-miR-3615 UCUCUCGGCUCCUCGCGGCUC 323 21     43 hsa-miR-4435 AUGGCCAGAGCUCACACAGAGG 230 22     43 hsa-miR-598 UACGUCAUCGUUGUCAUCGUCA 461 22     43 hsa-miR-126-5p CAUUAUUACUUUUGGUACGCG 462 21     42 hsa-miR-4671-3p UUAGUGCAUAGUCUUUGGUCU 301 21     41 hsa-miR-652-3p AAUGGCGCCACUAGGGUUGUG 442 21     41 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24     40 hsa-miR-4286 ACCCCACUCCUGGUACC 328 17     40 hsa-miR-590-3p UAAUUUUAUGUAUAAGCUAGU 463 21     40 hsa-miR-1285-3p UCUGGGCAACAAAGUGAGACCU 464 22     39 hsa-miR-2355-5p AUCCCCAGAUACAAUGGACAA 593 21     38 hsa-miR-550a-3p UGUCUUACUCCCUCAGGCACAU 283 22     38 hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU  92 22     37 hsa-miR-136-5p ACUCCAUUUGUUUUGAUGAUGGA 272 23     37 hsa-miR-1468 CUCCGUUUGCCUGUUUCGCUG 296 21     37 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24     37 hsa-miR-548b-5p AAAAGUAAUUGUGGUUUUGGCC 304 22     37 hsa-miR-664-3p UAUUCAUUUAUCCCCAGCCUACA 287 23     37 hsa-miR-99a-3p CAAGCUCGCUUCUAUGGGUCUG 367 22     37 hsa-miR-532-3p CCUCCCACACCCAAGGCUUGCA 252 22     36 hsa-miR-10b-5p UACCCUGUAGAACCGAAUUUGUG 465 23     33 hsa-miR-369-5p AGAUCGACCGUGUUAUAUUCGC 357 22     33 hsa-miR-3161 CUGAUAAGAACAGAGGCCCAGAU 466 23     32 hsa-miR-3940-3p CAGCCCGGAUCCCAGCCCACUU 239 22     32 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22     32 hsa-miR-219-2-3p AGAAUUGUGGCUGGACAUCUGU 467 22     31 hsa-miR-2277-5p AGCGCGGGCUGAGCGCUGCCAGUC 735 24     31 hsa-miR-4448 GGCUCCUUGGUCUAGGGGUA 231 20     31 hsa-miR-339-5p UCCCUGUCCUCCAGGAGCUCACG 402 23     30 hsa-miR-3613-5p UGUUGUACUUUUUUUUUUGUUC 469 22     30 hsa-miR-4775 UUAAUUUUUUGUUUCGGUCACU 302 22     30 hsa-miR-212-5p ACCUUGGCUCUAGACUGCUUACU 246 23     29 hsa-miR-324-5p CGCAUCCCCUAGGGCAUUGGUGU 354 23     27 hsa-miR-4326 UGUUCCUCUGUCUCCCAGAC 417 20     27 hsa-miR-582-3p UAACUGGUUGAACAACUGAACC 470 22     27 hsa-miR-34a-3p CAAUCAGCAAGUAUACUGCCCU 403 22     26 hsa-miR-106a-5p AAAAGUGCUUACAGUGCAGGUAG 471 23     25 hsa-miR-4745-5p UGAGUGGGGCUCCCGGGACGGCG 219 23     25 hsa-miR-769-3p CUGGGAUCUCCGGGGUCUUGGUU 337 23     25 hsa-miR-1268a CGGGCGUGGUGGUGGGGG 291 18     24 hsa-miR-154-3p AAUCAUACACGGUUGACCUAUU 472 22     24 hsa-miR-188-3p CUCCCACAUGCAGGGUUUGCA 200 21     24 hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA 473 22     24 hsa-miR-539-5p GGAGAAAUUAUCCUUGGUGUGU 234 22     24 hsa-miR-766-3p ACUCCAGCCCCACAGCCUCAGC 310 22     24 hsa-miR-30b-3p CUGGGAGGUGGAUGUUUACUUC 320 22     23 hsa-miR-3177-3p UGCACGGCACUGGGGACACGU 275 21     23 hsa-miR-191-3p GCUGCGCUUGGAUUUCGUCCCC 474 22     22 hsa-miR-296-3p GAGGGUUGGGUGGAGGCUCUCC 274 22     22 hsa-miR-296-5p AGGGCCCCCCCUCAAUCCUGU 258 21     22 hsa-miR-339-3p UGAGCGCCUCGACGACAGAGCCG 228 23     22 hsa-miR-501-5p AAUCCUUUGUCCCUGGGUGAGA 430 22     22 hsa-miR-200b-3p UAAUACUGCCUGGUAAUGAUGA 475 22     21 hsa-miR-212-3p UAACAGUCUCCAGUCACGGCC 348 21     21 hsa-miR-26b-3p CCUGUUCUCCAUUACUUGGCUC 391 22     21 hsa-miR-665 ACCAGGAGGCUGAGGCCCCU 309 20     21 hsa-miR-668 UGUCACUCGGCUCGGCCCACUAC 476 23     21 hsa-miR-146a-5p UGAGAACUGAAUUCCAUGGGUU 477 22     20 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19     20 hsa-miR-210 CUGUGCGUGUGACAGCGGCUGA 478 22     20 hsa-miR-3607-5p GCAUGUGAUGAAGCAAAUCAGU 249 22     20 hsa-miR-378a-5p CUCCUGACUCCAGGUCCUGUGU 217 22     20 hsa-miR-4449 CGUCCCGGGGCUGCGCGAGGCA 155 22     20 hsa-miR-138-5p AGCUGGUGUUGUGAAUCAGGCCG 379 23     19 hsa-miR-146b-3p UGCCCUGUGGACUCAGUUCUGG 381 22     18 hsa-miR-3065-3p UCAGCACCAGGAUAUUGUUGGAG 350 23     18 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18     18 hsa-miR-497-5p CAGCAGCACACUGUGGUUUGU 479 21     18 hsa-miR-500a-5p UAAUCCUUGCUACCUGGGUGAGA 303 23     18 hsa-miR-625-3p GACUAUAGAACUUUCCCCCUCA 307 22     18 hsa-miR-628-3p UCUAGUAAGAGUGGCAGUCGA 335 21     18 hsa-miR-1343 CUCCUGGGGCCCGCACUCUCGC 378 22     17 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21     17 hsa-miR-432-3p CUGGAUGGCUCCUCCAUGUCU 262 21     17 hsa-miR-4482-3p UUUCUAUUUCUCAGUGGGGCUC 361 22     17 hsa-miR-542-5p UCGGGGAUCAUCAUGUCACGAGA 433 23     17 hsa-miR-551b-3p GCGACCCAUACUUGGUUUCAG 434 21     17 hsa-miR-7-1-3p CAACAAAUCACAGUCUGCCAUA 480 22     17 hsa-miR-219-1-3p AGAGUUGAGUCUGGACGUCCCG 390 22     16 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17     16 hsa-miR-3661 UGACCUGGGACUCGGACAGCUG 481 22     16 hsa-miR-411-3p UAUGUAACACGGUCCACUAACC 482 22     16 hsa-miR-5096 GUUUCACCAUGUUGGUCAGGC 220 21     16 hsa-miR-577 UAGAUAAAAUAUUGGUACCUG 436 21     16 hsa-let-7i-3p CUGCGCAAGCUACUGCCUUGCU 483 22     15 hsa-miR-132-5p ACCGUGGCUUUCGAUUGUUACU 315 22     15 hsa-miR-140-5p CAGUGGUUUUACCCUAUGGUAG 380 22     15 hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC 346 21     15 hsa-miR-3187-3p UUGGCCAUGGGGCUGCGCGG 322 20     15 hsa-miR-342-5p AGGGGUGCUAUCUGUGAUUGA 278 21     15 hsa-miR-34b-3p CAAUCACUAACUCCACUGCCAU 404 22     15 hsa-miR-4661-5p AACUAGCUCUGUGGAUCCUGAC 484 22     15 hsa-miR-584-5p UUAUGGUUUGCCUGGGACUGAG 485 22     15 hsa-miR-744-3p CUGUUGCCACUAACCUCAACCU 486 22     15 hsa-miR-770-5p UCCAGUACCACGUGUCAGGGCCA 487 23     15 hsa-miR-3677-3p CUCGUGGGCUCUGGCCACGGCC 356 22     14 hsa-miR-425-3p AUCGGGAAUGUCGUGUCCGCCC 358 22     14 hsa-miR-548ah-3p CAAAAACUGCAGUUACUUUUGC 149 22     14 hsa-miR-5699 UCCUGUCUUUCCUUGUUGGAGC 488 22     14 hsa-miR-582-5p UUACAGUUGUUCAACCAGUUACU 489 23     14 hsa-miR-1185-2-3p AUAUACAGGGGGAGACUCUCAU 314 22     13 hsa-miR-1249 ACGCCCUUCCCCCCCUUCUUCA 490 22     13 hsa-miR-1255a AGGAUGAGCAAAGAAAGUAGAUU 341 23     13 hsa-miR-1910 CCAGUCCUGUGCCUGCCGCCU 236 21     13 hsa-miR-301a-5p GCUCUGACUUUAUUGCACUACU 491 22     13 hsa-miR-5001-3p UUCUGCCUCUGUCCAGGUCCUU 492 22     13 hsa-miR-5094 AAUCAGUGAAUGCCUUGAACCU 493 22     13 hsa-miR-628-5p AUGCUGACAUAUUUACUAGAGG 440 22     13 hsa-miR-629-5p UGGGUUUACGUUGGGAGAACU 441 21     13 hsa-miR-937 AUCCGCGCUCUGACUCUCUGCC 312 22     13 hsa-miR-940 AAGGCAGGGCCCCCGCUCCCC 366 21     13 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 269 27     12 hsa-miR-194-5p UGUAACAGCAACUCCAUGUGGA 345 22     12 hsa-miR-199b-3p ACAGUAGUCUGCACAUUGGUUA 494 22     12 hsa-miR-22-5p AGUUCUUCAGUGGCAAGCUUUA 495 22     12 hsa-miR-3605-3p CCUCCGUGUUACCUGUCCUCUAG 496 23     12 hsa-miR-3654 GACUGGACAAGCUGAGGAA 325 19     12 hsa-miR-504 AGACCCUGGUCUGCACUCUAUC 497 22     12 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24     11 hsa-miR-1299 UUCUGGAAUUCUGUGUGAGGGA 498 22     11 hsa-miR-188-5p CAUCCCUUGCAUGGUGGAGGG 499 21     11 hsa-miR-222-5p CUCAGUAGCCAGUGUAGAUCCU 349 22     11 hsa-miR-331-5p CUAGGUAUGGUCCCAGGGAUCC 500 22     11 hsa-miR-3939 UACGCGCAGACCACAGGAUGUC 261 22     11 hsa-miR-154-5p UAGGUUAUCCGUGUUGCCUUCG 501 22     10 hsa-miR-18a-3p ACUGCCCUAAGUGCUCCUUCUGG 502 23     10 hsa-miR-1908 CGGCGGGGACGGCGAUUGGUC 383 21     10 hsa-miR-200c-3p UAAUACUGCCGGGUAAUGAUGGA 347 23     10 hsa-miR-2116-3p CCUCCCAUGCCAAGAACUCCC 318 21     10 hsa-miR-302a-3p UAAGUGCUUCCAUGUUUUGGUGA 503 23     10 hsa-miR-3174 UAGUGAGUUAGAGAUGCAGAGCC 353 23     10 hsa-miR-326 CCUCUGGGCCCUUCCUCCAG 504 20     10 hsa-let-7g-3p CUGUACAGGCCACUGCCUUGC 505 21      9 hsa-miR-141-3p UAACACUGUCUGGUAAAGAUGG 295 22      9 hsa-miR-24-1-5p UGCCUACUGAGCUGAUAUCAGU 506 22      9 hsa-miR-3115 AUAUGGGUUUACUAGUUGGU 351 20      9 hsa-miR-3180-3p UGGGGCGGAGCUUCCGGAGGCC 400 22      9 hsa-miR-33a-5p GUGCAUUGUAGUUGCAUUGCA 355 21      9 hsa-miR-34c-3p AAUCACUAACCACACGGCCAGG 405 22      9 hsa-miR-3929 GAGGCUGAUGUGAGUAGACCACU 218 23      9 hsa-miR-4517 AAAUAUGAUGAAACUCACAGCUGAG 507 25      9 hsa-miR-576-3p AAGAUGUGGAAAAAUUGGAAUC 508 22      9 hsa-miR-1229 CUCUCACCACUGCCCUCCCACAG 509 23      8 hsa-miR-1289 UGGAGUCCAGGAAUCUGCAUUUU 343 23      8 hsa-miR-1915-5p ACCUUGCCUUGCUGCCCGGGCC 385 22      8 hsa-miR-23b-5p UGGGUUCCUGGCAUGCUGAUUU 510 22      8 hsa-miR-302a-5p ACUUAAACGUGGAUGUACUUGCU 511 23      8 hsa-miR-3938 AAUUCCCUUGUAGAUAACCCGG 512 22      8 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18      8 hsa-miR-4786-5p UGAGACCAGGACUGGAUGCACC 197 22      8 hsa-miR-589-3p UCAGAACAAAUGCCGGUUCCCAGA 438 24      8 hsa-miR-616-5p ACUCAAAACCCUUCAGUGACUU 439 22      8 hsa-miR-943 CUGACUGUUGCCGUCCUCCAG 338 21      8 hsa-miR-1237 UCCUUCUGCUCCGUCCCCCAG 370 21      7 hsa-miR-1915-3p CCCCAGGGCGACGCGGCGGG 384 20      7 hsa-miR-3620 UCACCCUGCAUCCCGCACCCAG 324 22      7 hsa-miR-3691-5p AGUGGAUGAUGGAGACUCGGUAC 409 23      7 hsa-miR-4426 GAAGAUGGACGUACUUU 359 17      7 hsa-let-7a-2-3p CUGUACAGCCUCCUAGCUUUCC 513 22      6 hsa-miR-10a-3p CAAAUUCGUAUCUAGGGGAAUA 514 22      6 hsa-miR-1287 UGCUGGAUCAGUGGUUCGAGUC 515 22      6 hsa-miR-145-5p GUCCAGUUUUCCCAGGAAUCCCU 516 23      6 hsa-miR-29b-1-5p GCUGGUUUCAUAUGGUGGUUUAGA 517 24      6 hsa-miR-3128 UCUGGCAAGUAAAAAACUCUCAU 518 23      6 hsa-miR-33b-5p GUGCAUUGCUGUUGCAUUGC 519 20      6 hsa-miR-3681-5p UAGUGGAUGAUGCACUCUGUGC 327 22      6 hsa-miR-3685 UUUCCUACCCUACCUGAAGACU 520 22      6 hsa-miR-3918 ACAGGGCCGCAGAUGGAGACU 521 21      6 hsa-miR-551b-5p GAAAUCAAGCGUGGGUGAGACC 522 22      6 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19      5 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21      5 hsa-miR-1304-5p UUUGAGGCUACAGUGAGAUGUG 523 22      5 hsa-miR-1538 CGGCCCGGGCUGCUGCUGUUCCU 524 23      5 hsa-miR-181c-3p AACCAUCGACCGUUGAGUGGAC 525 22      5 hsa-miR-193a-5p UGGGUCUUUGCGGGCGAGAUGA 526 22      5 hsa-miR-208b AUAAGACGAACAAAAGGUUUGU 388 22      5 hsa-miR-219-5p UGAUUGUCCAAACGCAAUUCU 527 21      5 hsa-miR-3159 UAGGAUUACAAGUGUCGGCCAC 528 22      5 hsa-miR-3173-5p UGCCCUGCCUGUUUUCUCCUUU 529 22      5 hsa-miR-3175 CGGGGAGAGAACGCAGUGACGU 530 22      5 hsa-miR-3200-5p AAUCUGAGAAGGCGCACAAGGU 531 22      5 hsa-miR-3662 GAAAAUGAUGAGUAGUGACUGAUG 326 24      5 hsa-miR-3928 GGAGGAACCUUGGAGCUUCGGC 413 22      5 hsa-miR-4709-3p UUGAAGAGGAGGUGCUCUGUAGC 532 23      5 hsa-miR-4787-3p GAUGCGCCGCCCACUGCCCCGCGC 533 24      5 hsa-miR-499a-5p UUAAGACUUGCAGUGAUGUUU 534 21      5 hsa-miR-545-3p UCAGCAAACAUUUAUUGUGUGC 242 22      5 hsa-miR-548u CAAAGACUGCAAUUACUUUUGCG 535 23      5 hsa-miR-659-5p AGGACCUUCCCUGAACCAAGGA 364 22      5 hsa-miR-1257 AGUGAAUGAUGGGUUCUGACC 372 21      4 hsa-miR-1292 UGGGAACGGGUUCCGGCAGACGCUG 536 25      4 hsa-miR-1914-5p CCCUGUGCCCGGCCCACUUCUG 537 22      4 hsa-miR-195-3p CCAAUAUUGGCUGUGCUGCUCC 538 22      4 hsa-miR-2110 UUGGGGAAACGGCCGCUGAGUG 389 22      4 hsa-miR-302c-5p UUUAACAUGGGGGUACCUGCUG 539 22      4 hsa-miR-3126-3p CAUCUGGCAUCCGUCACACAGA 394 22      4 hsa-miR-3126-5p UGAGGGACAGAUGCCAGAAGCA 352 22      4 hsa-miR-3150a-5p CAACCUCGACGAUCUCCUCAGC 540 22      4 hsa-miR-3157-3p CUGCCCUAGUCUAGCUGAAGCU 399 22      4 hsa-miR-323b-3p CCCAAUACACGGUCGACCUCUU 541 22      4 hsa-miR-335-3p UUUUUCAUUAUUGCUCCUGACC 542 22      4 hsa-miR-3607-3p ACUGUAAACGCUUUCUGAUG 543 20      4 hsa-miR-3653 CUAAGAAGUUGACUGAAG 544 18      4 hsa-miR-3663-3p UGAGCACCACACAGGCCGGGCGC 545 23      4 hsa-miR-376a-5p GUAGAUUCUCCUUCUAUGAGUA 410 22      4 hsa-miR-4423-3p AUAGGCACCAAAAAGCAACAA 662 21      4 hsa-miR-4423-5p AGUUGCCUUUUUGUUCCCAUGC 263 22      4 hsa-miR-4463 GAGACUGGGGUGGGGCC 300 17      4 hsa-miR-449a UGGCAGUGUAUUGUUAGCUGGU 547 22      4 hsa-miR-4511 GAAGAACUGUUGCAUUUGCCCU 548 22      4 hsa-miR-4640-3p CACCCCCUGUUUCCUGGCCCAC 329 22      4 hsa-miR-4800-3p CAUCCGUCCGUCUGUCCAC 549 19      4 hsa-miR-505-5p GGGAGCCAGGAAGUAUUGAUGU 550 22      4 hsa-miR-548a-3p CAAAACUGGCAAUUACUUUUGC 551 22      4 hsa-miR-570-3p CGAAAACAGCAAUUACCUUUGC 333 22      4 hsa-miR-663a AGGCGGGGCGCCGCGGGACCGC 365 22      4 hsa-miR-877-3p UCCUCUUCUCCCUCCUCCCAG 552 21      4 hsa-miR-103a-2-5p AGCUUCUUUACAGUGCUGCCUUG 553 23      3 hsa-miR-1268b CGGGCGUGGUGGUGGGGGUG 554 20      3 hsa-miR-1270 CUGGAGAUAUGGAAGAGCUGUGU 555 23      3 hsa-miR-1293 UGGGUGGUCUGGAGAUUUGUGC 556 22      3 hsa-miR-1322 GAUGAUGCUGCUGAUGCUG 557 19      3 hsa-miR-150-5p UCUCCCAACCCUUGUACCAGUG 558 22      3 hsa-miR-190b UGAUAUGUUUGAUAUUGGGUU 559 21      3 hsa-miR-193a-3p AACUGGCCUACAAAGUCCCAGU 386 22      3 hsa-miR-193b-5p CGGGGUUUUGAGGGCGAGAUGA 560 22      3 hsa-miR-199a-5p CCCAGUGUUCAGACUACCUGUUC 273 23      3 hsa-miR-20a-3p ACUGCAUUAUGAGCACUUAAAG 561 22      3 hsa-miR-216a UAAUCUCAGCUGGCAACUGUGA 562 22      3 hsa-miR-2682-5p CAGGCAGUGACUGUUCAGACGUC 563 23      3 hsa-miR-2964a-5p AGAUGUCCAGCCACAAUUCUCG 564 22      3 hsa-miR-3177-5p UGUGUACACACGUGCCAGGCGCU 565 23      3 hsa-miR-320c AAAAGCUGGGUUGAGAGGGU 566 20      3 hsa-miR-323a-5p AGGUGGUCCGUGGCGCGUUCGC 567 22      3 hsa-miR-3622a-5p CAGGCACGGGAGCUCAGGUGAG 568 22      3 hsa-miR-3912 UAACGCAUAAUAUGGACAUGU 569 21      3 hsa-miR-3934 UCAGGUGUGGAAACUGAGGCAG 570 22      3 hsa-miR-3942-3p UUUCAGAUAACAGUAUUACAU 414 21      3 hsa-miR-3942-5p AAGCAAUACUGUUACCUGAAAU 571 22      3 hsa-miR-4523 GACCGAGAGGGCCUCGGCUGU 572 21      3 hsa-miR-4640-5p UGGGCCAGGGAGCAGCUGGUGGG 573 23      3 hsa-miR-4671-5p ACCGAAGACUGUGCGCUAAUCU 574 22      3 hsa-miR-4709-5p ACAACAGUGACUUGCUCUCCAA 575 22      3 hsa-miR-4731-3p CACACAAGUGGCCCCCAACACU 425 22      3 hsa-miR-4731-5p UGCUGGGGGCCACAUGAGUGUG 576 22      3 hsa-miR-4762-5p CCAAAUCUUGAUCAGAAGCCU 577 21      3 hsa-miR-5010-5p AGGGGGAUGGCAGAGCAAAAUU 578 22      3 hsa-miR-502-5p AUCCUUGCUAUCUGGGUGCUA 579 21      3 hsa-miR-548d-5p AAAAGUAAUUGUGGUUUUUGCC 580 22      3 hsa-miR-548i AAAAGUAAUUGCGGAUUUUGCC 581 22      3 hsa-miR-548j AAAAGUAAUUGCGGUCUUUGGU 582 22      3 hsa-miR-5587-3p GCCCCGGGCAGUGUGAUCAUC 284 21      3 hsa-miR-1225-3p UGAGCCCCUGUGCCGCCCCCAG 369 22      2 hsa-miR-1227 CGUGCCACCCUUUUCCCCAG 583 20      2 hsa-miR-1252 AGAAGGAAAUUGAAUUCAUUUA 371 22      2 hsa-miR-1280 UCCCACCGCUGCCACCC 584 17      2 hsa-miR-1288 UGGACUGCCCUGAUCUGGAGA 585 21      2 hsa-miR-1303 UUUAGAGACGGGGUCUUGCUCU 586 22      2 hsa-miR-1306-3p ACGUUGGCUCUGGUGGUG 376 18      2 hsa-miR-139-5p UCUACAGUGCACGUGUCUCCAG 587 22      2 hsa-miR-149-3p AGGGAGGGACGGGGGCUGUGC 588 21      2 hsa-miR-16-1-3p CCAGUAUUAACUGUGCUGCUGA 589 22      2 hsa-miR-1909-5p UGAGUGCCGGUGCCUGCCCUG 590 21      2 hsa-miR-224-5p CAAGUCACUAGUGGUUCCGUU 591 21      2 hsa-miR-2276 UCUGCAAGUGUCAGAGGCGAGG 592 22      2 hsa-miR-2355-3p AUUGUCCUUGCUGUUUGGAGAU 468 22      2 hsa-miR-2964a-3p AGAAUUGCGUUUGGACAAUCAGU 392 23      2 hsa-miR-29c-5p UGACCGAUUUCUCCUGGUGUUC 594 22      2 hsa-miR-3074-3p GAUAUCAGCUCAGUAGGCACCG 595 22      2 hsa-miR-3120-3p CACAGCAAGUGUAGACAGGCA 596 21      2 hsa-miR-3130-5p UACCCAGUCUCCGGUGCAGCC 396 21      2 hsa-miR-3140-3p AGCUUUUGGGAAUUCAGGUAGU 597 22      2 hsa-miR-3155a CCAGGCUCUGCAGUGGGAACU 398 21      2 hsa-miR-3163 UAUAAAAUGAGGGCAGUAAGAC 598 22      2 hsa-miR-3167 AGGAUUUCAGAAAUACUGGUGU 599 22      2 hsa-miR-363-5p CGGGUGGAUCACGAUGCAAUUU 600 22      2 hsa-miR-3676-3p CCGUGUUUCCCCCACGCUUU 408 20      2 hsa-miR-378g ACUGGGCUUGGAGUCAGAAG 411 20      2 hsa-miR-4467 UGGCGGCGGUAGUUAUGGGCUU 360 22      2 hsa-miR-4498 UGGGCUGGCAGGGCAAGUGCUG 601 22      2 hsa-miR-4654 UGUGGGAUCUGGAGGCAUCUGG 420 22      2 hsa-miR-4659a-3p UUUCUUCUUAGACAUGGCAACG 603 22      2 hsa-miR-4662a-5p UUAGCCAAUUGUCCAUCUUUAG 604 22      2 hsa-miR-4683 UGGAGAUCCAGUGCUCGCCCGAU 605 23      2 hsa-miR-4738-3p UGAAACUGGAGCGCCUGGAGGA 606 22      2 hsa-miR-4746-3p AGCGGUGCUCCUGCGGGCCGA 607 21      2 hsa-miR-4748 GAGGUUUGGGGAGGAUUUGCU 608 21      2 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18      2 hsa-miR-491-5p AGUGGGGAACCCUUCCAUGAGG 429 22      2 hsa-miR-5000-3p UCAGGACACUUCUGAACUUGGA 609 22      2 hsa-miR-503 UAGCAGCGGGAACAGUUCUGCAG 610 23      2 hsa-miR-5189 UCUGGGCACAGGCGGAUGGACAGG 611 24      2 hsa-miR-548aq-3p CAAAAACUGCAAUUACUUUUGC 612 22      2 hsa-miR-548av-3p AAAACUGCAGUUACUUUUGC 613 20      2 hsa-miR-5584-5p CAGGGAAAUGGGAAGAACUAGA 332 22      2 hsa-miR-5690 UCAGCUACUACCUCUAUUAGG 435 21      2 hsa-miR-573 CUGAAGUGAUGUGUAACUGAUCAG 305 24      2 hsa-miR-597 UGUGUCACUCGAUGACCACUGU 614 22      2 hsa-miR-622 ACAGUCUGCUGAGGUUGGAGC 615 21      2 hsa-miR-636 UGUGCUUGCUCGUCCCGCCCGCA 616 23      2 hsa-miR-1193 GGGAUGGUAGACCGGUGACGUGC 617 23      1 hsa-miR-1224-3p CCCCACCUCCUCUCUCCUCAG 618 21      1 hsa-miR-122-5p UGGAGUGUGACAAUGGUGUUUG 720 22      1 hsa-miR-1228-5p GUGGGCGGGGGCAGGUGUGUG 620 21      1 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 340 26      1 hsa-miR-1247-5p ACCCGUCCCGUUCGUCCCCGGA 621 22      1 hsa-miR-1255b-5p CGGAUGAGCAAAGAAAGUGGUU 622 22      1 hsa-miR-1269b CUGGACUGAGCCAUGCUACUGG 623 22      1 hsa-miR-1272 GAUGAUGAUGGCAGCAAAUUCUGAAA 624 26      1 hsa-miR-1273c GGCGACAAAACGAGACCCUGUC 625 22      1 hsa-miR-1273e UUGCUUGAACCCAGGAAGUGGA 342 22      1 hsa-miR-1282 UCGUUUGCCUUUUUCUGCUU 626 20      1 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19      1 hsa-miR-1294 UGUGAGGUUGGCAUUGUUGUCU 627 22      1 hsa-miR-1306-5p CCACCUCCCCUGCAAACGUCCA 628 22      1 hsa-miR-1321 CAGGGAGGUGAAUGUGAU 377 18      1 hsa-miR-135a-5p UAUGGCUUUUUAUUCCUAUGUGA 629 23      1 hsa-miR-137 UUAUUGCUUAAGAAUACGCGUAG 630 23      1 hsa-miR-142-5p CAUAAAGUAGAAAGCACUACU 631 21      1 hsa-miR-143-5p GGUGCAGUGCUGCAUCUCUGGU 632 22      1 hsa-miR-15a-3p CAGGCCAUAUUGUGCUGCCUCA 633 22      1 hsa-miR-186-3p GCCCAAAGGUGAAUUUUUUGGG 382 22      1 hsa-miR-192-3p CUGCCAAUUCCAUAGGUCACAG 634 22      1 hsa-miR-19b-1-5p AGUUUUGCAGGUUUGCAUCCAGC 387 23      1 hsa-miR-200a-3p UAACACUGUCUGGUAACGAUGU 635 22      1 hsa-miR-204-3p GCUGGGAAGGCAAAGGGACGU 636 21      1 hsa-miR-214-3p ACAGCAGGCACAGACAGGCAGU 637 22      1 hsa-miR-29a-5p ACUGAUUUCUUUUGGUGUUCAG 393 22      1 hsa-miR-3064-5p UCUGGCUGUUGUGGUGUGCAA 638 21      1 hsa-miR-3116 UGCCUGGAACAUAGUAGGGACU 639 22      1 hsa-miR-3125 UAGAGGAAGCUGUGGAGAGA 640 20      1 hsa-miR-3127-3p UCCCCUUCUGCAGGCCUGCUGG 641 22      1 hsa-miR-3130-3p GCUGCACCGGAGACUGGGUAA 395 21      1 hsa-miR-3140-5p ACCUGAAUUACCAAAAGCUUU 397 21      1 hsa-miR-3157-5p UUCAGCCAGGCUAGUGCAGUCU 642 22      1 hsa-miR-3179 AGAAGGGGUGAAAUUUAAACGU 643 22      1 hsa-miR-3181 AUCGGGCCCUCGGCGCCGG 644 19      1 hsa-miR-3187-5p CCUGGGCAGCGUGUGGCUGAAGG 645 23      1 hsa-miR-3190-5p UCUGGCCAGCUACGUCCCCA 646 20      1 hsa-miR-3198 GUGGAGUCCUGGGGAAUGGAGA 647 22      1 hsa-miR-320b AAAAGCUGGGUUGAGAGGGCAA 648 22      1 hsa-miR-323b-5p AGGUUGUCCGUGGUGAGUUCGCA 401 23      1 hsa-miR-3591-5p UUUAGUGUGAUAAUGGCGUUUGA 649 23      1 hsa-miR-3619-5p UCAGCAGGCAGGCUGGUGCAGC 650 22      1 hsa-miR-3659 UGAGUGUUGUCUACGAGGGCA 651 21      1 hsa-miR-3674 AUUGUAGAACCUAAGAUUGGCC 652 22      1 hsa-miR-3679-3p CUUCCCCCCAGUAAUCUUCAUC 653 22      1 hsa-miR-375 UUUGUUCGUUCGGCUCGCGUGA 654 22      1 hsa-miR-378b ACUGGACUUGGAGGCAGAA 655 19      1 hsa-miR-3908 GAGCAAUGUAGGUAGACUGUUU 656 22      1 hsa-miR-3911 UGUGUGGAUCCUGGAGGAGGCA 657 22      1 hsa-miR-3913-5p UUUGGGACUGAUCUUGAUGUCU 658 22      1 hsa-miR-3917 GCUCGGACUGAGCAGGUGGG 659 20      1 hsa-miR-3944-3p UUCGGGCUGGCCUGCUGCUCCGG 660 23      1 hsa-miR-429 UAAUACUGUCUGGUAAAACCGU 661 22      1 hsa-miR-4421 ACCUGUCUGUGGAAAGGAGCUA 718 22      1 hsa-miR-4443 UUGGAGGCGUGGGUUUU 663 17      1 hsa-miR-4459 CCAGGAGGCGGAGGAGGUGGAG 664 22      1 hsa-miR-4473 CUAGUGCUCUCCGUUACAAGUA 665 22      1 hsa-miR-4479 CGCGCGGCCGUGCUCGGAGCAG 666 22      1 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17      1 hsa-miR-4504 UGUGACAAUAGAGAUGAACAUG 667 22      1 hsa-miR-4520b-3p UUUGGACAGAAAACACGCAGGU 668 22      1 hsa-miR-452-5p AACUGUUUGCAGAGGAAACUGA 669 22      1 hsa-miR-4636 AACUCGUGUUCAAAGCCUUUAG 670 22      1 hsa-miR-4659b-3p UUUCUUCUUAGACAUGGCAGCU 671 22      1 hsa-miR-4664-3p CUUCCGGUCUGUGAGCCCCGUC 672 22      1 hsa-miR-4665-5p CUGGGGGACGCGUGAGCGCGAGC 673 23      1 hsa-miR-4666a-5p AUACAUGUCAGAUUGUAUGCC 674 21      1 hsa-miR-4673 UCCAGGCAGGAGCCGGACUGGA 422 22      1 hsa-miR-4681 AACGGGAAUGCAGGCUGUAUCU 675 22      1 hsa-miR-4682 UCUGAGUUCCUGGAGCCUGGUCU 676 23      1 hsa-miR-4690-5p GAGCAGGCGAGGCUGGGCUGAA 677 22      1 hsa-miR-4699-5p AGAAGAUUGCAGAGUAAGUUCC 678 22      1 hsa-miR-4700-3p CACAGGACUGACUCCUCACCCCAGUG 424 26      1 hsa-miR-4706 AGCGGGGAGGAAGUGGGCGCUGCUU 679 25      1 hsa-miR-4721 UGAGGGCUCCAGGUGACGGUGG 680 22      1 hsa-miR-4728-3p CAUGCUGACCUCCCUCCUGCCCCAG 681 25      1 hsa-miR-4742-5p UCAGGCAAAGGGAUAUUUACAGA 682 23      1 hsa-miR-4747-3p AAGGCCCGGGCUUUCCUCCCAG 683 22      1 hsa-miR-4749-5p UGCGGGGACAGGCCAGGGCAUC 684 22      1 hsa-miR-4755-3p AGCCAGGCUCUGAAGGGAAAGU 685 22      1 hsa-miR-4763-5p CGCCUGCCCAGCCCUCCUGCU 686 21      1 hsa-miR-4766-3p AUAGCAAUUGCUCUUUUGGAA 687 21      1 hsa-miR-4781-3p AAUGUUGGAAUCCUCGCUAGAG 688 22      1 hsa-miR-4793-3p UCUGCACUGUGAGUUGGCUGGCU 689 23      1 hsa-miR-488-3p UUGAAAGGCUAUUUCUUGGUC 690 21      1 hsa-miR-4999-5p UGCUGUAUUGUCAGGUAGUGA 691 21      1 hsa-miR-5001-5p AGGGCUGGACUCAGCGGCGGAGCU 692 24      1 hsa-miR-5002-5p AAUUUGGUUUCUGAGGCACUUAGU 693 24      1 hsa-miR-5004-5p UGAGGACAGGGCAAAUUCACGA 694 22      1 hsa-miR-5006-3p UUUCCCUUUCCAUCCUGGCAG 695 21      1 hsa-miR-5088 CAGGGCUCAGGGAUUGGAUGGAG 696 23      1 hsa-miR-544a AUUCUGCAUUUUUAGCAAGUUC 697 22      1 hsa-miR-548al AACGGCAAUGACUUUUGUACCA 698 22      1 hsa-miR-548aq-5p GAAAGUAAUUGCUGUUUUUGCC 699 22      1 hsa-miR-548at-5p AAAAGUUAUUGCGGUUUUGGCU 700 22      1 hsa-miR-548au-5p AAAAGUAAUUGCGGUUUUUGC 701 21      1 hsa-miR-548b-3p CAAGAACCUCAGUUGCUUUUGU 702 22      1 hsa-miR-556-3p AUAUUACCAUUAGCUCAUCUUU 703 22      1 hsa-miR-5582-3p UAAAACUUUAAGUGUGCCUAGG 704 22      1 hsa-miR-5586-3p CAGAGUGACAAGCUGGUUAAAG 705 22      1 hsa-miR-5588-5p ACUGGCAUUAGUGGGACUUUU 706 21      1 hsa-miR-5683 UACAGAUGCAGAUUCUCUGACUUC 707 24      1 hsa-miR-5696 CUCAUUUAAGUAGUCUGAUGCC 708 22      1 hsa-miR-5701 UUAUUGUCACGUUCUGAUU 709 19      1 hsa-miR-5706 UUCUGGAUAACAUGCUGAAGCU 710 22      1 hsa-miR-592 UUGUGUCAAUAUGCGAUGAUGU 711 22      1 hsa-miR-603 CACACACUGCAAUUACUUUUGC 712 22      1 hsa-miR-624-3p CACAAGGUAUUGGUAUUACCU 713 21      1 hsa-miR-885-5p UCCAUUACACUACCCUGCCUCU 714 22      1 hsa-miR-933 UGUGCGCAGGGAGACCUCUCCC 715 22      1

TABLE 7 Microvesicles El MICROVESICLES CTX0E0307EI SEQ ID MIRNA READ MIRNA MIRNA.SEQUENCE NO: LENGTH COUNTS hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19 32723 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17 16225 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18 12878 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17  6746 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17   531 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17   500 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15   357 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20    44 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17    43 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22    33 hsa-miR-3195 CGCGCCGGGCCCGGGUU 716 17    28 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21    26 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22    24 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17    19 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24    19 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18    19 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18    19 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22    18 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22    15 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19     7 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24     7 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24     7 hsa-miR-5096 GUUUCACCAUGUUGGUCAGGC 220 21     7 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19     5 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22     5 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18     5 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22     5 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22     4 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22     4 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22     4 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22     4 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 269 27     4 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19     4 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21     4 hsa-miR-3654 GACUGGACAAGCUGAGGAA 325 19     4 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22     4 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21     3 hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC  59 21     3 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24     3 hsa-miR-3615 UCUCUCGGCUCCUCGCGGCUC 323 21     3 hsa-miR-3653 CUAAGAAGUUGACUGAAG 544 18     3 hsa-miR-3960 GGCGGCGGCGGAGGCGGGGG 416 20     3 hsa-miR-4448 GGCUCCUUGGUCUAGGGGUA 231 20     3 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  92 22     2 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22     2 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23     2 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23     2 hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU  36 21     2 hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 119 22     2 hsa-miR-3196 CGGGGCGGCAGGGGCCUC 717 18     2 hsa-miR-4419b GAGGCUGAAGGAAGAUGG 718 18     2 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC 129 23     2 hsa-miR-4486 GCUGGGCGAGGCUGGCA 719 17     2 hsa-miR-663a AGGCGGGGCGCCGCGGGACCGC 365 22     2 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23     2 hsa-let-7i-3p CUGCGCAAGCUACUGCCUUGCU 483 22     1 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  22 22     1 hsa-miR-1225-5p GUGGGUACGGCCCAGUGGGGGG 720 22     1 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 340 26     1 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22     1 hsa-miR-1275 GUGGGGGAGAGGCUGUC 162 17     1 hsa-miR-1280 UCCCACCGCUGCCACCC 584 17     1 hsa-miR-134 UGUGACUGGUUGACCAGAGGGG  94 22     1 hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC 121 23     1 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23     1 hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC  79 23     1 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22     1 hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU  90 21     1 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  66 23     1 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  31 22     1 hsa-miR-3182 GCUUCUGUAGUGUAGUC 721 17     1 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA  97 22     1 hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 101 22     1 hsa-miR-3607-3p ACUGUAAACGCUUUCUGAUG 543 20     1 hsa-miR-361-5p UUAUCAGAAUCUCCAGGGGUAC  70 22     1 hsa-miR-3652 CGGCUGGAGGUGUGAGGA 722 18     1 hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU  47 22     1 hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU  57 23     1 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23     1 hsa-miR-432-5p UCUUGGAGUAGGUCAUUGGGUGG  95 23     1 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18     1 hsa-miR-4426 GAAGAUGGACGUACUUU 359 17     1 hsa-miR-4449 CGUCCCGGGGCUGCGCGAGGCA 155 22     1 hsa-miR-4800-3p CAUCCGUCCGUCUGUCCAC 549 19     1 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 118 22     1 hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG   5 22     1 hsa-miR-493-3p UGAAGGUCUACUGUGUGCCAGG  83 22     1 hsa-miR-5095 UUACAGGCGUGAACCACCGCG 723 21     1 hsa-miR-556-3p AUAUUACCAUUAGCUCAUCUUU 703 22     1 hsa-miR-644b-5p UGGGCUAAGGGAGAUGAUUGGGUA 724 24     1 hsa-miR-664-5p ACUGGCUAGGGAAAAUGAUUGGAU 443 24     1 hsa-miR-760 CGGCUCUGGGUCUGUGGGGA 289 20     1 hsa-miR-941 CACCCGGCUGUGUGCACAUGUGC  60 23     1 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU  10 22     1 hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG  52 22     1

TABLE 8 Exosomes El EXOSOMES CTX0E03 07E1 SEQ MIRNA READ MIRNA MIRNA.SEQUENCE ID NO: LENGTH COUNTS hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19 83958 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17 22482 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18 20618 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17  6419 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17   904 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17   723 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15   174 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20    43 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22    41 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17    28 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22    26 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18    24 hsa-miR-4454 GGAUCCGAGUCACGGCACCA 299 20    22 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24    17 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22    17 hsa-miR-3195 CGCGCCGGGCCCGGGUU 716 17    17 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22    15 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24    15 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22    15 hsa-miR-5096 GUUUCACCAUGUUGGUCAGGC 220 21    14 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21    13 hsa-miR-3654 GACUGGACAAGCUGAGGAA 325 19    13 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18    12 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24    11 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18    11 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17    10 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24     8 hsa-miR-644b-5p UGGGCUAAGGGAGAUGAUUGGGUA 724 24     8 hsa-miR-664-5p ACUGGCUAGGGAAAAUGAUUGGAU 443 24     8 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22     7 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22     7 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22     6 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22     6 hsa-miR-127-3p UCGGAUCCGUCUGAGCUUGGCU  14 22     6 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19     6 hsa-miR-4449 CGUCCCGGGGCUGCGCGAGGCA 155 22     6 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC 129 23     6 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22     5 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 269 27     5 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19     5 hsa-miR-3653 CUAAGAAGUUGACUGAAG 544 18     5 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18     5 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22     4 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  25 21     4 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22     4 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21     4 hsa-miR-23a-3p AUCACAUUGCCAGGGAUUUCC  55 21     4 hsa-miR-4419b GAGGCUGAAGGAAGAUGG 718 18     4 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19     3 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21     3 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23     3 hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC  79 23     3 hsa-miR-3615 UCUCUCGGCUCCUCGCGGCUC 323 21     3 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23     3 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22     2 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU  27 22     2 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  22 22     2 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA  62 23     2 hsa-miR-106b-5p UAAAGUGCUGACAGUGCAGAU 170 21     2 hsa-miR-1273e UUGCUUGAACCCAGGAAGUGGA 342 22     2 hsa-miR-221-5p ACCUGGCAUACAAUGUAGAUUU  39 22     2 hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU  36 21     2 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  31 22     2 hsa-miR-3960 GGCGGCGGCGGAGGCGGGGG 416 20     2 hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU  92 22     1 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  53 22     1 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU  43 22     1 hsa-let-7i-3p CUGCGCAAGCUACUGCCUUGCU 483 22     1 hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG   2 23     1 hsa-miR-1181 CCGUCGCCGCCACCCGAGCCG 725 21     1 hsa-miR-1225-3p UGAGCCCCUGUGCCGCCCCCAG 369 22     1 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 340 26     1 hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA  35 24     1 hsa-miR-1296 UUAGGGCCCUGGCUCCAUCUCC 271 22     1 hsa-miR-1307-5p UCGACCGGACCUCGACCGGCU  91 21     1 hsa-miR-146b-5p UGAGAACUGAAUUCCAUAGGCU  19 22     1 hsa-miR-149-5p UCUGGCUCCGUGUCUUCACUCCC 121 23     1 hsa-miR-151a-5p UCGAGGAGCUCACAGUCUAGU  37 21     1 hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  78 22     1 hsa-miR-181a-2-3p ACCACUGACCGUUGACUGUACC 102 22     1 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23     1 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23     1 hsa-miR-198 GGUCCAGAGGGGAGAUAGGUUC 726 22     1 hsa-miR-204-5p UUCCCUUUGUCAUCCUAUGCCU  89 22     1 hsa-miR-20a-5p UAAAGUGCUUAUAGUGCAGGUAG 146 23     1 hsa-miR-219-5p UGAUUGUCCAAACGCAAUUCU 527 21     1 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22     1 hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC  59 21     1 hsa-miR-26b-3p CCUGUUCUCCAUUACUUGGCUC 391 22     1 hsa-miR-299-5p UGGUUUACCGUCCCACAUACAU 319 22     1 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 106 22     1 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC  71 22     1 hsa-miR-31-3p UGCUAUGCCAACAUAUUGCCAU 172 22     1 hsa-miR-3198 GUGGAGUCCUGGGGAAUGGAGA 647 22     1 hsa-miR-323a-3p CACAUUACACGGUCGACCUCU 158 21     1 hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU  81 23     1 hsa-miR-3607-3p ACUGUAAACGCUUUCUGAUG 543 20     1 hsa-miR-3651 CAUAGCCCGGUCGCUGGUACAUGA 727 24     1 hsa-miR-378a-3p ACUGGACUUGGAGUCAGAAGG  65 21     1 hsa-miR-379-5p UGGUAGACUAUGGAACGUAGG  18 21     1 hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU  57 23     1 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23     1 hsa-miR-425-5p AAUGACACGAUCACUCCCGUUGA 111 23     1 hsa-miR-4258 CCCCGCCACCGCCUUGG 728 17     1 hsa-miR-4426 GAAGAUGGACGUACUUU 359 17     1 hsa-miR-4443 UUGGAGGCGUGGGUUUU 663 17     1 hsa-miR-4448 GGCUCCUUGGUCUAGGGGUA 231 20     1 hsa-miR-4697-3p UGUCAGUGACUCCUGCCCCUUGGU 729 24     1 hsa-miR-4700-3p CACAGGACUGACUCCUCACCCCAGUG 424 26     1 hsa-miR-4700-5p UCUGGGGAUGAGGACAGUGUGU 730 22     1 hsa-miR-4797-3p UCUCAGUAAGUGGCACUCUGU 731 21     1 hsa-miR-484 UCAGGCUCAGUCCCCUCCCGAU 118 22     1 hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG   5 22     1 hsa-miR-494 UGAAACAUACACGGGAAACCUC 240 22     1 hsa-miR-500a-5p UAAUCCUUGCUACCUGGGUGAGA 303 23     1 hsa-miR-644b-3p UUCAUUUGCCUCCCAGCCUACA 442 22     1 hsa-miR-663a AGGCGGGGCGCCGCGGGACCGC 365 22     1

TABLE 9 Microvesicles EH MICROVESICLES CTX0E03 07EH SEQ MIRNA READ MIRNA MIRNA.SEQUENCE ID NO: LENGTH COUNTS hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19 78791 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17  6012 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17  3410 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18  1737 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20   319 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17   221 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17   114 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18    61 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17    51 hsa-miR-3195 CGCGCCGGGCCCGGGUU 716 17    41 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19    30 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22    22 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18    20 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18    12 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22    12 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24    11 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15    10 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22     8 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17     8 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22     8 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22     7 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19     7 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24     7 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC  52 23     6 hsa-miR-664-5p ACUGGCUAGGGAAAAUGAUUGGAU  91 24     6 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22     6 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22     5 hsa-miR-3653 CUAAGAAGUUGACUGAAG 544 18     5 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22     4 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22     4 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23     4 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24     4 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23     4 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22     3 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU  59 26     3 hsa-miR-127-3p UCGGAUCCGUCUGAGCUUGGCU  14 22     3 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23     3 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21     3 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22     3 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  66 23     3 hsa-miR-3960 GGCGGCGGCGGAGGCGGGGG 416 20     3 hsa-miR-485-3p GUCAUACACGGCUCUCCUCUCU 153 22     3 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22     2 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU  43 22     2 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19     2 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  25 21     2 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24     2 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23     2 hsa-miR-197-3p UUCACCACCUUCUCCACCCAGC 122 22     2 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23     2 hsa-miR-4468 AGAGCAGAAGGAUGAGAU 732 18     2 hsa-miR-644b-5p UGGGCUAAGGGAGAUGAUUGGGUA 724 24     2 hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 116 23     2 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  92 22     1 hsa-miR-1225-3p UGAGCCCCUGUGCCGCCCCCAG 369 22     1 hsa-miR-1254 AGCCUGGAAGCUGGAGCCUGCAGU 270 24     1 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21     1 hsa-miR-1275 GUGGGGGAGAGGCUGUC 162 17     1 hsa-miR-1296 UUAGGGCCCUGGCUCCAUCUCC 271 22     1 hsa-miR-1307-5p UCGACCGGACCUCGACCGGCU  91 21     1 hsa-miR-134 UGUGACUGGUUGACCAGAGGGG  94 22     1 hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  78 22     1 hsa-miR-17-5p CAAAGUGCUUACAGUGCAGGUAG 145 23     1 hsa-miR-1972 UCAGGCCAGGCACAGUGGCUCA 733 22     1 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22     1 hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA  63 22     1 hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC   6 21     1 hsa-miR-3065-5p UCAACAAAAUCACUGAUGCUGGA 226 23     1 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  31 22     1 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA  97 22     1 hsa-miR-342-3p UCUCACACAGAAAUCGCACCCGU  81 23     1 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21     1 hsa-miR-3652 CGGCUGGAGGUGUGAGGA 722 18     1 hsa-miR-376c AACAUAGAGGAAAUUCCACGU 185 21     1 hsa-miR-378a-3p ACUGGACUUGGAGUCAGAAGG  65 21     1 hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU  47 22     1 hsa-miR-433 AUCAUGAUGGGCUCCUCGGUGU 174 22     1 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18     1 hsa-miR-4448 GGCUCCUUGGUCUAGGGGUA 231 20     1 hsa-miR-4454 GGAUCCGAGUCACGGCACCA 299 20     1 hsa-miR-454-3p UAGUGCAAUAUUGCUUAUAGGGU 169 23     1 hsa-miR-4800-3p CAUCCGUCCGUCUGUCCAC 549 19     1 hsa-miR-493-3p UGAAGGUCUACUGUGUGCCAGG  83 22     1 hsa-miR-5095 UUACAGGCGUGAACCACCGCG 723 21     1 hsa-miR-574-3p CACGCUCAUGCACACACCCACA 253 22     1 hsa-miR-665 ACCAGGAGGCUGAGGCCCCU 309 20     1 hsa-miR-720 UCUCGCUGGGGCCUCCA  84 17     1 hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG  52 22     1 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22     1

TABLE 10 Exosomes EH EXOSOMES CTX0E03 07EH SEQ MIRNA READ MIRNA MIRNA.SEQUENCE ID NO: LENGTH COUNTS hsa-miR-1246 AAUGGAUUUUUGGAGCAGG  21 19 111092 hsa-miR-4492 GGGGCUGGGCGCGCGCC  34 17   5188 hsa-miR-4532 CCCCGGGGAGCCCGGCG  23 17   3368 hsa-miR-4488 AGGGGGCGGGCUCCGGCG  61 18   1389 hsa-miR-4485 UAACGGCCGCGGUACCCUAA  67 20    386 hsa-miR-4508 GCGGGGCUGGGCGCGCG 135 17    188 hsa-miR-4516 GGGAGAAGGGUCGGGGC 110 17    135 hsa-miR-4497 CUCCGGGACGGCUGGGC 232 17     73 hsa-miR-1973 ACCGUGCAAAGGUAGCAUA 171 19     50 hsa-miR-3195 CGCGCCGGGCCCGGGUU 716 17     48 hsa-miR-4466 GGGUGCGGGCCGGCGGGG 264 18     43 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU   1 22     20 hsa-miR-99b-5p CACCCGUAGAACCGACCUUGCG   4 22     19 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA   9 22     18 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU   7 22     18 hsa-miR-3676-5p AGGAGAUCCUGGGUU 280 15     17 hsa-miR-4792 CGGUGAGCGCUCGCUGGC 363 18     15 hsa-miR-664-5p ACUGGCUAGGGAAAAUGAUUGGAU 443 24     13 hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG   3 22     11 hsa-miR-1291 UGGCCCUGACUGAAGACCAGCAGU 294 24     10 hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG  29 22     10 hsa-miR-4284 GGGCUCACAUCACCCCAU 191 18     10 hsa-miR-663b GGUGGCCCGGCCGUGCCUGAGG 180 22      9 hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA  63 22      8 hsa-miR-3656 GGCGGGUGCGGGGGUGG 251 17      8 hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU  15 23      7 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU  12 22      6 hsa-miR-3654 GACUGGACAAGCUGAGGAA 325 19      6 hsa-miR-644b-5p UGGGCUAAGGGAGAUGAUUGGGUA 724 24      6 hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU  28 22      5 hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU  11 22      5 hsa-miR-1290 UGGAUUUUUGGAUCAGGGA 375 19      5 hsa-miR-4426 GAAGAUGGACGUACUUU 359 17      5 hsa-miR-5096 GUUUCACCAUGUUGGUCAGGC 220 21      5 hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA  42 22      4 hsa-miR-1273f GGAGAUGGAGGUUGCAGUG 292 19      4 hsa-miR-191-5p CAACGGAAUCCCAAAAGCAGCUG   8 23      4 hsa-miR-22-3p AAGCUGCCAGUUGAAGAACUGU  33 22      4 hsa-miR-3609 CAAAGUGAUGAGUAAUACUGGCUG 216 24      4 hsa-miR-3687 CCCGGACAGGCGUUCGUGCGACGU 190 24      4 hsa-miR-93-5p CAAAGUGCUGUUCGUGCAGGUAG 116 23      4 hsa-miR-1248 ACCUUCUUGUAUAAGCACUGUGCUAAA 269 27      3 hsa-miR-1273g-3p ACCACUGCACUCCAGCCUGAG 210 21      3 hsa-miR-151a-3p CUAGACUGAAGCUCCUUGAGG  25 21      3 hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU  16 24      3 hsa-miR-221-3p AGCUACAUUGUCUGCUGGGUUUC  79 23      3 hsa-miR-222-3p AGCUACAUCUGGCUACUGGGU  36 21      3 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 106 22      3 hsa-miR-4461 GAUUGAGACUAGUAGGGCUAGGC 129 23      3 hsa-miR-486-5p UCCUGUACUGAGCUGCCCCGAG   5 22      3 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC  13 22      3 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA  58 23      3 hsa-miR-98 UGAGGUAGUAAGUUGUAUUGUU  10 22      3 hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU  53 22      2 hsa-miR-134 UGUGACUGGUUGACCAGAGGGG  94 22      2 hsa-miR-151a-5p UCGAGGAGCUCACAGUCUAGU  37 21      2 hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA  78 22      2 hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG  30 22      2 hsa-miR-3124-3p ACUUUCCUCACUCCCGUGAAGU 734 22      2 hsa-miR-3653 CUAAGAAGUUGACUGAAG 544 18      2 hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU  17 22      1 hsa-let-7d-3p CUAUACGACCUGCUGCCUUUCU  92 22      1 hsa-let-7g-5p UGAGGUAGUAGUUUGUACAGUU  43 22      1 hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU  22 22      1 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA  62 23      1 hsa-miR-106b-5p UAAAGUGCUGACAGUGCAGAU 170 21      1 hsa-miR-1244 AAGUAGUUGGUUUGUAUGAGAUGGUU 340 26      1 hsa-miR-128 UCACAGUGAACCGGUCUCUUU 109 21      1 hsa-miR-1285-3p UCUGGGCAACAAAGUGAGACCU 464 22      1 hsa-miR-1307-3p ACUCGGCGUGGCGUCGGUCGUG 124 22      1 hsa-miR-140-3p UACCACAGGGUAGAACCACGG 138 21      1 hsa-miR-148b-3p UCAGUGCAUCACAGAACUUUGU  48 22      1 hsa-miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU  38 23      1 hsa-miR-193a-3p AACUGGCCUACAAAGUCCCAGU 386 22      1 hsa-miR-1972 UCAGGCCAGGCACAGUGGCUCA 733 22      1 hsa-miR-21-3p CAACACCAGUCGAUGGGCUGU  20 21      1 hsa-miR-2277-3p UGACAGCGCCCUGCCUGGCUC 735 21      1 hsa-miR-23a-3p AUCACAUUGCCAGGGAUUUCC  55 21      1 hsa-miR-23b-3p AUCACAUUGCCAGGGAUUACC  59 21      1 hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 119 22      1 hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC  46 21      1 hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC   6 21      1 hsa-miR-299-3p UAUGUGGGAUGGUAAACCGCUU 182 22      1 hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU  96 22      1 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  66 23      1 hsa-miR-31-3p UGCUAUGCCAACAUAUUGCCAU 172 22      1 hsa-miR-3196 CGGGGCGGCAGGGGCCUC 717 18      1 hsa-miR-3198 GUGGAGUCCUGGGGAAUGGAGA 647 22      1 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA  97 22      1 hsa-miR-329 AACACACCUGGUUAACCUCUUU 214 22      1 hsa-miR-339-5p UCCCUGUCCUCCAGGAGCUCACG 402 23      1 hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 101 22      1 hsa-miR-3607-5p GCAUGUGAUGAAGCAAAUCAGU 249 22      1 hsa-miR-3648 AGCCGCGGGGAUCGCCGAGGG 259 21      1 hsa-miR-376c AACAUAGAGGAAAUUCCACGU 185 21      1 hsa-miR-3960 GGCGGCGGCGGAGGCGGGGG 416 20      1 hsa-miR-411-3p UAUGUAACACGGUCCACUAACC 482 22      1 hsa-miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU  57 23      1 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU  41 23      1 hsa-miR-4417 GGUGGGCUUCCCGGAGGG 175 18      1 hsa-miR-4444 CUCGAGUUGGAAGAGGCG 418 18      1 hsa-miR-4499 AAGACUGAGAGGAGGGA 736 17      1 hsa-miR-4521 GCUAAGGAAGUCCUGUGCUCAG 233 22      1 hsa-miR-4680-5p AGAACUCUUGCAGUCUUAGAUGU 737 23      1 hsa-miR-4709-5p ACAACAGUGACUUGCUCUCCAA 575 22      1 hsa-miR-501-3p AAUGCACCCGGGCAAGGAUUCU  26 22      1 hsa-miR-644b-3p UUCAUUUGCCUCCCAGCCUACA 442 22      1 hsa-miR-654-3p UAUGUCUGCUGACCAUCACCUU 336 22      1 hsa-miR-9-3p AUAAAGCUAGAUAACCGAAAGU 183 22      1 hsa-miR-940 AAGGCAGGGCCCCCGCUCCCC 366 21      1 hsa-miR-99a-5p AACCCGUAGAUCCGAUCUUGUG  52 22      1

Identification of Top Ranking Coding and Non-Coding RNAs by GENCODE Analysis Performed in Exosomes, MV and Producer Cells

TABLE 11 Total number of sequence reads identified by using GENCODE in each tested samples CTX0E03 07EH CTX0E03 CTX0E03 CTX0E03 CTX0E03 CTX0E03 cells 07EH EXO 07EH MV 07EI cells 07EIE XO 07EI MV 18741941 12678688 10876797 22116110 16311289 835970

Using GENCODE database analysis of the sequence results, seven putative novel miRNA sequences were identified in exosomes (EXO), microvesicles (MV) and producer cells, as shown in Table 12. (nb CTX0E03 07E1 MV reads are misrepresented due to the lower amount of starting material—see Table 11). These data are shown graphically in FIG. 16, which shows that these sequences are preferentially shuttled into exosomes and microvesicles compared to the cells.

TABLE 12 Identification of putative novel miRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. CTX0E03 07EI MV reads are misrepresented due to the lower amount of starting material (Table 11). The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO AC079949.1 AC079949.1-201 57 Novel miRNA 2629 27006 AP000318.1 AP000318.1-201 64 Novel miRNA 1353 9379 AL161626.1 AL161626.1-201 57 Novel miRNA 471 4450 AC004943.1 AC004943.1-201 81 Novel miRNA 24 81 AL121897.1 AL121897.1-201 89 Novel miRNA 6 22 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV AC079949.1 14873 2425 11433 848 AP000318.1 11002 7469 2963 419 AL161626.1 3712 291 1263 129 AC004943.1 43 23 94 5 AL121897.1 14 2 30 3 Validation and of Novel miRNAs

AC079949.1-201 (SEQ ID NO: 738) Gene: AC079949.1 ENSG00000239776 >12 dna:chromosome chromosome:GRCh37:12: 127650616:127650672:1 GGCCGCGCCCCGTTTCCCAGGACAAAGGGCACTCCGCACCGGACCCT GGTCCCAGCG

For AC079949.1-201 putative mature miRNA, gaccaggguccggugcggagug (SEQ ID NO:745) was identified as the possible 5′ stem mature miRNA using MatureBayes, a tool for finding mature miRNA within a miRNA precursor sequence using a Naive Bays classifier. Its presence validation was performed using AGGGTCCGGTGCGGAGT (SEQ ID NO:746) primer sequence. This sequence was entered in mirbase (mirbase.org) and the following miRNA was found with similar sequence: Bos taurus miR-2887-1 (Accession No. MIMAT0013845).

bta-miR-2887: 9-20 (SEQ ID NO: 747) AC079949 (5) 2 ggguccggugcg 13 |||||||||||| bta-miR-2887 9 ggguccggugcg 20

The presence of this novel miRNA was tested by qRT-PCR on purified exosomes retro transcribed miRNA.

The same analysis was performed using the 3′ stem of AC079949, sequence TGCGGAGTGCCCTTTGTCCT (SEQ ID NO:748), but in this case no similar miRNA was identified in mirbase.

AP000318.1-201 (SEQ ID NO: 739) Gene: AP000318.1 ENSG00000266007 >21 dna:chromosome chromosome:GRCh37: 21:35677430:35677493:1 CCCACTCCCTGGCGCCGCTTGTGGAGGGCCCAAGTCCTTCTGATTGA GGCCCAACCCGTGGAAG

For AP000318.1-201 putative mature miRNA, ggagggcccaaguccuucugau (SEQ ID NO:744) was identified as the possible 5′ stem mature miRNA. Its presence validation was performed using GGAGGGCCCAAGTCCTTCTGAT (SEQ ID NO:749) primer sequence. Caenorhabditis remanei miR-55 stem-loop was identified as similar miRNA. Primer validation was again carried out by qRT-PCR.

crm-miR-55-5p: 4-17 (SEQ ID NO: 750) AP000318.1 20 cccaaguccuucug  7 ||||||| |||||| crm-miR-55-5p  4 cccaagugcuucug 17 AL161626.1-201 (SEQ ID NO: 740) Gene: AL161626.1 ENSG00000241781 >9 dna:chromosome chromosome:GRCh37:9: 79186731:79186787:1 CGCCGGGACCGGGGTCCGGGGCGGAGTGCCCTTCCTCCTGGGAAAC GGGGTGCGGC

For AL161626.1-201 putative mature miRNA, ggcggagugcccuucuuccugg (SEQ ID NO:743) was identified as the possible 5′ stem mature miRNA. Its presence validation was performed using CGGAGTGCCCTTCTTCCT (SEQ ID NO:751) primer sequence. Zea mays miR164c stem-loop and Achypodium distachyon miR164f stem-loop were identified as similar miRNA. Primer validation was again carried out by qRT-PCR.

zma-miR164c-3p: 4-15 (SEQ ID NO: 752) AL161626.1 5 gugcccuucuuc 16 |||||||||||| zma-miR164c-3p 4 gugcccuucuuc 15 AC004943.1 (SEQ ID NO: 741) Gene: AC004943.1 ENSG00000265573 >16 dna:chromosome chromosome:GRCh37:16: 72821592:72821672:-1 GCTTCACGTCCCCACCGGCGGCGGCGGCGGTGGCAGTGG CGGCGGCGGCGGCGGTGGCGGCGGCGGCGGCGGCGGCGG CTC AL121897.1 (SEQ ID NO: 742) Gene: AL121897.1 ENSG00000264308 >20 dna:chromosome chromosome:GRCh37:20: 30865503:30865591:1 GCCGCCCCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCC GCCGCCCGCTTTCGGCTCGGGCCTCAGGTGAGTCGGAGG GGCCGGGCGCC

Miscellaneous RNA (Misc_RNA), Including Novel Putative

Misc RNA is short for miscellaneous RNA, a general term for a series of miscellaneous small RNA. Miscellaneous transcript feature are not defined by other RNA keys.

List of top ranking previously known and novel misc RNAs identified using GENCODE sequence data set:

TABLE 13 Identification of misc_RNA, including putative novel misc_RNA, sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. (CTX0E03 07EI MV reads are misrepresented due to the lower amount of starting material - Table 11). The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO RPPH1 RPPH1-201 333 misc RNA 76 2229 RMRP RMRP-201 264 misc RNA 139 1803 RPPH1 RPPH1-001 638 misc RNA 182 931 VTRNA1-1 VTRNA1-1-201 99 misc RNA 43 720 Y_RNA Y_RNA.321-201 93 Novel misc RNA 159 196 Y_RNA Y_RNA.725-201 95 Novel misc RNA 1092 18 Y_RNA Y_RNA.125-201 96 Novel misc RNA 1079 15 Y_RNA Y_RNA.118-201 99 Novel misc RNA 134 12 Y_RNA Y_RNA.394-201 109 Novel misc RNA 9 9 Y_RNA Y_RNA.687-201 111 Novel misc RNA 36 6 Y_RNA Y_RNA.144-201 102 Novel misc RNA 129 5 Y_RNA Y_RNA.337-201 105 Novel misc RNA 7 4 Y_RNA Y_RNA.413-201 97 Novel misc RNA 136 4 Y_RNA Y_RNA.30-201 103 Novel misc RNA 74 3 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV RPPH1 1785 0 1077 197 RMRP 1443 191 659 87 RPPH1 1372 795 2017 157 VTRNA1-1 52 247 210 9 Y_RNA 661 960 903 217 Y_RNA 74 1005 39 11 Y_RNA 58 906 27 12 Y_RNA 9 156 45 7 Y_RNA 7 33 13 1 Y_RNA 15 103 41 10 Y_RNA 21 187 84 5 Y_RNA 0 15 4 0 Y_RNA 8 125 46 3 Y_RNA 3 62 21 2

Among the misc_RNA the following sequences were found preferentially down or up shuttled in exosomes and MV: RPHI, RMRP, and VTRNA1-1 up shuttled and Y_RNA.725-201, and Y_RNA.125-201 down respectively. RPHI is a ribonuclease P RNA component H1. RMRP gene encodes the RNA component of mitochondrial RNA processing endoribonuclease, which cleaves mitochondrial RNA at a priming site of mitochondrial DNA replication. This RNA also interacts with the telomerase reverse transcriptase catalytic subunit to form a distinct ribonucleoprotein complex that has RNA-dependent RNA polymerase activity and produces double-stranded RNAs that can be processed into small interfering RNA. VTRNA1-1 is vault RNA component 1. Vaults are large cytoplasmic ribonucleoproteins and they are composed of a major vault protein, MVP, 2 minor vault proteins, TEP1 and PARP4, and a non-translated RNA component, VTRNA1-1. Y_RNA.725-201, and Y_RNA.125-201 are novel misc RNAs and their function is not defined.

Metazoa Miscellaneous RNA

The signal recognition particle RNA, also known as 7SL, 6S, ffs, or 4.5S RNA, is the RNA component of the signal recognition particle (SRP) ribonucleoprotein complex. SRP is a universally conserved ribonucleoprotein that directs the traffic of proteins within the cell and allows them to be secreted. The SRP RNA, together with one or more SRP proteins contributes to the binding and release of the signal peptide. The RNA and protein components of this complex are highly conserved but do vary between the different kingdoms of life.

List of top ranking Metazoa misc RNAs identified using GENCODE sequence data set:

TABLE 14 Identification signal recognition particle RNA (misc_RNA) sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO Metazoa_SRP Metazoa_SRP.791-201 288 Metazoan signal 679 2324 recognition particle RNA Metazoa_SRP Metazoa_SRP.561-201 294 Metazoan signal 634 2006 recognition particle RNA Metazoa_SRP Metazoa_SRP.864-201 297 Metazoan signal 252 1884 recognition particle RNA Metazoa_SRP Metazoa_SRP.824-201 297 Metazoan signal 438 881 recognition particle RNA Metazoa_SRP Metazoa_SRP.72-201 278 Metazoan signal 441 630 recognition particle RNA Metazoa_SRP Metazoa_SRP.151-201 307 Metazoan signal 377 464 recognition particle RNA Metazoa_SRP Metazoa_SRP.208-201 277 Metazoan signal 382 410 recognition particle RNA Metazoa_SRP Metazoa_SRP.501-201 280 Metazoan signal 265 272 recognition particle RNA Metazoa_SRP Metazoa_SRP.682-201 298 Metazoan signal 12 52 recognition particle RNA Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV Metazoa_SRP 2058 771 2698 465 Metazoa_SRP 1683 744 2147 432 Metazoa_SRP 1544 78 170 148 Metazoa_SRP 958 505 1860 342 Metazoa_SRP 631 494 2184 349 Metazoa_SRP 470 432 1431 265 Metazoa_SRP 431 422 1104 242 Metazoa_SRP 266 236 434 44 Metazoa_SRP 21 10 13 2

RRNA (Ribosomal RNA)

Ribosomal RNA (rRNA) forms part of the protein-synthesizing organelle known as a ribosome and that is exported to the cytoplasm to help translate the information in messenger RNA (mRNA) into protein. Eukaryotic ribosome (80S) rRNA components are: large unit (rRNA 5S, 5.8S, and 28S) small unit (rRNA 18S). Both rRNA 28S and 5.8S are selectively up-shuttled in exosomes and MV.

List of top ranking rRNA identified using GENCODE sequence data set:

TABLE 15 Identification rRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO RNA5-8SP6 RNA5-8SP6-201 152 rRNA 205008 1148190 RNA28S5 RNA28S5-001 432 rRNA 86111 458585 RNA18S5 RNA18S5-001 599 rRNA 74634 52055 RNA5-8SP2 RNA5-8SP2-201 152 rRNA 6488 1719 RNA5-8SP5 RNA5-8SP5-201 152 rRNA 2794 7393 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV RNA5-8SP6 706558 213187 135909 14732 RNA28S5 516754 62829 390237 47483 RNA18S5 61639 116874 138484 14616 RNA5-8SP2 1540 9231 3112 149 RNA5-8SP5 3924 7314 3579 232 Small Nucleolar RNA: snoRNA

Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that primarily guides chemical modifications of other RNAs, mainly ribosomal RNAs, transfer RNAs and small nuclear RNAs. There are two main classes of snoRNA, the C/D box snoRNAs which are associated with methylation, and the H/ACA box snoRNAs which are associated with pseudouridylation.

List of top ranking snoRNA identified using GENCODE sequence data set:

TABLE 16 Identification of snoRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO SNORD3A SNORD3A-201 216 snoRNA 1433 2085 SNORD3C SNORD3C-201 216 snoRNA 1169 1702 SNORD29 SNORD29-201 65 snoRNA 28130 1633 SNORD83B SNORD83B-201 93 snoRNA 1835 675 SNORD30 SNORD30-201 70 snoRNA 29743 254 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV SNORD3A 1621 906 1732 120 SNORD3C 1220 639 1176 86 SNORD29 1070 36677 1752 45 SNORD83B 487 638 575 29 SNORD30 244 29071 283 24 Small Nuclear RNA (snRNA)

Small nuclear ribonucleic acid (snRNA), also commonly referred to as U-RNA, is a class of small RNA molecules that make up the major spliceosome are named U1, U2, U4, U5, and U6, and participate in several RNA-RNA and RNA-protein interactions. Their primary function is in the processing of pre-mRNA (hnRNA) in the nucleus. They have also been shown to aide in the regulation of transcription factors (7SK RNA) or RNA polymerase II (B2 RNA), and maintaining the telomeres.

List of top ranking snRNA identified using GENCODE sequence data set:

TABLE 17A Identification of snRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol ID Length RNA cells EXO MV cells EXO MV U2 U2.38-201 191 snRNA 1354 71596 49223 751 35290 1919 U2 U2.6-201 192 snRNA 834 15561 13594 303 8146 272 U1 U1.81-201 164 snRNA 584 10901 7307 91 3197 121 U1 U1.90-201 167 snRNA 533 9927 6689 48 2187 84 U2 U2.7-201 191 snRNA 201 9267 3109 288 6736 262 LincRNA and Novel lincRNA

Large intergenic non-coding RNAs (lincRNAs) are emerging as key regulators of diverse cellular processes. Determining the function of individual lincRNAs remains a challenge. Long non-coding RNAs (long ncRNAs, lncRNA) are non-protein coding transcripts longer than 200 nucleotides.

List of top ranking previously known and novel lincRNAs identified using GENCODE sequence data set:

TABLE 17B Identification of lincRNA and putative novel lincRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO RP11-108M9.3 RP11-108M9.3-002 1761 Novel lincRNA 244 159 RP11-329L6.1 RP11-329L6.1-001 507 Novel lincRNA 19 70 RP11-160E2.6 RP11-160E2.6-001 637 Novel lincRNA 228 67 AC004528.3 AC004528.3-001 107 Novel lincRNA 16 58 MALAT1 MALAT1-201 4585 lincRNA 150 308 GAS5 GAS5-007 2743 lincRNA 12024 215 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV RP11-108M9.3 240 539 324 45 RP11-329L6.1 41 29 84 2 RP11-160E2.6 115 489 74 6 AC004528.3 46 14 55 4 MALAT1 234 26 182 12 GAS5 120 46501 875 13

GAS5 lincRNA is highly expressed in cell producer compared to in exosomes and microvesicles (down shuttled in both exosomes and MV).

mRNA

Coding sequencing mRNA were also identified.

TABLE 18 Identification of mRNA sequences using GENCODE in exosomes (EXO), microvesicles (MV) and producer cells. The transcript IDs are taken from the Ensembl database (www.ensembl.org). Gene Transcript Type of CTX0E0307EH CTX0E0307EH Symbol ID Length RNA cells EXO EEF2 EEF2-201 9407 mRNA 710 578 MTRNR2L8 MTRNR2L8-201 1290 mRNA 1383 548 NES NES-001 8635 mRNA 668 406 VIM VIM-001 8316 mRNA 563 911 Gene CTX0E0307EH CTX0E0307EI CTX0E0307EI CTX0E0307EI Symbol MV cells EXO MV EEF2 449 1155 471 33 MTRNR2L8 642 1323 258 15 NES 234 1448 267 20 VIM 501 1500 618 36

Examples 17A-17C: Conclusion

The main scope of the deep sequence analysis was to identify their miRNA components in neural stem cell-derived vesicles (exosomes and microvesicles). This analysis identified a new set of known and novel miRNAs that are preferentially shuttled into both exosomes and MV. Among the identified miRNAs already included in mirbase database were hsa-miR-1246, hsa-miR-4488, hsa-miR-4492, hsa-miR-4508, hsa-miR-4516, hsa-miR-4532, and among the novel miRNAs were AC079949.1, AP000318.1, AL161626.1, AC004943.1, AL121897.1. Top ranking shuttled miRNAs, including novel ones were validated by qRT-PCR in exosomes.

The size distribution of shuttle RNA, as shown here, is mostly in the range of 20 to 200 nt and other RNA species are released by cells into the extracellular space. By deep sequencing and GENCODE sequence set analysis we found a greater complexity and diversity of non-coding RNA transcripts. We extended this analysis with detailed evaluation and this led to the discovery of preferentially up (defined as log 2 fold change ≥2) and down (defined as log 2 fold change ≤−2) shuttle of other non-coding RNAs in both exosomes and microvesicles. Differentially shuttled non coding RNA were found in almost all the non-coding RNA subtypes, ribosomal RNA (rRNA), small nucleolar (snoRNA), small nuclear RNA (snRNA), microRNA (miRNA), miscellaneous other RNA (misc_RNA, e.g. RMRP, vault RNA, metazoa SRP, and RNY), and large intergenic non-coding RNAs (lincRNAs).

The unequal distribution of the detected RNA species over cellular and shuttle RNA, combined with increasing evidence for their role in gene regulation strongly suggest that cells specifically release these RNAs to modify the function of target cells.

D) Deep Sequencing of CTX0E03 Cell and Exosome miRNA Expression from 6 Week Bioreactor Culture

Next generation deep sequencing was also carried out on CTX0E03 cells and their derived exosomes, following culture for six weeks in an Integra bioreactor. The results showed that hsa-miR-1246, hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are also up-shuttled in exosomes derived from 6 week Integra culture (6W). In EXO 6W a total of 61 miRNA types are up-shuttled. Up-shuttled miRNAs with more than 250 reads per exosome sample are listed in FIG. 13E.

Conclusions

Hsa-miR-1246, hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are still up-shuttled in EXO 6W as observed on proliferative EXO (07EI & EH; FIGS. 13A and 13B). New up-shuttled miRNAs are also identified, including hsa-miR-4792.

20.53% of the identified miRNA are up-shuttled in the exosomes derived from 6 week Integra CTX cultures (shown in FIG. 13C, middle panel). This compares to 99% of the identified miRNAs that are up-shuttled in the exosomes derived from proliferative CTX0E03 cultures (FIG. 13C, top panel).

E) Deep Sequencing of CTX0E03 Cell and Exosome miRNA Expression from 11 Week Bioreactor Culture

Next generation deep sequencing was also carried out on CTX0E03 cells and their derived exosomes, following culture for 11 weeks in an Integra bioreactor. Three samples were tested.

In sample 1, 9 miRNA species are up-shuttled, all of which have more than 250 reads, as shown in FIG. 13F.

In sample 2, 68 miRNA species are up-shuttled into the exosomes. The miRNAs with more than 250 reads per exosome sample are shown in FIG. 13G.

In sample 3, 47 miRNA species are up-shuttled. FIG. 13H shows the three miRNA species with a read count >250: hsa-miR-10b-5p, hsa-miR-1246 and hsa-miR-486-5p.

Conclusions

TABLE E1 W 11 summary table of reads and log2 values of miRNA types previously reported as up-shuttled in proliferative CTX0E03 exosomes. Reads Log2 MiRNA Cell1 Cell2 Cell3 EXO1 EXO2 EXO3 EXO1 EXO2 EXO3 hsa-miR-4488 0 0 1 0 0 0 N/A N/A N/A hsa-miR-4492 0 1 0 1 0 0 N/A N/A N/A hsa-miR-4532 0 0 0 0 0 0 N/A N/A N/A hsa-miR-1246 483 1122 3470 18 2726 24152 −4.20 1.26 2.99

Hsa-miR-1246 is present in 11W exosomes, but was only observed to be up-shuttled in EXO3.

Hsa-miR-4488, hsa-miR-4492, and hsa-miR-4532, identified in proliferative CTX0E03 cells and their exosomes, are almost absent in 11 week samples (both cells and exosomes).

Hsa-miR-486-5p was the only miRNA up-shuttled in all three EXO W11 samples.

An average 12.22% of the identified miRNAs are up-shuttled in the exosomes derived from 11 week Integra CTX0E03 cultures (FIG. 13C, lower panel).

Comparative Summary Tables

Comparative Analysis of miRNA Expression in EXO Samples Sorted by Largest Reads in EXO Derived from Proliferative CTX0E03/07EH

TABLE E2 Summary table listing miRNA reads and log2. Reads LOG2 EXO EXO EXO EXO1 EXO2 EXO3 EXO EXO1 EXO2 EXO3 MiRNA 07EH 07EI WK 6 WK 11 WK 11 WK 11 WK 6 WK 11 WK 11 WK 11 hsa-miR- 111092 83958 77678 18 2726 24152 −1.40 −13.43 −9.32 −5.96 1246 hsa-miR- 5188 22482 9528 1 −2.65 −15.82 4492 hsa-miR- 3368 6419 3463 −2.39 4532 hsa-miR- 1389 20618 11048 −2.12 4488 hsa-miR- 386 43 13 11 69 −5.46 −8.80 −5.93 4485 hsa-miR- 188 723 1245 20 −0.68 −9.51 4508 hsa-miR- 135 904 1153 −0.96 4516 hsa-miR- 73 28 61 −1.64 4497 hsa-miR- 50 5 1 −7.05 1973 hsa-miR- 48 17 14 −3.40 3195 hsa-miR- 43 12 15 9 −2.38 −5.99 4466 hsa-let- 20 15 18306 69521 496463 509272 7.80 9.77 9.47 9.72 7a-5p hsa-miR- 19 15 25938 6984 56360 50611 8.35 6.50 6.37 6.44 99b-5p hsa-miR- 18 41 35754 12191 134432 150516 8.01 6.50 6.82 7.21 21-5p hsa-miR- 18 7 15054 5504 89826 73306 8.00 6.59 7.48 7.41 92a-3p hsa-miR- 17 174 59 −2.88 3676-5p hsa-miR- 15 24 254 1.54 4792 hsa-miR- 13 8 1 −5.53 664-5p hsa-miR- 11 5 30124 22 56751 43080 9.68 −0.69 7.50 7.32 100-5p hsa-miR- 10 17 18 34 −1.83 −3.79 1291 hsa-miR- 10 4 5502 15 6580 9510 7.32 −1.15 4.48 5.24 16-5p hsa-miR- 10 11 5 −3.26 4284 hsa-miR- 9 26 39 −1.03 663b hsa-miR- 8 1383 5825 42402 29320 6.09 8.21 7.94 7.63 25-3p hsa-miR- 8 10 743 2023 1 4.20 5.69 −8.43 3656 hsa-miR- 7 1 81465 56064 1289686 1023049 12.19 11.69 13.08 12.96 181a-5p hsa-miR- 6 13 3 9 −3.90 −5.19 3654 hsa-miR- 6 17 18836 3542 49957 54929 8.45 6.08 6.76 7.12 26a-5p Log2 is calculated using the normalized ratio of either EXO 6 W or EXO 11 W samples/averaged reads in EXO derived from proliferative cells. Up-shuttled miRNAs (log2 > 2), in EXO derived from CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-shuttled (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs.

Comparative Analysis of miRNA Expression in EXO Samples Sorted by Largest Reads in EXO Derived from 6W Integra CTX0E03 Culture

TABLE E3 Summary table listing miRNA reads and log2. Reads LOG2 EXO EXO EXO EXO1 EXO2 EXO3 EXO EXO1 EXO2 EXO3 MiRNA 07EH 07EI WK 6 WK 11 WK 11 WK 11 WK 6 WK 11 WK 11 WK 11 hsa-miR- 7 1 81465 56064 1289686 1023049 12.19 11.69 13.08 12.96 181a-5p hsa-miR- 111092 83958 77678 18 2726 24152 −1.40 −13.43 −9.32 −5.96 1246 hsa-miR- 6 36828 29 22175 48371 11.39 1.13 7.57 8.92 127-3p hsa-miR- 18 41 35754 12191 134432 150516 8.01 6.50 6.82 7.21 21-5p hsa-miR- 11 5 30124 22 56751 43080 9.68 −0.69 7.50 7.32 100-5p hsa-miR- 19 15 25938 6984 56360 50611 8.35 6.50 6.37 6.44 99b-5p hsa-miR- 6 17 18836 3542 49957 54929 8.45 6.08 6.76 7.12 26a-5p hsa-let- 20 15 18306 69521 496463 509272 7.80 9.77 9.47 9.72 7a-5p hsa-miR- 4 1 17845 10674 130737 104349 10.49 9.79 10.27 10.17 191-5p hsa-miR- 1 15232 7344 33638 47061 12.55 11.55 10.60 11.31 27b-3p hsa-miR- 18 7 15054 5504 89826 73306 8.00 6.59 7.48 7.41 92a-3p hsa-miR- 1 12960 12 29712 13822 12.47 2.44 10.58 9.69 146b-5p hsa-let- 1 2 12914 6928 157331 149116 10.83 9.98 11.34 11.49 7i-5p hsa-miR- 3 2 12671 46 89141 64302 10.03 1.97 9.75 9.50 222-3p hsa-let- 1 2 12414 10.77 7c hsa-miR- 1389 20618 11048 −2.12 4488 hsa-miR- 5188 22482 9528 1 −2.65 −15.82 4492 hsa-let- 5 6 8914 34 86886 33259 8.40 0.41 8.59 7.43 7b-5p hsa-let- 5 6 8766 13898 293116 427140 8.38 9.09 10.35 11.11 7f-5p hsa-miR- 3 7 8141 73468 420313 291688 8.43 11.65 11.03 10.72 92b-3p hsa-miR- 1 3 7919 6713 226010 167200 9.72 9.53 11.46 11.25 181b-5p hsa-miR- 3 3 6391 4927 17702 12768 8.79 8.46 7.17 6.92 221-3p hsa-miR- 4 4 6107 2181 54267 37113 8.31 6.87 8.37 8.04 125b-5p hsa-miR- 3 4 6014 2776 26457 29135 8.49 7.42 7.53 7.89 151a-3p hsa-miR- 2 5613 15559 136508 96950 10.11 11.63 11.62 11.35 30a-5p hsa-miR- 10 4 5502 15 6580 9510 7.32 −1.15 4.48 5.24 16-5p hsa-miR- 4 1 5489 2914 8193 10780 8.79 7.92 6.27 6.89 22-3p hsa-miR- 1 5116 14 27513 17532 10.98 2.51 10.31 9.88 99a-5p Log2 is calculated using the normalized ratio of either EXO 6 W or EXO 11 W samples/averaged reads in EXO derived from proliferative cells. Up-shuttled miRNAs (log2 > 2), in EXO derived from CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-shuttled (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs.

Comparative Analysis of miRNA Expression in EXO Samples Sorted by Largest Reads in EXO3 Derived from 11W Integra CTX0E03 Culture

TABLE E4 Summary table listing miRNA reads and log2. Reads LOG2 EXO EXO EXO EXO1 EXO2 EXO3 EXO EXO1 EXO2 EXO3 MiRNA 07EH 07EI WK 6 WK 11 WK 11 WK 11 WK 6 WK 11 WK 11 WK 11 hsa-miR- 7 1 81465 56064 1289686 1023049 12.19 11.69 13.08 12.96 181a-5p hsa-let- 20 15 18306 69521 496463 509272 7.80 9.77 9.47 9.72 7a-5p hsa-let- 5 6 8766 13898 293116 427140 8.38 9.09 10.35 11.11 7f-5p hsa-miR- 3 7 8141 73468 420313 291688 8.43 11.65 11.03 10.72 92b-3p hsa-miR- 3 3 2196 155707 481660 263043 7.25 13.44 11.93 11.28 9-5p hsa-miR- 1 3 7919 6713 226010 167200 9.72 9.53 11.46 11.25 181b-5p hsa-miR- 18 41 35754 12191 134432 150516 8.01 6.50 6.82 7.21 21-5p hsa-let- 1 2 12914 6928 157331 149116 10.83 9.98 11.34 11.49 7i-5p hsa-miR- 4 1 17845 10674 130737 104349 10.49 9.79 10.27 10.17 191-5p hsa-miR- 2 5613 15559 136508 96950 10.11 11.63 11.62 11.35 30a-5p hsa-miR- 18 7 15054 5504 89826 73306 8.00 6.59 7.48 7.41 92a-3p hsa-miR- 1 3754 5840 132775 66316 10.69 11.37 12.74 11.96 10a-5p hsa-miR- 3 2 12671 46 89141 64302 10.03 1.97 9.75 9.50 222-3p hsa-let- 13106 68120 59498 7c-5p hsa-miR- 6 17 18836 3542 49957 54929 8.45 6.08 6.76 7.12 26a-5p hsa-miR- 1 1 538 2606 45587 52945 6.81 9.13 10.12 10.55 423-5p hsa-miR- 19 15 25938 6984 56360 50611 8.35 6.50 6.37 6.44 99b-5p hsa-miR- 6 36828 29 22175 48371 11.39 1.13 7.57 8.92 127-3p hsa-miR- 1 15232 7344 33638 47061 12.55 11.55 10.60 11.31 27b-3p hsa-miR- 11 5 30124 22 56751 43080 9.68 −0.69 7.50 7.32 100-5p hsa-let- 2 1932 5398 27921 41799 8.73 10.26 9.49 10.29 7e-5p hsa-miR- 3 1 3503 44199 20054 37232 8.47 12.17 7.89 9.01 486-5p hsa-miR- 4 4 6107 2181 54267 37113 8.31 6.87 8.37 8.04 125b-5p hsa-let- 5 6 8914 34 86886 33259 8.40 0.41 8.59 7.43 7b-5p hsa-miR- 3 15 833 22 33064 32491 4.32 −0.88 6.53 6.73 182-5p hsa-miR- 2 3946 22 26066 32148 9.76 2.32 9.39 9.91 30d-5p hsa-miR- 8 1383 5825 42402 29320 6.09 8.21 7.94 7.63 25-3p hsa-miR- 3 4 6014 2776 26457 29135 8.49 7.42 7.53 7.89 151a-3p Log2 is calculated using the normalized ratio of either EXO 6 W or EXO 11 W samples/averaged reads in EXO derived from proliferative cells. Up-shuttled miRNAs (log2 > 2), in EXO derived from CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-shuttled (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs. Conclusions for Comparative Summary of miRNA Reads Present in Exosome Samples

Hsa-miR-1246, hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are the most up-shuttled miRNA types in exosomes derived from proliferative CTX0E03 cells.

Hsa-miR-1246, hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are still present in EXO 6W sample, but hsa-miR-4492, hsa-miR-4532, and hsa-miR-4488 are almost absent in EXO 11W samples.

Hsa-miR-181a-5p, hsa-miR-1246, hsa-miR-127-3p, hsa-miR-21-5p, and hsa-miR-100-5p are the top 5 miRNAs present in EXO 6W sample.

Hsa-miR-181a-5p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-92b-3p, and hsa-miR-9-5p are the top 5 miRNAs present in EXO 11W samples.

Comparative Analysis of miRNA Expression in Cell Samples Sorted by Largest Reads in Proliferative Cell 07EH

TABLE E5 Summary table listing miRNA reads and log2. Reads LOG2 Cell Cells Cell Cell1 Cell2 Cell3 Cell Cell1 Cell2 Cell3 miRNA (07EH) (07EI) 6 WK WK 11 WK 11 WK 11 6 WK WK 11 WK 11 WK 11 hsa-let- 75110 305060 357507 82000 572638 945050 0.08 −0.68 −0.44 −0.58 7a-5p hsa-miR- 9794 242715 51788 7070 95904 269851 −1.46 −2.97 −1.78 −1.15 92b-3p hsa-miR- 11943 154626 109713 36935 165335 350731 0.06 −0.15 −0.55 −0.33 21-5p hsa-miR- 14359 137412 136842 15296 99662 238214 0.41 −1.39 −1.25 −0.86 92a-3p hsa-miR- 7064 110806 54214 4015 20215 70609 −0.40 −2.79 −3.03 −2.09 127-3p hsa-miR- 52451 109290 121101 8268 35093 40100 −0.61 −3.12 −3.60 −4.28 100-5p hsa-miR- 16900 91902 55177 15130 73464 113623 −0.66 −1.16 −1.45 −1.69 27b-3p hsa-miR- 12591 89150 58145 16783 74782 151339 −0.37 −0.80 −1.21 −1.06 191-5p hsa-miR- 9900 88724 164401 24518 127010 271289 1.27 −0.11 −0.30 −0.08 26a-5p hsa-miR- 39457 87399 46207 3177 14278 22554 −1.62 −4.12 −4.52 −4.72 99b-5p hsa-let- 10349 78395 61473 115717 457274 982774 −0.06 2.21 1.63 1.87 7f-5p hsa-miR- 6956 47686 180839 150467 1304081 1909336 2.15 3.25 3.80 3.48 181a-5p hsa-miR- 20310 41639 4938 465 1500 4379 −3.85 −5.90 −6.78 −6.10 486-5p hsa-miR- 2001 35465 16099 23958 94346 201534 −0.47 1.47 0.88 1.11 30a-5p hsa-miR- 11760 30440 14559 −1.61 98 hsa-miR- 2681 29047 15661 5186 22917 58870 −0.42 −0.65 −1.07 −0.57 151a-3p hsa-miR- 4089 27733 10626 2682 10247 30683 −1.16 −1.78 −2.42 −1.70 21-3p hsa-miR- 1977 27307 17522 4802 35022 65318 −0.06 −0.56 −0.26 −0.23 30d-5p hsa-let- 5103 27224 70342 1.43 7c hsa-miR- 52927 26908 28817 11983 49442 69645 −2.35 −2.25 −2.77 −3.14 10a-5p hsa-miR- 1826 26456 10088 5318 33593 54768 −0.79 −0.35 −0.26 −0.42 22-3p hsa-miR- 5531 25885 12376 2528 18519 49416 −1.10 −2.03 −1.72 −1.17 182-5p hsa-miR- 1422 22187 10960 13094 53385 90511 −0.39 1.23 0.69 0.59 222-3p hsa-miR- 1451 20960 9101 1406 12194 16095 −0.61 −1.94 −1.39 −1.85 125a-5p hsa-miR- 2173 19856 69449 8542 42494 81960 2.20 0.54 0.29 0.37 16-5p hsa-let- 2435 19774 61291 13225 75017 99021 1.96 1.11 1.05 0.58 7b-5p hsa-miR- 1386 19773 10790 1621 9192 17997 −0.28 −1.65 −1.72 −1.61 151a-5p hsa-let- 2449 19035 14175 7948 40674 84912 −0.12 0.41 0.20 0.39 7e-5p Log2 is calculated using the normalized ratio of either cell 6 W or cell 11 W samples/averaged reads in proliferative cells. Up-expressed miRNAs (log2 > 2), in CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-expressed (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs.

Comparative Analysis of miRNA Expression in Cell Samples Sorted by Largest Reads in Cells Cultured for 6 Week in Integra Flasks (Cell 6W)

TABLE E6 Summary table listing miRNA reads and log2. Reads LOG2 Cell Cells Cell Cell1 Cell2 Cell3 Cell Cell1 Cell2 Cell3 miRNA (07EH) (07EI) 6 WK WK 11 WK 11 WK 11 6 WK WK 11 WK 11 WK 11 hsa-let- 75110 305060 357507 82000 572638 945050 0.08 −0.68 −0.44 −0.58 7a-5p hsa-miR- 6956 47686 180839 150467 1304081 1909336 2.15 3.25 3.80 3.48 181a-5p hsa-miR- 9900 88724 164401 24518 127010 271289 1.27 −0.11 −0.30 −0.08 26a-5p hsa-miR- 14359 137412 136842 15296 99662 238214 0.41 −1.39 −1.25 −0.86 92a-3p hsa-miR- 52451 109290 121101 8268 35093 40100 −0.61 −3.12 −3.60 −4.28 100-5p hsa-miR- 11943 154626 109713 36935 165335 350731 0.06 −0.15 −0.55 −0.33 21-5p hsa-let- 5103 27224 70342 1.43 7c hsa-miR- 2173 19856 69449 8542 42494 81960 2.20 0.54 0.29 0.37 16-5p hsa-let- 10349 78395 61473 115717 457274 982774 −0.06 2.21 1.63 1.87 7f-5p hsa-let- 2435 19774 61291 13225 75017 99021 1.96 1.11 1.05 0.58 7b-5p hsa-miR- 12591 89150 58145 16783 74782 151339 −0.37 −0.80 −1.21 −1.06 191-5p hsa-miR- 16900 91902 55177 15130 73464 113623 −0.66 −1.16 −1.45 −1.69 27b-3p hsa-miR- 7064 110806 54214 4015 20215 70609 −0.40 −2.79 −3.03 −2.09 127-3p hsa-miR- 9794 242715 51788 7070 95904 269851 −1.46 −2.97 −1.78 −1.15 92b-3p hsa-miR- 518 7957 49128 113170 696970 1266994 3.25 5.82 5.87 5.87 9-5p hsa-miR- 39457 87399 46207 3177 14278 22554 −1.62 −4.12 −4.52 −4.72 99b-5p hsa-miR- 4552 8434 38088 7472 43047 20961 1.29 0.30 0.26 −1.64 146b-5p hsa-miR- 1002 17965 34339 2841 21418 24635 1.61 −0.62 −0.28 −0.94 125b-5p hsa-miR- 3973 1783 32042 483 1122 3470 1.56 −3.13 −4.48 −3.72 1246 hsa-miR- 52927 26908 28817 11983 49442 69645 −2.35 −2.25 −2.77 −3.14 10a-5p hsa-let- 3015 17802 21469 33910 167628 432785 0.40 2.43 2.16 2.67 7i-5p hsa-miR- 773 2767 19124 1826 11313 14604 2.54 0.51 0.58 0.08 99a-5p hsa-miR- 1977 27307 17522 4802 35022 65318 −0.06 −0.56 −0.26 −0.23 30d-5p hsa-let- 959 15467 16691 4240 19981 36131 0.75 0.14 −0.20 −0.21 7g-5p hsa-miR- 2001 35465 16099 23958 94346 201534 −0.47 1.47 0.88 1.11 30a-5p hsa-miR- 2681 29047 15661 5186 22917 58870 −0.42 −0.65 −1.07 −0.57 151a-3p hsa-miR- 11760 30440 14559 −1.61 98 hsa-miR- 113 1378 14322 1554 8147 18192 3.91 2.07 1.89 2.18 204-5p Log2 is calculated using the normalized ratio of either cell 6 W or cell 11 W samples/averaged reads in proliferative cells. Up-expressed miRNAs (log2 > 2), in CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-expressed (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs.

Comparative Analysis of miRNA Expression in Cell Samples Sorted by Largest Reads in Cells Cultured 11 Week in Integra Flasks (Cell1 W11)

TABLE E7 Summary table listing miRNA reads and log2. Reads LOG2 Cell Cells Cell Cell1 Cell2 Cell3 Cell Cell1 Cell2 Cell3 miRNA (07EH) (07EI) 6 WK WK 11 WK 11 WK 11 6 WK WK 11 WK 11 WK 11 hsa-miR- 6956 47686 180839 150467 1304081 1909336 2.15 3.25 3.80 3.48 181a-5p hsa-miR- 518 7957 49128 113170 696970 1266994 3.25 5.82 5.87 5.87 9-5P hsa-let- 10349 78395 61473 115717 457274 982774 −0.06 2.21 1.63 1.87 7f-5p hsa-let- 75110 305060 357507 82000 572638 945050 0.08 −0.68 −0.44 −0.58 7a-5p hsa-let- 3015 17802 21469 33910 167628 432785 0.40 2.43 2.16 2.67 7i-5p hsa-miR- 11943 154626 109713 36935 165335 350731 0.06 −0.15 −0.55 −0.33 21-5p hsa-miR- 1382 12606 11845 17620 135852 275865 0.30 2.24 2.62 2.77 181b-5p hsa-miR- 9900 88724 164401 24518 127010 271289 1.27 −0.11 −0.30 −0.08 26a-5p hsa-miR- 9794 242715 51788 7070 95904 269851 −1.46 −2.97 −1.78 −1.15 92b-3p hsa-miR- 14359 137412 136842 15296 99662 238214 0.41 −1.39 −1.25 −0.86 92a-3p hsa-miR- 2001 35465 16099 23958 94346 201534 −0.47 1.47 0.88 1.11 30a-5p hsa-miR- 12591 89150 58145 16783 74782 151339 −0.37 −0.80 −1.21 −1.06 191-5p hsa-let- 18010 106589 130919 7c-5p hsa-miR- 16900 91902 55177 15130 73464 113623 −0.66 −1.16 −1.45 −1.69 27b-3p hsa-let- 2435 19774 61291 13225 75017 99021 1.96 1.11 1.05 0.58 7b-5p hsa-miR- 1080 8893 3219 9325 40672 93044 −1.13 1.77 1.33 1.65 423-5p hsa-miR- 1422 22187 10960 13094 53385 90511 −0.39 1.23 0.69 0.59 222-3p hsa-let- 2449 19035 14175 7948 40674 84912 −0.12 0.41 0.20 0.39 7e-5p hsa-miR- 2173 19856 69449 8542 42494 81960 2.20 0.54 0.29 0.37 16-5p hsa-miR- 436 5303 8387 5633 31971 77502 1.19 1.98 1.92 2.33 25-3p hsa-miR- 7064 110806 54214 4015 20215 70609 −0.40 −2.79 −3.03 −2.09 127-3p hsa-miR- 52927 26908 28817 11983 49442 69645 −2.35 −2.25 −2.77 −3.14 10a-5p hsa-miR- 1977 27307 17522 4802 35022 65318 −0.06 −0.56 −0.26 −0.23 30d-5p hsa-miR- 2681 29047 15661 5186 22917 58870 −0.42 −0.65 −1.07 −0.57 151a-3p hsa-miR- 1826 26456 10088 5318 33593 54768 −0.79 −0.35 −0.26 −0.42 22-3p hsa-miR- 5531 25885 12376 2528 18519 49416 −1.10 −2.03 −1.72 −1.17 182-5p hsa-miR- 86 803 1186 2490 21343 44745 0.97 3.40 3.93 4.13 181a-3p hsa-miR- 52451 109290 121101 8268 35093 40100 −0.61 −3.12 −3.60 −4.28 100-5p Log2 is calculated using the normalized ratio of either cell 6 W or cell 11 W samples/averaged reads in proliferative cells. Up-expressed miRNAs (log2 > 2), in CTX0E03 cultured for 6 and 11 weeks in Integra flasks, are italicized and down-expressed (log2 < 2) in bold respectively. The table presents only the top 30 more abundant miRNAs. Conclusions for Comparative Summary of miRNA Reads Present in Cell Samples

Hsa-let-7a-5p, hsa-miR-92b-3p, hsa-miR-21-5p, hsa-miR-92a-3p, and hsa-miR-127-3p are the top 5 most expressed miRNA types in proliferative CTX0E03 cells.

Hsa-let-7a-5p, hsa-miR-181a-5p, hsa-miR-26a-5p, hsa-miR-92a-3p, hsa-miR-100-5p are the top 5 most expressed miRNA types in CTX0E03 Integra 6W culture.

Hsa-miR-181a-5p, hsa-miR-9-5p, hsa-let-7f-5p, hsa-let-7a-5p, and hsa-let-7i-5p are the top 5 most expressed miRNA types in CTX0E03 Integra 11W cultures.

Hsa-miR-181a-5p and hsa-miR-9-5p are up-expressed in all cell samples cultured in Integra flasks (6 and 11 weeks).

Hsa-let-7i-5p, hsa-let-7c-5p, hsa-miR-181a-3p and hsa-miR-181b-5p were solely up-expressed in W11 cells.

Hsa-miR-181 family seems to play an important role in CTX0E03 long term culture and possible differentiation.

Example 18: Proteomic Analysis Methods

Exosomes and microvesicle fractions were prepared from a CTX0E03 cell Integra culture (week 2), using differential ultracentrifugation. Exosomes and microvesicles were disrupted in modified RIPA buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1% SDS, 0.1% Triton X100, 10 mM DTT, 1× Complete protease inhibitor (Roche) and 1× PhosStop phosphatase inhibitor (Roche)) and subjected to manual shearing using a 1 mL tuberculin syringe and 25 gauge needle. Samples were re-quantitated post disruption using the Qubit fluorometer (Invitrogen). 20 ρ.g of each sample was loaded onto a 4-12% SDS-PAGE gel (Novex, Invitrogen). The gel was excised into forty segments per lane and gel slices were processed using a robot (ProGest, DigiLab) with the following protocol:

-   -   a) wash with 25 mM ammonium bicarbonate followed by         acetonitrile;     -   b) reduce with 10 mM dithiothreitol at 60° C. followed by         alkylation with 50 mM iodoacetamide at room temperature;     -   c) digest with trypsin (Promega) at 37° C. for 4 h;     -   d) quench with formic acid;     -   e) the supernatant was analysed by mass spectrometry directly         without further processing.

Mass Spectrometry

Each gel digest was analysed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with Jupiter Proteo resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 FWHM and 17,500 FWHM resolution, respectively.

Exosomes

2572 proteins were identified by Mass spectrometry in exosomes purified by ultracentrifugation. The exosomes were isolated from the initial stages of an Integra culture (week 2). The gene names and corresponding SWISSPROT accession numbers (in brackets) of all 2572 proteins are listed in Table 19 (in alphabetical order of gene name) and the 100 most abundant proteins are listed in Table 20, in order of decreasing abundance. The characteristic exosome markers CD9, CD81 and Alix (also known as PDCD6IP) are present in the most abundant 100 proteins.

TABLE 19 Gene names and SWISSPROT accession numbers of all 2572 proteins identified in CTX0E03 exosomes (listed in alphabetical order of gene name). A1BG (P04217), A2M (P01023), AACS (Q86V21), AAMP (Q13685), AARS (P49588), AARSD1 (Q9BTE6), AASDHPPT (Q9NRN7), ABCA3 (Q99758), ABCE1 (P61221), ABCF1 (Q8NE71), ABCF3 (Q9NUQ8), ABHD10 (Q9NUJ1), ABHD14B (Q96IU4), ABI1 (Q8IZP0), ABR (Q12979), ACAA2 (P42765), ACACA (Q13085), ACADVL (P49748), ACAP2 (Q15057), ACAT1 (P24752), ACAT2 (Q9BWD1), ACBD7 (Q8N6N7), ACLY (P53396), ACO1 (P21399), ACO2 (Q99798), ACOT1 (Q86TX2), ACOT13 (Q9NPJ3), ACOT7 (O00154), ACP1 (P24666), ACSL1 (P33121), ACSL3 (O95573), ACSL4 (O60488), ACSS2 (Q9NR19), ACTC1 (P68032), ACTG1 (P63261), ACTL6A (O96019), ACTN1 (P12814), ACTN4 (O43707), ACTR10 (Q9NZ32), ACTR1A (P61163), ACTR1B (P42025), ACTR2 (P61160), ACTR3 (P61158), ADAM10 (O14672), ADAM12 (O43184), ADAMTS15 (Q8TE58), ADAMTS16 (Q8TE57), ADAR (P55265), ADAT2 (Q7Z6V5), ADH5 (P11766), ADI1 (Q9BV57), ADK (P55263), ADRBK1 (P25098), ADRM1 (Q16186), ADSL (P30566), ADSS (P30520), AEBP1 (Q8IUX7), AFM (P43652), AGL (P35573), AGRN (O00468), AGT (P01019), AHCY (P23526), AHCYL1 (O43865), AHNAK (Q09666), AHSA1 (O95433), AHSG (P02765), AIDA (Q96BJ3), AIFM1 (O95831), AIMP1 (Q12904), AIMP2 (Q13155), AIP (O00170), AK1 (P00568), AK3 (Q9UIJ7), AK4 (P27144), AKAP12 (Q02952), AKAP9 (Q99996), AKR1A1 (P14550), AKR1B1 (P15121), AKR1C1 (Q04828), AKR7A2 (O43488), AKR7A3 (O95154), AKT1 (P31749), ALCAM (Q13740), ALDH16A1 (Q8IZ83), ALDH3A1 (P30838), ALDH7A1 (P49419), ALDH9A1 (P49189), ALDOA (P04075), ALDOC (P09972), ALKBH2 (Q6NS38), ALKBH4 (Q9NXW9), AMBP (P02760), AMDHD2 (Q9Y303), AMPD2 (Q01433), AMZ2 (Q86W34), ANAPC1 (Q9H1A4), ANAPC4 (Q9UJX5), ANAPC5 (Q9UJX4), ANAPC7 (Q9UJX3), ANKFY1 (Q9P2R3), ANKRD28 (O15084), ANP32A (P39687), ANP32B (Q92688), ANP32E (Q9BTT0), ANXA1 (P04083), ANXA2 (P07355), ANXA4 (P09525), ANXA5 (P08758), ANXA6 (P08133), ANXA7 (P20073), AP1B1 (Q10567), AP1G1 (O43747), AP1M1 (Q9BXS5), AP1S1 (P61966), AP1S2 (P56377), AP2A1 (O95782), AP2A2 (O94973), AP2B1 (P63010), AP2M1 (Q96CW1), AP2S1 (P53680), AP3B1 (O00203), AP3D1 (O14617), AP3M1 (Q9Y2T2), AP3S1 (Q92572), AP3S2 (P59780), AP4S1 (Q9Y587), APEH (P13798), APEX1 (P27695), API5 (Q9BZZ5), APIP (Q96GX9), APOA1 (P02647), APOA1BP (Q8NCW5), APOA2 (P02652), APOBEC3C (Q9NRW3), APOC2 (P02655), APOD (P05090), APOH (P02749), APOM (O95445), APPL1 (Q9UKG1), APRT (P07741), AQR (O60306), ARCN1 (P48444), ARF1 (P84077), ARF4 (P18085), ARF5 (P84085), ARF6 (P62330), ARFIP1 (P53367), ARFIP2 (P53365), ARHGAP1 (Q07960), ARHGAP12 (Q8IWW6), ARHGDIA (P52565), ARHGEF1 (Q92888), ARHGEF10 (O15013), ARHGEF7 (Q14155), ARIH1 (Q9Y4X5), ARIH2 (O95376), ARL1 (P40616), ARL2 (P36404), ARL3 (P36405), ARL6IP1 (Q15041), ARL8B (Q9NVJ2), ARMC10 (Q8N2F6), ARMC6 (Q6NXE6), ARMC8 (Q8IUR7), ARMC9 (Q7Z3E5), ARMCX3 (Q9UH62), ARPC1A (Q92747), ARPC1B (O15143), ARPC2 (O15144), ARPC3 (O15145), ARPC4 (P59998), ARPC5 (O15511), ARPC5L (Q9BPX5), ARRDC1 (Q8N5I2), ASB6 (Q9NWX5), ASCC1 (Q8N9N2), ASCC2 (Q9H1I8), ASCC3 (Q8N3C0), ASF1A (Q9Y294), ASH2L (Q9UBL3), ASMTL (O95671), ASNA1 (O43681), ASNS (P08243), ASS1 (P00966), ATG16L1 (Q676U5), ATG3 (Q9NT62), ATG4B (Q9Y4P1), ATG7 (O95352), ATIC (P31939), ATL3 (Q6DD88), ATM (Q13315), ATOX1 (O00244), ATP1A1 (P05023), ATP1B1 (P05026), ATP1B3 (P54709), ATP2B1 (P20020), ATP2B4 (P23634), ATP5B (P06576), ATP5E (P56381), ATP5I (P56385), ATP6AP2 (O75787), ATP6V0D1 (P61421), ATP6V1A (P38606), ATP6V1B2 (P21281), ATP6V1C1 (P21283), ATP6V1D (Q9Y5K8), ATP6V1E1 (P36543), ATP6V1G1 (O75348), ATP6V1H (Q9UI12), ATR (Q13535), ATRN (O75882), ATXN10 (Q9UBB4), B2M (P61769), B3GAT3 (O94766), B3GNT1 (O43505), B4GALT7 (Q9UBV7), BAG2 (O95816), BAIAP2 (Q9UQB8), BANF1 (O75531), BAT1 (Q13838), BAT3 (P46379), BBOX1 (O75936), BCAS2 (O75934), BCAT1 (P54687), BCCIP (Q9P287), BCL2L13 (Q9BXK5), BCLAF1 (Q9NYF8), BDH2 (Q9BUT1), BICD2 (Q8TD16), BLOC1S1 (P78537), BLVRA (P53004), BLVRB (P30043), BMP1 (P13497), BOLA2 (Q9H3K6), BPGM (P07738), BPHL (Q86WA6), BPNT1 (O95861), BRCC3 (P46736), BRE (Q9NXR7), BROX (Q5VW32), BRP16L (P0CB43), BSG (P35613), BST1 (Q10588), BTAF1 (O14981), BUB3 (O43684), BUD31 (P41223), BYSL (Q13895), BZW1 (Q7L1Q6), BZW2 (Q9Y6E2), C10orf119 (Q9BTE3), C10orf58 (Q9BRX8), C10orf76 (Q5T2E6), C11orf54 (Q9H0W9), C11orf68 (Q9H3H3), C12orf10 (Q9HB07), C14orf149 (Q96EM0), C14orf166 (Q9Y224), C15orf58 (Q6ZNW5), C16orf13 (Q96S19), C16orf80 (Q9Y6A4), C1D (Q13901), C1orf123 (Q9NWV4), C1orf50 (Q9BV19), C1orf57 (Q9BSD7), C1RL (Q9NZP8), C20orf11 (Q9NWU2), C20orf27 (Q9GZN8), C20orf4 (Q9Y312), C21orf59 (P57076), C22orf25 (Q6ICL3), C22orf28 (Q9Y3I0), C2orf29 (Q9UKZ1), C2orf79 (Q6GMV3), C3orf10 (Q8WUW1), C3orf26 (Q9BQ75), C3orf75 (Q0PNE2), C4orf27 (Q9NWY4), C4orf41 (Q7Z392), C5orf32 (Q9H1C7), C6orf130 (Q9Y530), C6orf211 (Q9H993), C7orf25 (Q9BPX7), C7orf28B (P86790), C7orf41 (Q8N3F0), C7orf59 (Q0VGL1), C9orf142 (Q9BUH6), C9orf23 (Q8N5L8), C9orf41 (Q8N4J0), C9orf64 (Q5T6V5), CA11 (O75493), CAB39 (Q9Y376), CACNA2D1 (P54289), CACYBP (Q9HB71), CAD (P27708), CADM1 (Q9BY67), CADM4 (Q8NFZ8), CALB1 (P05937), CALD1 (Q05682), CALM1 (P62158), CAMK2D (Q13557), CAND1 (Q86VP6), CAP1 (Q01518), CAPN1 (P07384), CAPN2 (P17655), CAPN5 (O15484), CAPNS1 (P04632), CAPS (Q13938), CAPZA1 (P52907), CAPZA2 (P47755), CAPZB (P47756), CARHSP1 (Q9Y2V2), CARKD (Q8IW45), CARM1 (Q86X55), CARS (P49589), CASK (O14936), CASP3 (P42574), CASP6 (P55212), CAT (P04040), CBFB (Q13951), CBR1 (P16152), CBR3 (O75828), CBS (P35520), CBWD2 (Q8IUF1), CBX1 (P83916), CBX3 (Q13185), CBX5 (P45973), CC2D1A (Q6P1N0), CC2D1B (Q5T0F9), CCAR1 (Q8IX12), CCBL1 (Q16773), CCBL2 (Q6YP21), CCDC22 (O60826), CCDC25 (Q86WR0), CCDC53 (Q9Y3C0), CCDC56 (Q9Y2R0), CCDC93 (Q567U6), CCNC (P24863), CCND2 (P30279), CCNH (P51946), CCT2 (P78371), CCT3 (P49368), CCT4 (P50991), CCT5 (P48643), CCT6A (P40227), CCT7 (Q99832), CCT8 (P50990), CD109 (Q6YHK3), CD151 (P48509), CD276 (Q5ZPR3), CD44 (P16070), CD47 (Q08722), CD59 (P13987), CD63 (P08962), CD81 (P60033), CD9 (P21926), CD99 (P14209), CDC16 (Q13042), CDC23 (Q9UJX2), CDC27 (P30260), CDC34 (P49427), CDC37 (Q16543), CDC40 (O60508), CDC42 (P60953), CDC5L (Q99459), CDCP1 (Q9H5V8), CDH2 (P19022), CDK1 (P06493), CDK2 (P24941), CDK2AP2 (O75956), CDK4 (P11802), CDK5 (Q00535), CDK5RAP3 (Q96JB5), CDK7 (P50613), CDKN2A (P42771), CDKN2AIP (Q9NXV6), CELSR1 (Q9NYQ6), CELSR2 (Q9HCU4), CEP57 (Q86XR8), CFL1 (P23528), CFL2 (Q9Y281), CHAC2 (Q8WUX2), CHAF1B (Q13112), CHD4 (Q14839), CHEK2 (O96017), CHERP (Q8IWX8), CHID1 (Q9BWS9), CHML (P26374), CHMP1B (Q7LBR1), CHMP2A (O43633), CHMP4A (Q9BY43), CHMP4B (Q9H444), CHMP6 (Q96FZ7), CHORDC1 (Q9UHD1), CHP (Q99653), CHRAC1 (Q9NRG0), CHST14 (Q8NCH0), CHST3 (Q7LGC8), CHURC1 (Q8WUH1), CIAO1 (O76071), CIAPIN1 (Q6FI81), CIRH1A (Q969X6), CKAP5 (Q14008), CKB (P12277), CLASP1 (Q7Z460), CLDN3 (O15551), CLEC18B (Q6UXF7), CLIC1 (O00299), CLIC4 (Q9Y696), CLLD6 (Q5W111), CLNS1A (P54105), CLP1 (Q92989), CLPB (Q9H078), CLTA (P09496), CLTC (Q00610), CLU (P10909), CMAS (Q8NFW8), CMBL (Q96DG6), CMPK1 (P30085), CNBP (P62633), CNDP2 (Q96KP4), CNN2 (Q99439), CNN3 (Q15417), CNOT1 (A5YKK6), CNOT10 (Q9H9A5), CNOT6L (Q96LI5), CNOT7 (Q9UIV1), CNP (P09543), COASY (Q13057), COBRA1 (Q8WX92), COG1 (Q8WTW3), COG2 (Q14746), COG3 (Q96JB2), COG4 (Q9H9E3), COG5 (Q9UP83), COG6 (Q9Y2V7), COG7 (P83436), COG8 (Q96MW5), COL11A1 (P12107), COL14A1 (Q05707), COL6A1 (P12109), COMMD1 (Q8N668), COMMD10 (Q9Y6G5), COMMD2 (Q86X83), COMMD3 (Q9UBI1), COMMD4 (Q9H0A8), COMMD5 (Q9GZQ3), COMMD6 (Q7Z4G1), COMMD7 (Q86VX2), COMMD8 (Q9NX08), COMMD9 (Q9P000), COMT (P21964), COPA (P53621), COPB1 (P53618), COPB2 (P35606), COPE (O14579), COPG (Q9Y678), COPG2 (Q9UBF2), COPS2 (P61201), COPS3 (Q9UNS2), COPS4 (Q9BT78), COPS5 (Q92905), COPS6 (Q7L5N1), COPS7A (Q9UBW8), COPS7B (Q9H9Q2), COPS8 (Q99627), COPZ1 (P61923), CORO1A (P31146), CORO1B (Q9BR76), CORO1C (Q9ULV4), CORO2B (Q9UQ03), COR07 (P57737), COTL1 (Q14019), COX5A (P20674), COX5B (P10606), COX6C (P09669), COX7A2 (P14406), CP (P00450), CPD (O75976), CPN2 (P22792), CPNE1 (Q99829), CPNE3 (O75131), CPNE7 (Q9UBL6), CPSF1 (Q10570), CPSF2 (Q9P2I0), CPSF3 (Q9UKF6), CPSF7 (Q8N684), CPXM1 (Q96SM3), CRIP2 (P52943), CRK (P46108), CRLF3 (Q8IUI8), CRTAP (O75718), CRYAB (P02511), CRYM (Q14894), CRYZ (Q08257), CRYZL1 (O95825), CS (O75390), CSDE1 (O75534), CSE1L (P55060), CSK (P41240), CSNK1A1 (P48729), CSNK2A1 (P68400), CSNK2B (P67870), CSRP1 (P21291), CSRP2 (Q16527), CSTB (P04080), CSTF1 (Q05048), CSTF2T (Q9H0L4), CSTF3 (Q12996), CTBP1 (Q13363), CTBP2 (P56545), CTNNA1 (P35221), CTNNB1 (P35222), CTNNBL1 (Q8WYA6), CTNND1 (O60716), CTPS (P17812), CTPS2 (Q9NRF8), CTR9 (Q6PD62), CTSC (P53634), CTSD (P07339), CTSF (Q9UBX1), CTSL2 (O60911), CTU1 (Q7Z7A3), CTU2 (Q2VPK5), CUL1 (Q13616), CUL2 (Q13617), CUL3 (Q13618), CUL4A (Q13619), CUL4B (Q13620), CUL5 (Q93034), CWF19L1 (Q69YN2), CXADR (P78310), CXorf26 (Q9BVG4), CYB5A (P00167), CYCS (P99999), CYFIP1 (Q7L576), CYFIP2 (Q96F07), CYR61 (O00622), DAG1 (Q14118), DAK (Q3LXA3), DARS (P14868), DAZAP1 (Q96EP5), DBI (P07108), DBN1 (Q16643), DBNL (Q9UJU6), DBR1 (Q9UK59), DCAF7 (P61962), DCAF8 (Q5TAQ9), DCD (P81605), DCK (P27707), DCLK1 (O15075), DCPS (Q96C86), DCTD (P32321), DCTN1 (Q14203), DCTN2 (Q13561), DCTN3 (O75935), DCTN4 (Q9UJW0), DCTN5 (Q9BTE1), DCTN6 (O00399), DCUN1D1 (Q96GG9), DCUN1D5 (Q9BTE7), DCXR (Q7Z4W1), DDA1 (Q9BW61), DDAH2 (O95865), DDB1 (Q16531), DDB2 (Q92466), DDI2 (Q5TDH0), DDR1 (Q08345), DDT (P30046), DDX1 (Q92499), DDX17 (Q92841), DDX19A (Q9NUU7), DDX21 (Q9NR30), DDX23 (Q9BUQ8), DDX39 (O00148), DDX3X (O00571), DDX5 (P17844), DDX51 (Q8N8A6), DDX6 (P26196), DECR1 (Q16698), DEF (Q68CQ4), DEFA1 (P59665), DENR (O43583), DERA (Q9Y315), DFFA (O00273), DHFR (P00374), DHPS (P49366), DHRS1 (Q96LJ7), DHRS11 (Q6UWP2), DHRS4 (Q9BTZ2), DHX15 (O43143), DHX16 (O60231), DHX29 (Q7Z478), DHX36 (Q9H2U1), DHX9 (Q08211), DIAPH1 (O60610), DIAPH2 (O60879), DIMT1L (Q9UNQ2), DIP2B (Q9P265), DIP2C (Q9Y2E4), DIS3 (Q9Y2L1), DIS3L2 (Q8IYB7), DKC1 (O60832), DLG1 (Q12959), DNAH17 (Q9UFH2), DNAJA1 (P31689), DNAJA2 (O60884), DNAJB1 (P25685), DNAJB4 (Q9UDY4), DNAJC13 (O75165), DNAJC3 (Q13217), DNAJC7 (Q99615), DNASE1L1 (P49184), DNM1 (Q05193), DNM1L (O00429), DNM2 (P50570), DNPEP (Q9ULA0), DOCK1 (Q14185), DOCK4 (Q8N1I0), DOCK5 (Q9H7D0), DOCK7 (Q96N67), DOHH (Q9BU89), DOM3Z (O77932), DPCD (Q9BVM2), DPH1 (Q9BZG8), DPH2 (Q9BQC3), DPH5 (Q9H2P9), DPM1 (O60762), DPP3 (Q9NY33), DPP9 (Q86TI2), DPY30 (Q9C005), DPYSL2 (Q16555), DPYSL3 (Q14195), DPYSL4 (O14531), DPYSL5 (Q9BPU6), DRG1 (Q9Y295), DRG2 (P55039), DSG1 (Q02413), DSP (P15924), DST (Q03001), DSTN (P60981), DTD1 (Q8TEA8), DTYMK (P23919), DUS2L (Q9NX74), DUSP12 (Q9UNI6), DUSP23 (Q9BVJ7), DUSP3 (P51452), DYM (Q7RTS9), DYNC1H1 (Q14204), DYNC1I2 (Q13409), DYNC1LI1 (Q9Y6G9), DYNC1LI2 (O43237), DYNC2H1 (Q8NCM8), DYNLL1 (P63167), DYNLL2 (Q96FJ2), DYNLRB1 (Q9NP97), DYNLT1 (P63172), ECHDC1 (Q9NTX5), ECHDC3 (Q96DC8), ECHS1 (P30084), ECM29 (Q5VYK3), EDC4 (Q6P2E9), EEA1 (Q15075), EEF1A1 (P68104), EEF1B2 (P24534), EEF1D (P29692), EEF1E1 (O43324), EEF1G (P26641), EEF2 (P13639), EEFSEC (P57772), EFEMP2 (O95967), EFHD2 (Q96C19), EFNB2 (P52799), EFTUD1 (Q7Z2Z2), EFTUD2 (Q15029), EGFR (P00533), EHD1 (Q9H4M9), EHD2 (Q9NZN4), EHD4 (Q9H223), EIF1 (P41567), EIF1AX (P47813), EIF2A (Q9BY44), EIF2AK2 (P19525), EIF2B1 (Q14232), EIF2B2 (P49770), EIF2B3 (Q9NR50), EIF2B4 (Q9UI10), EIF2B5 (Q13144), EIF2C2 (Q9UKV8), EIF2S1 (P05198), EIF2S2 (P20042), EIF2S3 (P41091), EIF3A (Q14152), EIF3B (P55884), EIF3C (Q99613), EIF3D (O15371), EIF3E (P60228), EIF3F (O00303), EIF3G (O75821), EIF3H (O15372), EIF3I (Q13347), EIF3J (O75822), EIF3K (Q9UBQ5), EIF3L (Q9Y262), EIF3M (Q7L2H7), EIF4A1 (P60842), EIF4A2 (Q14240), EIF4A3 (P38919), EIF4E (P06730), EIF4E2 (O60573), EIF4G1 (Q04637), EIF4G2 (P78344), EIF4G3 (O43432), EIF4H (Q15056), EIF5 (P55010), EIF5A (P63241), EIF5B (O60841), EIF6 (P56537), ELAC2 (Q9BQ52), ELAVL1 (Q15717), ELMO2 (Q96JJ3), ELP2 (Q6IA86), ELP3 (Q9H9T3), EMG1 (Q92979), EMILIN1 (Q9Y6C2), EML1 (O00423), EML2 (O95834), EML3 (Q32P44), EML4 (Q9HC35), ENAH (Q8N8S7), ENO1 (P06733), ENO2 (P09104), ENOPH1 (Q9UHY7), ENY2 (Q9NPA8), EPB41L2 (O43491), EPB41L3 (Q9Y2J2), EPHA2 (P29317), EPHB3 (P54753), EPHX1 (P07099), EPM2AIP1 (Q7L775), EPRS (P07814), ERH (P84090), ERI1 (Q8IV48), ERI3 (O43414), ERP44 (Q9BS26), ESD (P10768), ESYT1 (Q9BSJ8), ETF1 (P62495), ETFA (P13804), ETFB (P38117), EXOC1 (Q9NV70), EXOC2 (Q96KP1), EXOC3 (O60645), EXOC4 (Q96A65), EXOC5 (O00471), EXOC6 (Q8TAG9), EXOC7 (Q9UPT5), EXOC8 (Q8IYI6), EXOSC1 (Q9Y3B2), EXOSC2 (Q13868), EXOSC3 (Q9NQT5), EXOSC4 (Q9NPD3), EXOSC5 (Q9NQT4), EXOSC6 (Q5RKV6), EXOSC7 (Q15024), EXOSC8 (Q96B26), EXOSC9 (Q06265), EXTL3 (O43909), EYA3 (Q99504), EZR (P15311), F3 (P13726), F8 (P00451), F8A1 (P23610), FABP5 (Q01469), FABP7 (O15540), FADD (Q13158), FAF1 (Q9UNN5), FAH (P16930), FAHD2A (Q96GK7), FAM114A2 (Q9NRY5), FAM115A (Q9Y4C2), FAM120A (Q9NZB2), FAM125A (Q96EY5), FAM127A (A6ZKI3), FAM129B (Q96TA1), FAM136A (Q96C01), FAM168A (Q92567), FAM175B (Q15018), FAM188A (Q9H8M7), FAM3A (P98173), FAM3C (Q92520), FAM45B (Q6NSW5), FAM49B (Q9NUQ9), FAM82B (Q96DB5), FAM84B (Q96KN1), FAM98A (Q8NCA5), FAM98B (Q52LJ0), FARP1 (Q9Y4F1), FARP2 (O94887), FARSA (Q9Y285), FARSB (Q9NSD9), FASN (P49327), FAT1 (Q14517), FBL (P22087), FBLN2 (P98095), FBN1 (P35555), FBN2 (P35556), FBXL18 (Q96ME1), FBXO21 (O94952), FBXO22 (Q8NEZ5), FDFT1 (P37268), FDPS (P14324), FEN1 (P39748), FERMT1 (Q9BQL6), FERMT2 (Q96AC1), FGF1 (P05230), FGFRL1 (Q8N441), FGGY (Q96C11), FH (P07954), FHL1 (Q13642), FHL2 (Q14192), FHL3 (Q13643), FIS1 (Q9Y3D6), FKBP1A (P62942), FKBP3 (Q00688), FKBP4 (Q02790), FKBP5 (Q13451), FLII (Q13045), FLNA (P21333), FLNB (O75369), FLNC (Q14315), FLOT1 (O75955), FMNL2 (Q96PY5), FN3K (Q9H479), FN3KRP (Q9HA64), FNTA (P49354), FNTB (P49356), FOLR1 (P15328), FREM2 (Q5SZK8), FRMD8 (Q9BZ67), FSCN1 (Q16658), FSD1 (Q9BTV5), FTH1 (P02794), FTL (P02792), FTO (Q9C0B1), FTSJD2 (Q8N1G2), FUBP1 (Q96AE4), FUCA2 (Q9BTY2), FUK (Q8N0W3), FXR1 (P51114), G3BP1 (Q13283), G3BP2 (Q9UN86), G6PD (P11413), GAA (P10253), GALK1 (P51570), GALK2 (Q01415), GALNT1 (Q10472), GALNT2 (Q10471), GANAB (Q14697), GAP43 (P17677), GAPDH (P04406), GAPVD1 (Q14C86), GAR1 (Q9NY12), GARS (P41250), GART (P22102), GATSL2 (A6NHX0), GBA (P04062), GBE1 (Q04446), GCLM (P48507), GCN1L1 (Q92616), GDI1 (P31150), GDI2 (P50395), GEMIN5 (Q8TEQ6), GEMIN6 (Q8WXD5), GET4 (Q7L5D6), GFAP (P14136), GFPT1 (Q06210), GFPT2 (O94808), GGCT (O75223), GGPS1 (O95749), GINS1 (Q14691), GINS4 (Q9BRT9), GIPC1 (O14908), GIT1 (Q9Y2X7), GLA (P06280), GLB1 (P16278), GLB1L2 (Q8IW92), GLG1 (Q92896), GLIPR2 (Q9H4G4), GLMN (Q92990), GLO1 (Q04760), GLOD4 (Q9HC38), GLRX (P35754), GLRX3 (O76003), GLT25D1 (Q8NBJ5), GLTP (Q9NZD2), GLTPD1 (Q5TA50), GLUD1 (P00367), GLUL (P15104), GMDS (O60547), GMFB (P60983), GMPPA (Q96IJ6), GMPPB (Q9Y5P6), GMPR (P36959), GMPR2 (Q9P2T1), GMPS (P49915), GNA11 (P29992), GNA13 (Q14344), GNAI2 (P04899), GNAI3 (P08754), GNAQ (P50148), GNAS (Q5JWF2), GNB1 (P62873), GNB2 (P62879), GNB2L1 (P63244), GNB4 (Q9HAV0), GNE (Q9Y223), GNG12 (Q9UBI6), GNG4 (P50150), GNG5 (P63218), GNPDA1 (P46926), GNPNAT1 (Q96EK6), GOLGA7 (Q7Z5G4), GOLGB1 (Q14789), GOLIM4 (O00461), GOLM1 (Q8NBJ4), GOLPH3 (Q9H4A6), GORASP2 (Q9H8Y8), GPC1 (P35052), GPC4 (O75487), GPC6 (Q9Y625), GPD1L (Q8N335), GPI (P06744), GPLD1 (P80108), GPM6A (P51674), GPM6B (Q13491), GPN1 (Q9HCN4), GPR56 (Q9Y653), GPS1 (Q13098), GPX1 (P07203), GPX4 (P36969), GRB2 (P62993), GRHPR (Q9UBQ7), GRP (Q3ZCW2), GRPEL1 (Q9HAV7), GRWD1 (Q9BQ67), GSK3A (P49840), GSK3B (P49841), GSN (P06396), GSPT1 (P15170), GSS (P48637), GSTK1 (Q9Y2Q3), GSTM2 (P28161), GSTM3 (P21266), GSTM4 (Q03013), GSTO1 (P78417), GSTP1 (P09211), GSTT2 (POCG29), GSTZ1 (O43708), GTF2F2 (P13984), GTF2H2 (Q13888), GTF2I (P78347), GTF3C1 (Q12789), GTF3C2 (Q8WUA4), GTF3C4 (Q9UKN8), GTPBP1 (O00178), GUK1 (Q16774), GYG1 (P46976), GYS1 (P13807), H2AFY (O75367), H2AFZ (POC0S5), HADH (Q16836), HAGH (Q16775), HARS (P12081), HAT1 (O14929), HAUS3 (Q68CZ6), HAUS4 (Q9H6D7), HBA1 (P69905), HBB (P68871), HCFC1 (P51610), HDAC1 (Q13547), HDAC2 (Q92769), HDAC3 (O15379), HDHD2 (Q9H0R4), HDLBP (Q00341), HEATR1 (Q9H583), HEATR2 (Q86Y56), HEBP1 (Q9NRV9), HECTD3 (Q5T447), HEG1 (Q9ULI3), HELZ (P42694), HERC4 (Q5GLZ8), HEXB (P07686), HGS (O14964), HHIP (Q96QV1), HIBCH (Q6NVY1), HIF1AN (Q9NWT6), HINT1 (P49773), HIP1R (O75146), HIST1H1B (P16401), HIST1H1C (P16403), HIST1H2BM (Q99879), HIST1H2BO (P23527), HIST1H4A (P62805), HIST2H2AA3 (Q6FI13), HIST2H3A (Q71DI3), HK1 (P19367), HK2 (P52789), HLA-A (P30443), HLA-A (P01892), HLCS (P50747), HMGA1 (P17096), HMGB1 (P09429), HMGCL (P35914), HMGCS1 (Q01581), HMGN2 (P05204), HNRNPA1 (P09651), HNRNPA2B1 (P22626), HNRNPA3 (P51991), HNRNPAB (Q99729), HNRNPC (P07910), HNRNPD (Q14103), HNRNPF (P52597), HNRNPH1 (P31943), HNRNPH2 (P55795), HNRNPH3 (P31942), HNRNPK (P61978), HNRNPL (P14866), HNRNPM (P52272), HNRNPR (O43390), HNRNPU (Q00839), HNRNPUL2 (Q1KMD3), HNRPDL (O14979), HNRPLL (Q8WVV9), HOOK3 (Q86VS8), HP (P00738), HP1BP3 (Q5SSJ5), HPCAL1 (P37235), HPRT1 (P00492), HPX (P02790), HRAS (P01112), HS6ST2 (Q96MM7), HSD17B10 (Q99714), HSD17B4 (P51659), HSP90AA1 (P07900), HSP90AB1 (P08238), HSP90B1 (P14625), HSPA12A (O43301), HSPA14 (Q0VDF9), HSPA1A (P08107), HSPA2 (P54652), HSPA4 (P34932), HSPA4L (O95757), HSPA5 (P11021), HSPA8 (P11142), HSPA9 (P38646), HSPB1 (P04792), HSPB11 (Q9Y547), HSPBP1 (Q9NZL4), HSPD1 (P10809), HSPE1 (P61604), HSPG2 (P98160), HSPH1 (Q92598), HTATIP2 (Q9BUP3), HTRA1 (Q92743), HTT (P42858), HUWE1 (Q7Z6Z7), HYOU1 (Q9Y4L1), IARS (P41252), ICAM1 (P05362), IDE (P14735), IDH1 (O75874), IDH2 (P48735), IDI1 (Q13907), IDUA (P35475), IFI16 (Q16666), IFI35 (P80217), IFIT5 (Q13325), IFITM3 (Q01628), IGF1R (P08069), IGF2BP2 (Q9Y6M1), IGF2BP3 (O00425), IGF2R (P11717), IGFBP3 (P17936), IGSF3 (O75054), IGSF8 (Q969P0), IKBKAP (O95163), IL1RAP (Q9NPH3), ILF2 (Q12905), ILF3 (Q12906), ILK (Q13418), ILKAP (Q9H0C8), IMP4 (Q96G21), IMPA1 (P29218), IMPA2 (O14732), IMPAD1 (Q9NX62), IMPDH2 (P12268), INF2 (Q27J81), INPP1 (P49441), INPPL1 (O15357), INTS1 (Q8N201), INTS10 (Q9NVR2), INTS3 (Q68E01), INTS5 (Q6P9B9), IPO11 (Q9UI26), IPO13 (O94829), IPO4 (Q8TEX9), IPO5 (O00410), IPO7 (O95373), IPO8 (O15397), IPO9 (Q96P70), IQGAP1 (P46940), IRF2BP2 (Q7Z5L9), IRF3 (Q14653), IRGQ (Q8WZA9), ISG15 (P05161), ISOC1 (Q96CN7), ISPD (A4D126), ISYNA1 (Q9NPH2), ITFG3 (Q9H0X4), ITGA2 (P17301), ITGA3 (P26006), ITGA4 (P13612), ITGA5 (P08648), ITGA6 (P23229), ITGA7 (Q13683), ITGAV (P06756), ITGB1 (P05556), ITGB4 (P16144), ITGB8 (P26012), ITPA (Q9BY32), JAM3 (Q9BX67), JUP (P14923), KARS (Q15046), KBTBD4 (Q9NVX7), KBTBD6 (Q86V97), KCTD12 (Q96CX2), KDM1A (O60341), KEAP1 (Q14145), KHDRBS1 (Q07666), KHSRP (Q92945), KIAA0174 (P53990), KIAA0196 (Q12768), KIAA0319L (Q8IZA0), KIAA0664 (O75153), KIAA0776 (O94874), KIAA1033 (Q2M389), KIAA1279 (Q96EK5), KIAA1468 (Q9P260), KIAA1598 (A0MZ66), KIAA1797 (Q5VW36), KIAA1967 (Q8N163), KIF1A (Q12756), KIF3A (Q9Y496), KIF5B (P33176), KIF5C (O60282), KLC1 (Q07866), KLC2 (Q9H0B6), KLC4 (Q9NSK0), KLHDC3 (Q9BQ90), KLHL13 (Q9P2N7), KNG1 (P01042), KNTC1 (P50748), KPNA1 (P52294), KPNA2 (P52292), KPNA3 (O00505), KPNA4 (O00629), KPNA6 (O60684), KPNB1 (Q14974), KPRP (Q5T749), KRAS (P01116), KRIT1 (O00522), KRT13 (P13646), KRT14 (P02533), KRT71 (Q3SY84), KTN1 (Q86UP2), L1CAM (P32004), LAGE3 (Q14657), LAMA4 (Q16363), LAMA5 (O15230), LAMB1 (P07942), LAMC1 (P11047), LAMP1 (P11279), LAMP2 (P13473), LANCL1 (O43813), LANCL2 (Q9NS86), LAP3 (P28838), LARP1 (Q6PKG0), LARS (Q9P2J5), LASP1 (Q14847), LCAT (P04180), LCMT1 (Q9UIC8), LDHA (P00338), LDHB (P07195), LDLR (P01130), LEFTY2 (O00292), LEPRE1 (Q32P28), LFNG (Q8NES3), LGALS1 (P09382), LGALS3 (P17931), LGALS3BP (Q08380), LHFP (Q9Y693), LIMA1 (Q9UHB6), LIMS1 (P48059), LIN7C (Q9NUP9), LIPG (Q9Y5X9), LLGL1 (Q15334), LMCD1 (Q9NZU5), LMNA (P02545), LMNB1 (P20700), LOXL4 (Q96JB6), LPL (P06858), LRBA (P50851), LRCH3 (Q96II8), LRG1 (P02750), LRP1 (Q07954), LRRC20 (Q8TCA0), LRRC40 (Q9H9A6), LRRC47 (Q8N1G4), LRRC57 (Q8N9N7), LRSAM1 (Q6UWE0), LRWD1 (Q9UFC0), LSM1 (O15116), LSM12 (Q3MHD2), LSM2 (Q9Y333), LSM3 (P62310), LSM4 (Q9Y4Z0), LSM6 (P62312), LSM7 (Q9UK45), LSS (P48449), LTA4H (P09960), LTBP2 (Q14767), LTBP3 (Q9NS15), LUM (P51884), LYPLA1 (O75608), LYPLA2 (O95372), LYPLAL1 (Q5VWZ2), M6PR (P20645), MACF1 (Q9UPN3), MAD1L1 (Q9Y6D9), MAD2L1 (Q13257), MAEA (Q7L5Y9), MAGEE1 (Q9HCI5), MAGOHB (Q96A72), MALT1 (Q9UDY8), MAN1B1 (Q9UKM7), MAN2A1 (Q16706), MANBA (O00462), MAP1B (P46821), MAP1S (Q66K74), MAP2K1 (Q02750), MAP2K2 (P36507), MAP2K3 (P46734), MAP3K4 (Q9Y6R4), MAP4 (P27816), MAP4K4 (O95819), MAPK1 (P28482), MAPK12 (P53778), MAPK3 (P27361), MAPK9 (P45984), MAPKAPK2 (P49137), MAPKSP1 (Q9UHA4), MAPRE1 (Q15691), MAPRE3 (Q9UPY8), MARCKS (P29966), MARCKSL1 (P49006), MARK2 (Q7KZI7), MARS (P56192), MAT2A (P31153), MAT2B (Q9NZL9), MATR3 (P43243), MBD3 (O95983), MBNL1 (Q9NR56), MCAM (P43121), MCAT (Q8IVS2), MCM2 (P49736), MCM3 (P25205), MCM4 (P33991), MCM5 (P33992), MCM6 (Q14566), MCM7 (P33993), MCTS1 (Q9ULC4), MDH1 (P40925), MDH2 (P40926), MDK (P21741), MDN1 (Q9NU22), ME1 (P48163), ME2 (P23368), MED1 (Q15648), MED16 (Q9Y2X0), MED17 (Q9NVC6), MED18 (Q9BUE0), MED20 (Q9H944), MED22 (Q15528), MED23 (Q9ULK4), MED27 (Q6P2C8), MED30 (Q96HR3), MED31 (Q9Y3C7), MEMO1 (Q9Y316), MERIT40 (Q9NWV8), METAP1 (P53582), METAP2 (P50579), METT10D (Q86W50), METTL1 (Q9UBP6), METTL11A (Q9BV86), METTL13 (Q8N6R0), METTL2B (Q6P1Q9), METTL5 (Q9NRN9), MFAP2 (P55001), MFAP4 (P55083), MFGE8 (Q08431), MFI2 (P08582), MGAT4B (Q9UQ53), MGAT5 (Q09328), MGEA5 (O60502), MICAL1 (Q8TDZ2), MIF (P14174), MIF4GD (A9UHW6), MINA (Q8IUF8), MINK1 (Q8N4C8), MIOS (Q9NXC5), MIS12 (Q9H081), MKLN1 (Q9UL63), MLTK (Q9NYL2), MMP14 (P50281), MMS19 (Q96T76), MOB2 (Q70IA6), MOBKL1B (Q9H8S9), MOBKL2A (Q96BX8), MOBKL3 (Q9Y3A3), MOCS2 (O96033), MON2 (Q7Z3U7), MORC2 (Q9Y6X9), MOV10 (Q9HCE1), MOXD1 (Q6UVY6), MPI (P34949), MPP6 (Q9NZW5), MPRIP (Q6WCQ1), MPST (P25325), MPZL1 (O95297), MRC2 (Q9UBG0), MRI1 (Q9BV20), MRTO4 (Q9UKD2), MSH2 (P43246), MSN (P26038), MSTO1 (Q9BUK6), MTA1 (Q13330), MTA2 (O94776), MTAP (Q13126), MTHFD1 (P11586), MTHFS (P49914), MTM1 (Q13496), MTMR1 (Q13613), MTMR6 (Q9Y217), MTMR9 (Q96QG7), MTOR (P42345), MTPN (P58546), MTR (Q99707), MVD (P53602), MVK (Q03426), MVP (Q14764), MYADM (Q96S97), MYBBP1A (Q9BQG0), MYCBP (Q99417), MYD88 (Q99836), MYH10 (P35580), MYH9 (P35579), MYL12B (O14950), MYL6 (P60660), MYO18A (Q92614), MYO1B (O43795), MYO1C (O00159), MYO1E (Q12965), MYO6 (Q9UM54), MYOF (Q9NZM1), MZT1 (Q08AG7), NAA10 (P41227), NAA15 (Q9BXJ9), NAA16 (Q6N069), NAA20 (P61599), NAA30 (Q147X3), NAA38 (O95777), NAA50 (Q9GZZ1), NACA (Q13765), NADSYN1 (Q6IA69), NAE1 (Q13564), NAGK (Q9UJ70), NAGLU (P54802), NAMPT (P43490), NANS (Q9NR45), NAP1L1 (P55209), NAP1L4 (Q99733), NAPA (P54920), NAPG (Q99747), NAPRT1 (Q6XQN6), NARS (O43776), NASP (P49321), NCAM1 (P13591), NCAPD2 (Q15021), NCAPG (Q9BPX3), NCBP1 (Q09161), NCBP2 (P52298), NCDN (Q9UBB6), NCKAP1 (Q9Y2A7), NCKIPSD (Q9NZQ3), NCL (P19338), NCS1 (P62166), NCSTN (Q92542), NDRG3 (Q9UGV2), NDRG4 (Q9ULP0), NDUFA2 (O43678), NDUFA3 (O95167), NDUFA5 (Q16718), NDUFAB1 (O14561), NDUFS6 (O75380), NEDD4L (Q96PU5), NEFL (P07196), NEK9 (Q8TD19), NES (P48681), NF1 (P21359), NFIC (P08651), NFIX (Q14938), NFKB2 (Q00653), NHLRC2 (Q8NBF2), NHP2L1 (P55769), NID1 (P14543), NIP7 (Q9Y221), NIT1 (Q86X76), NIT2 (Q9NQR4), NLE1 (Q9NVX2), NLGN4X (Q8N0W4), NLN (Q9BYT8), NMD3 (Q96D46), NME1 (P15531), NME2 (P22392), NME3 (Q13232), NME7 (Q9Y5B8), NMT1 (P30419), NNMT (P40261), NOB1 (Q9ULX3), NOL11 (Q9H8H0), NOL6 (Q9H6R4), NOMO2 (Q5JPE7), NONO (Q15233), NOP10 (Q9NPE3), NOP2 (P46087), NOTCH1 (P46531), NOTCH3 (Q9UM47), NOVA2 (Q9UNW9), NPEPPS (P55786), NPLOC4 (Q8TAT6), NPM1 (P06748), NPM3 (O75607), NPTN (Q9Y639), NPW (Q8N729), NQ01 (P15559), NQ02 (P16083), NR2C2AP (Q86WQ0), NRAS (P01111), NRBP1 (Q9UHY1), NRBP2 (Q9NSY0), NRD1 (O43847), NRP2 (O60462), NSF (P46459), NSMAF (Q92636), NSMCE1 (Q8WV22), NSUN2 (Q08J23), NT5C (Q8TCD5), NT5DC1 (Q5TFE4), NTN1 (O95631), NUBP1 (P53384), NUBP2 (Q9Y5Y2), NUCB1 (Q02818), NUDC (Q9Y266), NUDCD1 (Q96RS6), NUDCD2 (Q8WVJ2), NUDT1 (P36639), NUDT10 (Q8NFP7), NUDT12 (Q9BQG2), NUDT16 (Q96DE0), NUDT16L1 (Q9BRJ7), NUDT2 (P50583), NUDT21 (O43809), NUDT4 (Q9NZJ9), NUDT5 (Q9UKK9), NUMA1 (Q14980), NUP188 (Q5SRE5), NUP37 (Q8NFH4), NUP43 (Q8NFH3), NUP54 (Q7Z3B4), NUP88 (Q99567), NUP93 (Q8N1F7), NUTF2 (P61970), NXN (Q6DKJ4), OBFC2B (Q9BQ15), OCRL (Q01968), ODZ2 (Q9NT68), ODZ3 (Q9P273), OGFOD1 (Q8N543), OGT (O15294), OLA1 (Q9NTK5), OLFML3 (Q9NRN5), OPA1 (O60313), OPLAH (O14841), OSBP (P22059), OSBPL1A (Q9BXW6), OSGEP (Q9NPF4), OTUB1 (Q96FW1), OVCA2 (Q8WZ82), OXCT1 (P55809), OXSR1 (O95747), P4HB (P07237), PA2G4 (Q9UQ80), PAAF1 (Q9BRP4), PABPC1 (P11940), PABPC4 (Q13310), PABPN1 (Q86U42), PACSIN2 (Q9UNF0), PACSIN3 (Q9UKS6), PAF1 (Q8N7H5), PAFAH1B1 (P43034), PAFAH1B2 (P68402), PAFAH1B3 (Q15102), PAICS (P22234), PAIP1 (Q9H074), PAK2 (Q13177), PALD (Q9ULE6), PALLD (Q8WX93), PANK4 (Q9NVE7), PAPOLA (P51003), PAPSS1 (O43252), PARF (Q3YEC7), PARK7 (Q99497), PARN (O95453), PARP1 (P09874), PARP4 (Q9UKK3), PARVA (Q9NVD7), PBK (Q96KB5), PBLD (P30039), PCBP1 (Q15365), PCBP2 (Q15366), PCDHB2 (Q9Y5E7), PCDHGB4 (Q9UN71), PCDHGC3 (Q9UN70), PCID2 (Q5JVF3), PCMT1 (P22061), PCNA (P12004), PCOLCE2 (Q9UKZ9), PCYT2 (Q99447), PDCD10 (Q9BUL8), PDCD2L (Q9BRP1), PDCD4 (Q53EL6), PDCD5 (O14737), PDCD6 (O75340), PDCD6IP (Q8WUM4), PDCL3 (Q9H2J4), PDDC1 (Q8NB37), PDE12 (Q6L8Q7), PDE6D (O43924), PDGFC (Q9NRA1), PDIA3 (P30101), PDIA6 (Q15084), PDLIM1 (O00151), PDLIM4 (P50479), PDLIM5 (Q96HC4), PDLIM7 (Q9NR12), PDRG1 (Q9NUG6), PDRO (Q6IAA8), PDS5A (Q29RF7), PDXK (O00764), PDXP (Q96GD0), PEA15 (Q15121), PEBP1 (P30086), PEF1 (Q9UBV8), PELO (Q9BRX2), PELP1 (Q8IZL8), PEPD (P12955), PFAS (O15067), PFDN2 (Q9UHV9), PFDN5 (Q99471), PFDN6 (O15212), PFKL (P17858), PFKM (P08237), PFKP (Q01813), PFN1 (P07737), PFN2 (P35080), PGAM1 (P18669), PGAM5 (Q96HS1), PGD (P52209), PGGT1B (P53609), PGK1 (P00558), PGLS (O95336), PGLYRP2 (Q96PD5), PGM1 (P36871), PGM2L1 (Q6PCE3), PGM3 (O95394), PGP (A6NDG6), PGRMC1 (O00264), PGRMC2 (O15173), PHF5A (Q7RTV0), PHGDH (O43175), PHKB (Q93100), PHLDA3 (Q9Y5J5), PHPT1 (Q9NRX4), PIK3CB (P42338), PIK3R4 (Q99570), PIN1 (Q13526), PIP4K2A (P48426), PIPOX (Q9P0Z9), PITPNB (P48739), PKM2 (P14618), PKP1 (Q13835), PLAA (Q9Y263), PLCD3 (Q8N3E9), PLCG1 (P19174), PLD3 (Q8IV08), PLEC (Q15149), PLEKHB2 (Q96CS7), PLIN3 (O60664), PLOD1 (Q02809), PLOD2 (O00469), PLOD3 (O60568), PLRG1 (O43660), PLS1 (Q14651), PLS3 (P13797), PLSCR3 (Q9NRY6), PLTP (P55058), PLXNA1 (Q9UIW2), PLXNB2 (O15031), PLXND1 (Q9Y4D7), PM20D2 (Q8IYS1), PML (P29590), PMM2 (O15305), PMPCA (Q10713), PMPCB (O75439), PMVK (Q15126), PNMA2 (Q9UL42), PNO1 (Q9NRX1), PNP (P00491), PODXL (O00592), POLA1 (P09884), POLD1 (P28340), POLD2 (P49005), POLE3 (Q9NRF9), POLR1A (O95602), POLR1B (Q9H9Y6), POLR1C (O15160), POLR1D (Q9Y2S0), POLR1E (Q9GZS1), POLR2A (P24928), POLR2B (P30876), POLR2C (P19387), POLR2E (P19388), POLR2G (P62487), POLR2H (P52434), POLR2J (P52435), POLR2L (P62875), POLR3A (O14802), POLR3B (Q9NW08), POLR3C (Q9BUI4), POLR3F (Q9H1D9), POP1 (Q99575), POP4 (O95707), POP5 (Q969H6), POP7 (O75817), PPA1 (Q15181), PPA2 (Q9H2U2), PPAT (Q06203), PPCS (Q9HAB8), PPIA (P62937), PPIB (P23284), PPID (Q08752), PPIF (P30405), PPIH (O43447), PPIL1 (Q9Y3C6), PPM1A (P35813), PPM1F (P49593), PPM1G (O15355), PPME1 (Q9Y570), PPP1CA (P62136), PPP1CB (P62140), PPP1CC (P36873), PPP1R7 (Q15435), PPP1R8 (Q12972), PPP2CA (P67775), PPP2CB (P62714), PPP2R1A (P30153), PPP2R2A (P63151), PPP2R4 (Q15257), PPP2R5C (Q13362), PPP2R5D (Q14738), PPP2R5E (Q16537), PPP3CA (Q08209), PPP4C (P60510), PPP4R1 (Q8TF05), PPP5C (P53041), PPP6C (O00743), PPP6R3 (Q5H9R7), PPPDE2 (Q6ICB0), PPT1 (P50897), PPWD1 (Q96BP3), PRCP (P42785), PRDX1 (Q06830), PRDX2 (P32119), PRDX3 (P30048), PRDX5 (P30044), PRDX6 (P30041), PREP (P48147), PREPL (Q4J6C6), PRIM1 (P49642), PRIM2 (P49643), PRKACA (P17612), PRKACB (P22694), PRKAG1 (P54619), PRKAR1A (P10644), PRKAR2A (P13861), PRKAR2B (P31323), PRKDC (P78527), PRMT1 (Q99873), PRMT3 (O60678), PRMT5 (O14744), PROM1 (O43490), PROSC (O94903), PRPF19 (Q9UMS4), PRPF31 (Q8WWY3), PRPF4 (O43172), PRPF4B (Q13523), PRPF8 (Q6P2Q9), PRPS1 (P60891), PRPS2 (P11908), PRPSAP1 (Q14558), PRPSAP2 (O60256), PRSS23 (O95084), PRTFDC1 (Q9NRG1), PSAT1 (Q9Y617), PSMA1 (P25786), PSMA2 (P25787), PSMA3 (P25788), PSMA4 (P25789), PSMA5 (P28066), PSMA6 (P60900), PSMA7 (O14818), PSMB1 (P20618), PSMB2 (P49721), PSMB3 (P49720), PSMB4 (P28070), PSMB5 (P28074), PSMB6 (P28072), PSMB7 (Q99436), PSMB8 (P28062), PSMC1 (P62191), PSMC2 (P35998), PSMC3 (P17980), PSMC4 (P43686), PSMC5 (P62195), PSMC6 (P62333), PSMD1 (Q99460), PSMD10 (O75832), PSMD11 (O00231), PSMD12 (O00232), PSMD13 (Q9UNM6), PSMD14 (O00487), PSMD2 (Q13200), PSMD3 (O43242), PSMD4 (P55036), PSMD5 (Q16401), PSMD6 (Q15008), PSMD7 (P51665), PSMD8 (P48556), PSMD9 (O00233), PSME1 (Q06323), PSME2 (Q9UL46), PSME3 (P61289), PSME4 (Q14997), PSMF1 (Q92530), PSMG1 (O95456), PSMG2 (Q969U7), PSMG3 (Q9BT73), PSPC1 (Q8WXF1), PSPH (P78330), PTBP1 (P26599), PTGES3 (Q15185), PTGFRN (Q9P2B2), PTGR1 (Q14914), PTGR2 (Q8N8N7), PTK2 (Q05397), PTK7 (Q13308), PTN (P21246), PTP4A1 (Q93096), PTPN1 (P18031), PTPN11 (Q06124), PTPN23 (Q9H3S7), PTPRA (P18433), PTPRG (P23470), PTPRZ1 (P23471), PUF60 (Q9UHX1), PUM1 (Q14671), PURB (Q96QR8), PUS7 (Q96PZ0), PVR (P15151), PWP1 (Q13610), PXDN (Q92626), PXK (Q7Z7A4), PYCR1 (P32322), PYCRL (Q53H96), PYGB (P11216), PYGL (P06737), QARS (P47897), QDPR (P09417), QKI (Q96PU8), QRICH1 (Q2TAL8), QSOX2 (Q6ZRP7), QTRT1 (Q9BXR0), RAB10 (P61026), RAB11A (P62491), RAB11FIP1 (Q6WKZ4), RAB12 (Q6IQ22), RAB13 (P51153), RAB14 (P61106), RAB18 (Q9NP72), RAB1A (P62820), RAB1B (Q9H0U4), RAB21 (Q9UL25), RAB22A (Q9UL26), RAB23 (Q9ULC3), RAB27A (P51159), RAB2A (P61019), RAB34 (Q9BZG1), RAB35 (Q15286), RAB3A (P20336), RAB3GAP1 (Q15042), RAB3GAP2 (Q9H2M9), RAB4A (P20338), RAB5A (P20339), RAB5B (P61020), RAB5C (P51148), RAB6A (P20340), RAB6B (Q9NRW1), RAB7A (P51149), RAB8A (P61006), RAB8B (Q92930), RABAC1 (Q9UI14), RABGAP1 (Q9Y3P9), RABGGTA (Q92696), RABGGTB (P53611), RABIF (P47224), RAC1 (P63000), RAD1 (O60671), RAD50 (Q92878), RAE1 (P78406), RAI14 (Q9P0K7), RALA (P11233), RALB (P11234), RALY (Q9UKM9), RAN (P62826), RANBP1 (P43487), RANBP2 (P49792), RANBP6 (O60518), RANBP9 (Q96S59), RANGAP1 (P46060), RAP1A (P62834), RAP1B (P61224), RAP1GDS1 (P52306), RAP2B (P61225), RARS (P54136), RASA1 (P20936), RBBP4 (Q09028), RBBP5 (Q15291), RBBP7 (Q16576), RBBP9 (O75884), RBM12 (Q9NTZ6), RBM15 (Q96T37), RBM17 (Q96I25), RBM22 (Q9NW64), RBM4 (Q9BWF3), RBMX (P38159), RBP1 (P09455), RBPJ (Q06330), RBX1 (P62877), RCC1 (P18754), RCC2 (Q9P258), RCL (O43598), RDX (P35241), RECQL (P46063), REEP5 (Q00765), REEP6 (Q96HR9), REPS1 (Q96D71), RFC4 (P35249), RFC5 (P40937), RFTN1 (Q14699), RHEB (Q15382), RHOA (P61586), RHOB (P62745), RHOC (P08134), RHOF (Q9HBH0), RHOG (P84095), RIC8A (Q9NPQ8), RMND5A (Q9H871), RNASEH2A (O75792), RNASEH2C (Q8TDP1), RNF123 (Q5XPI4), RNF20 (Q5VTR2), RNF213 (Q63HN8), RNF7 (Q9UBF6), RNGTT (O60942), RNH1 (P13489), RNMT (O43148), RNPEP (Q9H4A4), ROBLD3 (Q9Y2Q5), R0CK1 (Q13464), ROCK2 (O75116), ROR1 (Q01973), RP2 (O75695), RPA1 (P27694), RPA2 (P15927), RPA3 (P35244), RPE (Q96AT9), RPF2 (Q9H7B2), RPL10 (P27635), RPL10A (P62906), RPL11 (P62913), RPL12 (P30050), RPL13 (P26373), RPL13A (P40429), RPL14 (P50914), RPL15 (P61313), RPL17 (P18621), RPL18 (Q07020), RPL18A (Q02543), RPL19 (P84098), RPL21 (P46778), RPL22 (P35268), RPL22L1 (Q6P5R6), RPL23 (P62829), RPL23A (P62750), RPL24 (P83731), RPL26 (P61254), RPL27 (P61353), RPL27A (P46776), RPL28 (P46779), RPL3 (P39023), RPL30 (P62888), RPL31 (P62899), RPL32 (P62910), RPL34 (P49207), RPL35 (P42766), RPL35A (P18077), RPL36 (Q9Y3U8), RPL36A (P83881), RPL36AL (Q969Q0), RPL37A (P61513), RPL38 (P63173), RPL4 (P36578), RPL5 (P46777), RPL6 (Q02878), RPL7 (P18124), RPL7A (P62424), RPL8 (P62917), RPL9 (P32969), RPLP0 (P05388), RPLP1 (P05386), RPLP2 (P05387), RPP30 (P78346), RPP40 (O75818), RPRD1A (Q96P16), RPS10 (P46783), RPS11 (P62280), RPS12 (P25398), RPS13 (P62277), RPS14 (P62263), RPS15 (P62841), RPS15A (P62244), RPS16 (P62249), RPS17 (P08708), RPS18 (P62269), RPS19 (P39019), RPS2 (P15880), RPS20 (P60866), RPS21 (P63220), RPS23 (P62266), RPS24 (P62847), RPS25 (P62851), RPS26 (P62854), RPS27 (P42677), RPS27A (P62979), RPS27L (Q71UM5), RPS28 (P62857), RPS29 (P62273), RPS3 (P23396), RPS3A (P61247), RPS4X (P62701), RPS4Y1 (P22090), RPS5 (P46782), RPS6 (P62753), RPS6KA3 (P51812), RPS7 (P62081), RPS8 (P62241), RPS9 (P46781), RPSA (P08865), RQCD1 (Q92600), RRAGA (Q7L523), RRAS (P10301), RRAS2 (P62070), RRBP1 (Q9P2E9), RRM1 (P23921), RRM2 (P31350), RRM2B (Q7LG56), RRP12 (Q5JTH9), RRP9 (O43818), RSL1D1 (O76021), RSU1 (Q15404), RTCD1 (O00442), RTN3 (O95197), RTN4 (Q9NQC3), RUVBL1 (Q9Y265), RUVBL2 (Q9Y230), RWDD2B (P57060), S100A10 (P60903), S100A11 (P31949), S100A13 (Q99584), S100A16 (Q96FQ6), S100A4 (P26447), S100A6 (P06703), S100A8 (P05109), SAAL1 (Q96ER3), SACS (Q9NZJ4), SAE1 (Q9UBE0), SAFB2 (Q14151), SAMHD1 (Q9Y3Z3), SAP18 (O00422), SAR1A (Q9NR31), SARM1 (Q6SZW1), SARS (P49591), SART3 (Q15020), SBDS (Q9Y3A5), SBF1 (O95248), SCARB1 (Q8WTV0), SCARB2 (Q14108), SCFD1 (Q8WVM8), SCLY (Q96115), SCP2 (P22307), SCPEP1 (Q9HB40), SCRG1 (O75711), SCRIB (Q14160), SCRN1 (Q12765), SCRN2 (Q96FV2), SCYL1 (Q96KG9), SCYL2 (Q6P3W7), SDC1 (P18827), SDC2 (P34741), SDCBP (O00560), SDF4 (Q9BRK5), SDHA (P31040), SDK1 (Q7Z5N4), SDSL (Q96GA7), SEC11A (P67812), SEC13 (P55735), SEC22B (O75396), SEC23A (Q15436), SEC23B (Q15437), SEC23IP (Q9Y6Y8), SEC24A (O95486), SEC24B (O95487), SEC24C (P53992), SEC24D (O94855), SEC31A (O94979), SEH1L (Q96EE3), SELH (Q8IZQ5), SEMA3A (Q14563), SEPSECS (Q9HD40), 40787 (Q9NVA2), 37500 (Q15019), 38596 (Q99719), 39326 (Q16181), 39692 (Q92599), 40057 (Q9UHD8), SERBP1 (Q8NC51), SERPINA1 (P01009), SERPINA3 (P01011), SERPINA7 (P05543), SERPINB6 (P35237), SERPINB8 (P50452), SERPINE1 (P05121), SERPINE2 (P07093), SERPING1 (P05155), SERPINH1 (P50454), SETD3 (Q86TU7), SETD7 (Q8WTS6), SF3A1 (Q15459), SF3A2 (Q15428), SF3A3 (Q12874), SF3B1 (O75533), SF3B14 (Q9Y3B4), SF3B2 (Q13435), SF3B3 (Q15393), SF3B4 (Q15427), SF3B5 (Q9BWJ5), SFPQ (P23246), SFRP4 (Q6FHJ7), SGTA (O43765), SH3BP4 (Q9P0V3), SH3GL1 (Q99961), SH3GLB1 (Q9Y371), SHBG (P04278), SHC1 (P29353), SHMT1 (P34896), SHMT2 (P34897), SHOC2 (Q9UQ13), SHPK (Q9UHJ6), SKIV2L (Q15477), SKIV2L2 (P42285), SKP1 (P63208), SLC16A1 (P53985), SLC1A3 (P43003), SLC1A5 (Q15758), SLC29A1 (Q99808), SLC2A1 (P11166), SLC31A1 (O15431), SLC3A2 (P08195), SLC44A2 (Q8IWA5), SLC5A3 (P53794), SLC7A5 (Q01650), SLC9A3R1 (O14745), SLC9A3R2 (Q15599), SLIRP (Q9GZT3), SMAD4 (Q13485), SMARCA4 (P51532), SMARCA5 (O60264), SMARCC1 (Q92922), SMARCC2 (Q8TAQ2), SMARCD1 (Q96GM5), SMARCD2 (Q92925), SMARCE1 (Q969G3), SMC1A (Q14683), SMC2 (O95347), SMC3 (Q9UQE7), SMC4 (Q9NTJ3), SMC5 (Q8IY18), SMC6 (Q96SB8), SMCHD1 (A6NHR9), SMEK1 (Q6IN85), SMS (P52788), SMU1 (Q2TAY7), SMYD5 (Q6GMV2), SNAP23 (O00161), SNAPIN (O95295), SND1 (Q7KZF4), SNF8 (Q96H20), SNRNP200 (O75643), SNRNP40 (Q96DI7), SNRPA1 (P09661), SNRPB (P14678), SNRPD1 (P62314), SNRPD2 (P62316), SNRPD3 (P62318), SNRPE (P62304), SNRPF (P62306), SNRPG (P62308), SNTB1 (Q13884), SNUPN (O95149), SNX1 (Q13596), SNX12 (Q9UMY4), SNX17 (Q15036), SNX18 (Q96RF0), SNX2 (O60749), SNX27 (Q96L92), SNX3 (O60493), SNX5 (Q9Y5X3), SNX6 (Q9UNH7), SNX8 (Q9Y5X2), SNX9 (Q9Y5X1), S0D1 (P00441), SORD (Q00796), SORT1 (Q99523), SPAG9 (O60271), SPC24 (Q8NBT2), SPC25 (Q9HBM1), SPG21 (Q9NZD8), SPR (P35270), SPRYD4 (Q8WW59), SPTAN1 (Q13813), SPTBN1 (Q01082), SPTBN2 (O15020), SRGAP2 (O75044), SRI (P30626), SRM (P19623), SRP14 (P37108), SRP19 (P09132), SRP54 (P61011), SRP68 (Q9UHB9), SRP72 (O76094), SRP9 (P49458), SRPX (P78539), SRPX2 (O60687), SRR (Q9GZT4), SRRT (Q9BXP5), SRSF1 (Q07955), SRSF11 (Q05519), SRSF2 (Q01130), SRSF3 (P84103), SRSF6 (Q13247), SRSF7 (Q16629), SRSF9 (Q13242), SRXN1 (Q9BYN0), SSB (P05455), SSBP1 (Q04837), SSRP1 (Q08945), SSSCA1 (O60232), ST13 (P50502), STAG2 (Q8N3U4), STAM (Q92783), STAMBP (O95630), STAT1 (P42224), STAT3 (P40763), STIP1 (P31948), STK24 (Q9Y6E0), STK25 (O00506), STK38L (Q9Y2H1), STOM (P27105), STON2 (Q8WXE9), STRAP (Q9Y3F4), STUB1 (Q9UNE7), STX12 (Q86Y82), STX4 (Q12846), STX5 (Q13190), STX7 (O15400), STXBP1 (P61764), STXBP3 (O00186), STYX (Q8WUJ0), SUB1 (P53999), SUDS3 (Q9H7L9), SUGT1 (Q9Y2Z0), SUMO1 (P63165), SUPT16H (Q9Y5B9), SUPT4H1 (P63272), SUPT5H (O00267), SUPT6H (Q7KZ85), SVEP1 (Q4LDE5), SWAP70 (Q9UH65), SYMPK (Q92797), SYNCRIP (O60506), SYNE1 (Q8NF91), SYNE2 (Q8WXH0), SYNGR2 (O43760), SYNJ2BP (P57105), TAB1 (Q15750), TAF9 (Q9Y3D8), TAF9 (Q16594), TAGLN (Q01995), TAGLN2 (P37802), TALDO1 (P37837), TARDBP (Q13148), TARS (P26639), TATDN1 (Q6P1N9), TAX1BP3 (O14907), TBC1D13 (Q9NVG8), TBC1D15 (Q8TC07), TBC1D23 (Q9NUY8), TBC1D24 (Q9ULP9), TBC1D4 (O60343), TBC1D9B (Q66K14), TBCA (O75347), TBCB (Q99426), TBCD (Q9BTW9), TBCE (Q15813), TBL1XR1 (Q9BZK7), TCEA1 (P23193), TCEB1 (Q15369), TCEB2 (Q15370), TCERG1 (O14776), TCP1 (P17987), TDP2 (O95551), TEP1 (Q99973), TEX10 (Q9NXF1), TF (P02787), TFCP2 (Q12800), TFG (Q92734), TFRC (P02786), TGFB1 (P01137), TGFB2 (P61812), TGFBI (Q15582), TGM1 (P22735), TH1L (Q8IXH7), THBS1 (P07996), THBS3 (P49746), THG1L (Q9NWX6), THOC2 (Q8NI27), THOC3 (Q96J01), THOC5 (Q13769), THOC6 (Q86W42), THOC7 (Q6I9Y2), THOP1 (P52888), THUMPD1 (Q9NXG2), THY1 (P04216), THYN1 (Q9P016), TIA1 (P31483), TIGAR (Q9NQ88), TIMM13 (Q9Y5L4), TIMM50 (Q3ZCQ8), TIMM8B (Q9Y5J9), TIMM9 (Q9Y5J7), TIMP1 (P01033), TIPRL (O75663), TKT (P29401), TLN1 (Q9Y490), TLN2 (Q9Y4G6), TM9SF2 (Q99805), TM9SF3 (Q9HD45), TMED10 (P49755), TMED2 (Q15363), TMED7 (Q9Y3B3), TMED9 (Q9BVK6), TMEM167A (Q8TBQ9), TMEM2 (Q9UHN6), TMEM50B (P56557), TMEM87A (Q8NBN3), TMOD3 (Q9NYL9), TNC (P24821), TNPO1 (Q92973), TNP02 (O14787), TNP03 (Q9Y5L0), TOLLIP (Q9H0E2), TOMM20 (Q15388), TOMM22 (Q9NS69), TOMM34 (Q15785), TOMM5 (Q8N4H5), TOMM70A (O94826), TOP1 (P11387), TOP2B (Q02880), TOR1B (O14657), TP53BP1 (Q12888), TP53RK (Q96S44), TPI1 (P60174), TPM3 (P06753), TPM3L (A6NL28), TPM4 (P67936), TPMT (P51580), TPP1 (O14773), TPP2 (P29144), TPR (P12270), TPRG1L (Q5T0D9), TPRKB (Q9Y3C4), TPT1 (P13693), TRAF2 (Q12933), TRAP1 (Q12931), TRAPPC1 (Q9Y5R8), TRAPPC2L (Q9UL33), TRAPPC3 (O43617), TRAPPC4 (Q9Y296), TRAPPC5 (Q8IUR0), TRAPPC6A (O75865), TRAPPC6B (Q86SZ2), TRIM22 (Q8IYM9), TRIM25 (Q14258), TRIM28 (Q13263), TRIP12 (Q14669), TRIP13 (Q15645), TRIP6 (Q15654), TRMT1 (Q9NXH9), TRMT112 (Q9UI30), TRMT5 (Q32P41), TRMT6 (Q9UJA5), TRMT61A (Q96FX7), TRNT1 (Q96Q11), TROVE2 (P10155), TRRAP (Q9Y4A5), TSG101 (Q99816), TSKU (Q8WUA8), TSPAN14 (Q8NG11), TSPAN4 (O14817), TSPAN5 (P62079), TSPAN6 (O43657), TSPAN9 (O75954), TSSC1 (Q53HC9), TSTA3 (Q13630), TTC1 (Q99614), TTC37 (Q6PGP7), TTC38 (Q5R3I4), TTC5 (Q8N0Z6), TTC9C (Q8N5M4), TTL (Q8NG68), TTLL12 (Q14166), TTN (Q8WZ42), TTR (P02766), TTYH1 (Q9H313), TTYH2 (Q9BSA4), TTYH3 (Q9C0H2), TUBA1B (P68363), TUBA1C (Q9BQE3), TUBB (P07437), TUBB2A (Q13885), TUBB2B (Q9BVA1), TUBB2C (P68371), TUBB3 (Q13509), TUBB4 (P04350), TUBB6 (Q9BUF5), TUBG1 (P23258), TUBGCP2 (Q9BSJ2), TUBGCP3 (Q96CW5), TWF1 (Q12792), TWF2 (Q6IBS0), TXN (P10599), TXNDC17 (Q9BRA2), TXNDC9 (O14530), TXNL1 (O43396), TXNL4B (Q9NX01), TXNRD1 (Q16881), TYMS (P04818), U2AF1 (Q01081), U2AF2 (P26368), UAP1 (Q16222), UBA1 (P22314), UBA2 (Q9UBT2), UBA3 (Q8TBC4), UBA5 (Q9GZZ9), UBA6 (A0AVT1), UBE2D1 (P51668), UBE2D3 (P61077), UBE2E1 (P51965), UBE2G2 (P60604), UBE2I (P63279), UBE2J2 (Q8N2K1), UBE2K (P61086), UBE2L3 (P68036), UBE2M (P61081), UBE2N (P61088), UBE2O (Q9C0C9), UBE2V1 (Q13404), UBE2V2 (Q15819), UBE2Z (Q9H832), UBE3A (Q05086), UBE4A (Q14139), UBE4B (O95155), UBL3 (O95164), UBL4A (P11441), UBL5 (Q9BZL1), UBR1 (Q8IWV7), UBR4 (Q5T4S7), UBTD1 (Q9HAC8), UBXN1 (Q04323), UCHL1 (P09936), UCHL3 (P15374), UCHL5 (Q9Y5K5), UCK2 (Q9BZX2), UFC1 (Q9Y3C8), UFD1L (Q92890), UFSP2 (Q9NUQ7), UGDH (O60701), UGP2 (Q16851), UMPS (P11172), UNC119B (A6NIH7), UNC45A (Q9H3U1), UPF1 (Q92900), UPP1 (Q16831), UROD (P06132), UROS (P10746), USO1 (O60763), USP10 (Q14694), USP11 (P51784), USP14 (P54578), USP15 (Q9Y4E8), USP24 (Q9UPU5), USP39 (Q53GS9), USP5 (P45974), USP7 (Q93009), USP9X (Q93008), UTP15 (Q8TED0), UXS1 (Q8NBZ7), UXT (Q9UBK9), VAC14 (Q08AM6), VAMP3 (Q15836), VAMP5 (O95183), VAPA (Q9P0L0), VAPB (O95292), VARS (P26640), VASN (Q6EMK4), VASP (P50552), VAT1 (Q99536), VAV2 (P52735), VBP1 (P61758), VCAN (P13611), VCL (P18206), VCP (P55072), VIM (P08670), VPRBP (Q9Y4B6), VPS11 (Q9H270), VPS13C (Q709C8), VPS16 (Q9H269), VPS18 (Q9P253), VPS24 (Q9Y3E7), VPS25 (Q9BRG1), VPS26A (O75436), VPS26B (Q4G0F5), VPS28 (Q9UK41), VPS29 (Q9UBQ0), VPS33A (Q96AX1), VPS33B (Q9H267), VPS35 (Q96QK1), VPS36 (Q86VN1), VPS37B (Q9H9H4), VPS39 (Q96JC1), VPS45 (Q9NRW7), VPS4A (Q9UN37), VPS4B (O75351), VPS53 (Q5VIR6), VRK1 (Q99986), VTA1 (Q9NP79), VWA1 (Q6PCB0), VWA5A (O00534), WARS (P23381), WASF1 (Q92558), WASL (O00401), WDFY1 (Q8IWB7), WDR1 (O75083), WDR11 (Q9BZH6), WDR12 (Q9GZL7), WDR18 (Q9BV38), WDR26 (Q9H7D7), WDR33 (Q9C0J8), WDR4 (P57081), WDR43 (Q15061), WDR45L (Q5MNZ6), WDR48 (Q8TAF3), WDR5 (P61964), WDR54 (Q9H977), WDR55 (Q9H6Y2), WDR59 (Q6PJI9), WDR6 (Q9NNW5), WDR61 (Q9GZS3), WDR73 (Q6P4I2), WDR77 (Q9BQA1), WDR82 (Q6UXN9), WDR91 (A4D1P6), WDR92 (Q96MX6), WNK1 (Q9H4A3), XPNPEP1 (Q9NQW7), XPO1 (O14980), XPO4 (Q9C0E2), XPO5 (Q9HAV4), XPO6 (Q96QU8), XPO7 (Q9UIA9), XPOT (O43592), XRCC1 (P18887), XRCC5 (P13010), XRCC6 (P12956), XRN2 (Q9H0D6), YARS (P54577), YBX1 (P67809), YEATS4 (O95619), YES1 (P07947), YIPF4 (Q9BSR8), YKT6 (O15498), YPEL5 (P62699), YRDC (Q86U90), YTHDF2 (Q9Y5A9), YWHAB (P31946), YWHAE (P62258), YWHAG (P61981), YWHAH (Q04917), YWHAQ (P27348), YWHAZ (P63104), ZC3HAV1L (Q96H79), ZCCHC3 (Q9NUD5), ZER1 (Q7Z7L7), ZFPL1 (O95159), ZFR (Q96KR1), ZMAT2 (Q96NC0), ZNF259 (O75312), ZW10 (O43264), ZWILCH (Q9H900), ZYG11B (Q9C0D3), ZYX (Q15942), ZZEF1 (O43149).

TABLE 20 100 most abundant proteins (name and SwissProt accession number) observed in CTX0E03 exosomes Identified proteins Accession number Actin, cytoplasmic 2 P63261 Glyceraldehyde-3-phosphate dehydrogenase P04406 Histone H4 P62805 Pyruvate kinase isozymes M1/M2 P14618 Alpha-enolase P06733 Heat shock protein HSP 90-beta P08238 Ubiquitin-40S ribosomal protein S27a P62979 Heat shock cognate 71 kDa protein P11142 Haptoglobin P00738 Heat shock protein HSP 90-alpha P07900 Phosphoglycerate kinase 1 P00558 Actin, alpha cardiac muscle 1 P68032 40S ribosomal protein S3 P23396 Elongation factor 1-alpha 1 P68104 GTP-binding nuclear protein Ran P62826 Histone H2B type 1-M Q99879 Peptidyl-prolyl cis-trans isomerase A P62937 Profilin-1 P07737 Elongation factor 2 P13639 Fatty acid synthase P49327 Tubulin beta-2C chain P68371 Tubulin alpha-1B chain P68363 Tubulin beta chain P07437 40S ribosomal protein S11 P62280 Eukaryotic initiation factor 4A-I P60842 T-complex protein 1 subunit theta P50990 14-3-3 protein theta P27348 40S ribosomal protein S18 P62269 Tubulin beta-3 chain Q13509 T-complex protein 1 subunit beta P78371 40S ribosomal protein S16 P62249 Heat shock 70 kDa protein 1A/1B P08107 Histone H3.2 Q71DI3 Transketolase P29401 40S ribosomal protein SA P08865 Clusterin P10909 Fatty acid-binding protein, brain O15540 Hemopexin P02790 T-complex protein 1 subunit gamma P49368 Tubulin beta-2B chain Q9BVA1 Adenosylhomocysteinase P23526 T-complex protein 1 subunit eta Q99832 40S ribosomal protein S15a P62244 T-complex protein 1 subunit delta P50991 Vimentin P08670 Guanine nucleotide-binding protein subunit beta-2- P63244 like 1 Dihydropyrimidinase-related protein 3 Q14195 Elongation factor 1-gamma P26641 Fascin Q16658 Creatine kinase B-type P12277 X-ray repair cross-complementing protein 5 P13010 40S ribosomal protein S2 P15880 Histone H2A type 2-A Q6FI13 40S ribosomal protein S4, X isoform P62701 14-3-3 protein zeta/delta P63104 Heterogeneous nuclear ribonucleoprotein A1 P09651 CD81 antigen P60033 Keratin, type I cytoskeletal 14 P02533 ATP-citrate synthase P53396 40S ribosomal protein S9 P46781 Transgelin-2 P37802 Fructose-bisphosphate aldolase A P04075 Ubiquitin-like modifier-activating enzyme 1 P22314 Peroxiredoxin-1 Q06830 40S ribosomal protein S5 P46782 T-complex protein 1 subunit epsilon P48643 60S ribosomal protein L30 P62888 T-complex protein 1 subunit alpha P17987 60S ribosomal protein L12 P30050 Cofilin-1 P23528 Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 Eukaryotic translation initiation factor 5A-1 P63241 Phosphoglycerate mutase 1 P18669 Clathrin heavy chain 1 Q00610 Dihydropyrimidinase-related protein 2 Q16555 60S ribosomal protein L35a P18077 T-complex protein 1 subunit zeta P40227 Carbonyl reductase [NADPH] 1 P16152 40S ribosomal protein S3a P61247 Ferritin heavy chain P02794 Annexin A2 P07355 Myosin light polypeptide 6 P60660 Major vault protein Q14764 Heterogeneous nuclear ribonucleoprotein D0 Q14103 60S acidic ribosomal protein P0 P05388 X-ray repair cross-complementing protein 6 P12956 40S ribosomal protein S20 P60866 Protein arginine N-methyltransferase 1 Q99873 40S ribosomal protein S10 P46783 Transaldolase P37837 Histone H2B type 1- P23527 Triosephosphate isomerase P60174 Protein S100-A6 P06703 40S ribosomal protein S17 P08708 CD9 antigen P21926 Filamin-A P21333 Peptidyl-prolyl cis-trans isomerase FKBP4 Q02790 Programmed cell death 6-interacting protein Q8WUM4 Glutathione S-transferase P P09211 14-3-3 protein epsilon P62258

Microvesicles

2940 proteins were identified by Mass spectrometry in Microvesicles isolated from the initial stages of an Integra culture (week 2) and purified by centrifugation at 10,000×g. The gene names and corresponding SWISSPROT accession numbers (in brackets) of all 2940 proteins are listed in Table 21 (in alphabetical order of gene name) and the 100 most abundant proteins are listed in Table 22, in order of decreasing abundance.

TABLE 21 Gene names and SWISSPROT accession numbers of all 2940 proteins identified in CTX0E03 microvesicles (listed in alphabetical order of gene name). A1BG (P04217), AACS (Q86V21), AAMP (Q13685), AARS (P49588), AARSD1 (Q9BTE6), AASDHPPT (Q9NRN7), ABCA3 (Q99758), ABCC1 (P33527), ABCC4 (O15439), ABCE1 (P61221), ABCF1 (Q8NE71), ABCF2 (Q9UG63), ABCF3 (Q9NUQ8), ABHD14B (Q96IU4), ABI1 (Q8IZP0), ABR (Q12979), ACAA1 (P09110), ACAA2 (P42765), ACACA (Q13085), ACADM (P11310), ACADVL (P49748), ACAT1 (P24752), ACAT2 (Q9BWD1), ACBD6 (Q9BR61), ACBD7 (Q8N6N7), ACLY (P53396), ACO1 (P21399), ACO2 (Q99798), ACOT1 (Q86TX2), ACOT13 (Q9NPJ3), ACOT7 (O00154), ACOX1 (Q15067), ACOX3 (O15254), ACP1 (P24666), ACSL1 (P33121), ACSL3 (O95573), ACSL4 (O60488), ACSS2 (Q9NR19), ACTC1 (P68032), ACTG1 (P63261), ACTL6A (O96019), ACTN1 (P12814), ACTN4 (O43707), ACTR10 (Q9NZ32), ACTR1A (P61163), ACTR1B (P42025), ACTR2 (P61160), ACTR3 (P61158), ACY1 (Q03154), ADAM10 (O14672), ADAM9 (Q13443), ADAMTS15 (Q8TE58), ADAMTS16 (Q8TE57), ADAR (P55265), ADD1 (P35611), ADD3 (Q9UEY8), ADH5 (P11766), ADK (P55263), ADO (Q96SZ5), ADPRH (P54922), ADRBK1 (P25098), ADRM1 (Q16186), ADSL (P30566), ADSS (P30520), AEBP1 (Q8IUX7), AFM (P43652), AGL (P35573), AGPS (O00116), AGRN (O00468), AHCY (P23526), AHCYL1 (O43865), AHNAK (Q09666), AHNAK2 (Q8IVF2), AHSA1 (O95433), AHSG (P02765), AIDA (Q96BJ3), AIFM1 (O95831), AIMP1 (Q12904), AIMP2 (Q13155), AIP (O00170), AK1 (P00568), AK2 (P54819), AK3 (Q9UIJ7), AK4 (P27144), AKAP12 (Q02952), AKAP9 (Q99996), AKR1A1 (P14550), AKR1B1 (P15121), AKR1C1 (Q04828), AKR7A2 (O43488), AKR7A3 (O95154), AKT1 (P31749), ALCAM (Q13740), ALDH16A1 (Q8IZ83), ALDH18A1 (P54886), ALDH2 (P05091), ALDH3A1 (P30838), ALDH7A1 (P49419), ALDH9A1 (P49189), ALDOA (P04075), ALDOC (P09972), ALKBH2 (Q6NS38), ALOX12B (O75342), AMDHD2 (Q9Y303), AMPD2 (Q01433), ANAPC1 (Q9H1A4), ANAPC4 (Q9UJX5), ANAPC5 (Q9UJX4), ANAPC7 (Q9UJX3), ANKFY1 (Q9P2R3), ANKRD17 (O75179), ANKRD28 (O15084), ANKRD52 (Q8NB46), ANP32A (P39687), ANP32B (Q92688), ANP32E (Q9BTT0), ANXA1 (P04083), ANXA11 (P50995), ANXA2 (P07355), ANXA3 (P12429), ANXA4 (P09525), ANXA5 (P08758), ANXA6 (P08133), ANXA7 (P20073), AP1B1 (Q10567), AP1G1 (O43747), AP1M1 (Q9BXS5), AP1S2 (P56377), AP2A1 (O95782), AP2A2 (O94973), AP2B1 (P63010), AP2M1 (Q96CW1), AP2S1 (P53680), AP3B1 (O00203), AP3D1 (O14617), AP3M1 (Q9Y2T2), AP3S1 (Q92572), AP4S1 (Q9Y587), APEH (P13798), APEX1 (P27695), API5 (Q9BZZ5), APIP (Q96GX9), APMAP (Q9HDC9), APOA2 (P02652), APOBEC3C (Q9NRW3), APOH (P02749), APOL2 (Q9BQE5), APPL1 (Q9UKG1), APRT (P07741), AQR (O60306), ARAF (P10398), ARCN1 (P48444), ARF1 (P84077), ARF4 (P18085), ARF6 (P62330), ARFGAP2 (Q8N6H7), ARFIP1 (P53367), ARFIP2 (P53365), ARG1 (P05089), ARHGAP1 (Q07960), ARHGAP5 (Q13017), ARHGDIA (P52565), ARHGEF1 (Q92888), ARHGEF10 (O15013), ARHGEF6 (Q15052), ARHGEF7 (Q14155), ARIH1 (Q9Y4X5), ARIH2 (O95376), ARL1 (P40616), ARL2 (P36404), ARL3 (P36405), ARL6IP1 (Q15041), ARL8A (Q96BM9), ARL8B (Q9NVJ2), ARMC10 (Q8N2F6), ARMC6 (Q6NXE6), ARMC8 (Q8IUR7), ARMC9 (Q7Z3E5), ARPC1A (Q92747), ARPC1B (O15143), ARPC2 (O15144), ARPC3 (O15145), ARPC4 (P59998), ARPC5 (O15511), ARPC5L (Q9BPX5), ASAH1 (Q13510), ASCC1 (Q8N9N2), ASCC3 (Q8N3C0), ASMTL (O95671), ASNA1 (O43681), ASNS (P08243), ASPSCR1 (Q9BZE9), ASS1 (P00966), ATAD3A (Q9NVI7), ATE1 (O95260), ATG101 (Q9BSB4), ATG16L1 (Q676U5), ATG3 (Q9NT62), ATG4B (Q9Y4P1), ATG7 (O95352), ATIC (P31939), ATL3 (Q6DD88), ATM (Q13315), ATOX1 (O00244), ATP1A1 (P05023), ATP1B1 (P05026), ATP1B3 (P54709), ATP2A2 (P16615), ATP2B1 (P20020), ATP2B4 (P23634), ATP5A1 (P25705), ATP5B (P06576), ATP5C1 (P36542), ATP5E (P56381), ATP5F1 (P24539), ATP5H (O75947), ATP5I (P56385), ATP5L (O75964), ATP5O (P48047), ATP6AP1 (Q15904), ATP6AP2 (O75787), ATP6V0A1 (Q93050), ATP6V0D1 (P61421), ATP6V1A (P38606), ATP6V1B2 (P21281), ATP6V1C1 (P21283), ATP6V1D (Q9Y5K8), ATP6V1E1 (P36543), ATP6V1G1 (O75348), ATP6V1H (Q9UI12), ATR (Q13535), ATRN (O75882), ATXN10 (Q9UBB4), B2M (P61769), B3GAT3 (O94766), B3GNT1 (O43505), BAG2 (O95816), BAG5 (Q9UL15), BAIAP2 (Q9UQB8), BANF1 (O75531), BAT1 (Q13838), BAT3 (P46379), BCAM (P50895), BCAS2 (O75934), BCAT1 (P54687), BCCIP (Q9P287), BCL2L12 (Q9HB09), BDH2 (Q9BUT1), BICD2 (Q8TD16), BLMH (Q13867), BLVRA (P53004), BLVRB (P30043), BMP1 (P13497), BOLA2 (Q9H3K6), BOP1 (Q14137), BPGM (P07738), BPNT1 (O95861), BRCC3 (P46736), BRE (Q9NXR7), BRIX1 (Q8TDN6), BROX (Q5VW32), BRP16L (POCB43), BSG (P35613), BST1 (Q10588), BTAF1 (O14981), BUB3 (O43684), BUD31 (P41223), BYSL (Q13895), BZW1 (Q7L1Q6), BZW2 (Q9Y6E2), C10orf119 (Q9BTE3), C10orf58 (Q9BRX8), C10orf76 (Q5T2E6), C11orf54 (Q9H0W9), C11orf68 (Q9H3H3), C12orf10 (Q9HB07), C12orf57 (Q99622), C14orf149 (Q96EM0), C14orf166 (Q9Y224), C14orf21 (Q86U38), C15orf58 (Q6ZNW5), C16orf13 (Q96S19), C16orf61 (Q9NRP2), C16orf80 (Q9Y6A4), C18orf21 (Q32NC0), C18orf8 (Q96DM3), C1orf123 (Q9NWV4), C1orf128 (Q9GZP4), C1orf57 (Q9BSD7), C20orf11 (Q9NWU2), C20orf4 (Q9Y312), C21orf33 (P30042), C21orf59 (P57076), C22orf28 (Q9Y3I0), C3orf10 (Q8WUW1), C3orf26 (Q9BQ75), C3orf75 (Q0PNE2), C4orf27 (Q9NWY4), C4orf41 (Q7Z392), C4orf43 (Q96EY4), C5orf33 (Q4G0N4), C6orf211 (Q9H993), C7orf28B (P86790), C7orf50 (Q9BRJ6), C7orf59 (Q0VGL1), C8orf33 (Q9H7E9), C9orf142 (Q9BUH6), C9orf23 (Q8N5L8), C9orf41 (Q8N4J0), C9orf64 (Q5T6V5), CA11 (O75493), CA12 (O43570), CA2 (P00918), CAB39 (Q9Y376), CACNA2D1 (P54289), CACYBP (Q9HB71), CAD (P27708), CADM1 (Q9BY67), CADM4 (Q8NFZ8), CALB1 (P05937), CALD1 (Q05682), CALM1 (P62158), CALR (P27797), CALU (O43852), CAMK1 (Q14012), CAMK2D (Q13557), CAMKV (Q8NCB2), CAND1 (Q86VP6), CANX (P27824), CAP1 (Q01518), CAPN1 (P07384), CAPN2 (P17655), CAPN5 (O15484), CAPN7 (Q9Y6W3), CAPNS1 (P04632), CAPRIN1 (Q14444), CAPS (Q13938), CAPZA1 (P52907), CAPZA2 (P47755), CAPZB (P47756), CARHSP1 (Q9Y2V2), CARKD (Q8IW45), CARM1 (Q86X55), CARS (P49589), CASK (O14936), CASP14 (P31944), CASP3 (P42574), CASP7 (P55210), CAT (P04040), CBFB (Q13951), CBR1 (P16152), CBR3 (O75828), CBS (P35520), CBX1 (P83916), CBX3 (Q13185), CBX5 (P45973), CC2D1A (Q6P1N0), CCAR1 (Q8IX12), CCBL2 (Q6YP21), CCDC102B (Q68D86), CCDC22 (O60826), CCDC25 (Q86WR0), CCDC93 (Q567U6), CCND2 (P30279), CCNY (Q8ND76), CCT2 (P78371), CCT3 (P49368), CCT4 (P50991), CCT5 (P48643), CCT6A (P40227), CCT7 (Q99832), CCT8 (P50990), CD109 (Q6YHK3), CD151 (P48509), CD276 (Q5ZPR3), CD44 (P16070), CD46 (P15529), CD47 (Q08722), CD58 (P19256), CD59 (P13987), CD63 (P08962), CD81 (P60033), CD9 (P21926), CD97 (P48960), CD99 (P14209), CDC123 (O75794), CDC16 (Q13042), CDC23 (Q9UJX2), CDC34 (P49427), CDC37 (Q16543), CDC40 (O60508), CDC42 (P60953), CDC42BPB (Q9Y5S2), CDC5L (Q99459), CDCP1 (Q9H5V8), CDH2 (P19022), CDK1 (P06493), CDK2 (P24941), CDK4 (P11802), CDK5 (Q00535), CDK5RAP3 (Q96JB5), CDK7 (P50613), CDKN2A (P42771), CDKN2AIP (Q9NXV6), CECR5 (Q9BXW7), CELF1 (Q92879), CELSR1 (Q9NYQ6), CELSR2 (Q9HCU4), CFL1 (P23528), CFL2 (Q9Y281), CHCHD3 (Q9NX63), CHD4 (Q14839), CHEK2 (O96017), CHERP (Q8IWX8), CHID1 (Q9BWS9), CHMP1A (Q9HD42), CHMP1B (Q7LBR1), CHMP2A (O43633), CHMP4A (Q9BY43), CHMP4B (Q9H444), CHMP5 (Q9NZZ3), CHMP6 (Q96FZ7), CHN1 (P15882), CHORDC1 (Q9UHD1), CHP (Q99653), CHRAC1 (Q9NRG0), CHST3 (Q7LGC8), CIAO1 (O76071), CIAPIN1 (Q6FI81), CIRBP (Q14011), CIRH1A (Q969X6), CISD2 (Q8N5K1), CKAP4 (Q07065), CKAP5 (Q14008), CKB (P12277), CLASP1 (Q7Z460), CLIC1 (O00299), CLIC4 (Q9Y696), CLLD6 (Q5W111), CLNS1A (P54105), CLPB (Q9H078), CLTA (P09496), CLTC (Q00610), CLTCL1 (P53675), CLU (P10909), CMBL (Q96DG6), CMC1 (Q7Z7K0), CMPK1 (P30085), CMTM6 (Q9NX76), CNBP (P62633), CNDP2 (Q96KP4), CNN2 (Q99439), CNN3 (Q15417), CNNM3 (Q8NE01), CNOT1 (A5YKK6), CNOT10 (Q9H9A5), CNOT6L (Q96LI5), CNP (P09543), COASY (Q13057), COBRA1 (Q8WX92), COG1 (Q8WTW3), COG3 (Q96JB2), COG4 (Q9H9E3), COG5 (Q9UP83), COG6 (Q9Y2V7), COL11A1 (P12107), COL14A1 (Q05707), COL18A1 (P39060), COL6A1 (P12109), COMMD10 (Q9Y6G5), COMMD2 (Q86X83), COMMD3 (Q9UBI1), COMMD5 (Q9GZQ3), COMMD8 (Q9NX08), COMMD9 (Q9P000), COMT (P21964), COPA (P53621), COPB1 (P53618), COPB2 (P35606), COPE (O14579), COPG (Q9Y678), COPG2 (Q9UBF2), COPS2 (P61201), COPS3 (Q9UNS2), COPS4 (Q9BT78), COPS5 (Q92905), COPS6 (Q7L5N1), COPS7A (Q9UBW8), COPS7B (Q9H9Q2), COPS8 (Q99627), CORO1B (Q9BR76), CORO1C (Q9ULV4), CORO2B (Q9UQ03), CORO7 (P57737), COTL1 (Q14019), COX4NB (O43402), COX5A (P20674), COX5B (P10606), COX6C (P09669), CP (P00450), CPD (O75976), CPNE1 (Q99829), CPNE2 (Q96FN4), CPNE3 (O75131), CPNE4 (Q96A23), CPNE7 (Q9UBL6), CPOX (P36551), CPSF1 (Q10570), CPSF2 (Q9P2I0), CPSF3 (Q9UKF6), CPSF3L (Q5TA45), CPSF6 (Q16630), CPSF7 (Q8N684), CPXM1 (Q96SM3), CRABP2 (P29373), CRIP2 (P52943), CRK (P46108), CRLF3 (Q8IUI8), CRNKL1 (Q9BZJ0), CRTAP (O75718), CRYAB (P02511), CRYM (Q14894), CRYZ (Q08257), CRYZL1 (O95825), CS (O75390), CSDE1 (O75534), CSE1L (P55060), CSK (P41240), CSNK1A1 (P48729), CSNK2A1 (P68400), CSNK2A2 (P19784), CSNK2B (P67870), CSRP1 (P21291), CSRP2 (Q16527), CSTB (P04080), CSTF1 (Q05048), CSTF2T (Q9H0L4), CSTF3 (Q12996), CTBP1 (Q13363), CTBP2 (P56545), CTNNA1 (P35221), CTNNAL1 (Q9UBT7), CTNNB1 (P35222), CTNNBL1 (Q8WYA6), CTNND1 (O60716), CTPS (P17812), CTPS2 (Q9NRF8), CTR9 (Q6PD62), CTSC (P53634), CTSD (P07339), CTSF (Q9UBX1), CTSL2 (O60911), CTTN (Q14247), CTU1 (Q7Z7A3), CUL1 (Q13616), CUL2 (Q13617), CUL3 (Q13618), CUL4A (Q13619), CUL4B (Q13620), CUL5 (Q93034), CUL7 (Q14999), CXADR (P78310), CXCL14 (O95715), CXorf26 (Q9BVG4), CXorf38 (Q8TB03), CYB5R3 (P00387), CYC1 (P08574), CYCS (P99999), CYFIP1 (Q7L576), CYFIP2 (Q96F07), CYR61 (O00622), DAB1 (O75553), DAD1 (P61803), DAG1 (Q14118), DAK (Q3LXA3), DAPK3 (O43293), DARS (P14868), DAZAP1 (Q96EP5), DBI (P07108), DBN1 (Q16643), DBNL (Q9UJU6), DCAF7 (P61962), DCAF8 (Q5TAQ9), DCBLD2 (Q96PD2), DCK (P27707), DCLK1 (O15075), DCPS (Q96C86), DCTD (P32321), DCTN1 (Q14203), DCTN2 (Q13561), DCTN3 (O75935), DCTN4 (Q9UJW0), DCTN5 (Q9BTE1), DCTN6 (O00399), DCUN1D1 (Q96GG9), DCUN1D3 (Q8IWE4), DCUN1D5 (Q9BTE7), DCXR (Q7Z4W1), DDA1 (Q9BW61), DDAH1 (O94760), DDAH2 (O95865), DDB1 (Q16531), DDB2 (Q92466), DDI2 (Q5TDH0), DDOST (P39656), DDR1 (Q08345), DDT (P30046), DDX1 (Q92499), DDX17 (Q92841), DDX18 (Q9NVP1), DDX19A (Q9NUU7), DDX20 (Q9UHI6), DDX21 (Q9NR30), DDX23 (Q9BUQ8), DDX24 (Q9GZR7), DDX27 (Q96GQ7), DDX39 (O00148), DDX3X (O00571), DDX46 (Q7L014), DDX47 (Q9H0S4), DDX49 (Q9Y6V7), DDX5 (P17844), DDX50 (Q9BQ39), DDX51 (Q8N8A6), DDX52 (Q9Y2R4), DDX54 (Q8TDD1), DDX55 (Q8NHQ9), DDX56 (Q9NY93), DDX6 (P26196), DECR1 (Q16698), DECR2 (Q9NUI1), DEF (Q68CQ4), DEK (P35659), DENR (O43583), DERA (Q9Y315), DFFA (O00273), DFFB (O76075), DHCR24 (Q15392), DHCR7 (Q9UBM7), DHFR (P00374), DHPS (P49366), DHRS11 (Q6UWP2), DHRS4 (Q9BTZ2), DHX15 (O43143), DHX16 (O60231), DHX29 (Q7Z478), DHX30 (Q7L2E3), DHX32 (Q7L7V1), DHX36 (Q9H2U1), DHX37 (Q8IY37), DHX38 (Q92620), DHX9 (Q08211), DIAPH1 (O60610), DIAPH2 (O60879), DIMT1L (Q9UNQ2), DIP2A (Q14689), DIP2B (Q9P265), DIP2C (Q9Y2E4), DIS3 (Q9Y2L1), DIS3L2 (Q8IYB7), DKC1 (O60832), DLAT (P10515), DLD (P09622), DLG1 (Q12959), DLGAP4 (Q9Y2H0), DLST (P36957), DMD (P11532), DNAJA1 (P31689), DNAJA2 (O60884), DNAJB1 (P25685), DNAJB11 (Q9UBS4), DNAJB4 (Q9UDY4), DNAJB6 (O75190), DNAJC13 (O75165), DNAJC2 (Q99543), DNAJC3 (Q13217), DNAJC7 (Q99615), DNASE1L1 (P49184), DNM1 (Q05193), DNM1L (O00429), DNM2 (P50570), DNMT1 (P26358), DNPEP (Q9ULA0), DOCK1 (Q14185), DOCK4 (Q8N1I0), DOCK5 (Q9H7D0), DOCK7 (Q96N67), DOCK9 (Q9BZ29), DOHH (Q9BU89), DPCD (Q9BVM2), DPH2 (Q9BQC3), DPH5 (Q9H2P9), DPM1 (O60762), DPM3 (Q9P2X0), DPP3 (Q9NY33), DPP9 (Q86TI2), DPY30 (Q9C005), DPYSL2 (Q16555), DPYSL3 (Q14195), DPYSL4 (O14531), DPYSL5 (Q9BPU6), DRG1 (Q9Y295), DRG2 (P55039), DSC1 (Q08554), DSG1 (Q02413), DSP (P15924), DST (Q03001), DSTN (P60981), DTD1 (Q8TEA8), DTNA (Q9Y4J8), DTYMK (P23919), DUS2L (Q9NX74), DUS3L (Q96G46), DUSP12 (Q9UNI6), DUSP3 (P51452), DYM (Q7RTS9), DYNC1H1 (Q14204), DYNC1I2 (Q13409), DYNC1LI1 (Q9Y6G9), DYNC1LI2 (O43237), DYNC2H1 (Q8NCM8), DYNLL1 (P63167), DYNLL2 (Q96FJ2), DYNLRB1 (Q9NP97), DYNLT1 (P63172), EBNA1BP2 (Q99848), ECE1 (P42892), ECHDC1 (Q9NTX5), ECHS1 (P30084), ECM29 (Q5VYK3), EDC3 (Q96F86), EDC4 (Q6P2E9), EEA1 (Q15075), EEF1A1 (P68104), EEF1B2 (P24534), EEF1D (P29692), EEF1E1 (O43324), EEF1G (P26641), EEF2 (P13639), EEF2K (O00418), EEFSEC (P57772), EFEMP2 (O95967), EFHD2 (Q96C19), EFTUD1 (Q7Z2Z2), EFTUD2 (Q15029), EGFR (P00533), EHD1 (Q9H4M9), EHD2 (Q9NZN4), EHD3 (Q9NZN3), EHD4 (Q9H223), EIF1AX (P47813), EIF2A (Q9BY44), EIF2AK2 (P19525), EIF2AK4 (Q9P2K8), EIF2B1 (Q14232), EIF2B2 (P49770), EIF2B3 (Q9NR50), EIF2B4 (Q9UI10), EIF2B5 (Q13144), EIF2C1 (Q9UL18), EIF2C2 (Q9UKV8), EIF2S1 (P05198), EIF2S2 (P20042), EIF2S3 (P41091), EIF3A (Q14152), EIF3B (P55884), EIF3C (Q99613), EIF3D (O15371), EIF3E (P60228), EIF3F (O00303), EIF3G (O75821), EIF3H (O15372), EIF3I (Q13347), EIF3J (O75822), EIF3K (Q9UBQ5), EIF3L (Q9Y262), EIF3M (Q7L2H7), EIF4A1 (P60842), EIF4A2 (Q14240), EIF4A3 (P38919), EIF4E (P06730), EIF4G1 (Q04637), EIF4G2 (P78344), EIF4H (Q15056), EIF5 (P55010), EIF5A (P63241), EIF5B (O60841), EIF6 (P56537), ELAC2 (Q9BQ52), ELAVL1 (Q15717), ELMO2 (Q96JJ3), ELP2 (Q6IA86), ELP3 (Q9H9T3), EMD (P50402), EMG1 (Q92979), EML1 (O00423), EML2 (O95834), EML3 (Q32P44), EML4 (Q9HC35), ENAH (Q8N8S7), ENC1 (O14682), ENO1 (P06733), ENO2 (P09104), ENOPH1 (Q9UHY7), ENY2 (Q9NPA8), EPB41L2 (O43491), EPB41L3 (Q9Y2J2), EPDR1 (Q9UM22), EPHA2 (P29317), EPHB2 (P29323), EPHB3 (P54753), EPHB4 (P54760), EPHX1 (P07099), EPM2AIP1 (Q7L775), EPN1 (Q9Y6I3), EPRS (P07814), ERBB2IP (Q96RT1), ERGIC1 (Q969X5), ERH (P84090), ERI1 (Q8IV48), ERI3 (O43414), ERLIN2 (O94905), ERO1L (Q96HE7), ERP29 (P30040), ERP44 (Q9BS26), ESD (P10768), ESYT1 (Q9BSJ8), ETF1 (P62495), ETFA (P13804), ETFB (P38117), EXOC1 (Q9NV70), EXOC2 (Q96KP1), EXOC3 (O60645), EXOC4 (Q96A65), EXOC5 (O00471), EXOC6 (Q8TAG9), EXOC6B (Q9Y2D4), EXOC7 (Q9UPT5), EXOC8 (Q8IYI6), EXOSC1 (Q9Y3B2), EXOSC10 (Q01780), EXOSC2 (Q13868), EXOSC3 (Q9NQT5), EXOSC4 (Q9NPD3), EXOSC5 (Q9NQT4), EXOSC6 (Q5RKV6), EXOSC7 (Q15024), EXOSC8 (Q96B26), EXOSC9 (Q06265), EZR (P15311), F11R (Q9Y624), F8 (P00451), F8A1 (P23610), FABP5 (Q01469), FABP7 (O15540), FADD (Q13158), FAH (P16930), FAHD1 (Q6P587), FAHD2A (Q96GK7), FAM115A (Q9Y4C2), FAM120A (Q9NZB2), FAM125A (Q96EY5), FAM127A (A6ZKI3), FAM129A (Q9BZQ8), FAM129B (Q96TA1), FAM136A (Q96C01), FAM175B (Q15018), FAM3C (Q92520), FAM45B (Q6NSW5), FAM49B (Q9NUQ9), FAM82B (Q96DB5), FAM84B (Q96KN1), FAM96B (Q9Y3D0), FAM98A (Q8NCA5), FAM98B (Q52LJ0), FANCI (Q9NVI1), FAR1 (Q8WVX9), FARP1 (Q9Y4F1), FARP2 (O94887), FARSA (Q9Y285), FARSB (Q9NSD9), FAS (P25445), FASN (P49327), FAT1 (Q14517), FAU (P62861), FBL (P22087), FBLN2 (P98095), FBN1 (P35555), FBN2 (P35556), FBXL18 (Q96ME1), FBXO21 (O94952), FBXO22 (Q8NEZ5), FBXW11 (Q9UKB1), FCF1 (Q9Y324), FDFT1 (P37268), FDPS (P14324), FDXR (P22570), FEN1 (P39748), FERMT1 (Q9BQL6), FERMT2 (Q96AC1), FFR (Q9UID3), FGFBP3 (Q8TAT2), FH (P07954), FHL1 (Q13642), FHL2 (Q14192), FHL3 (Q13643), FIBP (O43427), FKBP10 (Q96AY3), FKBP1A (P62942), FKBP2 (P26885), FKBP3 (Q00688), FKBP4 (Q02790), FKBP5 (Q13451), FLG (P20930), FLG2 (Q5D862), FLII (Q13045), FLNA (P21333), FLNB (O75369), FLNC (Q14315), FLOT1 (O75955), FLOT2 (Q14254), FMNL2 (Q96PY5), FN3K (Q9H479), FN3KRP (Q9HA64), FNTA (P49354), FNTB (P49356), FOLR1 (P15328), FREM2 (Q5SZK8), FRG1 (Q14331), FRMD5 (Q7Z6J6), FRMD8 (Q9BZ67), FRYL (O94915), FSCN1 (Q16658), FSD1 (Q9BTV5), FTH1 (P02794), FTL (P02792), FTO (Q9C0B1), FTSJD2 (Q8N1G2), FUBP1 (Q96AE4), FUBP3 (Q96I24), FUCA2 (Q9BTY2), FUK (Q8N0W3), FUS (P35637), FXR1 (P51114), FXR2 (P51116), FYCO1 (Q9BQS8), FYN (P06241), G3BP1 (Q13283), G3BP2 (Q9UN86), G6PD (P11413), GAA (P10253), GALK1 (P51570), GALK2 (Q01415), GALNT1 (Q10472), GALNT2 (Q10471), GALNT7 (Q86SF2), GAN (Q9H2C0), GANAB (Q14697), GAP43 (P17677), GAPDH (P04406), GAPVD1 (Q14C86), GAR1 (Q9NY12), GARS (P41250), GART (P22102), GATSL2 (A6NHX0), GBA (P04062), GBE1 (Q04446), GBF1 (Q92538), GCDH (Q92947), GCLC (P48506), GCLM (P48507), GCN1L1 (Q92616), GDI1 (P31150), GDI2 (P50395), GEMIN4 (P57678), GEMIN5 (Q8TEQ6), GEMIN6 (Q8WXD5), GET4 (Q7L5D6), GFAP (P14136), GFM1 (Q96RP9), GFPT1 (Q06210), GFPT2 (O94808), GGCT (O75223), GGPS1 (O95749), GINS1 (Q14691), GINS2 (Q9Y248), GINS4 (Q9BRT9), GIPC1 (O14908), GIT1 (Q9Y2X7), GLA (P06280), GLB1L2 (Q8IW92), GLE1 (Q53GS7), GLG1 (Q92896), GLIPR2 (Q9H4G4), GLMN (Q92990), GLO1 (Q04760), GLOD4 (Q9HC38), GLRX (P35754), GLRX3 (O76003), GLT25D1 (Q8NBJ5), GLT25D2 (Q8IYK4), GLTP (Q9NZD2), GLUD1 (P00367), GLUL (P15104), GMDS (O60547), GMFB (P60983), GMPPA (Q96IJ6), GMPPB (Q9Y5P6), GMPR (P36959), GMPR2 (Q9P2T1), GMPS (P49915), GNA11 (P29992), GNA12 (Q03113), GNA13 (Q14344), GNAI1 (P63096), GNAI2 (P04899), GNAI3 (P08754), GNAQ (P50148), GNAS (Q5JWF2), GNB1 (P62873), GNB1L (Q9BYB4), GNB2 (P62879), GNB2L1 (P63244), GNB4 (Q9HAV0), GNE (Q9Y223), GNG10 (P50151), GNG12 (Q9UBI6), GNG4 (P50150), GNG5 (P63218), GNL3 (Q9BVP2), GNPDA1 (P46926), GNPNAT1 (Q96EK6), GOLGA7 (Q7Z5G4), GOLM1 (Q8NBJ4), GOLPH3 (Q9H4A6), GORASP2 (Q9H8Y8), GOT1 (P17174), GOT2 (P00505), GPC1 (P35052), GPC4 (O75487), GPC6 (Q9Y625), GPD1L (Q8N335), GPHN (Q9NQX3), GPI (P06744), GPM6A (P51674), GPN1 (Q9HCN4), GPR50 (Q13585), GPR56 (Q9Y653), GPS1 (Q13098), GPSM1 (Q86YR5), GPX1 (P07203), GPX4 (P36969), GRB2 (P62993), GRHPR (Q9UBQ7), GRP (Q3ZCW2), GRWD1 (Q9BQ67), GSDMA (Q96QA5), GSK3A (P49840), GSK3B (P49841), GSN (P06396), GSPT1 (P15170), GSR (P00390), GSS (P48637), GSTK1 (Q9Y2Q3), GSTM2 (P28161), GSTM3 (P21266), GSTM4 (Q03013), GSTO1 (P78417), GSTP1 (P09211), GSTT2 (P0CG29), GSTZ1 (O43708), GTF2E2 (P29084), GTF2F2 (P13984), GTF2H3 (Q13889), GTF2I (P78347), GTF3C2 (Q8WUA4), GTF3C3 (Q9Y5Q9), GTF3C4 (Q9UKN8), GTPBP1 (O00178), GTPBP4 (Q9BZE4), GUK1 (Q16774), GYG1 (P46976), GYS1 (P13807), H1F0 (P07305), H1FX (Q92522), H2AFX (P16104), H2AFY (O75367), H2AFZ (P0C0S5), HADH (Q16836), HADHA (P40939), HARS (P12081), HAT1 (O14929), HAUS3 (Q68CZ6), HAUS4 (Q9H6D7), HBA1 (P69905), HBB (P68871), HBS1L (Q9Y450), HBXIP (O43504), HCFC1 (P51610), HDAC1 (Q13547), HDAC2 (Q92769), HDDC2 (Q7Z4H3), HDGF (P51858), HDGFRP2 (Q7Z4V5), HDHD2 (Q9H0R4), HDLBP (Q00341), HEATR1 (Q9H583), HEATR2 (Q86Y56), HEBP1 (Q9NRV9), HECTD3 (Q5T447), HERC4 (Q5GLZ8), HEXB (P07686), HGS (O14964), HHIP (Q96QV1), HINT1 (P49773), HINT2 (Q9BX68), HINT3 (Q9NQE9), HIP1R (O75146), HIST1H1B (P16401), HIST1H1C (P16403), HIST1H1D (P16402), HIST1H1E (P10412), HIST1H2AD (P20671), HIST1H2BJ (P06899), HIST1H2BM (Q99879), HIST1H2BO (P23527), HIST1H4A (P62805), HIST2H2AA3 (Q6FI13), HIST2H2AB (Q8IUE6), HIST2H2BE (Q16778), HIST2H3A (Q71DI3), HIST3H2BB (Q8N257), HK1 (P19367), HK2 (P52789), HLA-A (P30443), HLA-A (P01892), HLA-B (P03989), HMGA1 (P17096), HMGB1 (P09429), HMGB2 (P26583), HMGCL (P35914), HMGCS1 (Q01581), HMGN1 (P05114), HMGN2 (P05204), HMGN4 (O00479), HNRNPA0 (Q13151), HNRNPA1 (P09651), HNRNPA2B1 (P22626), HNRNPA3 (P51991), HNRNPAB (Q99729), HNRNPC (P07910), HNRNPD (Q14103), HNRNPF (P52597), HNRNPH1 (P31943), HNRNPH2 (P55795), HNRNPH3 (P31942), HNRNPK (P61978), HNRNPL (P14866), HNRNPM (P52272), HNRNPR (O43390), HNRNPU (Q00839), HNRNPUL1 (Q9BUJ2), HNRNPUL2 (Q1KMD3), HNRPDL (O14979), HNRPLL (Q8WVV9), HOOK3 (Q86VS8), HP (P00738), HP1BP3 (Q5SSJ5), HPCAL1 (P37235), HPRT1 (P00492), HPX (P02790), HRAS (P01112), HRNR (Q86YZ3), HSD17B10 (Q99714), HSD17B12 (Q53GQ0), HSD17B4 (P51659), HSDL2 (Q6YN16), HSP90AA1 (P07900), HSP90AB1 (P08238), HSP90B1 (P14625), HSPA12A (O43301), HSPA14 (Q0VDF9), HSPA1A (P08107), HSPA4 (P34932), HSPA4L (O95757), HSPA5 (P11021), HSPA8 (P11142), HSPA9 (P38646), HSPB1 (P04792), HSPBP1 (Q9NZL4), HSPD1 (P10809), HSPE1 (P61604), HSPG2 (P98160), HSPH1 (Q92598), HTRA1 (Q92743), HTT (P42858), HUWE1 (Q7Z6Z7), HYOU1 (Q9Y4L1), IARS (P41252), ICAM1 (P05362), IDE (P14735), IDH1 (O75874), IDH2 (P48735), IDH3A (P50213), IDI1 (Q13907), IFI16 (Q16666), IFIT5 (Q13325), IFITM3 (Q01628), IFRD2 (Q12894), IFT172 (Q9UG01), IGF1R (P08069), IGF2BP2 (Q9Y6M1), IGF2BP3 (O00425), IGF2R (P11717), IGFBP3 (P17936), IGFBP5 (P24593), IGHG1 (P01857), IGHG2 (P01859), IGSF3 (O75054), IGSF8 (Q969P0), IKBKAP (O95163), IKBKB (O14920), IL1RAP (Q9NPH3), ILF2 (Q12905), ILF3 (Q12906), ILK (Q13418), ILKAP (Q9H0C8), IMMT (Q16891), IMP3 (Q9NV31), IMPA1 (P29218), IMPA2 (O14732), IMPAD1 (Q9NX62), IMPDH1 (P20839), IMPDH2 (P12268), INA (Q16352), INF2 (Q27J81), INPP1 (P49441), INPPL1 (O15357), INTS10 (Q9NVR2), INTS3 (Q68E01), INTS7 (Q9NVH2), INTS8 (Q75QN2), IPO11 (Q9UI26), IPO4 (Q8TEX9), IPO5 (O00410), IPO7 (O95373), IPO8 (O15397), IPO9 (Q96P70), IQGAP1 (P46940), IRF2BP2 (Q7Z5L9), IRF3 (Q14653), IRGQ (Q8WZA9), ISOC1 (Q96CN7), ISYNA1 (Q9NPH2), ITFG3 (Q9H0X4), ITGA2 (P17301), ITGA3 (P26006), ITGA4 (P13612), ITGA5 (P08648), ITGA6 (P23229), ITGA7 (Q13683), ITGAV (P06756), ITGB1 (P05556), ITGB1BP1 (O14713), ITGB3 (P05106), ITGB4 (P16144), ITGB5 (P18084), ITGB8 (P26012), ITPA (Q9BY32), JAM3 (Q9BX67), JUP (P14923), KARS (Q15046), KATNB1 (Q9BVA0), KBTBD6 (Q86V97), KCTD21 (Q4G0X4), KDM1A (O60341), KEAP1 (Q14145), KHDRBS1 (Q07666), KHSRP (Q92945), KIAA0020 (Q15397), KIAA0090 (Q8N766), KIAA0174 (P53990), KIAA0196 (Q12768), KIAA0664 (O75153), KIAA0776 (O94874), KIAA1033 (Q2M389), KIAA1279 (Q96EK5), KIAA1598 (A0MZ66), KIAA1797 (Q5VW36), KIAA1949 (Q6NYC8), KIAA1967 (Q8N163), KIDINS220 (Q9ULH0), KIF1A (Q12756), KIF2A (O00139), KIF5B (P33176), KIF5C (O60282), KLC1 (Q07866), KLHDC4 (Q8TBB5), KLHL13 (Q9P2N7), KLHL22 (Q53GT1), KLHL26 (Q53HC5), KNTC1 (P50748), KPNA1 (P52294), KPNA2 (P52292), KPNA3 (O00505), KPNA4 (O00629), KPNA6 (O60684), KPNB1 (Q14974), KPRP (Q5T749), KRAS (P01116), KRIT1 (O00522), KRT13 (P13646), KRT14 (P02533), KRT71 (Q3SY84), KTN1 (Q86UP2), L1CAM (P32004), LACTB2 (Q53H82), LAMA1 (P25391), LAMA4 (Q16363), LAMA5 (O15230), LAMB1 (P07942), LAMB2 (P55268), LAMC1 (P11047), LAMP1 (P11279), LAMP2 (P13473), LANCL1 (O43813), LANCL2 (Q9NS86), LAP3 (P28838), LARP1 (Q6PKG0), LARS (Q9P2J5), LAS1L (Q9Y4W2), LASP1 (Q14847), LBR (Q14739), LCMT1 (Q9UIC8), LDHA (P00338), LDHB (P07195), LDLR (P01130), LEFTY2 (O00292), LEPRE1 (Q32P28), LGALS1 (P09382), LGALS3 (P17931), LGALS3BP (Q08380), LGALS7 (P47929), LIMA1 (Q9UHB6), LIMS1 (P48059), LIN7C (Q9NUP9), LIPG (Q9Y5X9), LLGL1 (Q15334), LMAN1 (P49257), LMAN2 (Q12907), LMCD1 (Q9NZU5), LMNA (P02545), LMNB1 (P20700), LMNB2 (Q03252), LNPEP (Q9UIQ6), LOH12CR1 (Q969J3), LONP1 (P36776), LOR (P23490), LOXL4 (Q96JB6), LPHN2 (O95490), LPL (P06858), LRBA (P50851), LRG1 (P02750), LRP1 (Q07954), LRPPRC (P42704), LRRC1 (Q9BTT6), LRRC40 (Q9H9A6), LRRC47 (Q8N1G4), LRRC57 (Q8N9N7), LRRC59 (Q96AG4), LRRC8A (Q8IWT6), LRSAM1 (Q6UWE0), LSM1 (O15116), LSM12 (Q3MHD2), LSM2 (Q9Y333), LSM4 (Q9Y4Z0), LSM6 (P62312), LSM7 (Q9UK45), LSS (P48449), LTA4H (P09960), LTBP2 (Q14767), LTBP3 (Q9NS15), LTN1 (O94822), LUC7L (Q9NQ29), LUC7L2 (Q9Y383), LUC7L3 (O95232), LYAR (Q9NX58), LYPLA1 (O75608), LYPLA2 (O95372), LYPLAL1 (Q5VWZ2), LZTR1 (Q8N653), M6PR (P20645), MACF1 (Q9UPN3), MACF1 (Q96PK2), MACROD1 (Q9BQ69), MAD1L1 (Q9Y6D9), MAD2L1 (Q13257), MAGEE1 (Q9HCI5), MAK16 (Q9BXY0), MALT1 (Q9UDY8), MAN1A2 (O60476), MAN1B1 (Q9UKM7), MAN2C1 (Q9NTJ4), MAP1B (P46821), MAP1LC3A (Q9H492), MAP1LC3B2 (A6NCE7), MAP2K1 (Q02750), MAP2K2 (P36507), MAP2K3 (P46734), MAP2K4 (P45985), MAP2K7 (O14733), MAP4 (P27816), MAP4K4 (O95819), MAPK1 (P28482), MAPK14 (Q16539), MAPK3 (P27361), MAPKSP1 (Q9UHA4), MAPRE1 (Q15691), MAPRE3 (Q9UPY8), MARCKS (P29966), MARCKSL1 (P49006), MARK2 (Q7KZI7), MARS (P56192), MAT2A (P31153), MAT2B (Q9NZL9), MATR3 (P43243), MBD3 (O95983), MBLAC2 (Q68D91), MBNL1 (Q9NR56), MBNL2 (Q5VZF2), MCAM (P43121), MCM2 (P49736), MCM3 (P25205), MCM4 (P33991), MCM5 (P33992), MCM6 (Q14566), MCM7 (P33993), MCTS1 (Q9ULC4), MDH1 (P40925), MDH2 (P40926), MDK (P21741), MDN1 (Q9NU22), ME1 (P48163), ME2 (P23368), MED1 (Q15648), MED10 (Q9BTT4), MED11 (Q9P086), MED17 (Q9NVC6), MED18 (Q9BUE0), MED20 (Q9H944), MED23 (Q9ULK4), MED24 (O75448), MED28 (Q9H204), MED31 (Q9Y3C7), MEMO1 (Q9Y316), MEN1 (O00255), MERIT40 (Q9NWV8), METAP1 (P53582), METAP2 (P50579), METT10D (Q86W50), METTL1 (Q9UBP6), METTL11A (Q9BV86), METTL13 (Q8N6R0), METTL2B (Q6P1Q9), METTL5 (Q9NRN9), METTL9 (Q9H1A3), MFAP2 (P55001), MFAP4 (P55083), MFGE8 (Q08431), MFI2 (P08582), MGEA5 (O60502), MICA (Q29983), MICAL1 (Q8TDZ2), MIF (P14174), MINA (Q8IUF8), MIOS (Q9NXC5), MKI67IP (Q9BYG3), MLEC (Q14165), MLLT4 (P55196), MLST8 (Q9BVC4), MLTK (Q9NYL2), MMP14 (P50281), MMP2 (P08253), MMS19 (Q96T76), MOB2 (Q70IA6), MOBKL1B (Q9H8S9), MOBKL2A (Q96BX8), MOBKL3 (Q9Y3A3), MOCS2 (O96033), MOGS (Q13724), MON2 (Q7Z3U7), MORC2 (Q9Y6X9), MOV10 (Q9HCE1), MOXD1 (Q6UVY6), MPG (P29372), MPI (P34949), MPP6 (Q9NZW5), MPRIP (Q6WCQ1), MPST (P25325), MPZL1 (O95297), MRC2 (Q9UBG0), MRE11A (P49959), MRI1 (Q9BV20), MRPS27 (Q92552), MRPS28 (Q9Y2Q9), MRPS33 (Q9Y291), MRPS34 (P82930), MRPS6 (P82932), MRTO4 (Q9UKD2), MSH2 (P43246), MSH3 (P20585), MSH6 (P52701), MSN (P26038), MSTO1 (Q9BUK6), MTA1 (Q13330), MTA2 (O94776), MTAP (Q13126), MTHFD1 (P11586), MTHFS (P49914), MTM1 (Q13496), MTMR1 (Q13613), MTMR2 (Q13614), MTMR6 (Q9Y217), MTMR9 (Q96QG7), MTOR (P42345), MTPN (P58546), MTR (Q99707), MTRR (Q9UBK8), MVD (P53602), MVK (Q03426), MVP (Q14764), MX1 (P20591), MYADM (Q96S97), MYBBP1A (Q9BQG0), MYCBP (Q99417), MYD88 (Q99836), MYH10 (P35580), MYH14 (Q7Z406), MYH9 (P35579), MYL12B (O14950), MYL6 (P60660), MYO18A (Q92614), MYO1B (O43795), MYO1C (O00159), MYO1E (Q12965), MYO5A (Q9Y4I1), MYO6 (Q9UM54), MYOF (Q9NZM1), NAA10 (P41227), NAA15 (Q9BXJ9), NAA16 (Q6N069), NAA25 (Q14CX7), NAA38 (O95777), NAA50 (Q9GZZ1), NACA (Q13765), NAE1 (Q13564), NAGK (Q9UJ70), NAGLU (P54802), NAMPT (P43490), NANS (Q9NR45), NAP1L1 (P55209), NAP1L4 (Q99733), NAPA (P54920), NAPG (Q99747), NAPRT1 (Q6XQN6), NARFL (Q9H6Q4), NARS (O43776), NASP (P49321), NAT10 (Q9H0A0), NAT9 (Q9BTE0), NCAM1 (P13591), NCAN (O14594), NCAPD2 (Q15021), NCAPG (Q9BPX3), NCBP1 (Q09161), NCCRP1 (Q6ZVX7), NCDN (Q9UBB6), NCKAP1 (Q9Y2A7), NCKIPSD (Q9NZQ3), NCL (P19338), NCLN (Q969V3), NCS1 (P62166), NCSTN (Q92542), NDOR1 (Q9UHB4), NDRG3 (Q9UGV2), NDRG4 (Q9ULP0), NDUFA2 (O43678), NDUFA7 (O95182), NDUFAB1 (O14561), NDUFB4 (O95168), NDUFC2 (O95298), NDUFS5 (O43920), NDUFS6 (O75380), NEDD8 (Q15843), NEFL (P07196), NEFM (P07197), NEK6 (Q9HC98), NEK9 (Q8TD19), NES (P48681), NF1 (P21359), NF2 (P35240), NFIX (Q14938), NHLRC2 (Q8NBF2), NHP2L1 (P55769), NID1 (P14543), NIP7 (Q9Y221), NIPSNAP1 (Q9BPW8), NIT1 (Q86X76), NIT2 (Q9NQR4), NKRF (O15226), NLE1 (Q9NVX2), NLGN4X (Q8N0W4), NLN (Q9BYT8), NMD3 (Q96D46), NME2 (P22392), NME3 (Q13232), NME7 (Q9Y5B8), NMT1 (P30419), NNMT (P40261), NOB1 (Q9ULX3), NOC2L (Q9Y3T9), NOC3L (Q8WTT2), NOC4L (Q9BVI4), NOG (Q13253), NOL11 (Q9H8H0), NOL6 (Q9H6R4), NOL9 (Q5SY16), NOMO2 (Q5JPE7), NONO (Q15233), NOP10 (Q9NPE3), NOP16 (Q9Y3C1), NOP2 (P46087), NOP56 (O00567), NOP58 (Q9Y2X3), NOS1AP (O75052), NOSIP (Q9Y314), NOTCH2 (Q04721), NOVA2 (Q9UNW9), NPC1 (O15118), NPC2 (P61916), NPEPPS (P55786), NPLOC4 (Q8TAT6), NPM1 (P06748), NPTN (Q9Y639), NPW (Q8N729), NQO1 (P15559), NQO2 (P16083), NRAS (P01111), NRBP1 (Q9UHY1), NRD1 (O43847), NRP1 (O14786), NRP2 (O60462), NSDHL (Q15738), NSF (P46459), NSUN2 (Q08J23), NSUN5 (Q96P11), NSUN6 (Q8TEA1), NT5C (Q8TCD5), NT5C2 (P49902), NT5C3L (Q969T7), NT5E (P21589), NTN1 (O95631), NUBP1 (P53384), NUBP2 (Q9Y5Y2), NUCB1 (Q02818), NUCKS1 (Q9H1E3), NUDC (Q9Y266), NUDCD1 (Q96RS6), NUDCD2 (Q8WVJ2), NUDT1 (P36639), NUDT10 (Q8NFP7), NUDT16 (Q96DE0), NUDT16L1 (Q9BRJ7), NUDT21 (O43809), NUDT4 (Q9NZJ9), NUDT5 (Q9UKK9), NUMA1 (Q14980), NUP188 (Q5SRE5), NUP210 (Q8TEM1), NUP37 (Q8NFH4), NUP43 (Q8NFH3), NUP54 (Q7Z3B4), NUP62 (P37198), NUP85 (Q9BW27), NUP88 (Q99567), NUP93 (Q8N1F7), NUTF2 (P61970), NXF1 (Q9UBU9), NXN (Q6DKJ4), NXT1 (Q9UKK6), OAT (P04181), OBSL1 (O75147), OCRL (Q01968), ODR4 (Q5SWX8), ODZ2 (Q9NT68), ODZ3 (Q9P273), OGFOD1 (Q8N543), OGT (O15294), OLA1 (Q9NTK5), OLFML3 (Q9NRN5), OPA1 (O60313), ORC3 (Q9UBD5), OSBP (P22059), OSBPL6 (Q9BZF3), OSGEP (Q9NPF4), OTUB1 (Q96FW1), OVCA2 (Q8WZ82), OXCT1 (P55809), OXSR1 (O95747), P4HA1 (P13674), P4HB (P07237), PA2G4 (Q9UQ80), PAAF1 (Q9BRP4), PABPC1 (P11940), PABPC4 (Q13310), PABPN1 (Q86U42), PACSIN2 (Q9UNF0), PACSIN3 (Q9UKS6), PAF1 (Q8N7H5), PAFAH1B1 (P43034), PAFAH1B2 (P68402), PAFAH1B3 (Q15102), PAICS (P22234), PAIP1 (Q9H074), PAK1IP1 (Q9NWT1), PAK2 (Q13177), PALD (Q9ULE6), PALLD (Q8WX93), PANK4 (Q9NVE7), PAPOLA (P51003), PAPSS1 (O43252), PARK7 (Q99497), PARN (O95453), PARP1 (P09874), PARP4 (Q9UKK3), PARVA (Q9NVD7), PBLD (P30039), PCBD1 (P61457), PCBP1 (Q15365), PCBP2 (Q15366), PCDHB2 (Q9Y5E7), PCDHGC3 (Q9UN70), PCID2 (Q5JVF3), PCMT1 (P22061), PCNA (P12004), PCOLCE2 (Q9UKZ9), PCYOX1 (Q9UHG3), PCYOX1L (Q8NBM8), PCYT2 (Q99447), PDCD10 (Q9BUL8), PDCD11 (Q14690), PDCD4 (Q53EL6), PDCD5 (O14737), PDCD6 (O75340), PDCD6IP (Q8WUM4), PDCL3 (Q9H2J4), PDDC1 (Q8NB37), PDE12 (Q6L8Q7), PDGFRA (P16234), PDIA3 (P30101), PDIA4 (P13667), PDIA5 (Q14554), PDIA6 (Q15084), PDLIM1 (O00151), PDLIM4 (P50479), PDLIM5 (Q96HC4), PDLIM7 (Q9NR12), PDRO (Q6IAA8), PDS5A (Q29RF7), PDS5B (Q9NTI5), PDXK (O00764), PDXP (Q96GD0), PEA15 (Q15121), PEBP1 (P30086), PECI (O75521), PEF1 (Q9UBV8), PELO (Q9BRX2), PELP1 (Q8IZL8), PEPD (P12955), PES1 (O00541), PFAS (O15067), PFDN1 (O60925), PFDN2 (Q9UHV9), PFDN4 (Q9NQP4), PFDN5 (Q99471), PFDN6 (O15212), PFKL (P17858), PFKM (P08237), PFKP (Q01813), PFN1 (P07737), PFN2 (P35080), PGAM1 (P18669), PGAM5 (Q96HS1), PGD (P52209), PGGT1B (P53609), PGK1 (P00558), PGLS (O95336), PGLYRP2 (Q96PD5), PGM1 (P36871), PGM2L1 (Q6PCE3), PGM3 (O95394), PGP (A6NDG6), PGRMC1 (O00264), PGRMC2 (O15173), PHB (P35232), PHB2 (Q99623), PHF5A (Q7RTV0), PHF6 (Q8IWS0), PHGDH (O43175), PHKB (Q93100), PHLDA1 (Q8WV24), PHLDA3 (Q9Y5J5), PHLDB1 (Q86UU1), PHPT1 (Q9NRX4), PI15 (O43692), PI4KA (P42356), PICALM (Q13492), PIGT (Q969N2), PIK3CA (P42336), PIK3R4 (Q99570), PIN1 (Q13526), PIP4K2A (P48426), PIP4K2B (P78356), PIP4K2C (Q8TBX8), PIPOX (Q9P0Z9), PIPSL (A2A3N6), PITPNB (P48739), PKM2 (P14618), PKP1 (Q13835), PLAA (Q9Y263), PLCB3 (Q01970), PLCD1 (P51178), PLCD3 (Q8N3E9), PLCG1 (P19174), PLCG2 (P16885), PLD3 (Q8IV08), PLEC (Q15149), PLIN2 (Q99541), PLIN3 (O60664), PLK1 (P53350), PLOD1 (Q02809), PLOD2 (O00469), PLOD3 (O60568), PLRG1 (O43660), PLS1 (Q14651), PLS3 (P13797), PLSCR3 (Q9NRY6), PLTP (P55058), PLXNA1 (Q9UIW2), PLXNB2 (O15031), PLXND1 (Q9Y4D7), PMM2 (O15305), PMPCA (Q10713), PMPCB (O75439), PMVK (Q15126), PNMA2 (Q9UL42), PNN (Q9H307), PNO1 (Q9NRX1), PNP (P00491), PNPLA2 (Q96AD5), PODXL (O00592), POLD1 (P28340), POLD2 (P49005), POLE3 (Q9NRF9), POLR1A (O95602), POLR1B (Q9H9Y6), POLR1C (O15160), POLR1D (Q9Y2S0), POLR2A (P24928), POLR2B (P30876), POLR2C (P19387), POLR2E (P19388), POLR2G (P62487), POLR2H (P52434), POLR2J (P52435), POLR2K (P53803), POLR3A (O14802), POLR3B (Q9NW08), POLR3C (Q9BUI4), POP1 (Q99575), POP4 (O95707), POP7 (O75817), POR (P16435), PPA1 (Q15181), PPA2 (Q9H2U2), PPAN (Q9NQ55), PPAP2A (O14494), PPAT (Q06203), PPCS (Q9HAB8), PPFIBP1 (Q86W92), PPIA (P62937), PPIB (P23284), PPIC (P45877), PPID (Q08752), PPIF (P30405), PPIH (O43447), PPIL1 (Q9Y3C6), PPM1F (P49593), PPM1G (O15355), PPME1 (Q9Y570), PPP1CA (P62136), PPP1CB (P62140), PPP1CC (P36873), PPP1R14B (Q96C90), PPP1R7 (Q15435), PPP1R8 (Q12972), PPP2CA (P67775), PPP2CB (P62714), PPP2R1A (P30153), PPP2R2A (P63151), PPP2R2D (Q66LE6), PPP2R4 (Q15257), PPP2R5D (Q14738), PPP2R5E (Q16537), PPP3CA (Q08209), PPP4C (P60510), PPP4R1 (Q8TF05), PPP5C (P53041), PPP6C (O00743), PPP6R3 (Q5H9R7), PPPDE2 (Q6ICB0), PPT1 (P50897), PPWD1 (Q96BP3), PRCP (P42785), PRDX1 (Q06830), PRDX2 (P32119), PRDX3 (P30048), PRDX4 (Q13162), PRDX6 (P30041), PREP (P48147), PREPL (Q4J6C6), PRIM1 (P49642), PRIM2 (P49643), PRKAA1 (Q13131), PRKACA (P17612), PRKACB (P22694), PRKAG1 (P54619), PRKAR1A (P10644), PRKAR2A (P13861), PRKCA (P17252), PRKCI (P41743), PRKCSH (P14314), PRKDC (P78527), PRKRA (O75569), PRMT1 (Q99873), PRMT10 (Q6P2P2), PRMT3 (O60678), PRMT5 (O14744), PRMT7 (Q9NVM4), PROSC (O94903), PRPF19 (Q9UMS4), PRPF3 (O43395), PRPF31 (Q8WWY3), PRPF4 (O43172), PRPF40A (O75400), PRPF4B (Q13523), PRPF6 (O94906), PRPF8 (Q6P2Q9), PRPS1 (P60891), PRPS2 (P11908), PRPSAP2 (O60256), PRRC1 (Q96M27), PRSS23 (O95084), PRTFDC1 (Q9NRG1), PSAP (P07602), PSAT1 (Q9Y617), PSD3 (Q9NYI0), PSENEN (Q9NZ42), PSIP1 (O75475), PSMA1 (P25786), PSMA2 (P25787), PSMA3 (P25788), PSMA4 (P25789), PSMA5 (P28066), PSMA6 (P60900), PSMA7 (O14818), PSMB1 (P20618), PSMB2 (P49721), PSMB3 (P49720), PSMB4 (P28070), PSMB5 (P28074), PSMB6 (P28072), PSMB7 (Q99436), PSMC1 (P62191), PSMC2 (P35998), PSMC3 (P17980), PSMC4 (P43686), PSMC5 (P62195), PSMC6 (P62333), PSMD1 (Q99460), PSMD10 (O75832), PSMD11 (O00231), PSMD12 (O00232), PSMD13 (Q9UNM6), PSMD14 (O00487), PSMD2 (Q13200), PSMD3 (O43242), PSMD4 (P55036), PSMD5 (Q16401), PSMD6 (Q15008), PSMD7 (P51665), PSMD8 (P48556), PSMD9 (O00233), PSME1 (Q06323), PSME2 (Q9UL46), PSME3 (P61289), PSME4 (Q14997), PSMG1 (O95456), PSMG2 (Q969U7), PSPC1 (Q8WXF1), PSPH (P78330), PTBP1 (P26599), PTGES2 (Q9H7Z7), PTGES3 (Q15185), PTGFRN (Q9P2B2), PTGR1 (Q14914), PTHLH (P12272), PTK2 (Q05397), PTK7 (Q13308), PTMA (P06454), PTN (P21246), PTP4A1 (Q93096), PTPN1 (P18031), PTPN11 (Q06124), PTPN23 (Q9H3S7), PTPRA (P18433), PTPRE (P23469), PTPRG (P23470), PTPRJ (Q12913), PTPRZ1 (P23471), PUF60 (Q9UHX1), PURA (Q00577), PURB (Q96QR8), PUS1 (Q9Y606), PUS7 (Q96PZ0), PVR (P15151), PVRL2 (Q92692), PWP1 (Q13610), PWP2 (Q15269), PXDN (Q92626), PXK (Q7Z7A4), PXN (P49023), PYCR1 (P32322), PYCRL (Q53H96), PYGB (P11216), PYGL (P06737), QARS (P47897), QDPR (P09417), QKI (Q96PU8), QTRT1 (Q9BXR0), RAB10 (P61026), RAB11A (P62491), RAB11FIP1 (Q6WKZ4), RAB12 (Q6IQ22), RAB13 (P51153), RAB14 (P61106), RAB18 (Q9NP72), RAB1A (P62820), RAB1B (Q9H0U4), RAB21 (Q9UL25), RAB22A (Q9UL26), RAB23 (Q9ULC3), RAB27A (P51159), RAB2A (P61019), RAB2B (Q8WUD1), RAB32 (Q13637), RAB34 (Q9BZG1), RAB35 (Q15286), RAB3A (P20336), RAB3GAP1 (Q15042), RAB3GAP2 (Q9H2M9), RAB4A (P20338), RAB5A (P20339), RAB5B (P61020), RAB5C (P51148), RAB6A (P20340), RAB7A (P51149), RAB8A (P61006), RAB8B (Q92930), RABAC1 (Q9UI14), RABGAP1 (Q9Y3P9), RABGGTA (Q92696), RABGGTB (P53611), RABL2A (Q9UBK7), RABL3 (Q5HYI8), RAC1 (P63000), RAC3 (P60763), RAD23B (P54727), RAD50 (Q92878), RAE1 (P78406), RAF1 (P04049), RALA (P11233), RALB (P11234), RALY (Q9UKM9), RAN (P62826), RANBP1 (P43487), RANBP2 (P49792), RANGAP1 (P46060), RAP1A (P62834), RAP1B (P61224), RAP1GDS1 (P52306), RAP2B (P61225), RAPH1 (Q70E73), RARS (P54136), RASA1 (P20936), RASA3 (Q14644), RBBP4 (Q09028), RBBP5 (Q15291), RBBP7 (Q16576), RBM12 (Q9NTZ6), RBM14 (Q96PK6), RBM15 (Q96T37), RBM22 (Q9NW64), RBM25 (P49756), RBM26 (Q5T8P6), RBM28 (Q9NW13), RBM39 (Q14498), RBM4 (Q9BWF3), RBM8A (Q9Y5S9), RBMX (P38159), RBP1 (P09455), RBPJ (Q06330), RBX1 (P62877), RCC1 (P18754), RCC2 (Q9P258), RCL (O43598), RCL1 (Q9Y2P8), RCN1 (Q15293), RDH11 (Q8TC12), RDH13 (Q8NBN7), RDX (P35241), RECQL (P46063), RELA (Q04206), REPS1 (Q96D71), RETSAT (Q6NUM9), RFC2 (P35250), RFC3 (P40938), RFC4 (P35249), RFC5 (P40937), RFFL (Q8WZ73), RFTN1 (Q14699), RHEB (Q15382), RHOA (P61586), RHOB (P62745), RHOC (P08134), RHOF (Q9HBH0), RHOG (P84095), RHOT2 (Q8IXI1), RIC8A (Q9NPQ8), RNASEH2C (Q8TDP1), RNF114 (Q9Y508), RNF20 (Q5VTR2), RNF213 (Q63HN8), RNF7 (Q9UBF6), RNGTT (O60942), RNH1 (P13489), RNMT (O43148), RNPEP (Q9H4A4), ROBLD3 (Q9Y2Q5), ROCK1 (Q13464), ROCK2 (O75116), RP2 (O75695), RPA1 (P27694), RPA2 (P15927), RPA3 (P35244), RPE (Q96AT9), RPF2 (Q9H7B2), RPIA (P49247), RPL10 (P27635), RPL10A (P62906), RPL11 (P62913), RPL12 (P30050), RPL13 (P26373), RPL13A (P40429), RPL14 (P50914), RPL15 (P61313), RPL17 (P18621), RPL18 (Q07020), RPL18A (Q02543), RPL19 (P84098), RPL21 (P46778), RPL22 (P35268), RPL22L1 (Q6P5R6), RPL23 (P62829), RPL23A (P62750), RPL24 (P83731), RPL26 (P61254), RPL26L1 (Q9UNX3), RPL27 (P61353), RPL27A (P46776), RPL28 (P46779), RPL29 (P47914), RPL3 (P39023), RPL30 (P62888), RPL31 (P62899), RPL32 (P62910), RPL34 (P49207), RPL35 (P42766), RPL35A (P18077), RPL36 (Q9Y3U8), RPL36A (P83881), RPL36AL (Q969Q0), RPL37 (P61927), RPL37A (P61513), RPL38 (P63173), RPL4 (P36578), RPL5 (P46777), RPL6 (Q02878), RPL7 (P18124), RPL7A (P62424), RPL7L1 (Q6DKI1), RPL8 (P62917), RPL9 (P32969), RPLP0 (P05388), RPLP1 (P05386), RPLP2 (P05387), RPN1 (P04843), RPN2 (P04844), RPP30 (P78346), RPP38 (P78345), RPRD1A (Q96P16), RPRD1B (Q9NQG5), RPS10 (P46783), RPS11 (P62280), RPS12 (P25398), RPS13 (P62277), RPS14 (P62263), RPS15 (P62841), RPS15A (P62244), RPS16 (P62249), RPS17 (P08708), RPS18 (P62269), RPS19 (P39019), RPS2 (P15880), RPS20 (P60866), RPS21 (P63220), RPS23 (P62266), RPS24 (P62847), RPS25 (P62851), RPS26 (P62854), RPS27 (P42677), RPS27A (P62979), RPS27L (Q71UM5), RPS28 (P62857), RPS29 (P62273), RPS3 (P23396), RPS3A (P61247), RPS4X (P62701), RPS4Y1 (P22090), RPS5 (P46782), RPS6 (P62753), RPS6KA1 (Q15418), RPS6KA3 (P51812), RPS7 (P62081), RPS8 (P62241), RPS9 (P46781), RPSA (P08865), RQCD1 (Q92600), RRAGC (Q9HB90), RRAS2 (P62070), RRBP1 (Q9P2E9), RRM1 (P23921), RRM2 (P31350), RRM2B (Q7LG56), RRP1 (P56182), RRP12 (Q5JTH9), RRP1B (Q14684), RRP7A (Q9Y3A4), RRP9 (O43818), RRS1 (Q15050), RSL1D1 (O76021), RSL24D1 (Q9UHA3), RSPRY1 (Q96DX4), RSU1 (Q15404), RTCD1 (O00442), RTKN (Q9BST9), RTN3 (O95197), RTN4 (Q9NQC3), RUVBL1 (Q9Y265), RUVBL2 (Q9Y230), RWDD2B (P57060), S100A10 (P60903), S100A11 (P31949), S100A13 (Q99584), S100A16 (Q96FQ6), S100A2 (P29034), S100A4 (P26447), S100A6 (P06703), S100A7 (P31151), S100A8 (P05109), S100A9 (P06702), SAAL1 (Q96ER3), SACS (Q9NZJ4), SAE1 (Q9UBE0), SAMHD1 (Q9Y3Z3), SAP18 (O00422), SAR1A (Q9NR31), SARM1 (Q6SZW1), SARNP (P82979), SARS (P49591), SARS2 (Q9NP81), SART3 (Q15020), SBDS (Q9Y3A5), SBF1 (O95248), SCARB1 (Q8WTV0), SCARB2 (Q14108), SCCPDH (Q8NBX0), SCFD1 (Q8WVM8), SCFD2 (Q8WU76), SCP2 (P22307), SCPEP1 (Q9HB40), SCRG1 (O75711), SCRIB (Q14160), SCRN1 (Q12765), SCRN2 (Q96FV2), SCYL1 (Q96KG9), SDC2 (P34741), SDC4 (P31431), SDCBP (O00560), SDCCAG1 (O60524), SDCCAG3 (Q96C92), SDHA (P31040), SDHB (P21912), SDK1 (Q7Z5N4), SDSL (Q96GA7), SEC13 (P55735), SEC14L2 (O76054), SEC22B (O75396), SEC23A (Q15436), SEC23B (Q15437), SEC23IP (Q9Y6Y8), SEC24A (O95486), SEC24B (O95487), SEC24C (P53992), SEC24D (O94855), SEC31A (O94979), SEC61B (P60468), SEC61G (P60059), SEH1L (Q96EE3), SELH (Q8IZQ5), SELO (Q9BVL4), SEMA3A (Q14563), SENP3 (Q9H4L4), SEPSECS (Q9HD40), 40422 (Q9P0V9), 40787 (Q9NVA2), 37500 (Q15019), 38596 (Q99719), 39326 (Q16181), 40057 (Q9UHD8), SERBP1 (Q8NC51), SERPINB12 (Q96P63), SERPINB3 (P29508), SERPINB6 (P35237), SERPINH1 (P50454), SESN2 (P58004), SET (Q01105), SETD3 (Q86TU7), SF3A1 (Q15459), SF3A2 (Q15428), SF3A3 (Q12874), SF3B1 (O75533), SF3B14 (Q9Y3B4), SF3B2 (Q13435), SF3B3 (Q15393), SF3B4 (Q15427), SF3B5 (Q9BWJ5), SFN (P31947), SFPQ (P23246), SFRP4 (Q6FHJ7), SFXN3 (Q9BWM7), SGTA (O43765), SH3BGRL3 (Q9H299), SH3BP4 (Q9P0V3), SH3GL1 (Q99961), SH3GLB1 (Q9Y371), SHC1 (P29353), SHMT1 (P34896), SHMT2 (P34897), SHOC2 (Q9UQ13), SHPK (Q9UHJ6), SIRT5 (Q9NXA8), SKIV2L (Q15477), SKIV2L2 (P42285), SKP1 (P63208), SLC12A2 (P55011), SLC12A4 (Q9UP95), SLC16A1 (P53985), SLC1A3 (P43003), SLC1A5 (Q15758), SLC25A10 (Q9UBX3), SLC25A11 (Q02978), SLC25A13 (Q9UJS0), SLC25A22 (Q9H936), SLC25A3 (Q00325), SLC25A5 (P05141), SLC25A6 (P12236), SLC26A2 (P50443), SLC29A1 (Q99808), SLC29A2 (Q14542), SLC2A1 (P11166), SLC30A1 (Q9Y6M5), SLC38A1 (Q9H2H9), SLC3A2 (P08195), SLC44A2 (Q8IWA5), SLC4A2 (P04920), SLC4A7 (Q9Y6M7), SLC5A3 (P53794), SLC5A6 (Q9Y289), SLC6A8 (P48029), SLC7A1 (P30825), SLC7A5 (Q01650), SLC9A3R1 (O14745), SLC9A3R2 (Q15599), SLIRP (Q9GZT3), SLK (Q9H2G2), SMAD1 (Q15797), SMAD2 (Q15796), SMARCA4 (P51532), SMARCA5 (O60264), SMARCB1 (Q12824), SMARCC1 (Q92922), SMARCC2 (Q8TAQ2), SMARCD2 (Q92925), SMC1A (Q14683), SMC2 (O95347), SMC3 (Q9UQE7), SMC4 (Q9NTJ3), SMC5 (Q8IY18), SMCHD1 (A6NHR9), SMEK1 (Q6IN85), SMG1 (Q96Q15), SMN1 (Q16637), SMS (P52788), SMU1 (Q2TAY7), SMYD3 (Q9H7B4), SMYD5 (Q6GMV2), SNAP23 (O00161), SND1 (Q7KZF4), SNF8 (Q96H20), SNRNP200 (O75643), SNRNP40 (Q96DI7), SNRNP70 (P08621), SNRPA1 (P09661), SNRPB (P14678), SNRPB2 (P08579), SNRPD1 (P62314), SNRPD2 (P62316), SNRPD3 (P62318), SNRPE (P62304), SNRPF (P62306), SNRPG (P62308), SNTB1 (Q13884), SNTB2 (Q13425), SNX1 (Q13596), SNX12 (Q9UMY4), SNX17 (Q15036), SNX18 (Q96RF0), SNX2 (O60749), SNX27 (Q96L92), SNX3 (O60493), SNX5 (Q9Y5X3), SNX6 (Q9UNH7), SNX9 (Q9Y5X1), SOD1 (P00441), SOD2 (P04179), SORD (Q00796), SORT1 (Q99523), SPATS2L (Q9NUQ6), SPC24 (Q8NBT2), SPCS2 (Q15005), SPCS3 (P61009), SPG21 (Q9NZD8), SPIN1 (Q9Y657), SPR (P35270), SPRR1B (P22528), SPRR2E (P22531), SPTAN1 (Q13813), SPTBN1 (Q01082), SPTBN2 (O15020), SR140 (O15042), SRBD1 (Q8N5C6), SRCRL (A1L4H1), SRGAP2 (O75044), SRI (P30626), SRM (P19623), SRP14 (P37108), SRP19 (P09132), SRP54 (P61011), SRP68 (Q9UHB9), SRP72 (O76094), SRP9 (P49458), SRPK1 (Q96SB4), SRPR (P08240), SRPRB (Q9Y5M8), SRPX (P78539), SRPX2 (O60687), SRR (Q9GZT4), SRRM1 (Q8IYB3), SRRM2 (Q9UQ35), SRRT (Q9BXP5), SRSF1 (Q07955), SRSF10 (O75494), SRSF11 (Q05519), SRSF2 (Q01130), SRSF3 (P84103), SRSF5 (Q13243), SRSF6 (Q13247), SRSF7 (Q16629), SRSF9 (Q13242), SRXN1 (Q9BYN0), SSB (P05455), SSBP1 (Q04837), SSR1 (P43307), SSR3 (Q9UNL2), SSRP1 (Q08945), SSSCA1 (O60232), SSU72 (Q9NP77), ST13 (P50502), STAG1 (Q8WVM7), STAM (Q92783), STAMBP (O95630), STAT1 (P42224), STAT2 (P52630), STAT3 (P40763), STAU1 (O95793), STIP1 (P31948), STK10 (O94804), STK24 (Q9Y6E0), STK25 (O00506), STK38 (Q15208), STK38L (Q9Y2H1), STOM (P27105), STOML2 (Q9UJZ1), STON2 (Q8WXE9), STRAP (Q9Y3F4), STT3A (P46977), STUB1 (Q9UNE7), STX12 (Q86Y82), STX4 (Q12846), STX5 (Q13190), STXBP1 (P61764), STXBP3 (O00186), STYX (Q8WUJ0), SUB1 (P53999), SUCLA2 (Q9P2R7), SUCLG2 (Q96I99), SUGT1 (Q9Y2Z0), SULF2 (Q8IWU5), SUMO1 (P63165), SUPT16H (Q9Y5B9), SUPT4H1 (P63272), SUPT5H (O00267), SUPT6H (Q7KZ85), SUSD5 (O60279), SVEP1 (Q4LDE5), SVIL (O95425), SWAP70 (Q9UH65), SYMPK (Q92797), SYNCRIP (O60506), SYNGR2 (O43760), SYNJ2BP (P57105), SYNM (O15061), SYPL1 (Q16563), TAB1 (Q15750), TAF9 (Q9Y3D8), TAGLN (Q01995), TAGLN2 (P37802), TALDO1 (P37837), TAOK1 (Q7L7X3), TARDBP (Q13148), TARS (P26639), TATDN1 (Q6P1N9), TAX1BP3 (O14907), TBC1D13 (Q9NVG8), TBC1D15 (Q8TC07), TBC1D23 (Q9NUY8), TBC1D24 (Q9ULP9), TBC1D4 (O60343), TBC1D9B (Q66K14), TBCA (O75347), TBCB (Q99426), TBCC (Q15814), TBCD (Q9BTW9), TBCE (Q15813), TBK1 (Q9UHD2), TBL1XR1 (Q9BZK7), TBL2 (Q9Y4P3), TBL3 (Q12788), TBPL1 (P62380), TCEA1 (P23193), TCEB1 (Q15369), TCEB2 (Q15370), TCERG1 (O14776), TCF25 (Q9BQ70), TCP1 (P17987), TELO2 (Q9Y4R8), TEX10 (Q9NXF1), TEX15 (Q9BXT5), TF (P02787), TFCP2 (Q12800), TFG (Q92734), TFRC (P02786), TGFB1 (P01137), TGFB2 (P61812), TGFBI (Q15582), TGFBRAP1 (Q8WUH2), TGM1 (P22735), TGM3 (Q08188), TH1L (Q8IXH7), THBS1 (P07996), THBS3 (P49746), THG1L (Q9NWX6), THOC2 (Q8NI27), THOC3 (Q96J01), THOC5 (Q13769), THOC6 (Q86W42), THOC7 (Q6I9Y2), THOP1 (P52888), THTPA (Q9BU02), THUMPD1 (Q9NXG2), THUMPD3 (Q9BV44), THY1 (P04216), THYN1 (Q9P016), TIA1 (P31483), TIAL1 (Q01085), TIGAR (Q9NQ88), TIMM13 (Q9Y5L4), TIMM44 (O43615), TIMM50 (Q3ZCQ8), TIMM8A (O60220), TIMM8B (Q9Y5J9), TIMM9 (Q9Y5J7), TIMP2 (P16035), TIPRL (O75663), TJP1 (Q07157), TKT (P29401), TLN1 (Q9Y490), TLN2 (Q9Y4G6), TM9SF3 (Q9HD45), TMED10 (P49755), TMED2 (Q15363), TMED5 (Q9Y3A6), TMED7 (Q9Y3B3), TMED9 (Q9BVK6), TMEFF2 (Q9UIK5), TMEM132A (Q24JP5), TMEM2 (Q9UHN6), TMEM30A (Q9NV96), TMEM33 (P57088), TMOD3 (Q9NYL9), TMPO (P42166), TMX1 (Q9H3N1), TNC (P24821), TNKS1BP1 (Q9C0C2), TNPO1 (Q92973), TNPO2 (O14787), TNPO3 (Q9Y5L0), TOM1L2 (Q6ZVM7), TOMM20 (Q15388), TOMM34 (Q15785), TOMM5 (Q8N4H5), TOMM70A (O94826), TOP1 (P11387), TOP2A (P11388), TOP2B (Q02880), TP53I3 (Q53FA7), TP53RK (Q96S44), TPBG (Q13641), TPD52 (P55327), TPI1 (P60174), TPM1 (P09493), TPM2 (P07951), TPM3 (P06753), TPM3L (A6NL28), TPM4 (P67936), TPP2 (P29144), TPT1 (P13693), TRA2A (Q13595), TRA2B (P62995), TRAF2 (Q12933), TRAP1 (Q12931), TRAPPC1 (Q9Y5R8), TRAPPC2L (Q9UL33), TRAPPC3 (O43617), TRAPPC4 (Q9Y296), TRAPPC5 (Q8IUR0), TRIM16 (O95361), TRIM22 (Q8IYM9), TRIM25 (Q14258), TRIM26 (Q12899), TRIM28 (Q13263), TRIM47 (Q96LD4), TRIM5 (Q9C035), TRIO (O75962), TRIP13 (Q15645), TRIP6 (Q15654), TRMT1 (Q9NXH9), TRMT112 (Q9UI30), TRMT5 (Q32P41), TRMT6 (Q9UJA5), TRMT61A (Q96FX7), TRNT1 (Q96Q11), TROVE2 (P10155), TRRAP (Q9Y4A5), TSG101 (Q99816), TSKU (Q8WUA8), TSN (Q15631), TSPAN14 (Q8NG11), TSPAN6 (O43657), TSR1 (Q2NL82), TSSC1 (Q53HC9), TSTA3 (Q13630), TTC1 (Q99614), TTC15 (Q8WVT3), TTC27 (Q6P3X3), TTC37 (Q6PGP7), TTC38 (Q5R3I4), TTC7B (Q86TV6), TTC9C (Q8N5M4), TTL (Q8NG68), TTLL12 (Q14166), TTN (Q8WZ42), TTYH1 (Q9H313), TTYH3 (Q9C0H2), TUBA1B (P68363), TUBA4A (P68366), TUBB (P07437), TUBB2B (Q9BVA1), TUBB2C (P68371), TUBB3 (Q13509), TUBB6 (Q9BUF5), TUBG1 (P23258), TUBGCP2 (Q9BSJ2), TUBGCP3 (Q96CW5), TUFM (P49411), TWF1 (Q12792), TWF2 (Q6IBS0), TXN (P10599), TXNDC17 (Q9BRA2), TXNDC5 (Q8NBS9), TXNDC9 (O14530), TXNL1 (O43396), TXNRD1 (Q16881), TYK2 (P29597), TYMS (P04818), U2AF1 (Q01081), U2AF2 (P26368), UAP1 (Q16222), UBA1 (P22314), UBA2 (Q9UBT2), UBA3 (Q8TBC4), UBA52 (P62987), UBA6 (A0AVT1), UBE2D1 (P51668), UBE2D3 (P61077), UBE2E1 (P51965), UBE2G2 (P60604), UBE2I (P63279), UBE2J2 (Q8N2K1), UBE2K (P61086), UBE2L3 (P68036), UBE2M (P61081), UBE2N (P61088), UBE2O (Q9C0C9), UBE2S (Q16763), UBE2V1 (Q13404), UBE2V2 (Q15819), UBE3A (Q05086), UBE3C (Q15386), UBE4A (Q14139), UBE4B (O95155), UBFD1 (O14562), UBL3 (O95164), UBL4A (P11441), UBL5 (Q9BZL1), UBLCP1 (Q8WVY7), UBP1 (Q9NZI7), UBQLN2 (Q9UHD9), UBR1 (Q8IWV7), UBR4 (Q5T4S7), UBTD1 (Q9HAC8), UBXN1 (Q04323), UBXN6 (Q9BZV1), UCHL1 (P09936), UCHL3 (P15374), UCHL5 (Q9Y5K5), UCK2 (Q9BZX2), UFC1 (Q9Y3C8), UFD1L (Q92890), UGDH (O60701), UGGT1 (Q9NYU2), UGP2 (Q16851), ULK3 (Q6PHR2), UMPS (P11172), UNC119B (A6NIH7), UNC45A (Q9H3U1), UPF1 (Q92900), UPP1 (Q16831), UQCRC1 (P31930), UQCRC2 (P22695), UQCRFS1 (P47985), URB1 (O60287), URB2 (Q14146), UROD (P06132), UROS (P10746), USO1 (O60763), USP10 (Q14694), USP11 (P51784), USP13 (Q92995), USP14 (P54578), USP15 (Q9Y4E8), USP24 (Q9UPU5), USP39 (Q53GS9), USP5 (P45974), USP7 (Q93009), USP9X (Q93008), UTP15 (Q8TED0), UTP18 (Q9Y5J1), UTP20 (O75691), UTP6 (Q9NYH9), UTRN (P46939), UXS1 (Q8NBZ7), UXT (Q9UBK9), VAC14 (Q08AM6), VAMP3 (Q15836), VAMP5 (O95183), VAPA (Q9P0L0), VAPB (O95292), VARS (P26640), VASP (P50552), VAT1 (Q99536), VAV2 (P52735), VBP1 (P61758), VCAN (P13611), VCL (P18206), VCP (P55072), VDAC1 (P21796), VDAC2 (P45880), VDAC3 (Q9Y277), VIM (P08670), VPRBP (Q9Y4B6), VPS11 (Q9H270), VPS13A (Q96RL7), VPS13C (Q709C8), VPS16 (Q9H269), VPS18 (Q9P253), VPS24 (Q9Y3E7), VPS25 (Q9BRG1), VPS26A (O75436), VPS26B (Q4G0F5), VPS28 (Q9UK41), VPS29 (Q9UBQ0), VPS33A (Q96AX1), VPS33B (Q9H267), VPS35 (Q96QK1), VPS36 (Q86VN1), VPS37B (Q9H9H4), VPS39 (Q96JC1), VPS41 (P49754), VPS45 (Q9NRW7), VPS4A (Q9UN37), VPS4B (O75351), VPS53 (Q5VIR6), VPS8 (Q8N3P4), VRK1 (Q99986), VTA1 (Q9NP79), VWA1 (Q6PCB0), VWA5A (O00534), WARS (P23381), WASF2 (Q9Y6W5), WASL (O00401), WBSCR22 (O43709), WDFY1 (Q8IWB7), WDR1 (O75083), WDR11 (Q9BZH6), WDR12 (Q9GZL7), WDR18 (Q9BV38), WDR26 (Q9H7D7), WDR3 (Q9UNX4), WDR36 (Q8NI36), WDR4 (P57081), WDR43 (Q15061), WDR45L (Q5MNZ6), WDR48 (Q8TAF3), WDR5 (P61964), WDR54 (Q9H977), WDR6 (Q9NNW5), WDR61 (Q9GZS3), WDR73 (Q6P4I2), WDR74 (Q6RFH5), WDR75 (Q8IWA0), WDR77 (Q9BQA1), WDR82 (Q6UXN9), WDR92 (Q96MX6), WHSC2 (Q9H3P2), WRNIP1 (Q96S55), XP32 (Q5T750), XPC (Q01831), XPNPEP1 (Q9NQW7), XPO1 (O14980), XPO4 (Q9C0E2), XPO5 (Q9HAV4), XPO6 (Q96QU8), XPO7 (Q9UIA9), XPOT (O43592), XRCC1 (P18887), XRCC5 (P13010), XRCC6 (P12956), XRN2 (Q9HOD6), YARS (P54577), YBX1 (P67809), YES1 (P07947), YKT6 (O15498), YRDC (Q86U90), YTHDC1 (Q96MU7), YTHDF2 (Q9Y5A9), YWHAB (P31946), YWHAE (P62258), YWHAG (P61981), YWHAH (Q04917), YWHAQ (P27348), YWHAZ (P63104), ZC3H15 (Q8WU90), ZC3HAV1 (Q7Z2W4), ZC3HAV1L (Q96H79), ZCCHC3 (Q9NUD5), ZFAND1 (Q8TCF1), ZFR (Q96KR1), ZMAT2 (Q96NC0), ZNF259 (O75312), ZNF326 (Q5BKZ1), ZNF330 (Q9Y3S2), ZNF622 (Q969S3), ZNF765 (Q7L2R6), ZNFX1 (Q9P2E3), ZW10 (O43264), ZWILCH (Q9H900), ZYG11B (Q9C0D3), ZYX (Q15942).

TABLE 22 100 most abundant proteins (name and SwissProt accession number) in CTX0E03 microvesicles Accession Identified proteins number Actin, cytoplasmic 2 P63261 Histone H4 P62805 Histone H2B Q99879 Histone H3.2 Q71DI3 Histone H2B type 1 P23527 Glyceraldehyde-3-phosphate dehydrogenase P04406 Histone H2A type 2-A Q6FI13 Ubiquitin-40S ribosomal protein S27a P62979 Annexin A2 P07355 Alpha-enolase P06733 Pyruvate kinase isozymes M1/M2 P14618 60S ribosomal protein L6 Q02878 Histone H2B type 2-E Q16778 Heat shock cognate 71 kDa protein P11142 Actin, alpha cardiac muscle 1 P68032 Heat shock protein HSP 90-beta P08238 Histone H2B type 1-J P06899 Elongation factor 1-alpha 1 P68104 Tubulin beta-2C chain P68371 60S ribosomal protein L18 Q07020 Tubulin beta chain P07437 40S ribosomal protein S2 P15880 40S ribosomal protein S11 P62280 Histone H2B type 3-B Q8N257 Tubulin alpha-1B chain P68363 40S ribosomal protein S3 P23396 40S ribosomal protein S3a P61247 Histone H2A type 1-D P20671 Elongation factor 2 P13639 Heat shock protein HSP 90-alpha P07900 GTP-binding nuclear protein Ran P62826 60S ribosomal protein L4 P36578 40S ribosomal protein S9 P46781 Profilin-1 P07737 60S ribosomal protein L13a P40429 Phosphoglycerate kinase 1 P00558 Fatty acid synthase P49327 Annexin A1 P04083 Histone H2A.Z P0C0S5 Vimentin P08670 40S ribosomal protein S6 P62753 Moesin P26038 Peptidyl-prolyl cis-trans isomerase A P62937 60S ribosomal protein L26 P61254 60S ribosomal protein L3 P39023 40S ribosomal protein S8 P62241 60S ribosomal protein L28 P46779 Ezrin P15311 40S ribosomal protein S4, X isoform P62701 60S ribosomal protein L7a P62424 60S ribosomal protein L13 P26373 60S ribosomal protein L7 P18124 40S ribosomal protein S23 P62266 60S ribosomal protein L5 P46777 Eukaryotic initiation factor 4A-I P60842 40S ribosomal protein S24 P62847 Tubulin beta-2B chain Q9BVA1 60S ribosomal protein L8 P62917 60S ribosomal protein L15 P61313 60S ribosomal protein L10 P27635 Peroxiredoxin-1 Q06830 Keratin, type I cytoskeletal 14 P02533 14-3-3 protein theta P27348 40S ribosomal protein S18 P62269 Transketolase P29401 60S ribosomal protein L24 P83731 Histone H1.5 P16401 Cofilin-1 P23528 Dihydropyrimidinase-related protein 3 Q14195 60S ribosomal protein L21 P46778 60S ribosomal protein L36 Q9Y3U8 Sodium/potassium-transporting ATPase subunit alpha-1 P05023 40S ribosomal protein S16 P62249 T-complex protein 1 subunit gamma P49368 Heterogeneous nuclear ribonucleoprotein A1 P09651 60S ribosomal protein L14 P50914 Heat shock 70 kDa protein 1A/1B P08107 T-complex protein 1 subunit theta P50990 60S ribosomal protein L30 P62888 Protein S100-A6 P06703 40S ribosomal protein SA P08865 CD44 antigen P16070 60S ribosomal protein L35a P18077 Tubulin beta-3 chain Q13509 T-complex protein 1 subunit delta P50991 4F2 cell-surface antigen heavy chain P08195 T-complex protein 1 subunit beta P78371 Myosin-9 P35579 Adenosylhomocysteinase P23526 Filamin-A P21333 Fatty acid-binding protein, brain O15540 Myristoylated alanine-rich C-kinase substrate P29966 T-complex protein 1 subunit eta Q99832 Fascin Q16658 Fructose-bisphosphate aldolase A P04075 60S ribosomal protein L27 P61353 60S ribosomal protein L17 P18621 Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 60S ribosomal protein L10a P62906 60S ribosomal protein L35 P42766

Discussion of Proteomic Data

CD63 (also known as MLA1 and TSPAN30), TSG101 (also known as ESCRT-I complex subunit TSG101), CD109 (also known as 150 kDa TGF-beta-1-binding protein) and thy-1 (also known as CD90) were detected in both exosomes and microvesicles.

Other tetraspanins were also detected: Tetraspanin-4, -5, -6, -9 and 14 were detected in the exosome fraction; tetraspanins-6 and -14 were detected in the microvesicles.

CD133 (also known as AC133, Prominin-1, PROM1, PROML1 and MSTP061) was detected in the exosomes but not the microvesicles.

CD53 (also known as MOX44 and TSPAN25), CD82 (also known as KAI1, SAR2, ST6 and TSPAN27), CD37 (also known as TSPAN26) and CD40 ligand (also known as CD40LG, CD40L and TNFSF5) were not detected in the exosomes or the microvesicles.

Nestin, GFAP and tubulin beta-3 chain (also known as TUBB3) were detected in both the exosome and microvesicle fractions, with tubulin beta-3 chain being particularly prominent within the top 100 proteins in both fractions. Sox2, DCX, GALC, GDNF and IDO were not detected.

Selectins and TNFRI (also known as TNF receptor 1, TNFRSF1A, TNFAR and TNFR1) were not detected.

Integrin alpha-2, -3, -4, -5, -6, -7, —V and integrin beta-1, -4 and -8 were detected in both exosome and microvesicle fractions. Integrin beta-3 and -5 were detected in the microvesicles only.

MHC Class I antigens (e.g. HLA_A1, HLA-A2 and HLA-B27) were detected in both the exosomes and microvesicles.

Cell-adhesion molecules (e.g. CADM1, CADM4, ICAM1, JAM3, L1CAM, NCAM) were detected in both the exosomes and microvesicles.

Cytoskeletal proteins (e.g. actin, vimentin, keratins, catenins, dystroglucan, neurofilament polypeptide, microtubule-associated protein, tubulin, desmoplaktin, plectin, plakophilin, septin, spectrin, talin, vinculin and zyxin) were detected in both the exosome and microvesicle fractions.

GTPases, clathrin, chaperones, heat-shock proteins (e.g. Hsp90, Hsp70), splicing factors, translation factors, annexins and growth factors (e.g. TGF-beta) were detected in both the exosomes and microvesicles.

Galectin-3, TIMP-1, thrombosponding-1, EGF receptor and CSK were detected in both the exosomes and microvesicles.

FIGS. 17A, 17B, 17C, and 17D compare the proteomic data from the exosomes and microvesicles. FIG. 17A illustrates the number of unique proteins within each micro particle population, isolated from week 2 Integra culture system. FIG. 17B compares the biological processes associated with the identified proteins within each micro particle population, isolated from week 2 Integra system. The proteins identified within exosomes and microvesicles are associated with very similar biological processes.

Proteins associated with biotin metabolism were only found in exosomes and proteins involved in tryptophan biosynthesis and taurine/alpha-linolenic acid metabolism were only identified in microvesicles.

FIG. 17C compares the CTX0E03 proteome to the Mesenchymal Stem Cell exosome proteome disclosed in Lai et al 2012, in which a total of 857 proteins were identified in exosomes released from mesenchymal stem cells.

FIG. 17D compares the biological processes associated with the identified proteins within the MSC derived exosomes (Lim 2012) with the neural stem cell derived exosomes of the invention. The three biological processes found to be associated with the MSC derived exosomes only are (in decreasing order of significance): Asthma; phenylalanine, tyrosine and tryptophan biosynthesis; and primary immunodeficiency. The thirty biological processes found to be associated only with the neural stem cell derived exosomes are shown in FIG. 18; the most significant biological function identified relates to RNA polymerase.

A further comparison of the 197 biological processes shared by both MSC derived exosomes and NSC derived exosomes shows that NSC exosomes contain notably more processes involved in RNA degradation, the Ribosome and spliceosomes, when compared to MSC exosomes.

The above comparison indicates a number of significant differences between NSC derived exosomes and MSC derived exosomes (as characterised by Lim et al 2012). The 4 most significant biological differences identified as present in NSC exosomes compared to being very low/absent in those identified by the Lim's group, all involve proteins associated with the production, packaging, function and degradation of genetic material, i.e RNA polymerase, RNA degradation, Ribosome and spliceosomes.

Example 20: Functional Analysis of Individual miRNAs Methods MiRNA Mimic Transfection and Evaluation of Cell Proliferation by Cyquant

Twenty four hours prior to transfection, glioma cells, U373 or U87, were seeded into a 96 well plate. MiRNA transfection optimization was performed using AllStars Negative Control siRNA AF 488 (Qiagen). MiRNA transfection efficiency was 100% when the following conditions were used. 20 nM of each miRNA mimics (Qiagen), hsa miR 1246 (SEQ ID No. 21), hsa miR 4492 (SEQ ID no. 34), hsa miR 4532 (SEQ ID No. 23), and hsa miR 4488 (SEQ ID No. 61) were combined with LIPOFECTAMINE® 2000 (Invitrogen) and transfection performed according to manufacturer's instructions.

Experiment 1 (U373MG; 2500 Cells/Well; 10% FBS)

2500 U373MG cells were seeded per 96 well and cultured in DMEM glutamax/10% FBS for 24 hrs, 48 hrs and 72 hrs post transfection. Cell proliferation was measured by CYQUANT® Cell Proliferation Assay Kit (Invitrogen). Briefly, following removal of the culture medium, 200 μl of the CYQUANT® GR dye/cell-lysis buffer was added into each well of the 96 well plate and incubated for 15 min. Fluorescence intensity of each well was obtained using a GLOMAX™ 96 microplate (Promega) plate counter at excitation and emission wavelengths of 480 and 520 nm, respectively.

Experiment 2 (U373MG; 2500 Cell/Well; 2% FBS)

2500 U373MG cells were seeded per 96 well and cultured in DMEM glutamax/2% FBS for 24 hrs, 48 hrs and 72 hrs post transfection. Cell proliferation was measured by CYQUANT® Cell Proliferation Assay Kit (Invitrogen). Briefly, following removal of the culture medium, 200 μl of the CYQUANT® GR dye/cell-lysis buffer was added into each well of the 96 well plate and incubated for 15 min. Fluorescence intensity of each well was obtained using a GLOMAX™ 96 microplate (Promega) plate counter at excitation and emission wavelengths of 480 and 520 nm, respectively.

Experiment 3 (U87; 9000 Cells/Well; Basal)

9000 U87 cells were seeded per 96 well and cultured in EMEM+2 nM glutamine for 0 hrs, 24 hrs, 48 hrs and 72 hrs post transfection. Cell proliferation was measured by CYQUANT® Cell Proliferation Assay Kit (Invitrogen). Briefly, following removal of the culture medium, 200 μl of the CYQUANT® GR dye/cell-lysis buffer was added into each well of the 96-well plate and incubated for 15 min. Fluorescence intensity of each well was obtained using a GLOMAX™ 96 Microplate (Promega) plate counter at excitation and emission wavelengths of 480 and 520 nm, respectively.

Results

Next generation sequence (NGS) analysis of miRNA contents in CTX0E03 derived exosomes revealed the presence of a set of top ranked miRNAs, hsa mir 1246, hsa mir 4488, hsa mir 4492, and hsa mir 4532. To assess the functionality of these individual miRNAs in reducing glioma cell proliferation, each (mimic) miRNA was transfected into two cell line models of glioma: U373MG and U87.

The incidence of reduction of cell proliferation was dependent on the glioma model and cell culturing conditions, but each of the four miRNAs tested significantly reduced tumour cell proliferation in at least one of the models. hsa mir 4492 and hsa mir 4532 significantly reduced cell proliferation in each of the models tested. The results of Experiments 1 to 3 are shown in FIGS. 23A, 23B and 23C, respectively.

Example 21: Tolerability and Pilot Efficacy of Exosomes in U-87MG Human Glioblastoma Subcutaneous Xenografts Objective

To assess the tolerability and pilot efficacy of exosomes in U-87MG subcutaneous xenografts

Methods Animals

Number 30 No. of Groups & No per 5 groups, 5 mice/group Group Species Mus musculus Strain Athymic nude (Hsd:AthymicNude-Fxn1^(nu)) Age 5-7 weeks Gender Female Body Weight N/A Animal ID Transponder chip according to PRECOS Standard Operating Methods (SOMs) Acclimatisation ≥1 week Implantation site Left flank Anaesthesia In accordance with PRECOS SOMs Housing According to PPL 70/7317 and PRECOS Standard Operating Procedures (SOPs) Animal Harlan UK

Cell Lines, In Vitro Expansion

Cell Line Name U-87MG Supplier and catalogue ECACC, 89081402 number Culture Medium EMEM culture medium (Sigma, UK) containing 10% (v/v) heat inactivated foetal bovine serum (Hyclone, Thermo Scientific, UK) Number of mice to be 30 implanted Number of cells per mouse 8 × 10⁶ per mouse Matrigel/Cultrex/PBS/other PBS supplemented with 0.1% glucose Volume of diluent per 0.1 mL mouse Number of batches 1

Cells will be harvested, washed in the culture medium described above and cells with viability of ≥90% will be re-suspended for in vivo administration. Cells will be stored on ice for a minimum period of time (e.g. no longer than 30 minutes) prior to implantation.

Implantation

TRANSPONDER IMPLANTATION: Implanted at initiation (tumour implantation).

TUMOUR IMPLANTATION: 8×10⁶ viable cells in 100 μl PBS+0.1% glucose will be injected subcutaneously into the left flank of each mouse. A total of 30 mice will be implanted.

Data Capture

Body weight, dosing and any comments relating to clinical condition will be captured in real-time using the study management software, StudyDirector (StudyLog Systems Inc.).

Data will be exported into Microsoft Excel and/or GraphPad Prism for subsequent data analysis and transformation.

Study specific data capture schedules will be created in Excel and completed by the study team. These data capture schedules will include study specific clinical observations; the recording of these observations and will be included in the final report and uploaded to the study folder at the end of the study.

Body Weight:

Mice will be weighed ×3 weekly during the dosing phase, weekly thereafter; clinical condition monitored daily for the duration of the study by an experienced technician.

Tumour Monitoring (Inc. BLI):

Tumour will be measured 3 times a week and tumour volumes will be estimated using the formula 0.5(L×W²) by measuring the tumour in two dimensions using electronic callipers for the duration of the study.

Treatment Initiation and Duration:

The mice will be randomly allocated to the treatment groups (e.g. using a stratified randomisation software tool) such that there is a similar distribution of tumour size within and between treatment groups. Dosing will be initiated when the mean tumour volume of groups approximates 100-150 mm³. The study will terminate 3 weeks following initiation.

Test & Reference Substance Id Storage & Formulation Test & Reference Substance ID and Storage.

Compound Compound Vehicle Vehicle Vehicle Post-formulation Compound ID Source Storage Name Source Storage storage Exosome 0 Reneuron Ltd −80° C. 0.9% saline ReNeuron Ltd. 2-8° C. 2-8° C. Kept on ice during administration Temozolomide PRECOS Ltd RT powder 10% DMSO PRECOS n/a +4° C.

Prepare dosing solutions freshly made before dosing.

Dosing

Mice will be dosed according to the following dosing schedule:

Dosing Frequency Group Dose Dose (bid/qd/tid) (No per Dose Volume conc. including wording group) Compound ID mg/kg (mg/ml) (mg/ml) Route e.g. twice daily etc. 1(5) Vehicle n/a 50 μl¹ 0 Intratumoural Once only 2(5) Exosome 0 1 50 μl¹ TBD² Intratumoural Once only 3(5) Exosome 0 0.5 50 μl¹ TBD² Intratumoural Once only 4(5) Exosome 0 0.1 50 μl¹ TBD² Intratumoural Once only 5(5) Temozolomide 5 10.0 5 p.o. Daily (q.d.) ¹Dose calculated on mean body weight and delivered in a fixed volume of 50 μl. ²Concentration to be determined, dependent upon mean group body weight.

Study Endpoints/Body Weight Loss (BWL) During the Study

-   -   Terminate any mouse with sudden body weight loss approaching 20%     -   Any mouse with continuous BWL approaching 20% over several daily         measurements will be removed and terminated.

After one measurement of body weight loss (BWL)>10%, a dose holiday will be given to the individual mouse. All dose holidays must be recorded on a Protocol Deviation.

Whether to give dose holidays to all the mice or the individual mouse in the group should be done so in consultation with the client, but is ultimately at the Named Persons (or appointed deputies) discretion based on the severity/incidence of the BWL.

Termination

Each mouse will remain in the study until terminated (day 21), or until circumstances necessitate removal of an animal from the study e.g. loss of clinical condition and/or body weight.

Animals may also be terminated at any time during the study if any adverse effects are noted according to Home Office Project Licence PPL 70/7317.

Termination will be performed in accordance with United Kingdom Home Office Animals, (Scientific Procedures) Act 1986 and PRECOS SOPs.

Terminal Samples

At termination the tumour will be excised and weighed. Tumours will be fixed in 10% Neutral Buffered Formalin and processing to FFPE blocks.

Animal Welfare and Regulation Guidelines Housing and Environment

Mice will be housed and cared for in accordance with the UK Animals (Scientific Procedures) Act 1986 (ASPA) and in line with the Directive 2010/63/EU of the European Parliament and of the Council of 22 Sep. 2010 “on the protection of animals used for scientific purposes” and according to the and PRECOS Policies, SOPs and SOMs.

Animal Welfare Monitoring

This study will be conducted in line with the FELASSA Guidelines on Pain & Suffering in Experimental Animals and the NCRI Guidelines for the welfare and use of animals in Cancer Research (Workman et al., British Journal of Cancer (2010) 102, 1555-1577).

An experienced technician will check the condition of the mice at least daily. Unexpected adverse effects will be recorded and reported to the Named Animal Care & Welfare Officer (NACWO) and Named Veterinary Surgeon (NVS).

Animals may be terminated at any time during the study if any unexpected adverse effects are noted according to Home Office Project Licence PPL 70/7317 and the permitted severity band.

Statistics and Reporting Statistical Methods

Statistical analysis if required will be performed in appropriate using the Minitab or PRISM statistical programmes for the PC.

Results

Tumours were implanted on day 0 and measured from day 6; tumours were measured three times weekly by callipers and the tumour volume calculated. When tumours reached a mean tumour volume of ˜165 mm³ they were assigned to treatment groups based on mean tumour volume per cage in order to achieve a minimum amount of variation between and within groups.

The individual tumour volumes of each group on the day of assignment are presented in FIG. 24; the mice were dosed on study day 12. The raw data for individual tumour volumes can be found in FIG. 32.

Mouse body weights were monitored for the duration of the study. The data, expressed as the mean+standard error of the mean (% of the pre-dose weight), is presented graphically in FIG. 25 (the dotted vertical line indicates the commencement of the dosing phase); the raw data for individual body weights can be found in FIGS. 30 and 31, absolute and relative measurements respectively. Body weight was stable over the duration of the study for each of the test agents and no adverse effects relating to the dosing protocols were documented in any of the treatment groups.

Mouse IDs recruited in dosing groups 1-4 received a single dose of increasing dose levels of Exosome 0 on study day 12. The Temozolomide dosing phase continued until study day 46 (35 oral doses). However, a number of mice were terminated prior to this point due to a number of listed adverse effects (see FIG. 34; tumours reached the maximum permitted size as defined by UKCCCR guidelines (mean diameter 15 mm)).

FIG. 26 summarises the mean tumour volume for the treatment groups measured during the study, expressed as the group mean+standard error of the mean (% of the pre-dose volume).

One tumour from vehicle group 1 (ID4; 00077E7FDB-14) failed to demonstrate progressive growth following assignment and regressed to zero volume by day 29, as this is an untreated group the mouse has been classified as an outlier and removed from all analysis.

Loss of mice due to early terminations results in a reduction of the mean tumour volume from day 27 onwards. FIG. 27 displays the tumour volume data (group mean+standard error of the mean; % pre-dose volume) of FIG. 26 but in a truncated format i.e. all the line plots are graphed up to study day 25 before termination as a result of adverse effects occurred. The raw data for individual tumour volumes and individual tumour plots are detailed in appendices 3 and 4 respectively.

Mean tumour volumes were analysed statistically using a two-way ANOVA test (FIG. 27 data set; GraphPad Prism; GraphPad Software, Inc.) for day 25. (The tumour volume data of G1 mouse ID14 was excluded from the statistical analysis; individual TV plots detailed in Appendix 4.) Although there was a trend showing reduction in tumour volume for both 1 mg/kg Exosome 0 (group 2) and Temozolomide (group 5), no statistically significant reduction in tumour volume was observed when compared to the vehicle group over the course of the study (GraphPad Prism; two-way ANOVA). The Bonferroni multiple comparison post-test did indicate a statistically significant reduction in tumour volume on day 25 for group 5 versus group 1 (p>0.01).

Terminal tumour weights were analysed statistically using a one-way ANOVA test (GraphPad Prism; GraphPad Software, Inc.); individual group comparisons were carried out on the total group tumour weights. No statistically significant differences among the mean tumour weight for each treatment group were observed using one-way ANOVA (p=0.2703).

From the final tumour weight assessment (FIG. 28; expressed as group mean+standard error of the mean (tumour weight)), what is noticeable in the Exosome 0 1 mg/kg dosing group (group 1) is that some of the tumours showed sensitivity to the treatment (IDs 12 and 21). Additionally, Temozolomide appears to increase the latency of the tumour instead of a significant decrease in tumour volume.

In survival analysis (FIG. 29) utilising mean tumour diameter (15 mm) as the humane survival endpoint, a trend in increased survival was observed for 1 mg/kg Exosome 0 and Temozolomide. However, no significant increase in survival for any of the treatment groups was observed when compared with the vehicle group (p=0.3651; Log-Rank (Mantel-Cox) test; GraphPad Prism; GraphPad Software, Inc.). Temozolomide did result in an increase in survival compared with the two lower doses of Exosome 0 (groups 3 and 4; p≥0.05).

Discussion

The primary objective of this pilot study was to assess the effect of several doses of Exosome 0 on the growth of U87MG subcutaneous glioblastoma xenografts and a dose of Temozolomide; an oral alkylating agent commonly used for the treatment of glioblastoma multiforme.

The agents under test in this study were well tolerated with no loss of body weight or adverse effects relating to treatment noted; however, tumour size and ulceration resulted in a decrease in mice per group from day 27. As the group sizes in this pilot study were already small the statistical significance that could be achieved with the test agents was therefore limited. The three dosing levels of the Exosome 0 were inefficacious in significantly reducing tumour volume (or tumour weight) when compared to the vehicle group, however, 40% of the tumours treated with the highest dose of Exosome 0 (1 mg/kg; Group 1) showed sensitivity to the treatment.

Similarly the reduction in tumour size with Temozolomide was not significant, which also suggest the group sizes were too small to achieve statistical significance.

A trend in increased survival was also observed for 1 mg/kg Exosome 0 and Temozolomide however significance was not achieved versus the vehicle group.

In conclusion, the dose levels of the Exosome 0 used in this study were well tolerated, but efficacy was emerging but not significant which was confounded by group size. Samples collected from this study could be analysed further for effect on proliferation, angiogenesis, necrosis and apoptosis. Further investigation using larger group sizes and higher dose of Exosome, if tolerated and soluble, could yield significant results.

Example 22: Histological Evaluation of Slides for U-87MG Human Glioblastoma Subcutaneous Xenografts Summary

Tissues for histopathological examination (from Example 21) were stained with haematoxylin and eosin before being subjected to histopathological evaluation. This examination was to determine any differences in the appearance of U87 human glioblastoma tumours in animals given Exosome 0 or Temozolomide when compared to those given a vehicle alone.

In one animal given 1 mg/kg Exosome 0 there was a particularly dramatic and effective ablation of the tumour mass.

Study Aims

The study was designed to investigate the properties of Exosome 0 in an in vivo model of tumourogenesis. This study was an investigation of the activity of this product in vivo, to assess tolerability and compare with an existing agent (temozolomide).

Temozolomide is an oral chemotherapy drug. It is an alkylating agent used for the treatment of glioblastoma. Temozolomide is also indicated for relapsed Grade III anaplastic astrocytoma, replacing the less well tolerated PCV (Procarbazine-Lomustine-Vincristine) regimen.

Methods

Histological Examination to determine any differences in the appearance of U87 human glioblastoma tumours in animals given Exosome 0 or Temozolomide when compared to those given a vehicle alone.

Results 1. Microscopic Findings

The tumours examined were large ovoid masses of apparently comparable sizes in the majority of cases, although the masses in animals 12 (Exosome 1.0 mg/kg), 1 and 9 (Temozolomide) were noticeably smaller. The majority of the tumours had necrotic centres and other necrotic foci with in the mass. The extent of the necrosis was quite variable and did affect the appearance of the tumours, but there was no clear difference in the extent of necrosis between the groups. The tumour cells themselves were clonal with a little dysplasia and occasional apoptotic cells. The mitotic rate was relatively low and appeared to be consistent between treatment groups. The response of the host seemed variable, with several showing no evidence of a host response at all while other showed a slight to moderate inflammatory response with some fibroplasia in occasional animals forming a rudimentary capsule.

a) Vehicle Controls

The tumours in the vehicle control group all had the appearance as described above. The extent of central necrosis was minimal in animal 20, but in the rest of the animals was fairly extensive. The inflammatory response in 17 was greater than in the other members of this group.

b) Exosome 0 (1 mg/kg)

The majority of tumours had an appearance that was indistinguishable from the tumours that were seen in the vehicle control animals. There was however one animal (12) where there was a dramatic response. In this animal the tumour appeared to have completely infarcted and there were no viable tumour cells visible in the section presented, only dense fibrous tissue and a slight infiltration of inflammatory cells, a large proportion of which appeared to be macrophages.

c) Exosome 0 (0.5 mg/kg)

The tumours in this group had an appearance that was indistinguishable from the tumours that were seen in the vehicle control animals.

d) Exosome 0 (0.1 mg/kg)

The tumours in this group had an appearance that was indistinguishable from the tumours that were seen in the vehicle control animals.

e) Temozolomide (5 mg/kg)

Three of the tumours in this group had an appearance that was indistinguishable from the tumours that were seen in the vehicle control animals, but there were two animals (1 and 9) where there seemed to be a response to treatment. In both animals the tumour had shrunk to quite a small size but there still appeared to be a substantial number of tumour cells in the section. These cells displayed rather more atypia than was seen in the other tumours, perhaps indicating an selective killing of the majority of cells, but potentially a selection of a more malignant phenotype by the test item. In two of the remaining animals (19 and 25) in this group tumours appeared similar in size to those seen in the vehicle control, there was however a clearly reduce cellularity compared to the vehicle control groups, but the increased atypia seen in animals 1 and 9 was again apparent. In the remaining animal the appearance was similar to the vehicle control.

2. Discussion and Conclusion

The consistent appearance of the tumour indicates a robust test system, which is suitable for assessment of efficacy. In one animal given 1 mg/kg Exosome 0 there was a particularly dramatic and effective ablation of the tumour mass. In the animals that had received Temozolomide effects were seen in more animals, but the long term efficacy is perhaps more questionable as the effect appeared to be the selection of more atypical tumour cells, potentially with resistance to Temozolomide.

Given the consistency of the tumour appearance, it would suggest that the genotype of the tumours is well preserved and that, without being bound by theory—the large difference seen in animal 12 may be a result of a specific Exozome/host interaction, rather than a direct effect of Exosome 0 on the tumour.

REFERENCES

-   Ambros et al RNA 2003. 9: 277-279 -   Banerjee, S., Williamson, D., Habib, N., Gordon, M.,     Chataway, J. (2011) Age and Ageing 40:7-13 -   Chung et al., Cell Stem Cell, 2, 113-117, 2008 -   Dai, L. J., Moniri, M. R., Zeng, Z. R. et al. (2011) Cancer Lett     305(1):8-20. -   Ding, D. C., Shyu, W. C., Lin S. Z. (2011) Cell Transplant 20: 5-14 -   Einstein, O., Ben-Hur, T. (2008) Arch Neurol 65:452-456 -   Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th     edition, ISBN: 0683306472 -   Hassani Z, O'Reilly J, Pearse Y, Stroemer P, Tang E, Sinden J, Price     J, Thuret S. “Human neural progenitor cell engraftment increases     neurogenesis and microglial recruitment in the brain of rats with     stroke.” PLoS One. 2012; 7(11):e50444. doi:     10.1371/journal.pone.0050444. Epub 2012 Nov. 21. -   Hodges et al. Cell Transplant. 2007; 16(2):101-15 -   Horie, N., Pereira, N. P., Niizuma, K. Sun, G. et al. (2011) Stem     Cells 29:274-285. -   Hulkower, K. I., Herber, R. L., (2011) Pharmaceutics 3:107-124 -   Katare et al., Clinical-grade human neural stem cells promote     reparative neovascularization in mouse models of hindlimb ischemia.     Arteriosclerosis, Thrombosis and Vascular Biology, vol 34, no. 2,     pp. 408-418 -   Katsuda, Kosaka, Takeshita, Ochiya. Proteomics 2013, 00, 1-17 -   Katsuda, Tsuchiya, Kosaka, Yoshioka, Takagaki, Oki, Takeshita,     Sakai, Kuroda, Ochiya. Scientific Reports 2013, 3:1197, p 1-11. -   Klimanskaya et al., 2006, Nature 444:481-485 -   Kornblum, Stroke 2007, 38:810-816 -   Lai et al “Proteolytic Potential of the MSC Exosome Proteome:     Implications for an Exosome-Mediated Delivery of Therapeutic     Proteasome”. International Journal of Proteomics (2012) Article ID     971907, 14 pages. -   Littlewood, T. D., Hancock, D. C., Danielian, P. S. et al. (1995)     Nucleic Acid Research 23:1686-1690. -   Miljan, E. A. & Sinden, J. D. (2009) Current Opinion in Molecular     Therapeutics 4:394-403 -   Miljan E A, Hines S J, Pande P, Corteling R L, Hicks C, Zbarsky V,     Umachandran, M, Sowinski P, Richardson S, Tang E, Wieruszew M, Patel     S, Stroemer P, Sinden J D. Implantation of c-mycER TAM immortalized     human mesencephalic-derived clonal cell lines ameliorates behavior     dysfunction in a rat model of Parkinson's disease. Stem Cells Dev.     2009 March; 18(2):307-19 -   Mitchell et al Journal of Immunological Methods 335 (2008) 98-105     Pollock et al, Exp Neurol. 2006 May; 199(1):143-55. -   Mark F Pittenger; Alastair M Mackay; Stephen C Beck; Rama K Jaiswal;     et al Science; Apr. 2, 1999; 284, 5411 -   Shah, K., (2012) Adv Drug Deliv Rev 64(8):739-748. -   Smith, E. J., Stroemer, R. P., Gorenkova, N., Nakajima, M. et     al. (2012) Stem Cells 30:785-796. -   Stevenato, L., Corteling, R., Stroemer, P., Hope, A. et al. (2009)     BMC Neuroscience 10:86 -   Stroemer, P., Patel, S., Hope, A., Oliveira, C., Pollock, K.,     Sinden, J. (2009) Neurorehabil Neural Repair 23: 895-909. -   Thëry, C., Ostrowski, M., Segura, E. et al. (2009) Nature Reviews     Immunology 9: 581-593 -   Thier et al, “Direct Conversion of Fibroblasts into Stably     Expandable Neural Stem Cells”. Cell Stem Cell. 2012 Mar. 20. -   Timmers, L., Lim, S. K., Arslan, F., Armstrong, J. S. et al. (2007)     Stem Cell Res 1: 129-137 -   Yuan, S. J., Martin, J., Elia, J., Flippin, J. et al. (2011) PLoS     ONE 6:e17540 

What is claimed is:
 1. A method for treating cancer, comprising administering to a subject in need thereof an exosome isolated from a stem cell, wherein the exosome is loaded with one or more exogenous nucleic acids, lipids, proteins, drugs, prodrugs, therapeutic or diagnostic agents.
 2. The method according to claim 1, wherein the stem cell is a neural stem cell.
 3. The method according to claim 1, wherein the exosome is loaded with an exogenous nucleic acid that is a coding, non-coding or regulatory nucleic acid.
 4. The method according to claim 2, wherein the exosome is loaded with an exogenous nucleic acid that is a coding, non-coding or regulatory nucleic acid.
 5. The method according to claim 1, wherein the exosome is loaded with an exogenous therapeutic protein.
 6. The method according to claim 2, wherein the exosome is loaded with an exogenous therapeutic protein.
 7. The method according to claim 1, wherein the cancer is glioma.
 8. The method according to claim 7, wherein the glioma is nestin-positive glioma.
 9. The method according to claim 8, wherein the treatment comprises inhibiting migration of the glioma cells.
 10. The method according to claim 8, wherein the treatment comprises inducing differentiation of the glioma cells.
 11. The method of claim 1, wherein the exosome is isolated from a neural stem cell that: (a) is proliferating; (b) does not express doublecortin or glial fibrillary acidic protein; and/or (c) has been cultured in a multi-compartment bioreactor for less than 4 weeks and optionally no more than 1 week.
 12. The method of claim 1, wherein the exosome is isolated from a neural stem cell line.
 13. The method of claim 12, wherein the neural stem cell line is conditionally-immortalised and/or grown in serum free medium.
 14. The method of claim 12, wherein the neural stem cell line is a stem cell line selected from the group of: CTX0E03 having ECACC Accession No. 04091601, STR0005 having ECACC Accession No. 04110301, or HPC0A07 having ECACC Accession No.
 04092302. 15. The method of claim 1, wherein the exosome has: (a) a size of between 30 nm and 1000 nm, or between 30 and 200 nm, or between 30 and 100 nm, as determined by electron microscopy; or (b) a density in sucrose of 1.1-1.2 g/ml.
 16. A method of preparing a cancer therapy comprising stem cell exosomes, wherein the method of preparing comprises the step of: loading exogenous protein, nucleic acid, lipid, drug, prodrug, therapeutic agent or diagnostic agent into the stem cell exosomes.
 17. The method of claim 16 wherein, prior to the loading step, the exosomes are isolated from the cells that produced them, and wherein the loading step comprises direct loading into the exosome of the exogenous protein, nucleic acid, lipid, drug, prodrug, therapeutic agent or diagnostic agent.
 18. The method of claim 16, wherein the stem cell that produces the exosome is engineered to introduce the exogenous protein, nucleic acid, lipid, drug, prodrug, therapeutic agent or diagnostic agent into the exosome. 